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Summary 
Background  
Cardiovascular disease (CVD) is one of the major causes of morbidity and mortality 
worldwide. Clinical guidelines, based on the results of randomised controlled trials, state 
that effective secondary prevention therapies should be prescribed following a diagnosis of 
particular CVD unless there are contraindications. Although evidence shows that use of 
evidence based pharmacotherapies after diagnosis of CVD reduces mortality and disease 
progression, many inequalities exist in prescribing practice. Many studies have 
documented that women and the elderly are less likely to receive evidence based therapies 
than men and the young, respectively. Greater socioeconomic deprivation has also been 
shown to be associated with lower rates of prescribing of therapies. However, prior studies 
have all focussed on one particular CVD or failed to adjust for confounders. Also, few 
studies have examined trends in the prescribing of evidence based pharmacotherapies over 
time and documented whether prescribing inequalities are static, narrowing or widening. 
This project aims to describe the pharmacotherapy received by patients with CVD in 
Scotland, and to describe the factors associated with prescribing of evidence based 
pharmacotherapy. 
Methods  
In this retrospective cohort study I examined a linked database of primary care records 
(Continuous Morbidity Records) and secondary care records (Scottish Morbidity Records) 
covering 238064 individuals in Scotland (approximately 6% of the total population) from 
1997 to 2005. Patients with a first diagnosis (defined as a first hospitalisation or first 
recording of the diagnosis in primary or secondary care) of myocardial infarction (MI), 
angina, and peripheral arterial disease (PAD) were identified. Patients who died within the 
first 30 days of diagnosis/first hospitalisation were excluded from further analysis. Data on 
prescribing of evidence based therapies (angiotensin converting enzyme inhibitors 
(ACEI)/angiotensin receptor blockers (ARBs), β-blockers, statins and antiplatelet agents 
[aspirin or clopidogrel]) within 30 days of diagnosis was obtained from primary care 
database records.  Multivariable logistic regression was conducted to examine the 
association between prescribing of evidence based pharmacotherapies and age, sex, 
socioeconomic status, comorbidities and year of diagnosis. 
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Results  
Between 1997 and 2005, 4305 (83.4%) patients with a first diagnosis of MI, 7210 (98.6%) 
with angina, and 3385 (95.8%) with PAD had survived to 30 days after their first 
diagnosis. 
Increasing age was associated with lower odds of being prescribed evidence based 
therapies. This association persisted after adjustment for sex, socioeconomic status, year of 
diagnosis, and comorbidities. In general, older patients ≥ 85 were significantly less 
commonly prescribed evidence based therapy (EBTs), however they were significantly 
prescribed nitrates (OR 1.29; 95% CI 1.05-1.59, P< 0.01) for angina. 
Generally men were more likely to be prescribed evidence based therapies than women. 
After adjustment, prescribing of evidence based therapies was significantly higher in men 
with a MI for β-blockers (OR 1.18; 95% CI1.04-1.33, P< 0.01), ACEI/ARBs (OR1.26; 
95% CI1.05-1.47, P< 0.01) in angina, and statins in men (OR 1.39; 95% CI1.01-1.93, P< 
0.04) with PAD and coronary heart disease (CHD). In contrast, men diagnosed with 
isolated PAD were significantly less commonly prescribed statins than women (OR 0.73; 
95% CI0.59-0.91, P< 0.004). 
Prescribing of evidence based therapies varied negligibly between the most deprived and 
least deprived patients. These minor differences disappeared after adjustment except for β-
blockers which were significantly less likely to be prescribed for patients who had been 
diagnosed with angina and were residing in quintile 9 compared to the least deprived area 
(OR 0.76, 95% CI 0.58-1.00, p= 0.05).  
Prescribing of evidence based therapies increased between 1997 and 2005, particularly for 
ACEIs/ARBs, β-blockers, statins and antiplatelet agents.  
Generally the presence of comorbidities was associated with lower odds of being 
prescribed evidence based therapies.  
When comparing prescribing rates between the different diagnoses, patients with a first MI 
were more likely to be prescribed ACEI/ARBs, β-blockers, statins, aspirin and clopidogrel 
compared to angina. All evidence based therapies were less likely to be prescribed for 
those with PAD compared to patients with a MI or angina. 
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Conclusion  
In conclusion, I have shown that prescribing of evidence based therapies has improved 
over time, though rates remain low. Prescribing evidence based therapies is inequitable, 
though not always significant, for age, sex, and socioeconomic status. Concomitant disease 
decreased the odds of being prescribed evidence based therapies. More studies are needed 
to identify the reasons for the prescribing inequalities and low rates observed. Further 
studies are needed to examine the existence of other inequalities in using evidence based 
therapies such as dosing and to find strategies to improve prescribing rates.       
.   
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1.0 Introduction  
This thesis will examine the prescribing inequality of evidence-based therapy for 
cardiovascular disease, in particular myocardial infarction (MI), angina and peripheral 
arterial disease (PAD) using primary and secondary data sets in Scotland. For consistency I 
will refer to evidence-based therapy (EBT) in this thesis. Literature surrounding this topic 
will be reviewed to examine the relationship between age, sex, socio-economic, 
comorbidity and calendar year and prescribing EBT.  
 
In chapter one, I will discuss different aspects related to this study including the 
pharmacological treatment for cardiovascular disease, patients’ compliance and adherence 
to medications, socioeconomic measurement, and finally I will discuss the 
pharmacotherapy key trials for MI, angina and PAD. In chapter two, I will describe the 
literature examining the prescribing of EBT inequalities for age, sex, socioeconomic 
deprivation, comorbidities and the prescribing trend for MI, angina and PAD. In the next 
chapter I will state the aims and objectives of this thesis. In chapter four, I will describe the 
data sets resources (Continuous Morbidity records and Scottish Morbidity Records), the 
cohort studied in these analyses, and also the statistical methods used to analyse the data. 
In chapter five, I will present the results of the analyses performed which have examined 
the prescribing inequalities of EBTs for age, sex, socioeconomic deprivation, 
comorbidities and calendar year after first diagnosis of MI, angina, PAD and PAD/CHD, 
furthermore, I will discuss these results in subsequent sections under each disease. Chapter 
six is an overall discussion and summary of this thesis finding, then chapter 7 and 8 discuss 
the study’s strength/ limitations and conclusion, respectively.         
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1.1 Background 
 CVD is one of the most common causes of death worldwide.
1,2 
In the United Kingdom 
(UK) more than one in three deaths (35%) are due to CVD, and approximately 198000 
deaths are attributable to CVD every year.
3
  
Several risk factors can increase the likelihood of developing any CVD. These risk factors 
are either modifiable, for example hypertension or non-modifiable such as age. In addition, 
once a person develops CVD, modification of risk factors can reduce morbidity and 
mortality.
4
 
A number of effective therapies exist that reduce the risk of morbidity and/or mortality in 
patients with CVD. These therapies are mainly, but are not limited to, pharmacotherapies. 
This thesis will examine a number of cardiovascular diseases, namely coronary heart 
disease (CHD) which includes (myocardial infarction (MI) and angina), and peripheral 
arterial disease (PAD) and examine the pharmacoepidemiology of evidence based drug 
therapies for each of these diseases.  
1.1.1 Non-communicable disease 
Non-communicable diseases (NCDs), also known as chronic disease, have been considered 
as a leading cause of death worldwide.
5,6
  They account for 60% of all deaths and 44% of 
premature deaths.
7
 These diseases are not transmissible disease and they form a group of 
diseases that are not mainly caused by infection such as HIV/AIDS.
5
 
CVD such as stroke and MI, chronic respiratory disease such as asthma, cancer, and 
endocrine diseases such as diabetes are the main group of NCDs. It has been reported that 
more than 36 million die annually due to NCDs. These groups of diseases already 
disproportionately affect low and middle-income countries where nearly 80% of NCD 
deaths (29 million) are reported. With an expectation of Africa, NCDs have been 
considered the leading causes of death in all regions.
5,6
 A large portion of countries 
healthcare budgets are already utilised by these diseases. For instance, World Economic 
Forum and Harvard University have reported that chronic diseases are currently costing 
2% of the global gross domestic product (GDP), with a tendency to cost the global 
economy US$30 trillion over the next two decades.
5,7
  
All age groups and all regions are affected by NCDs with a tendency to be more associated 
with older age groups. However, evidence shows that more than 9 million of all deaths 
attributed to NCDs occur before the age of 60, 90% of these "premature" deaths occurred 
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in low and middle income countries. Unhealthy diets, physical inactivity, exposure to 
tobacco smoke or the effects of the harmful use of alcohol have all been considered as the 
leading risk factors that contribute to NCDs .
5
 Physical inactivity and smoking are the most 
common contributable risk factors.
7
 In spite of the ability to modify and change these risk 
factors, they are still the main cause of NCDs and death. For example, tobacco is the main 
cause of six million deaths annually, physical inactivity accounts for 3.2 million deaths 
every year, and approximately 1.7 million deaths are due to low fruit and vegetable 
consumption.
5
   
In May 2013, a set of measures to tackle the global NCDs challenge were adopted by 
the 66
th
 World Health Assembly. They endorsed a new Global Action Plan on 
NCDs containing suggested actions for WHO, countries and international partners. These 
actions involved working to improve multi-stakeholder collaboration and adopting 
a global monitoring framework. Twenty-five indicators of progress and nine voluntary 
global targets have been laid out by the framework to:  
 
 Reduce  the percentage of avoidable, premature deaths from the leading NCDs by 
25% 
 Reduce the risk of NCDs by decreasing the previously mentioned leading 
behaviours such as  tobacco use, harmful alcohol use, physical inactivity, and 
eating unhealthy diets including consuming excess salt/sodium 
 Stop the increase in diabetes and obesity, and reduce population levels of high 
blood pressure 
 Increase the ability of accessing essential medicines and technologies for NCDs as 
well as promoting suitable use of drug therapy to reduce the chances of heart 
attacks and strokes. 
 
 
 
 
 
25 
 
1.2  Pharmacological basis for medications used in the management of 
myocardial infarction, angina and peripheral arterial disease  
 
1.2.1  Antiplatelet agents 
Platelet aggregation and thrombosis play a central role in the development of a number of 
diseases caused by atherosclerosis. Ischaemic stroke, MI, angina and PAD are primarily 
caused by the occlusion of arteries by the formation of thrombus.
8
 Antiplatelet agents are 
used to prevent and treat thrombosis related disease including MI, angina, PAD, stroke, 
and for secondary prevention in these disorders.
9
 Antiplatelet agents inhibit platelet 
aggregation by different mechanisms of action. The antiplatelet agents currently available 
for clinical use are aspirin (a cyclo-oxygenase inhibitor), dipyridamole (phosphodiesterase 
inhibitor), thienopyridines derivatives (clopidogrel, ticlopidine, prasugrel), glycoprotein 
IIb/IIIa receptors antagonists (abciximab, tirofiban, eptifibatide), and nucleoside 
/nucleotide inhibitors (ticagrelor, cangrelor).  Aspirin (acetylsalicylic acid) is the most 
widely used antiplatelet agent. It is the first line of treatment for patients with vascular 
disease unless contraindicated.
9-13
 It works by inhibiting cyclooxygenase (COX)-1 which 
leads to platelet inhibition through inhibition of thromboxane A2. 
There are several clinical indications for aspirin such as stable angina, unstable angina, the 
treatment of acute MI, post-MI, post coronary bypass surgery and after coronary 
angioplasty, PAD and stroke.
13
 A number of clinical trials have demonstrated the 
beneficial effects of aspirin in CVD (I will discuss these in the next chapter). The most 
common side effects include dyspepsia, nausea, vomiting, gastrointestinal (GI) bleeding, 
increased bleeding time, and gastric irritation. The major contraindications are GI bleeding, 
history of GI bleeding and active peptic ulcers.
13
  High doses of aspirin are associated with 
an increased risk of GI side effects though the risk is reduced by using lower daily doses 
(75-300mg daily). Despite this the population burden of bleeding on low dose aspirin used 
for the treatment of CVD is still high given the prevalence of the diseases for which it is 
indicated.
14,15
 While aspirin does have serious side effects its efficacy and availability 
mean that it has a central role in the treatment of atherothrombotic disease.  
 
Aspirin has been used for many years but more recently drugs that irreversibly inhibit the 
binding of adenosine diphosphate (ADP) to its receptor in the platelet surface (P2Y12 
receptor) thus inhibiting platelet aggregation have been developed. The thienopyridine 
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group of drugs including clopidogrel and ticlopidine were the first developed. They are 
also commonly used in patients at risk of atherothrombotic events.  These drugs have been 
shown to reduce the risk of new or further thrombus formation.
9,10,16,17
 Ticlopidine and 
clopidogrel can be used as an alternative when aspirin is contraindicated or the patient 
cannot tolerate the side effects of aspirin. The use of ticlopidine was limited because of its 
serious side effects of neutropenia and thrombotic thrombocytopenia.
13,18
 Clopidogrel is 
more widely used as it does not have these side effects. It also has better GI tolerability 
than aspirin although the risk of bleeding is still present.
15
 Prasugrel has been available 
more recently. It may be more efficacious than clopidogrel in the setting of acute MI, 
however this is at the expense of more bleeding.
19
 Prasugrel only became available at the 
end of the period covered by the data and was not in use during the period of this study.  
 
More recently the nucleoside /nucleotide inhibitors (ticagrelor, cangrelor) have been 
developed and tested. They again inhibit the P2Y12 receptor to prevent platelet aggregation. 
They are more potent than clopidogrel and are associated with higher rates of bleeding. 
Their efficacy has only recently been demonstrated and they were not available for use 
during the period covered by the data in this thesis. Therefore they were not included in the 
analysis. The glycoprotein IIb/IIIa receptors antagonists (abciximab, tirofiban, eptifibatide) 
are only used in intravenous form in the setting of acute coronary syndromes (ACS) in 
hospital. They are indicated for use in unstable patients who are due to receive coronary 
angioplasty and during angioplasty for certain groups. They are therefore not included in 
the analysis of the data used in this thesis.  
 
Of the antiplatelet drugs discussed above, only aspirin and clopidogrel are included in the 
analyses. The other drugs are only used in intravenous form in hospital or were developed 
and available for use after the period of this study. The evidence surrounding the use of 
aspirin and clopidogrel is discussed in the next chapter.  
1.2.2  Beta-blockers  
Beta blockers (β-blockers) are indicated in the treatment of a number of CVDs including 
angina, MI and PAD.
20
 β-blockers act by blocking the β-adrenoceptors found in the heart 
(β1 receptor) and peripheral vascular and bronchial smooth muscle cells (β2 receptor). 
Therefore the binding of epinephrine and norepinephrine to these receptors is blocked 
leading to inhibition of the effects of the sympathetic nervous system. 
20-22
 β-blockers 
reduce the work of the heart through negative chronotropic and inotropic effects (i.e. they 
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decrease heart rate and myocardial contractility) and therefore reduce myocardial oxygen 
demand. This reduction in myocardial oxygen demand improves the symptoms of angina. 
The increase in diastolic filling time due the negative inotropic effect of β-blockers 
prolongs myocardial perfusion through longer filling of the coronary arteries that occurs 
during diastole. Furthermore, β-blockers limit infarct size and improve survival in patients 
who have had a MI. 
20,23
  
 
The β-blockers can be broadly categorised according to their perceived cardioselectivity. 
The first generation β-blockers (e.g. propranolol, timolol) inhibit both β1 and β2 receptors 
and are therefore not cardioselective. They may lead to a greater risk of causing 
bronchospasm and vasoconstriction through smooth muscle contraction as a result of 
blocking β2 receptors. The selective β-blockers (acebutolol, atenolol, betaxolol, bisoprolol, 
celiprolol and metoprolol) are potentially less likely to cause these side effects as they 
mainly act on the β1 receptors. The cardioselectivity of these β-blockers falls as the dose 
increases. The non-selective but combined β-blockers (carvedilol, nadolol) have both β-
blocker and other vasodilator effects. Nebivolol and carvedilol cause a direct vasodilation 
potentially via nitric oxide release, pindalol and acebutolol have an intrinsic 
sympathomimetic activity on β2 receptors leading to smooth muscle relaxation and 
vasodilation and labetalol and carvedilol also have alpha blocking activity. A number of 
randomised clinical trials have demonstrated the efficacy of β-blockers leading to their 
central place in guidelines (these will be discussed in the next chapter). Although they are 
widely used and recommended this class of drugs have a number of side effects and 
contraindications. Their side effects arise from their mechanism of action. Smooth muscle 
effects cause bronchospasm and cold extremities and their negative chronotropic effect can 
cause excessive bradycardia.
22,24,25
  In addition, the drugs can cause insomnia (which is 
thought to occur due to the drugs crossing the blood brain barrier).
22,26
 
 
The use of β-blockers is recommended for the treatment and prevention of angina, MI and 
prevention of cardiovascular events in patients with PAD. In the current thesis all β-
blockers were examined.  
1.2.3 Angiotensin converting enzyme inhibitors/ angiotensin receptor blockers 
Angiotensin converting enzyme inhibitors (ACEI) and angiotensin-II receptors blockers 
(ARB) both act on renin angiotensin system (RAS). ACEIs inhibit the conversion of 
angiotensin-I to angiotensin-II by angiotensin converting enzyme (which is found in the 
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pulmonary and renal endothelium) and ARBs block the angiotensin 1 and 2 receptors (AT1 
and AT2) inhibiting the action of angiotensin II. Angiotensin II is a potent vasoconstrictor, 
it increases sympathetic activity, causes tubular sodium, chloride and water retention 
directly and through the formation of aldosterone by the adrenal cortex and via ADH 
secretion causes further water retention. All of these effects lead to an increase in blood 
pressure, afterload on the heart and coupled with its direct actions on the heart through 
inhibition of cardiac contractility, cell communication, and electrical impulse propagation 
and promotion of apoptosis (cell death) mean that angiotensin II is central to the 
development of CVD and the risk of death or other adverse outcomes in those with 
cardiovascular disease.
27-31
  
 
The use of ACEI and ARBs has been shown to have many favourable effects in 
cardiovascular disease. They reduce blood pressure, reduce infarct size in MI and inhibit 
adverse remodelling preventing the onset of heart failure (HF). They also improve survival 
in those with cardiovascular or PAD (see next section). However, drugs inhibiting the RAS 
also have a number of side effects that can limit their use in practice. They promote the 
retention of potassium, as angiotensin II which they inhibit promotes the excretion of 
potassium. They also can cause worsening of renal failure and because of their effect on 
the RAS they are contraindicated in renal artery stenosis (as they cause a fall in renal 
perfusion pressure). All ACEIs can also cause angioedema through the inhibition of 
bradykinin breakdown which is also mediated by angiotensin converting enzyme.
30
 This 
effect is also responsible for a dry cough which can occur with ACEIs. While these effects 
are particularly relevant for ACEIs a small subset who take an ARB can also develop 
angioedema.
32
  In practice the commonest reason for this group of drugs not to be 
prescribed is impairment of renal function, hyperkalaemia and hypotension. 
33
 The final 
issue that has been discussed is whether ARBs are equivalent to ACEIs in their ability to 
prevent adverse outcomes. As noted above, their different mechanism of action may reduce 
the likelihood of certain side effects. Theoretically they were thought to be better at 
inhibiting the effects of angiotensin II as angiotensin II can still be produced through non-
ACE dependant pathways even if an ACEI is used.
34
 However, clinical outcome trials have 
established their equivalence and not superiority for a number of cardiovascular outcomes 
as will be discussed in the next section. 
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For this thesis I considered any ACEI or ARB as a potential drug. Given that ARBs can be 
used instead of ACEI for patients with side effects such as cough, they are combined into 
one group.    
 
1.2.4 Calcium channel blockers 
Calcium plays an important role in maintaining the tone of smooth muscle cells and in the 
contraction in the myocardium. Normally the concentration of calcium ions (Ca2
+
) is 
higher outside cells than inside, and it influxes into vascular smooth muscle and 
myocardial cells through L-type calcium channels. This increase in intracellular Ca2
+
 
concentration stimulates smooth muscle and myocardial contraction. Calcium channel 
blockers (CCBs) antagonize this effect by blocking L-type calcium channels and 
preventing the influx of calcium ions into cells. This in turn leads to the drugs being 
negatively inotropic and causing peripheral vasodilation. This effect is common to both the 
non-dihydropyridene (non-DHP) subclass (which includes the drugs verapamil and 
diltiazem) and the dihydropyridenes (amlodipine, nifedipine, lecarnidipine, felodipine 
etc.). The DHP are more selective for the vascular smooth muscle and hence are less 
negatively inotropic than the non-DHP class of CCBs. The non-DHP drugs also inhibit the 
sino-atrial and atrioventricular node, reducing heart rate further, adding to their negative 
effect on cardiac output.
35-37
  
 
The class of CCB used is therefore determined by comorbidities and interactions with 
other prescribed drugs. CCBs are useful for patients who have bronchospasm or airways 
disease who cannot tolerate β-blockers. The negatively inotropic effect of the non-DHP 
class means that they are contra-indicated in patients with HF and their rate-limiting effects 
means that they cannot be used with β-blockers or in those with existing atrioventricular 
disease (the DHP class can be used).
38,39
 In general, CCBs are well tolerated but side 
effects occur from their vasodilation properties such as dizziness, hypotension, headache 
and flushing.
35,40,41 
 Constipation is a common side effect in the elderly with the non-DHP 
class. Some important drug interactions between the non-DHP and other drugs commonly 
prescribed in patients with CVD must be noted. In addition to lowering heart rate the non-
DHP also inhibit the digoxin transporter increasing serum concentrations of digoxin, 
increasing the risk of digoxin toxicity and heart block. Verapamil is an inhibitor of the 
hepatic CYP3A enzyme involved in the breakdown of statins, theophylline (used in 
asthma, a common reason to use the non-DHP drugs over β-blockers) and cyclosporin. 
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Despite these issues the CCB drugs are used commonly as they improve angina, reduce 
blood pressure and in the case of the non-DHP verapamil may improve outcomes post-
MI.
42
 All CCBs were considered under one class for this thesis as there is not definitive 
evidence that one sub-class is preferable to another as will be discussed in the next chapter.
 
 
1.2.5 HMG-CoA reductase inhibitors 
A number of drugs are available to reduce cholesterol. The fibrates (fenofibrate, 
gemfibrozil, benzofibrate, fenofibrate) reduce triglyceride levels. The nicotinic acid niacin 
is thought to act via inhibition of free fatty acid release from tissues therefore reducing the 
creation of cholesterols by the liver. The bile acid sequestrants (cholestyramine, 
colesevelam and colestipol bind to bile acids, which contain cholesterol, and promote their 
excretion in the gastrointestinal tract, reducing cholesterol levels. None of these drugs have 
convincingly shown reductions in mortality or morbidity in trial. The inhibitors of the liver 
enzyme responsible for forming cholesterol, 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA), have been shown to effectively lower lipid levels and reduce morbidity and 
mortality.
43-45
 As such the statins (simvastatin, pravastatin, fluvastatin, atorvastatin, 
rosuvastatin, lovastatin) are the drug of choice for reducing cholesterol and improving 
outcomes in patients with cardiovascular disease.  Guidelines suggest commencing a statin 
therapy in patients established CHD with total cholesterol level >4.5 mmol/L, and LDL 
cholesterol >2.5 mmol/L.
44
 In addition to lowering LDL cholesterol (associated with worse 
outcomes) they increase the levels of HDL cholesterol (with increased levels reducing the 
risk of cardiovascular events.
35,46 
The statins may also have other so-called pleomorphic 
effects such as improving endothelial function, stabilising coronary plaques (the rupture of 
which are responsible for myocardial infarction) and inhibiting inflammatory response to 
atherosclerosis.
46,47
 The statins are contraindicated in patients with liver impairment and 
they can cause an elevation in liver enzymes. The commonest side effect of the drugs is on 
the skeletal muscle and the drugs can cause muscle pain and more rarely rhabdomyolysis 
(disintegration or dissolution of muscle).
35
 A number of clinical trials which will be 
discussed in the next chapter have demonstrated that statins reduce morbidity and mortality 
in primary and secondary prevention of CVD.
48
 Therefore in this thesis I will examine 
statins as the evidence based therapy for the outcomes examined.  
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1.2.6 Nitrates  
Nitrates are commonly used for the treatment of angina. Through a nitric oxide free radical 
the drugs induce vasodilation even when endogenous nitric oxide production is low or 
impaired. An unstable nitric oxide free radical is released from the nitrate molecule of the 
drugs. Prolonged administration of the drugs can lead to formation of a compound called 
peroxynitrate and this inhibits endothelial production of nitric oxide and may be one of the 
mechanisms behind the phenomenon of nitrate tolerance.
49,50
 This occurs when the patients 
have been on nitrates without a break for a long time. To prevent this nitrates are 
administered with a nitrate free period usually overnight when the patient is less active. 
The nitrates preferentially dilate large coronary arteries and arterioles. As a result they lead 
to a reduction in afterload via arterial dilation, reduction in preload through venous 
dilatation and consequently reduced myocardial oxygen requirements. The nitrates are 
therefore used to relieve the symptom of angina. Short acting preparations (given 
sublingually to prevent metabolism in the liver) are effective at quickly relieving chest pain 
by their coronary vasodilation effects. The longer acting nitrate preparations (given in 
tablet form or as transdermal patches) are effective at improving symptoms and exercise 
tolerance in patients with angina.  
 
As a result of their vasodilatory action the commonest side effect is headache, 30-60% of 
patients receiving nitrate therapy with long acting preparations will experience headache. 
Other side effects are postural hypotension, facial flushing and tachycardia, again all a 
consequence of their vasodilatory actions.
51-53
 Nitrates have very few contraindications and 
may have to be used in caution with other vasodilating medications such as CCBs. The 
major interaction is between phosphodiesterase-5 inhibitors (e.g. sildenafil (Viagra)) where 
co-administration may lead to catastrophic vasodilation and circulatory collapse.  Unlike 
many of the other drugs discussed the nitrates have not been shown to improve morbidity 
or mortality in patients with cardiovascular disease. The only exception is HF where the 
administration of isosorbide dinitrate may improve outcomes when administered with 
hydralazine (another vasodilator) in some patients. Nitrates are therefore used to treat 
symptoms and not improve outcomes.     
1.2.7 Potassium channel opener “Nicorandil” 
Nicorandil is relatively new class of anti-anginal medication. It is a potassium channel 
activator that is used in the management of stable angina. Nicorandil has a dual effect, a 
nitrate-like effect and activation of ATP sensitive potassium channels.
54
 These actions 
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produce vasodilatation in systemic and coronary arteries. This mechanism leads to a 
reduction in both preload and afterload.
54,55
 As with other vasodilators the drugs must be 
used with caution in those with low blood pressure or receiving other vasodilator 
medications. As with other vasodilators, the side effects reflect vasodilation and include 
headache, hypotension, dizziness, fatigue and flushing. A rare but more serious 
complication of gastrointestinal ulceration is recognised and resolves after stopping the 
drug.
54,56 
There are studies of nicorandil that have demonstrated improvements in 
morbidity in patients with angina. Therefore nicorandil is considered a useful treatment for 
angina. 
 
1.2.8 Ivabradine  
Ivabradine is a new heart rate lowering drug which has selective and specific inhibitor 
effects on If channel in the sino-atrial node. This effect leads to a reduced heart rate at rest 
or during exercise. Therefore, ivabradine maintains myocardial contractility, 
atrioventricular conduction and ventricular repolarization and is thought to be purely a 
heart rate lowering drug. It therefore reduces the metabolic needs of the heart, improving 
angina symptoms. It is useful in patients who cannot tolerate or have a contraindication to 
β-blockers.57,58 Ivabradine is contraindicated in patients with sino-atrial disease and should 
not be used with rate limiting CCBs (verapamil and diltiazem) as the risk of heart block 
and bradycardia is high.
59
 Common side effects are bradycardia, first-degree heart block, 
headache, dizziness and blurred vision (as the If channel is also present in the retina). Less 
common side effects include: diarrhoea, nausea, constipation, palpitation, dyspnoea and 
muscle cramp. Ivabradine reduces angina and has been tested in angina and HF (see next 
section). As such is it considered a third or fourth line therapy in the treatment of angina.  
1.2.9 Oral anticoagulants  
Vitamin K plays an essential role in blood clotting. It is important in the formation and 
production of vitamin-K dependant clotting factors (VII, IX, X, and II). Warfarin inhibits 
the production of these clotting factors and is therefore an anticoagulant drug.
60
 The drug 
must be monitored as it has unpredictable pharmacokinetics which alter between patients 
(due to genetic differences) and within patients (due to changes in catabolism, diet (see 
below) or concomitant drugs). It has a narrow therapeutic window where the benefits of its 
anticoagulant effects are observed. Over-anticoagulation increases the risk and rate of 
bleeding, most usually from the gastrointestinal tract or in the brain causing haemorrhagic 
33 
 
stroke. While the effects of over-anticoagulation can be reversed with vitamin K, 
administration of blood clotting factors may be needed in life threatening bleeding. 
Warfarin also interacts with a multitude of drugs and foods making it a difficult drug to 
safely administer. Coupled with the need for regular monitoring and dose adjustment it is a 
drug with low adherence rates. However, it is an effective anticoagulant and it is used for 
secondary prevention following MI where it may be used as an alternative for those 
intolerant of antiplatelet agents (mainly aspirin or clopidogrel). Also it is considered after 
MI in patients who are already taking warfarin for other comorbidities such as atrial 
fibrillation or deep-vein thrombosis (DVT).
61
 Caution must be used when prescribing the 
drug in conjunction with aspirin as the risk of bleeding increases. Warfarin is 
contraindicated in haemorrhagic stroke, peptic ulcer disease, uncontrolled hypertension 
and clinically significant bleeding or bleeding disorders.  More recently novel oral 
anticoagulants have been developed. These include direct factor Xa inhibitors 
(rivaroxaban, apixiban, edoxaban) and direct thrombin inhibitors (dabigatran). However, 
these were not available or indicated during the period of this study. At present they are not 
licenced for use in CHD or PAD. For this reason the anticoagulant examined is warfarin.   
 
1.2.10 Cilostazol  
Cilostazol is a 2-oxoquinolone derivative and selective inhibitor for the phosphodiesterase-
3. It has antiplatelet aggregation, vasodilator and antithrombotic effects. It is used to 
improve blood flow in peripheral arteries and improves walking distance in those with 
PAD. It should be avoided in patients with a predisposition of bleeding, history of 
ventricular tachycardia, HF or severe renal impairment. The most common side effects that 
may appear when using cilostazol are tachycardia,  palpitations, gastrointestinal 
disturbances, dizziness, headache and chest pain.
62,63
    
 
1.2.11 Naftidrofuryl 
Naftidrofuryl is a vasodilator drug use to improve walking distance in patients with 
intermittent claudication. It is a selective serotonin “5HT2” receptors antagonist in the 
smooth muscle cell which may lead to vasodilation in the peripheral circulation.
64,65
 It is 
normally tolerated in the recommended dose, however few undesirable effects can be 
recognised such as nausea, diarrhoea, rashes, epigastric pain, headache, dizziness.
63
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1.2.12 Pentoxifilline (Oxpentifylline) 
Pentoxifylline acts by lowering blood viscosity and increasing the flexibility of red blood 
cells both of which are thought to lead to improved blood flow in the peripheries. It may 
also decrease the risk of thrombus formation.
66
 It is contraindicated in patients with 
cerebral haemorrhage, acute MI. Its side effects include nausea, vomiting, diarrhoea, 
dizziness, sleep disturbances,  headache.
63
 Its efficacy in reducing morbidity or mortality 
has not been proven but it may improve symptoms.  
 
Summary  
The drugs used to treat MI, angina and PAD overlap. As can be seen from the description 
of the pharmacological actions of the drugs above, the mechanisms of action of the drug 
mean that they are useful in each of these conditions. In the next chapter I will discuss the 
evidence base for the use of each of these drugs in MI, angina and PAD.  
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1.3 Coronary Heart Diseases  
CHD occurs when atherosclerosis of the coronary arteries is present. An individual with 
CHD may have no symptoms, exertional chest pain (angina) or sudden occlusion of a 
coronary artery which leads to a MI. In the UK approximately 50% of CVD deaths are 
directly related to the CHD.
4
 Annually around 8,000 people die in Scotland because of 
CHD
 5
 despite the observation that CHD mortality has declined in the last 10 years by 
42%.
67,68
 However, effective evidence based therapies, which reduce morbidity and 
mortality in those with CHD, i.e. for secondary prevention, are available and I will discuss 
these in relation to MI and angina. 
1.3.1 Angina  
 1.3.1.1 Evidence based pharmacotherapy and secondary prevention in angina 
A number of effective therapies for the treatment of angina exist. Drugs may be used to 
control symptoms and others to reduce mortality. The management of angina symptoms is 
usually initiated with one drug (mono therapy), however, if this is not sufficient to improve 
symptoms then combination therapy is required.
25,69
   
Calcium channel blockers  
CCBs are effective in the treatment of angina. The selection of a CCB is based on 
comorbidity and drug interactions. For example HF and bradycardia or AV block limit the 
choice to dihydropyridines (e.g. amlodipine or felodipine).
70 
CCBs improve angina 
symptoms by coronary vasodilatation and reduction in myocardial oxygen demand.
41,71
 
Dizziness, hypotension, headache, palpitation, flushing, and nausea are commonly 
observed with dihydropyridines such as nifedipine, but less so with long acting 
diyhydropyridines such as amlodipine and non-dihydropyridines e.g. diltiazem or 
verapamil.
41
 Rate limiting CCBs (diltiazem and verapamil) are contraindicated and should 
be avoided in patients with HF, and in patients with bradycardia or AV block.
39
 
The extent of efficacy and tolerability of two different types of CCB has been assessed in a 
randomised double-blind study.
72
 Amlodipine once daily and modified release diltiazem 
once daily were compared in one study. Patients were randomised to amlodipine 
(5mg/day) or diltiazem modified release (240mg/day) for two weeks, then the dose 
increased to (10mg/day) and (360mg/day), respectively. There was no significant 
difference between the two treatments. In comparison to the baseline, both treatments were 
significantly associated with increase in time to onset of angina (<0.001) for diltiazem and 
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(0.002) for amlodipine, time to maximal exercise (<0.001) for both treatments. In addition, 
both drugs were similarly effective in reducing the number of angina attacks and the 
frequency of use of glyceryl trinitrate. Amlodipine and diltiazem were associated with a 
low rate of side effects, and the most common reported side effects were oedema, headache 
and palpitations.
72
 
A further study compared amlodipine (2.5-10 mg a day) with diltiazem (60-120 mg three 
times/ day).
73
 Both drugs resulted in an improvement of time to onset of angina, time to 
maximal exercise, and time to 1 mm ST segment depression. They also reduced glyceryl 
trinitrate consumption (median decline in consumption for amlodipine was 0.75 
tablet/week and 1 tablet/ week for diltiazem) and frequency of angina attacks (1.5 
attacks/week for amlodipine and 3 attacks/ week for diltiazem).  
Angina prognosis study in Stockholm (APSIS)
74
 included 809 patients age under 70 years 
old with stable angina. Patients were blindly randomised to receive either verapamil 
(240mg/ twice a day) or metoprolol (200mg/ a day). After a median follow-up for 3.4 
years, mortality was 6.2% in verapamil and 5.4% in metoprolol (p=0.63). At the end of the 
study 24.3% of verapamil treated and 26.1% of metoprolol treated patients had non-fatal 
cardiovascular events (MI, stroke, PAD and angina).  
Nitrates 
In the management of an acute angina attack the most effective drug is a nitrate taken 
either as a sublingual tablet or spray of glyceryl trinitrate.
25
 Vascular smooth muscle 
dilatation is the principal effect of nitrates. This leads to reduced cardiac preload and 
afterload which results in decreasing myocardial oxygen requirement. A further effect is 
dilatation of the coronary arteries which increase the coronary artery blood flow and 
consequently increased oxygen supply.
51,53
 
For the chronic treatment of angina in a double blind study, 97 elderly patients with stable 
angina were randomised for either to receive amlodipine (5-10 mg/day) or isosorbide 
mononitrate at dose (25-50 mg/day) for 28 weeks. At the end of this study amlodipine was 
significantly better than isosorbide mononitrate in improving the total exercise time 
p=0.016.
75
 
Combination of isosorbide mononitrate with atenolol showed a preferable effect than 
nifedipine with atenolol or atenolol alone in a double blind study.
76
 Eighteen patients (age 
rage 47-67 years) with angina were randomised to atenolol (100mg/day) and placebo, 
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atenolol (100mg/day) and nifedipine (40mg/day), atenolol (100mg/day) and isosorbide 
mononitrate (40mg/day), or triple therapy. After 4 weeks, there were no significant 
differences in all tested parameters including angina attack rates, glyceryl trinitrate 
consumption, exercise duration to onset of angina or 1mm ST depression or symptoms 
free. However, combination of atenolol/ isosorbide mononitrate was associated with longer 
exercise duration than atenolol alone (mean difference 46, 95% CI 18-88, p=0.005), 
atenolol with nifedipine (mean difference 36, 95% CI 2-71, p=0.04), triple therapy (mean 
difference 28, 95%CI 6-61, p=0.1).     
Beta blocker  
β-blockers are considered a first line therapy for the long term management of chronic 
angina. However, these should be avoided in patients with asthma, severe bradycardia, 
high degree atrioventricular block
77
  and decompensated left ventricular failure.
25,78
 β-
blockers improve angina symptoms through reducing the heart rate and myocardial 
contractility which both lead to reduce myocardial oxygen demand.
79
 Side effects include 
fatigue, lethargy, insomnia, nightmares, sexual dysfunction.
26
       
The atenolol silent ischemic study (ASIST)
80
 examined the effect of atenolol on daily 
ischaemia due to CHD in 306 outpatients. Patients were randomised to either placebo or 
atenolol (100mg/day). After four weeks of treatment, compared to placebo, atenolol 
reduced the frequency (mean ± SD, 3.6±4.2 vs. 1.7±4.6 episode, p<0.001) and average 
duration (30±3.3 vs. 16.4±6.7 minutes, p<0.001) of ischaemic episodes per 48 hours of 
ambulatory electrocardiography (ECG) monitoring. The average heart rate after four weeks 
for placebo was 74.9 beats/minutes vs. 63.2 beats/minutes (p=0.0001) for atenolol. 
Furthermore, atenolol improved event free survival (death, resuscitation of ventricular 
tachycardia/ fibrillation, myocardial infarction, hospitalisation for unstable angina, 
aggravation of angina or revascularisation, p< 0.006). However, there was no significant 
reduction in the endpoint of death or non-fatal MI among atenolol treated patients over 
placebo (relative risk [RR], 0.55; 95% confidence interval [CI], 0.22-1.33, p=0.175).
80
   
Although the sample size in the ASIST study was small and the duration of follow-up was 
only one year, this study provided evidence of the beneficial effect of atenolol in the 
management of patients with silent ischaemia.
80
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Combination therapy of β-blocker and calcium channel blocker  
The effect of combination treatment versus monotherapy of stable angina has been 
investigated in the International Multicentre Angina Exercise (IMAGE) study.
81,82
 Patients 
who reported stable angina symptoms for ≥ 6 months and had a positive exercise tolerance 
test were enrolled in this study. This study took place over 10 weeks and was divided into 
two stages. Firstly patients had an exercise test at baseline and they were allocated to 
double-blind treatment for 6 weeks with either metoprolol (100mg/ day) or nifedipine 
(20mg twice/day). Then in the next four weeks patients treated with metoprolol were 
randomised additionally to either placebo or nifedipine and patients treated with nifedipine 
were also randomised to the addition of metoprolol or placebo. Exercise tolerance tests 
were repeated at week 6 and week 10. Both metoprolol and nifedipine were effective and 
mean exercise time increased in comparison to baseline (p < 0.01), metoprolol was 
significantly more effective than nifedipine (p < 0.05).  Combination therapy led to a 
considerable increase in mean exercise tolerance  (p < 0.05) compared to placebo.
81,82
 
The total ischaemic burden European trial (TIBT)
83
 included 608 patients aged between 40 
and 79 years with stable angina. Patients were randomly selected to receive atenolol 50mg/ 
twice a day, nifedipine 20mg/twice a day, or combination therapy of atenolol/nifedipine. 
After 6 weeks follow-up atenolol and combination therapy were associated with significant 
(p<0.01) fall in heart rate, however, nifedipine was associated with slight increase in heart 
rate. Furthermore, after 6 weeks the total exercise time, time to 1 mm ST segment 
depression, and maximal ST segment depression, significantly improved in all treatment 
groups compared to the baseline.   
A meta-analysis
84
 of 22 randomised trials compared monotherapy with a β-blocker to 
combination of β-blocker and CCB, and 10 studies comparing monotherapy with a CCB to 
a combination of a CCB and a β-blocker. This meta-analysis demonstrated that combined 
therapies were significantly more effective than a β-blocker and increased the time to 1 
mm ST segment depression by 8% (p < 0.001), increased total exercise duration by 5%, 
and increased the time to the onset of angina pain by 12% (p < 0.001). However, only the 
time to 1mm ST segment depression was significantly increased with the combined 
therapy compared to CCB alone by 9% (p < 0.001).
84
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“Potassium channel openers” nicorandil 
Nicorandil is a potassium channel activator used in the management of stable angina. This 
drug is used in combination with other drugs in patients who have not achieved symptom 
control.
78
 Nicorandil has a dual effect, a nitrate-like effect and activation of ATP sensitive 
potassium channels.
54
 These actions produce vasodiltation in systemic and coronary 
arteries. This mechanism leads to a reduction in both preload and afterload.
55
 The most 
common reported adverse effects of nicorandil are headache, hypotension, dizziness, 
fatigue, flushing, and, rarely, gastrointestinal ulceration such as small intestinal ulceration 
and anal ulceration.
 56
  
The efficacy of nicorandil in the management of patients with angina was investigated in 
the Impact of Nicorandil in Angina (IONA) study.
85,86
 This was a randomised double-
blind, placebo controlled trial. Over 5000 patients randomly assigned for either nicorandil 
(20 mg twice a day) or placebo. Patients were followed up for approximately 36 months in 
order to identify whether nicorandil could reduce the incidence of coronary events in 
patients with stable angina and additional risk factors. It was reported that nicorandil 
significantly reduced the primary end points (incidence of fatal CHD, non-fatal myocardial 
infarction or unplanned hospitalisation for cardiac chest pain) compared to placebo group 
from 15.5% to 13.1% (Hazard ratio [HR] 0.83; 95% CI 0.72–0.97; p=0.014).87-89  
The efficacy of nicorandil in comparison to amlodipine in improving angina symptoms 
was examined in a double blind study (Study of Women's Health Across the Nation 
(SWAN) study).
90
 Patients were randomised to receive either nicorandil (10mg/twice a 
day) or amlodipine (5mg/day) for 8 weeks, then after 2-4 weeks according to the patient’s 
clinical condition the doses were increased to 20 mg twice a day for nicorandil and 10 mg/ 
day for amlodipine, respectively. In both groups time to onset of ST segment depression 
was increased (from 4.7 to 5.1 for nicorandil, and from 5.1 to 5.7 for amlodipine), though it 
was not statistically significant in the nicorandil group. In addition, time to onset of angina 
was increased significantly (5.2 to 6.1 per minutes for nicorandil, and 5.6 to 7.0 per 
minutes for amlodipine).
90
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Other antianginal drugs 
Ivabradine 
Ivabradine is a new heart rate lowering drug which has selective and specific inhibitor 
effects on If channel in the sino-atrial node (SAN) pacemaker current. This effect leads to a 
reduced heart rate at rest or during exercise. Patients with stable angina who cannot 
tolerate β-blocker can alternatively use ivabradine.57,58 
The safety and efficacy of ivabradine was demonstrated in a randomised double blind 
placebo controlled trial.
57,58,91
 In this study 360 patients with stable angina were 
randomised to receive one of three doses of ivabradine (2.5, 5 or 10 mg twice a day) or a 
placebo. After two weeks of ivabradine use, there was a significant reduction in heart rate 
for all doses compared to the placebo (p<0.05). Furthermore, the time to 1 mm ST segment 
depression during exercise tolerance test (ETT) significantly increased in the ivabradine 
5mg and 10mg doses compared to placebo. Ivabradine reduced the frequency of angina 
and the use of short acting nitrates.  
A randomised double blind controlled trial,
92
 including 939 patients with stable angina to 
compare ivabradine efficacy atenolol. Patients were randomised to receive one of the 
following regimens: ivabradine 5 mg twice daily for 4 weeks followed by ivabradine 7.5 
mg twice daily for 12 weeks. Ivabradine 5 mg twice daily for 4 weeks followed by 
ivabradine 10 mg twice daily for 12 weeks, or atenolol 50 mg once daily for 4 weeks 
followed by atenolol 100 mg once daily for 12 weeks. At 16 weeks, patients who were 
assigned to receive ivabradine 7.5 mg twice daily and 10 mg twice daily had a mean 
increase of time to limiting angina of 91.8 +/- 131.1 s and 96.9 +/-121.1 s, respectively, at 
trough drug concentrations, versus 85.4 +/- 133.7 s for atenolol 100 mg once daily 
(P<0.001 for noninferiority of ivabradine). The efficacy of ivabradine relative to atenolol 
was also established for time to angina onset (P<0.001 for noninferiority). 
 
A placebo-controlled randomised trial
93
 assessed the frequency of angina attacks at the end 
of an open label phase. Hundred and sixty one patients with stable angina were assigned to 
ivabradine 10 mg twice daily for 3 months, then they were blindly randomised for two 
weeks to receive one of the following regimens: ivabradine 2.5 mg twice daily, ivabradine 
5 mg twice daily, ivabradine 10 mg twice daily, or a placebo. At the end of this 3-month 
period, the number of angina attacks per week was significantly lower than at baseline, 
decreasing from 4.14 +/- 5.58 attacks per week to 0.95 +/- 2.24 attacks per week 
41 
 
(P<0.001). The consumption of short-acting nitrates decreased from 2.28 +/- 3.74 
tablets/week to 0.50 +/- 1.14 tablet/week (P<0.001) during the same period. In a 
subsequent 1-week withdrawal period following the 3-month open-label phase, angina 
attack frequency increased by 0.74 +/- 1.95 attacks per week for patients assigned to the 
placebo (P=0.067). 
 
Angiotensin converting enzyme inhibitor (ACEI) 
The beneficial effect of ACEIs in patients with HF and MI has been proven in a number of 
trials, however, the benefits of ACEIs in patients with CHD is conflicting.
94
 Six 
randomised controlled trials of patients with CHD and preserved left ventricular systolic 
function were combined in a meta-analysis. Approximately 33,500 patients with CHD 
were randomised to ACEI or placebo. Patients randomised to ACEI showed a decrease in 
cardiovascular mortality (RR 0.83; 95%CI 0.72-0.96, p=0.01), non-fatal MI (RR 0.84, 95% 
CI0.75-0.94, p=0.003).
94
  
The heart outcomes prevention evaluation (HOPE) study randomised 9297 high risk 
patients who had evidence of vascular disease or diabetes with one other cardiovascular 
risk factor and without evidence of left ventricular dysfunction or HF, to ramipril 
10mg/day or placebo. The ramipril group significantly reduced the risk of death, had MI or 
stroke compared to the placebo (RR 0.78; 95%CI 70-86, p<0.001).
95
 In EUROPA,
96
 there 
was a randomised control trial, in which patients with stable CHD were randomised to 
perindopril or placebo. Perindopril significantly reduced the composite outcome for 
cardiovascular mortality, non-fatal MI and resuscitated cardiac arrest (RR 0.80, 95% CI 9-
29, p=0003). 
In contrast, two studies showed no benefit of ACEI in patients with stable CHD. The 
quinapril ischaemic event (QUIET) and PEACE trials randomised patients with stable 
CHD to quinapril and trandolapril or placebo, respectively.
97,98
 Compared to the placebo, 
these studies did not show significant difference in the rates of death due to cardiovascular 
causes, non-fatal MI, coronary revascularisation.             
Lipid lowering drugs “statins” 
Lipid lowering drugs reduce the risk of atherosclerosis.
43,99,100
 The European guidelines 
suggest commencing a statin therapy in patients established CHD with total cholesterol 
level >4.5 mmol/L, and LDL cholesterol >2.5 mmol/L.
99
 The Heart protection study 
(HPS),
101
 randomised patients (with coronary disease, other occlusive arterial disease or 
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diabetes) to simvastatin 40mg/ day or a placebo. HPS demonstrated that simvastatin 
significantly reduced coronary mortality rate by 18% (5.7% vs. 6.9%, p<0.001), and also 
reduced the rate of a major coronary event including non-fatal MI and coronary death (RR 
0.73; 95% CI 0.67-0.79, p<0.0001).  
In a large meta-analysis of 14 randomised trials that included patients with stable angina,
102
  
there was a 19% reduction in coronary mortality (95% CI 0.76-0.85, p<0.0001), and 
reduction in MI or coronary mortality (RR 0.77; 95%CI 0.74-0.80, p<0.001) with statin 
therapy.          
Antiplatelet therapy  
In a large double blind trial, Swedish angina pectoris aspirin trial (SAPAT),
103
 2035 
patients with stable angina were randomised to receive aspirin 75mg/ day or placebo. 
Patients were followed-up approximately for more than four years. Compared to the 
placebo group, aspirin reduced the composite outcome for cardiovascular event including 
MI and sudden death (RR 0.66; 95%CI 24-49, p=0.003).   
A meta-analysis for randomised control trials,
104
 included 135000 patients with CVD 
including angina. It involved 287 randomised trials and aspirin was the most studied 
antiplatelet therapy. The use of antiplatelet therapy reduced the serious vascular events 
include non-fatal MI, non-fatal stroke and vascular mortality.  Other meta-analysis of six 
randomised trials for patients with stable CVD showed that aspirin reduced the risk of 
cardiovascular events including non-fatal MI, non-fatal stroke, and cardiovascular death 
(RR 0.79; 95% CI 0.76-0.98).  
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1.3.2 Myocardial Infarction (MI)  
1.3.2.1 Evidence based pharmacotherapy in secondary prevention in MI 
 
Patients with an acute MI are at high risk of recurrence or other cardiovascular events 
including cardiovascular death. Recurrence of MI within one year is between 8 and 
10%.
3,4,67
 Several groups of medications can be used to help prevent recurrence and death. 
These medications include antiplatelet agents (aspirin or clopidogrel), ACE inhibitors or 
ARBs, β-blockers and statins.105-107 The effectiveness of these medications has been 
established in large randomised clinical trials. 
Antiplatelet therapy 
It is recommended that all patients post MI be prescribed an antiplatelet agent. A large 
meta-analysis of 25 trials demonstrated that antiplatelet agents reduced the risk of death 
and re-infarction by 25% post-MI.
105,108
 At three years follow up, in the 1410 patients with 
MI included, aspirin reduced the incidence of new coronary events by 52%.
109
  
In the Clopidogrel versus aspirin in patients at risk of ischaemic event (CAPRIE) trial
110,111
 
compared to aspirin, use of clopidogrel was associated with 8.7% relative risk reduction 
(95% CI 0.3–16.5 p=0.043) in ischaemic stroke, MI, or vascular death. Clopidogrel had a 
similar safety profile to aspirin, therefore, clopidogrel is considered as a suitable alternative 
for aspirin in patients who are intolerant of aspirin.  
In the randomised control trial, Clopidogrel in Unstable angina to prevent Recurrent Event 
(CURE),
112
 12,562 patients with  unstable angina or ST elevation MI to placebo or 
clopidogrel, in addition to different doses of aspirin. Patients were followed up from three 
months to a year. Compared to the placebo, the clopidogrel group had a significantly lower 
risk of cardiovascular death, MI or stroke (RR 0.8; 95% CI 0.72-0.9, p<0.001).     
Beta blocker  
The initiation of a β-blocker post-MI is strongly recommended on the basis of several 
pieces of evidence. Several trials and meta-analyses support the use of β-blockers due to 
their ability to reduce all-cause mortality, re-infarction and sudden cardiac death post 
MI.
113
 Two trials were particularly instrumental in establishing the use of β-blockers. In the 
β-blocker heart attack trial (BHAT) patients were randomised to propranolol or placebo. 
Mortality was reduced by 26% in the propranolol group compared with placebo (p<0.05), 
and re-infarction by 23% within a 2 year follow up.
114,115
 The Norwegian Multicentre 
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Study (NMS) showed that compared with placebo, timolol associated with a 31% 
reduction in mortality in patients <65 years and a 43% reduction in patients aged 65-74 
years.
115-117
 A meta-analysis of 31 trials found that initiation of β-blockers in patients post- 
MI reduced the odds of mortality by 23% in comparison to placebo.
118
  
Angiotensin converting enzyme inhibitors (ACEI) 
A number of trials have established strong evidence for adding an ACEI to the 
management of patients following a MI. These trials have shown that ACEIs reduce 
mortality post-MI,  MI recurrence and the development of heart HF.
113,119
  
In the Survival and Ventricular Enlargement (SAVE) trial,
120
 patients with left ventricular 
ejection fraction (LVEF)  ≤ 40% were randomised to receive captopril (50mg three times a 
day) or placebo. Captopril significantly reduced all-cause mortality by 19% (95% CI 3-32, 
p=0.019), cardiovascular mortality by 21% (95% CI 5-35, p=0.014), and reduced the risk 
of progression to severe HF by 36% (p<0.03).  
In the Acute Infarction Ramipril Efficacy (AIRE),
121
 patients with evidence of HF after MI 
were assigned to either ramipril (5mg twice a day) or placebo. Ramipril significantly 
reduced the risk of death (RR 0.73; 95% CI 11-40, p=0.002) and the risk of the composite 
endpoint of death, reinfarction, severe HF or stroke (RR 0.81; 95% CI 5-31, p=0.008).  
The Trandolapril Cardiac Evaluation (TRACE) study,
122
 randomised patients who had a 
MI with evidence of left ventricular systolic dysfunction (LVSD) to receive trandolapril 
(4mg/ day) or placebo. This study demonstrated that trandolapril reduced mortality by 22% 
(95% CI 0.67-0.91, p=0.001) and there was a 25% (95% CI 0.63-0.89, p=0.001) reduction 
in the risk of cardiovascular mortality. The relative risk reduction of recurrent MI was not 
significant (RR 0.86; 95% CI 0.66-1.13, p=0.29).   
The effect of an ACEI post-MI in patient without HF or LVSD was assessed in the GISSI-
3 trial.
123
 In this trial approximately 20000 patients were assigned to receive lisinopril 
(10mg/day or open control for 6 weeks follow up). Lisinopril was associated with a 
significant reduction in overall mortality (OR 0.88; 95%CI 0.79-0.99).  
In the ISSI-4 trial 
124
 patients were randomised to captopril at a target dose (50mg twice a 
day) or placebo. Treatment was initiated within the first 24 hours post MI. Captopril 
reduced mortality by 7% in the first five weeks. 
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In a randomised double blind trial,
125
 patients who had experienced MI and complicated by 
HF or left ventricular dysfunction were randomised to receive valsartan (angiotensin 
receptor blocker “ARBs”), or captopril (ACEI), or both drugs. Patients were approximately 
followed up for 24 months. This study showed that valsartan is as effective as captopril in 
patients with high risk of cardiovascular events post MI. Compared to the captopril group, 
the hazard ratio [HR] for all causes of death in the valsartan group was 1.00 (97.5% CI 
0.90-1.11; p=0.98). Furthermore, there was no difference in the mortality rate due to 
cardiovascular cause, reinfarction, or hospitalisation due to HF (p=0.2).       
Lipid Lowering drugs – “Statins”  
Dyslipidaemia is one of the major modifiable risk factors that increases the risk of CHD.
126
 
Improvement in CHD mortality and morbidity was demonstrated in several clinical 
trials.
119
  
The Scandinavian Simvastatin survival study (4S) 
127
 included 4444 men and women with 
angina or acute MI who had elevated cholesterol  concentrations (5.5-8.0 mmol/L). 
Patients were randomised to receive placebo or simvastatin (20mg/day). Simvastatin 
reduced all-cause mortality (HR 0.70; 95% CI 0.58-0.85, p=0.0003). Simvastatin also 
reduced the risk of major coronary events including coronary death, non-fatal MI, silent 
MI, or resuscitated cardiac arrest (HR 0.66; 95% CI0.59-0.75, p<0.0001). 
The long-term intervention with pravastatin in ischemic disease (LIPID) study,
128
 assessed 
the effect of pravastatin (40mg/ day) in reducing mortality in patients with CHD (acute MI 
or hospitalisation due to unstable angina). In a double-blind randomised design study, 9014 
patients were followed up for six years. Patients’ cholesterol levels ranged from 4-7 
mmol/L and they all had a history of MI or hospitalisation for unstable angina. The 
primary end point was mortality from CHD. The relative risk reduction of death due to 
CHD with pravastatin was 24% (95% CI 12-35; p < 0.001), and for all-cause mortality was 
22% (95% CI 13-31, p < 0.001).  
The Cholesterol And Recurrent Events (CARE) 
129
 study recruited 4159 patients (3583 
men and 576 women) post-MI who had a plasma total cholesterol level below 6.2 mmol/L 
and LDL levels of 3-4.5 mmol/L. Patients were randomised to  pravastatin (40mg/ day) or 
placebo. The primary end point, which was a fatal coronary event or a nonfatal MI, 
occurred in 10.2% of the pravastatin group and in 13.2% of the placebo group, an absolute 
difference of 3% and a 24% relative reduction in risk (95% CI 9-36, P = 0.003). 
46 
 
Summary 
CHD is a major public health problem and constitutes the majority of mortality due to 
cardiovascular diseases. A number of pharmacotherapies have been shown to reduce 
morbidity and/or mortality in patients and are therefore recommended in guidelines 
published by the major cardiovascular societies and guideline groups.
105,107,119,130
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1.3.3 Peripheral arterial disease (PAD) 
1.3.3.1 Evidence based pharmacotherapy in secondary prevention in PAD 
In the management of PAD the control of atherosclerotic risk factors is important to slow 
progression. As PAD is associated with further cardiovascular events such as MI and 
stroke the goal of pharmacological therapy in PAD is to reduce the risk of a further CVD 
event as well as reducing the risk of death.
131,132
   
 
Pharmacological treatment of intermittent claudication  
One of the aims of the treatment of PAD, particularly in those with intermittent 
claudication, is to improve a patient’s quality of life. A number of drugs are said to 
improve symptoms and these include cilostazol, naftidrofuryl and pentoxifilline. 
 
Cilostazol 
Cilostazol is a 2-oxoquinolone derivative, selective inhibitors for the phosphodiesterase III 
with antiplatelet, vasodilator and antithrombotic effects. It is mainly used for PAD to 
improve walking distance. It is contraindicated in patients with HF, and can cause 
tachycardia and palpitations as side effect.
133
    
Four randomised controlled trials have demonstrated that walking distance in patients with 
intermittent claudication improved when they were treated with cilostazol.
134-137
 Walking 
distance improved with cilostazol from 40% to 60% compared with placebo after 12 to 24 
weeks of treatment.
135,136
 A meta-analysis of six trials which compared cilostazol to 
placebo showed that maximal treadmill walking distance improved significantly among 
cilostazol group (p<0.0001).
138
 A meta-analysis of 8 randomised placebo control trials 
showed that cilostazol significantly (p<0.05) improved the maximal walk distance by 50% 
and pain-free by 67% compared to placebo.
139
   
Naftidrofuryl 
Naftidrofuryl is a vasodilator drug use to improve walking distance in patients with 
intermittent claudication. It is a selective serotonin “5HT2” receptors antagonist in the 
smooth muscle cell which may lead to vasodilation in the peripheral circulation.
140,141
    
Naftidrofuryl has been shown to improve pain-free treadmill walking distance, however 
the maximum distance does not improve.
142-144
 A meta-analysis of five studies with a total 
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of 888 patients showed that naftidrofuryl significantly (p<0.002) increased pain-free 
walking distance by 26% compared to the placebo.
145
 
Pentoxifilline (Oxpentifylline) 
Pentoxifylline acts through increasing red blood cell flexibility which may contribute to 
improving blood flow via blood vessels, also decreasing the potential of platelet and 
thrombus formation.
146
 
In a meta-analysis pentoxifilline showed no significant effect compared to the placebo in 
increasing maximal treadmill walking distance. Therefore its clinical effectiveness in the 
management of intermittent claudication is considered marginal.
147,148
     
Angiotensin converting enzyme inhibitors (ACEI)  
ACEIs have been widely studied in CHD but they also reduce morbidity and mortality in 
patients with PAD. The Heart Outcomes Prevention Evaluation (HOPE) study
149
 
demonstrated that ramipril reduced the risk of MI, stroke or cardiovascular mortality in 
patients with symptomatic PAD by approximately 25%.
148,150
 The double blind ongoing 
telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET),
151
 
randomised patients who were at high risk of vascular events, including PAD, to 
telmisartan (ARBs), ramipril (ACEI) or both drugs. The difference between the two groups 
was not significant for the primary outcome including cardiovascular death, MI, stroke, or 
hospitalisation due to HF (RR 1.01; 95% CI 0.94-1.09, p=0.83).  
Beta blocker   
β-blockers have been shown in many randomised trials to reduce the risk of death due to 
CVD. However, it is considered to be controversial to prescribe a β-blocker for patients 
with PAD.
152,153
 This issue arose after a number of case reports that use of β-blockers 
worsened claudication.
154
 There is no evidence from randomised trials showing that β-
blockers negatively affect walking distance in patients with PAD. In contrast, a few 
randomised trials were conducted and showed that β-blockers had no affect on walking 
distance.
153,155
  Eleven randomised control trials were combined in a meta-analysis.
152
 It 
demonstrated that β-blockers are not associated with worsening walking distance or 
symptoms of intermittent claudication in patients with mild to moderate PAD.  A meta-
analysis of 6 randomised control studies found that β-blockers (atenolol, propranolol, 
pindolol and metoprolol) did not adversely affect walking distance in patients with 
intermittent claudication.
156
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Lipid Lowering drugs – “Statins”  
Lipid lowering therapy, mainly through statins, has been shown to reduce the onset of PAD 
and reduce vascular events in those with PAD. In the Scandinavian Simvastatin Survival 
Study (4S)
157
 simvastatin reduced the frequency of new intermittent claudication in 
patients post-MI or with angina from 3.6% for placebo to 2.3% with simvastatin.
 148,158
 
Furthermore, compared to patients who received a placebo, simvastatin was associated 
with lower relative risk of new or deteriorating intermittent claudication (RR 0.6; 95%CI 
0.4-0.9).
147,159
 The Heart Protection Study (HPS)
160
 randomised a wide range of patients 
with CVD, including those with PAD, to either simvastatin or placebo. Simvastatin was 
associated with 22% relative risk reduction (95% CI 15-29, p<0.0001) in vascular events 
(non-fatal MI, coronary death, stroke, coronary and non-coronary revascularisation) in the 
subgroup of individuals with PAD. 
Antiplatelet therapy  
Antiplatelet therapy reduces the risk of thrombus formation which consequently reduces 
further vascular events including PAD. In large randomised controlled trial, aspirin alone 
or in combination with dipyridamole reduced progression of established PAD.
161
 A 
systematic review of randomised controlled trials demonstrated the efficacy of antiplatelet 
drugs in high risk patients. Among patients with PAD, antiplatelet drugs reduced the risk 
of serious vascular events (non-fatal MI, non-fatal stroke, or vascular death) by 23% 
(p=0.004).
150,162
 In the subgroup analysis of the CAPRIE trial,
110
 clopidogrel was more 
effective than aspirin in reducing ischaemic events in patients with symptomatic PAD, a 
relative risk reduction of 23% (95% CI 8.9-36.2, p=0.0028).  
 
Summary 
In the secondary prevention of CVD in patients with PAD, ACEI/ARBs, β-Blockers, 
statins and antiplatelet agents are all recommended. Cilostazol and naftidrofuryl are 
recommended to reduce intermittent claudication symptoms in those with PAD.  
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Summary 
A large number of clinical trials and meta-analyses have examined the use of a number of 
pharmacotherapies to reduce morbidity and/or mortality in patients with MI, angina and 
PAD. While each of these diseases occurs as a result of atherosclerosis of the arteries, not 
all drugs reduce morbidity and mortality in all groups. However, a consistent group of 
antiplatelet agents, β-blockers, ACEI/ARBs and statins emerges from the evidence. This 
combination of drugs is a core set of drugs that patients with angina, post-MI or with PAD 
should be taking. I will now go on to explore the pharmacoepidemiology of each of these 
drugs in patients with angina, post-MI or PAD.  
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1.4 Adherence and compliance  
“Compliance” “adherence” and “concordance” are the three different terms used to 
describe the patient behaviours in using their medications after a diagnosis with a chronic 
disease such as MI. Following closely and correctly all the therapeutic indications 
prescribed by health care providers such as physicians is known as compliance which 
eventually means “the extent to which patients are obedient and follow the prescriber’s 
recommendations”.163-165 To be defined as a “compliant patient”, the patient has to 
accurately follow the directions for taking the medication and should adhere to any special 
instructions provided by the prescriber and/or pharmacist. The compliant patient takes 
medication at the appropriate strength, in the correct dosage form, at the requested time of 
day and night within the proper interval for the treatment period. Medication adherence, 
however, reflects an agreement between patient and prescriber (such as health care 
providers). This agreement mainly sets out the recommendations by the prescriber in terms 
of the extent to which patients take medications, the way that is agreed upon in the 
treatment plan.
165-167
 As “compliance” suggests that the patient is passively following the 
prescriber’s orders and that the treatment plan is not based on a therapeutic alliance or 
contract established between the patient and the physician, the word “adherence” is 
preferred by many health care providers.
165
 The patient’s agreement to the 
recommendations is an essential requirement in adherence which is not the case in 
compliance.
168
 “Concordance”, is a fairly recent term used in the UK and it is sometimes 
incorrectly used as a synonym for adherence. The definition of this term has changed over 
time from one which focused on the consultation process (where therapeutic decisions are 
agreed between a doctor and patient incorporating the latter’s views) to a more detailed 
concept which includes patient support in medicine taking.
164
 
A number of behavioural and system factors influence a patient’s adherence to therapy. 
Living alone, low socioeconomic status, higher number of medications taken, higher 
medication costs, lack of prescription drug coverage by insurance plans in other health care 
systems, higher number of physicians caring for a patient, depression, cognitive 
impairment, treatment of asymptomatic disease, side effects of  medications, complex 
treatment regimens, and financial issues have been considered as risk factors for poor 
adherence. Moreover, some other common modifiable predictors of poor adherence have 
been identified. These include treatment complexity, polypharmacy, cost and duration of 
medication regimen (for acute conditions).
165,169-172
 These factors are all pertinent for 
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patients with CVD who are often elderly, with multiple comorbidities and are prescribed 
many medications for the rest of their life.  
 
In developed countries, an average of 50% adherence to therapies has been described by 
extensive reviews of the literature.
168,173,174
 Patients with CVD are commonly non-adherent 
to medications. In their study, Jackevicius et al.
175
 found that approximately 24% of 
patients did not even fill their cardiac medications by day 7 of discharge following an acute 
MI. Furthermore, one study found that within one month around 34% of patients 
discharged after a MI  had stopped at least one of their prescribed aspirin, statin or β-
blocker and 12%  had stopped all three medications.
175,176
 These findings have been 
replicated by others, Newby et al.
177
 reported that at 6-9 months after a diagnosis of CHD, 
only 71% continued to take aspirin, after a MI less than half of patients (46%) continued to 
take β-blockers, 44% lipid-lowering agents, and only 21% took all 3 medications. In 
another study, only 40% of patients have been shown to continue taking statins two years 
after a hospitalisation for acute coronary syndrome.
176,178
  
 
Due to the serious consequences of poor adherence to long term therapies, it is an 
important issue in the management of chronic conditions. The consequences include 
worsening of the underlying disease, higher mortality, and greater health care costs.
165,167-
169
 Although many causes have been identified for non˗adherence, they generally fall into 
two categories: intentional and unintentional. Unintentional non˗adherence occurs when 
some barriers, that are beyond the patient’s control, prevent patients from following the 
agreed treatment plan. Examples of these include instructions which are difficult to 
understand, poor recall of instructions or medication plan, problems with using the 
treatment such as physically administering the medication e.g. coordinating using a spray 
or inhaler, cost, or simply forgetting to take it. Intentional non˗adherence, however, occurs 
when the patient deliberately decides not to follow the treatment recommendations.
166
  
 
Medication adherence can be assessed by direct and indirect methods. In direct methods, 
patients can be observed in terms of taking medications, “direct observed therapy”, and 
drug or metabolite concentrations and biological markers can be measured in the blood or 
urine. For some drugs, using the direct methods is a satisfactory and commonly used 
means of assessing adherence. For instance, the serum concentration of antiepileptic drugs 
such as phenytoin or valproic acid can be assessed using these methods as subtherapeutic 
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levels will probably reflect poor adherence or suboptimal dose strengths.
165
 The drawbacks 
of direct methods include costs and susceptibility to distortion of samples by the patient.  
     
In indirect methods, however, patients can be asked about the ease of taking their 
prescribed medications, or their diaries can be reviewed. In addition, the indirect methods 
can utilise prescription refill rates, pill counts, assessing clinical response, monitoring for 
clinical response, electronic monitoring devices, and collecting patient questionnaires, 
scales or surveys.
165,167
 The most common method used to measure adherence is pill counts 
which involve counting the number of pills that remain in the patient’s medication bottles 
or vials. This method is simple but it carries some drawbacks. For instance, medicines can 
be switched between bottles and pills can be discarded by patients before visits to 
demonstrate adherence to the treatment regimen. For these reasons, the reliability of this 
method is questionable and this technique should not be considered as a satisfactory tool 
for measuring adherence.
179-182
 
In a health care system where there is no cost barrier to prescriptions (e.g. the NHS in 
Scotland or the Department of Veterans Affairs Health Care System in the USA, or other 
countries with universal drug coverage), rates of refilling of prescriptions has been 
considered as an accurate measure of overall adherence. Measuring the cashing of 
prescriptions at several points in time, however, is an essential factor for the reliability of 
this method.
183-185
 Readily available objective information on rates of refilling 
prescriptions can be obtained by using a medical system that utilises electronic medical 
records. In addition, patient’s responses to direct questions or on questionnaires can be 
corroborated using this method. 
 
The time of opening bottles, dispensing drops (as in the case of glaucoma), or activating a 
canister (as in the case of asthma can be precisely recorded by electronic monitors. These 
expensive techniques have been used for approximately 30 years.
182,186-188
 A precise and 
detailed insight into patients’ behaviour in taking medication can be obtained by these 
indirect methods of measuring adherence. Although this approach provides the most 
accurate and valuable data on adherence in difficult clinical situations and in the setting of 
clinical trials and adherence research, it, however, does not document whether the patient 
actually ingested the correct drug or correct dose.
189,190
 For instance, the data may be 
invalidated by opening a container and not taking the medication, taking the wrong amount 
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of medication, placing the medication into another container or taking multiple doses out 
of the container at the same time. 
Adherence and compliance are therefore a major issue in CVD but difficult to accurately 
quantify in routine practice and therefore overcome. Using pill boxes and calendars are 
some of the more basic methods that have been used to improve adherence. Patient 
education and outreach are the most effective methods of improving adherence.
191,192
 
Giving free access to medications can help to a certain degree
193
 but non-adherence is still 
common in those countries with little or no cost medication.
194
 Therefore, non-adherence 
remains an issue that will require concerted efforts to overcome. It must be borne in mind 
as I discuss prescribing trends that most studies report prescribed therapies and on the basis 
of studies quoted above the proportion actually taking the drug on a regular and ongoing 
basis will be lower.  
 
 
  
55 
 
2.0 The Prescribing of Evidence Based Pharmacotherapy in 
CVD   
2.1 The risk-treatment paradox 
The treatment of chronic diseases such as CVD has been determined by the results of 
multiple randomised controlled clinical trials. This evidence is collected and assessed by 
professional groups such as the European Society of Cardiology, the American College of 
Cardiology and American Heart Association, and collated into guidelines that summarise 
the evidence into a form accessible to clinicians.
195
 These guidelines make 
recommendations as to what medications should be prescribed in various conditions. 
Adherence to these guidelines is associated with better outcomes.
195
 It has been 
demonstrated in numerous studies that the absolute benefits of evidence based therapies are 
highest in the patients at highest risk of morbidity and mortality. Patients may be at higher 
risk due to the presence of comorbidities, age and disease related factors e.g. size of a 
MI.
196
 Therefore, more aggressive intervention may be needed in the highest-risk 
patients.
197
 However, multiple studies have shown that these high-risk patients are less 
likely to receive appropriate medications and therapies to reduce risk and if they do receive 
them they may do so at a lower dose.
198-201
 This phenomenon is referred to as the “risk-
treatment paradox”.  
The risk-treatment paradox has been consistently described.
198,202,203
 McAlister et al.
198
 
reviewed 3871 patients diagnosed with CHD by coronary angiography at three cardiac 
centres in Alberta between February 2004 and December 2005 and defined them as being 
at low, medium or high risk on the basis of coronary anatomy. They reported that high risk 
patients were less likely to be prescribed ACEI, 44.5% high risk vs. 55.6% low risk (OR 
0.64; 95% CI, 0.51-0.81). Even after adjusting for sociodemographic factors the risk-
treatment paradox was still evident (OR 0.66; 95% CI, 0.52-0.84).   
Some factors such as older age, greater likelihood of comorbidities, and later presentation 
after symptom onset have contributed to this risk-treatment paradox in women.
202
 
However, as noted, even eligible patients are at risk of the risk-treatment paradox.  In 
general, clinicians preferentially initiate treatment in low-risk individuals compared to 
higher risk patients. Clinicians tend to overestimate risks of preventative treatments and 
underestimate the benefits of preventative treatments.
204,205
  This difference is thought to 
be partly responsible for the risk-treatment paradox.
198,200,206-210
 Therefore creating and 
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adhering to guidelines may be one method by which to reduce this paradox and evidence 
suggests that involvement in guideline initiatives may reduce the paradox.
211
  
The risk-paradox remains important for clinicians and patients but also for researchers. For 
clinicians and patients, avoiding the paradox is crucial as absolute benefits of therapy are 
greatest in those patients at the highest baseline risk. For researchers, drawing conclusions 
about treatment effects on the basis of associations between treatment and outcomes needs 
to be done with care in observational data as the risk-treatment paradox is an important 
confounder in these studies.
199
 
 
2.2 Literature search  
This literature review examines the pharmacoepidemiology of each of the therapies used in 
the prevention and treatment of MI, angina and PAD. I will focus on studies describing the 
prescribing inequalities of EBTs after MI, angina, PAD for sex, age, socioeconomic status 
and comorbidities. Furthermore, I searched for literature surrounding the trends in 
prescribing of EBTs. Search dates were not restricted to ensure that all articles describing 
trends over time were found.  
 The following databases were searched: Medline, EMBASE, Web of Knowledge and 
Google scholar (which searches conference proceedings). The search strategy was 
constructed using different key words including evidence based therapies, factors, 
prescribing, diseases and comorbidities, the full search strategy is given in Appendix 1. 
Appropriate synonyms were also used, for example gender, male, female, men and women 
were all used when searching for literature on sex differences. The grey literature was 
searched using the terms “prescribing inequalities”, or “prescribing trends” and MI, angina 
or PAD. Studies that examined invasive therapy such as percutaneous coronary 
intervention (PCI) and that did not include pharmacological therapy were excluded. A 
secondary search from the reference list of selected papers was reviewed and citation 
checks carried out to identify more related articles. Abstracts were excluded as a full 
assessment of the methods and potential biases of observational data is not possible for the 
limited information of an abstract. The literature search strategy was checked by the 
Medical, Veterinary and Life Science (MVLS) librarian. The number of studies that were 
identified and excluded at each stage of the review are presented in a flow diagram in 
Appendix 2. The reporting quality of observational studies was assessed using the 
Strengthening the Reporting of Observational studies in Epidemiology (STROBE). The 
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STROBE statement checklist consists of 22 items in a paper on epidemiological studies 
and defines appropriate reporting details. The statement covers reporting of results and also 
other aspects such as the title, abstract, introduction, methods and discussion. In this study 
the STROBE statement was used to assess each reviewed study and a score out of 22 was 
calculated for each study report. This score and assessment forms the basis for the 
discussion about the methods and results of the studies found in the literature review.   
2.3 Evidence based therapies (EBTs) 
Evidence based medicine has been defined as a conscientious, explicit and judicious use of 
current best evidence in making decisions about the care of individual patients.
212
 Part of 
this decision making process is selecting appropriate pharmacotherapies that have been 
shown to improve outcomes in randomised clinical trials. While prescribing of evidence 
based therapies (EBTs) has improved over time, many studies suggest that there is 
suboptimal use of these medications among patients diagnosed with CHD and PAD. The 
prescribing of EBTs is influenced by many factors. A number of studies have demonstrated 
that inequalities in prescribing exist. I will discuss the literature examining differences in 
prescribing of EBTs for CHD, MI, angina and PAD by age, sex, socioeconomic status, 
calendar year and the presence of comorbidities.  
2.4 Inequality in prescribing of EBTs for CHD  
2.4.1 Inequalities by age in prescribing of EBTs for CHD 
Unadjusted analyses  
A number of studies demonstrated that older patients with CHD are less likely to receive 
EBTs for secondary prevention. This association has been reported in different studies 
from a number of countries (Table 1, unadjusted studies). The majority of unadjusted 
analysis studies reported that older people are less likely to be prescribed EBTs for 
secondary prevention. Three studies reported that aspirin was prescribed more frequently 
for younger patients.
213-215
 However, one small study
214
 reported that older women were 
more likely to be prescribed aspirin than younger women (66.7 vs. 51.9%), suggesting an 
interaction between age and sex. This interaction, however, was not confirmed, as no 
statistical analyses were carried out. The majority of unadjusted studies reported that older 
patients were more commonly prescribed ACEIs or ARBs than younger patients.
213-216
 
Prescription rates for β-blockers were generally higher among younger than older patients. 
However, one study
214
 of 802 patients reported that older patients were prescribed β-
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blockers more often than younger patients (80.4 vs. 79.8%, for men, 88.9 vs. 59.3%, for 
women), with this sex difference again suggesting an interaction. Statins were more often 
prescribed for younger than older patients.
214-218
 Few studies examined age inequalities in 
prescribing of CCBs. Two unadjusted studies reported that CCBs were more commonly 
prescribed for older patients.
214,215
 Two studies reported that older patients were more often 
prescribed nitrates than younger patients.
213,214
  
 
Adjusted analyses  
Age related prescribing inequalities were also demonstrated in a number of studies in 
adjusted analyses. Younger patients were more likely to be treated with aspirin than older 
patients.
219-221
 Two studies, however, have reported that older age was associated with a 
higher odd of being prescribed an antiplatelet agent (aspirin or clopidogrel) and aspirin 
alone.
222,223
 The study by Salomaa et al.
224
 was the only study to show that the prescribing 
of ACEI was higher in older patients compared with younger (odds ratio (OR) 1.19; 95% 
confidence interval (CI) 1.15-1.24). All adjusted analyses reported that β-blockers were 
more frequently prescribed for younger as opposed to older patients.
220,222-226
 Younger 
patients were also more likely to be prescribed a statin.
221,223,226-229
 In the only adjusted 
study examining the association between age and the prescription of CCBs, the authors 
have adjusted for sex only and found that older patients were less likely to receive CCBs 
(OR 0.86; 95% CI 0.77-1.00).
226
  
 
A number of studies examined the relationship between age and the prescribing of EBTs 
following a diagnosis of CHD. In different observational study designs, the majority of 
previous studies agreed that older age groups were less likely to have received EBTs 
compared to younger age groups (Table 1). These studies, however, were limited by a 
number of factors including study design, data collection methods, and/or statistical 
methods. 
 
Limitations in the reporting of the literature 
The STROBE scores for literature that described the association between age and 
prescribing of EBTs ranged from 45% to 73% (Table 1). While study design was 
mentioned in the majority of abstracts, this wasn’t the case in a few studies, where no study 
design was evident in the title or abstract.
215,224,226,227,229
 Moreover, a number of studies did 
not clearly define the background, objectives, study design, methods results and 
conclusions in the abstract.
224,226,227,229
 Authors should state clear specific objectives to 
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clarify what is to be achieved by the study, the rationale of the study design and methods, 
statistical analysis and results. While most studies stated their objectives clearly, three 
studies did not.
214,216,224
 One study did not describe the study design in the methods.
223
 
Furthermore, a few studies did not describe those who participated in their studies, or did 
not clearly define the variables used or the data sources utilised.
213,216,227-229
  
 
Potential bias is one of the most important factors that may influence the results of an 
observational study. The STROBE guidelines state that biases should be identified and 
reported. I will discuss the biases below but only one study
222
 discussed potential sources 
of bias. Although a number of studies were associated with potential biases, the authors, 
however, did not describe them either in the methods or limitations.
221,224
 Two studies 
poorly described the methods that they used to examine age-related association in 
prescribing EBTs.
227,228
 Reid et al.
228 
did not explain how the data on EBTs prescriptions 
were obtained and what were the variables of interest. DeWilde et al.
227
 did not describe 
the study design clearly, and were not clear on how they obtained EBT prescriptions for 
analysis. In addition, most studies did not describe any sensitivity analyses, subgroup 
analyses, or interactions. 
 
Five studies did not report the final number of eligible patients that were included in 
theanalyses.
214,216,218,223,228
 The characteristics of patients included were not described in 
four studies, making it hard to judge the generalisability of the results.
215,221,226,229
 A clear 
and full presentation of outcomes including unadjusted results and results adjusted for 
potential confounders can significantly help the reader to compare and judge the magnitude 
and direction of the influence of the confounders. In seven studies, this was not performed 
and no confounders were included.
213,216,222,223,225,226,228
 Finally, a number of studies failed 
to recognise and discuss their limitations.
214-216,221,223,225
  
 
Limitations in the design and analysis of studies included in the literature review 
Observational studies are associated with a number of potential sources of bias. Bias in 
observational research is a systematic deviation or error that can influence the validity of 
the results.
230,231
 It can occur at any stage of the research including study design, data 
collection, patient recruitment and data analysis. Different types of biases are often found 
in observational studies including selection bias, observer or measurement bias, recall bias, 
and for systematic reviews and meta-analyses, publication bias.
232,233
 Three studies were 
limited by recall bias as prescribing of EBTs was obtained from patient self-
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reporting.
214,219,228
 Furthermore, patient’s self-reporting of a diagnosis of CHD occurred in 
two studies.
219,228
 Self-reporting is less accurate than electronic records as it depends on a 
patient’s memory to recall information and it is therefore potentially biased, as under-
reporting may occur.
232,233
 Thus, data obtained from electronic records or case notes should 
be more accurate than self-reported data. Four studies were limited by selection 
bias.
221,222,224,225,227 
Selection bias occurs if there is a systematic difference between the 
subjects enrolled in a study and those who were not.
233
 The sample is therefore 
unrepresentative of the patient population in general. For instance, Salomaa et al.
224
 
excluded patients who died within 180 days, which could lead to a survivor bias and 
selection of healthier individuals, on average, compared to the entire cohort who may have 
been more likely to be prescribed EBTs. Similarly, Mathour et al.
222 
excluded patients who 
did not tolerate drugs, therefore potentially excluding sicker patients. DeWilde et al.
227
 
selected 142 out of 300 primary care practices that participated in a specific reporting 
programme, with a potential overestimation in prescribing as patients were already in self-
selected practices that were more likely to have higher prescribing standards.  
 
All previous studies were conducted using primary care data sets, secondary care data sets, 
or single hospital study. Stable angina is commonly diagnosed in a primary care setting 
based on patients’ presentation. This therefore might lead to the fact that diagnosing angina 
in primary care is less valid when compared to diagnosing this medical condition in a 
hospital setting. PAD is often diagnosed in primary care whereas MI is rarely first 
diagnosed in primary care and most often presents to secondary care as an emergency 
(excluding those who die suddenly). Therefore using primary care records to identify those 
with MI may lead to under ascertainment bias.
224,227
 
 
A number of studies were limited by the validity of the diagnoses of CHD. A number of 
studies identified patients diagnosed with angina based on whether the patient was 
receiving a prescription for nitrates and aspirin prescriptions.
215,226,229
 Although these drugs 
are commonly used for CHD, they also can be prescribed for other conditions where the 
EBTs examined may not be indicated, thus potentially underestimating the prescribing 
rates of EBTs.  
 
Potential confounders including socioeconomic status, comorbidities, age and sex can 
influence the prescribing of EBTs. They could influence the association between the 
exposure and the outcome. This, therefore, will result in unadjusted results being less 
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reliable compared to adjusted results. Although it is well known that socioeconomic status 
is associated with poorer health outcomes and prescribing of EBTs, only three studies, 
however, adjusted their analyses for socioeconomic status.
219,222,223
 
 
A number of other limitations were also identified in the literature. For example studies 
were limited to examining one or two EBTs only.
219,227
 Although this may not affect a 
study’s quality, examining prescribing for more EBTs provides a more complete overview 
of how drugs are prescribed after a particular diagnoses. Using a general drug class such as 
“lipid lowering drugs” may lead to overestimation of prescribing for recommended 
secondary prevention drugs such as statins by including drugs that are not indicated or less 
recommended such as fibrates. Three studies grouped “lipid lowering” drugs including 
statins to examine in the association between age and prescribing of EBTs.
213,222,224
 Finally, 
a number of studies limited their analyses to specific age categories such as those over 64 
years or those less than 75 years of age, limiting the generalisability of the 
results.
215,221,225,226,229
  
In summary, there were a number of limitations in the literature surrounding the 
association between age and the prescribing of EBTs in CHD. There was also a wide range 
in the quality of reporting of studies as assessed by the STROBE guidelines. A few studies 
achieved a quality score of over 70%. These studies, however, were associated with a 
number of limitations that have already been discussed above such as selection bias and 
small sample size. Although the studies by Salomaa et al.
224
 and Simpson et al.
223
 were not 
the best reported studies, they did have a number of strengths over other studies such as 
adequate sample size, a long period of study, wide range of medications and analyses 
adjusted for different confounders. Despite the limitations of the literature, these studies 
demonstrated that older patients are generally less commonly prescribed most EBTs than 
younger patients. 
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Table 1 Inequalities by age in prescribing of EBTs for CHD  
Study Design /year  Age 
range/subject  
Prescribing 
 
Medications 
 
Prescribing 
percentage 
Eldest vs. youngest 
age group 
OR, 95% CI 
Old vs. young 
Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Williams et al215  
 
Ireland  
Cross-sectional 
 
 
1999-2000 
>65 vs. ≤ 65 
 
 
N=15590 
 
From national 
primary care 
prescribing data 
(GMS 
ACEI 
Aspirin 
β-blockers 
Statins 
CCB 
Not reported 1.51 (1.41-1.63) 
0.92 (0.85-0.99) 
0.66 (0.62-0.71) 
0.50 (0.46-0.53) 
1.14 (1.10-1.20) 
Unadjusted  Not reported 
<0.001 
<0.001 
<0.001 
Not reported 
12/22 
 
(54%) 
Maggioni et al218 
 
 
 
 
Italy   
Longitudinal cohort 
 
 
 
 
 
Jan-June 2007 
<50 
 50-59 
 60-69 
 70-79 
 ≥ 80 
 
N= 3078 
Discharge 
records 
(administrative 
data sets)  
Statins  Not reported 1.00 
1.38 (0.78-2.46) 
1.21 (0.72-2.04) 
0.82 (0.50-1.36) 
0.28 (0.17-0.47) 
Unadjusted  Not reported  14/22 
 
(64%) 
Lee H Y et al217 
 
USA 
Longitudinal cohort 
 
 
2003-05 
<40, 45-64, ¶  65-79, 
≥ 80 
 
N=1135 
Following 
patients 
prescription for 3 
months 
ACEI/ARBs 
β-blockers 
Statins  
Not reported 0.47 (0.28-0.78) 
0.25 (0.15-0.42) 
0.27 (0.17-0.45) 
Unadjusted  0.003 
P<0.001 
P<0.001 
14.5/22 
 
(68%) 
Bischoff et al216 
 
 
 
 
 
 
Germany   
Cross-sectional survey 
  
  
 
 
 
 
NA 
18-34,35-44,45-54 
¶,55-64,65-74, ≥ 75 
 
N=6969 
 
Primary care 
datasets 
 
men 
 
Women 
ACEI‡ 
ARBs  
β-blocker 
statins  
 
ACEI‡ 
ARBs  
β-blocker 
statins 
54 vs. 52  
20 vs. 18 
50 vs. 68 
38 vs. 54 
 
48 vs. 42 
17 vs. 15 
45 vs. 55 
34 vs. 39 
Not reported  Unadjusted  Not reported  10/22 
 
(45%) 
Michou et al214 
 
 
 
 
 
 
 
 
Finland  
Longitudinal  cohort 
 
 
 
 
 
 
 
 
2001-04 
 
<30, 30-64 ¶, 65-74 
& ≥ 75 
 
 
Men=581 
 
 
 
 
 
Women=221 
Patient reported  ACEI 
ARBs 
Aspirin 
β-blockers 
CCB 
Clopidogrel 
Nitrates 
Statins 
Warfarin 
 
ACEI 
29.4 vs. 32.1 
8.80 vs. 5.4 
68.6 vs.70.0 
80.4 vs. 79.8 
15.7 vs. 14.3 
3.90 vs. 14.9 
60.8 vs. 26.2 
68.6  vs. 73.8 
29.4  vs. 13.1 
 
18.5 vs. 22.2 
Not reported Unadjusted Not reported 13/22 
 
(59%) 
63 
 
ARBs 
Aspirin 
β-blockers 
CCB 
Clopidogrel 
Nitrates 
Statins 
Warfarin 
17.6 vs. 13.3  
66.7 vs. 51.9 
88.9 vs. 59.3 
29.6 vs. 13.9 
7.40 vs. 8.30 
70.4 vs. 18.5 
55.6 vs. 85.2 
7.40 vs. 10.2 
Ferrari et al213 
 
 
 
 
 
Multi-national  
Prospective 
Longitudinal cohort 
 
 
 
 
Nov 2009-July 10 
<65, 65-74, ≥ 75 
 
 
 
Men  
 
N=33280 
 
Women 
Confirmed by 
physician 
(outpatients 
clinic)  
ACEI 
ARBs 
Aspirin 
β-blockers 
LLD 
Long nitrate  
 
ACEI 
ARBs 
Aspirin 
β-blockers 
LLD 
Long nitrate 
47.0 vs. 55.5 
29.0 vs. 22.1 
79.2 vs. 91.5 
68.4 vs. 78.4 
90.2 vs. 94.2 
26.8 vs. 19.1 
 
39.6 vs. 49.7 
38.5 vs. 27.3 
82.8 vs. 89.1 
69.1 vs. 77.9 
88.5 vs. 90.9 
30.1 vs.23.5 
Not reported Unadjusted Not reported 14/22 
 
(64%) 
Salomaa et al224 
 
 
Finland 
Longitudinal cohort 
 
 
1995-2003 
35-64 
65-74 
 
N=53353 
Within 3 months 
post discharge, 1st 
CHD 
ACEI 
β-blocker 
LLD 
Not reported 1.19 (1.15-1.24) 
0.77 (0.74-0.81) 
0.55 (0.53-0.58) 
Sex, study year, diabetes status 
and university hospital district 
Not reported 13.5/22 
(61%) 
Reid et al228 
 
 
UK  
Cross-sectional  
 
 
1998 
<65 , 65-74 
≥ 75 
 
N=760 
Confirmed by 
patients 
Statins  Not reported 0.75 (0.38-0.85) 
0.11 (0.06-0.21) 
Sex  Not reported  11/22 
(50%) 
Simpson et al223 
 
Scotland  
Cross-sectional   
 
 
1997-2002 
<55, 55-64 
65-74, ≥ 75* 
 
N=14453 
Data obtained 
from GP records  
CMR 
ACEI 
Antiplatelet 
β-blocker 
Statins 
Not reported 0.8 (0.7-0.9) 
1.8 (1.6-2.0) 
0.5 (0.4-0.6) 
0.3 (0.3-0.4) 
Sex, deprivation, diabetes, 
hypertension, heart failure,      
and practice differences  
Not reported 13/22 
(59%) 
Schoenenbe-
rger et al220 
 
Switzerland   
Prospective 
Longitudinal cohort  
 
2001-2006 
<55, 51-60, 61-70, 
71-80 & ≥ 81 
 
N=11930 
At hospital Aspirin  
β-blocker 
Clopidogrel  
87.2 vs. 96.7  
60.0 vs. 78.5 
0.97 (0.96-0.98) 
0.98 (0.98-0.99) 
Sex, comorbidities, and Killip 
class 
p<0.001 
p<0.001 
 
Teeling et al229 
 
Ireland 
Cross-sectional 
 
Jan1998-Dec 2002 
< 65 vs. ≥ 65 ¶ 
 
N=344000 
Post discharge Statins  Not reported 2.16 (2.07-2.25) Sex Not reported 10/22 
 
(45.5%) 
64 
 
Mathur et al222 
 
 
 
UK  
Cross-sectional  
 
 
 
2009-10 
35-44, 45-54, ¶ 55-
64, 56-74, 75-84, ≥ 
85 
 
N=10933 
Collect the last 
drug record in the 
GP 
ACEI/ARBs 
Aspirin 
β-blockers 
LLD 
68.2 vs. 75.4 
86.7 vs. 87.3 
66.7 vs. 80.0 
84.3 vs. 92.8 
0.75 (0.63-0.90) 
1.20 (0.91-1.59) 
0.60 (0.48-0.74) 
0.45 (0.34-0.60) 
Sex, ethnicity, deprivation, 
comorbidity, drug exclusion    
Not reported  15.7/22 
 
(73%) 
DeWilde et al227 
 
England & 
Wales 
Not clear 
 
 
 
1998  
35-44, 45-54, 55-64 
¶, 56-74, 75-84 
 
 
N=30448 
Prescribing data 
from GP   
Statins  10.4 vs. 43.8 0.16 (0.15-0.18)+ 
 
Sex, regional health authority,  
time since diagnosis, smoking 
status   
Not reported  11.5/22 
 
(53%) 
Kassab et al225 
 
 
 
Malaysia 
Cross-sectional 
 
 
 
2009-10 
≥ 65 vs. <65 
 
 
 
N=380 
Clinical records 
for discharge 
medications 
 
1st CHD 
β-blockers 
 
Not reported 0.39 (0.17-0.88) Sex, CHD subtype, diabetes, 
hypertension, hyperlipidaemia, 
current smoking, previous MI,  
CABG, PCI 
0.02 13.5/22 
 
(60%) 
Vermeer et al221 
 
 
Australia  
Cross-sectional 
 
 
4 months  
Jan-April 2007  
>65 vs. ≤ 65 
 
 
 
N=169 
At discharge 
from medical 
records database 
1st CHD 
ACEI/ARBs 
Aspirin/clopidogrel 
β-blockers 
Not reported 0.28 (0.11-0.70) 
0.19 (0.07-0.54) 
0.35 (0.14-0.89) 
Sex, CHD type,  diabetes, 
hypertension, current smoking, 
MI, CABG, PCI 
0.007 
0.028 
0.002 
16/22 
 
(72%) 
Opotowsky et 
al219  
 
USA 
Cross-sectional 
 
 
2000-02 
<65, 65-74¶ 
>75 
 
N=1869 
Confirmed by 
patients 
Aspirin  Not reported 0.74 (0.54-1.01)§ Sex, insurance status, 
education level, ethnicity, 
demographic, diabetes, MI, 
asthma, hypertension 
Not available 17/22 
 
(77.7%) 
Usher et al226 
 
 
 
Ireland  
Cross-sectional  
 
 
January-December 
2001 
65-69, 70-74 
≥ 75 
 
N=9124 
From national 
primary care 
prescribing data 
(GMS) 
ACEI 
ARBs  
β-blocker 
CCB  
Statins  
Not reported 0.99 (0.89-1.12) 
0.83 (0.64-1.07) 
0.57 (0.51-0.64) 
0.86 (0.77-1.00) 
0.34 (0.31-0.39) 
 Sex Not significant 
Not significant 
<0.0001 
Not significant 
<0.0001 
11/22 
 
(50%) 
 
 * presented OR is only for patients over 75 for year 2002, ¶= reference, + Unadjusted OR 0.15 (0.14-0.16), §=after excluding patients with contraindication 0.58 (0.38-0.88), ‡ All results were approximated from the figure and 
first raw for men and the follow raw for women, ǁ patients with contraindication for each drug were excluded from the analysis. GMS=General Medical Services scheme, LLD=Lipid lowering drugs, CABG=Coronary artery bypass 
graft, PCI=Percutaneous coronary intervention,  AF=Arterial fibrillation, PAD= peripheral arterial disease, DM=diabetes mellitus, CKD=chronic kidney disease, COPD= chronic obstructive pulmonary disease, PUD=peptic ulcer 
disease, GERD= gastro-esophageal reflux disease, ADR=adverse dug reaction, LVEF= Left ventricular ejection fraction, PTCA= Percutanous transluminal coronary angioplasty 
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2.4.2 Inequalities by sex in prescribing of EBTs for CHD 
Unadjusted analyses  
Sex inequalities in prescribing of EBTs have been reported in several studies (Table 2, 
unadjusted studies). It has been reported that men are more likely to receive a range of 
EBTs than women.
234-237
 In unadjusted studies the prescription of EBTs including aspirin, 
ACEI/ARBs, β-blockers, statins, clopidogrel, and warfarin was more frequent in 
men.
217,218,238-241
 Only one cohort study of patients with a history of CHD reported an 
opposite trend though it was not statistically significant.
214
  
Adjusted analyses  
In multivariable adjusted analyses, five studies reported that women were less likely to be 
prescribed aspirin than men.
215,219,222,242,243
 After excluding patients with a contraindication 
for aspirin, the difference was attenuated though women remained significantly less likely 
to receive aspirin (OR 0.68; CI 95% 0.48-0.97, p=0.002).
219
 Use of ACEI or ARBs was 
higher among men compared to women in most studies.
215,222,223,226
 However, three studies 
found no statistically significant difference in prescribing of ACEI by sex. Three of these 
studies, however, were limited by a small sample size.
243-245
 In an age-adjusted analysis, 
women were significantly more likely to receive ARBs (OR 1.56; 95% CI 1.28-1.88, 
p<0.0001).
226
 β-blockers were more likely to be prescribed for men than women.215,222-
224,226,243-245
 Similarly, studies reported that men were more likely than women to be 
receiving a statin.
215,221,223,226-229,242-244,246,247
 Two studies reported that women were more 
likely to receive statins, though one was not significant and the other was only adjusted for 
age.
226,244
 Prescribing of CCBs was higher among women in one study (p=0.16).
245
  
Although a number of studies examined differences in EBT use between men and women 
after a diagnosis of CHD, and reported that men are more likely to receive EBTs than 
women, particularly β-blockers and statins, there was wide variation in reporting. Due to 
the variation of the quality of the reporting in the studies the literature was also assessed 
using STROBE checklist. 
 
Limitations in the reporting of the literature 
A number of studies that reported sex inequalities have also been discussed in section 2.4.1 
where they were discussed in relation to prescribing inequalities by age.
214,219,221-224,226-229
  
Therefore the limitations in reporting of the literature will only be discussed in relation to 
literature that was not discussed in section 2.4.1. The score for the literature that described 
66 
 
the association between sex and prescribing of EBTs after CHD ranged from 50% to the 
highest score 72% (Table 2).  
One study did not report the study design either in the title or abstract,
243
 although all other 
studies did. The abstract included and described the background, objectives, methods, 
finding and conclusion in all of the studies. All studies described a clear scientific 
introduction and specific objectives, with the exception of  one study.
246
 Different items 
should be included in the methods section including the study design. All studies reported 
their study design except the study by Doyle et al.
246
 Eligibility criteria determine which 
patients are included in the analyses and these were not described in one study.
241
 Studies’ 
variables including exposure, outcome, predictors and potential confounders were not 
documented in two studies, making interpretation of the results difficult.
245,246
 Doyle et 
al.
246 
did not describe the medications and the diagnoses clearly, i.e. it is not clear whether 
the diagnosis was a new case or prevalent case, definite or suspected. 
Observational studies can be subject to different potential sources of biases. To minimize 
this, the researcher, ideally, should explain for readers what measures have been taken. 
Different types of bias were identified in three of the previous studies
241,246,247
, however, 
only one study explained and discussed those biases.
242
 All studies described the sample 
size and subject recruitment. Studies reported the analysis methods and the type of tests 
that were used including adjustment for possible confounders, however, one study did 
not.
243
  
The number of eligible patients included in the analyses was not mentioned in three 
studies.
238,241,243 
Patient characteristics were not reported in two studies.
238,241
 Moreover, 
three studies neither  explained clearly their study outcomes nor did they report the number 
of outcomes.
238,242,246
 The main finding is usually summarized briefly in the discussion 
section. All except one study discussed the main outcome measure in the discussion.
238
 
Although it is essential to report study limitations to identify any source of potential bias 
and confounding that could have affected results, four studies failed to discuss their 
limitations.
238,241,245,246
 Two studies were limited by selection bias,
242,247
 and one by recall 
bias.
241 
Lack of interpretation and explanation of association between sex inequalities and 
prescribing of EBTs were identified in five studies.
240,241,242,245,247
 Three studies 
acknowledged the financial support for their studies to allow for assessment of potential 
conflicts of interest.
241, 243, 244
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Limitations in the design and analysis of studies included in the literature review 
A number of gaps were also identified in the previous literature. Since the prescribing of 
EBTs is the main focus of these studies, many of the previous studies were limited to one 
or two drugs.
219,221,227,228,229,240,242,246,247
 One study included a wide range of EBTs to 
identify prescribing inequalities by sex. This study, however, was unadjusted and had a 
small sample size. Furthermore, this study obtained data about prescribing of EBTs from 
patient recall leading to “recall bias”.214 This bias was also identified in the study by 
Nilsson et al.
241
 Two studies identified patients with CHD using nitrates and aspirin which 
may be insensitive.
215,226
 Furthermore, these studies were only adjusted for age. Enriquez 
et al.
243
 adjusted their results for various confounders and EBTs but this study examined 
prescribing in small sample sizes and did not report how prescriptions of EBTs were 
obtained. Also, the same study examined prescribing of EBTs based on a single hospital 
database.  
In summary, there were a number of limitations in the literature surrounding the 
association between sex and prescribing of EBTs in CHD. There was also a wide range in 
the quality of reporting of studies as assessed by the STROBE guidelines. Although some 
studies were well reported, they were, however, associated with some limitations. 
Hippisley-Cox et al.
240
 for instance, limited their analyses to unadjusted analyses, and used 
non-specific drug therapy. Ye Xin et al.
247
 had a large sample size in their study and results 
were adjusted for potential confounders, but not deprivation and their study was limited to 
statins. Two studies were reported to a high standard and had a number of strengths over 
other studies.
223,244 
These studies were adjusted for a wide range of confounders, included 
essential EBTs, and used a medical records database to obtain diagnoses and medications. 
The consistent message from these studies was that women are less commonly prescribed 
β-blockers. There were some conflicting results for other EBTs but in general women were 
less likely to receive EBTs than men.  
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Table 2  Inequalities by sex in prescribing of EBTs for CHD 
 
Study Design/year subject   Prescribing Medications Prescribing 
percentage 
Women vs. men 
OR, 95% CI 
Women vs. men 
Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Hippisley-Cox et 
al240 
 
 England 
Cross-sectional  
 
 
  Not reported 
Women=2783 
 
Men=3108 
From GP records  Aspirin 
β-blockers 
LLD 
71 vs. 76 
49 vs. 51  
31 vs. 21 
Not reported  Unadjusted p<0.0001 
0.14 
15.5/22 
 
(70%) 
Michou et al214  
 
 
Finland 
 
Retrospective cohort 
 
2001-04 
Women=221 
 
Men=581 
 
Obtained from 
patients  
ACEI 
ARBs 
β-blockers 
CCB 
Nitrates 
Statins 
Aspirin 
Warfarin 
Clopidogrel  
20.4 vs. 32.9 
12.4 vs. 6.90 
68.3 vs. 80.8 
22.2 vs. 17.4 
36.7 vs. 36.5 
75.6 vs. 69.9 
58.8 vs. 69.7 
10.0 vs. 16.9 
6.80 vs. 11.9 
Not reported  Unadjusted p<0.001 
Not significant 
p<0.001 
Not significant 
Not significant 
Not significant 
p<0.01 
p<0.05 
p<0.05 
13/22 
 
(59%) 
Maggioni et al218 
 
Italy   
Cross-sectional 
 
Jan-June 2007 
N=3078 
 
 
Discharge 
records  
Statins  Not reported  0.71 (0.58-0.88) Unadjusted  Not reported 14/22 
 
(64%) 
Lee H Y et al217 
 
USA 
Cohort   
 
2003-05 
N=1135 
 
 
Following 
patients 
prescription for 3 
months 
ACEI/ARBs 
β-blockers 
Statins 
Not reported  0.80 (0.59-1.08) 
0.97 (0.72-1.31) 
0.65 (0.48-0.87) 
Unadjusted  0.15 
0.83 
0.01 
14.5/22 
 
(68%) 
Brady et al239 
 
UK 
Cross-sectional 
 
4 weeks in Mrch1997, 
and in August 1998 
Women=9898 
 
Men=14533 
 
Practice records  Aspirin 
β-blockers 
statins 
46 vs. 53  
19 vs. 23 
13 vs. 18 
Not reported  Unadjusted Not reported  12/22 
 
(54%) 
Nilsson et al241 
 
Sweden  
Longitudinal cohort 
 
1998, for 3 years 
Follow up  
N=9135  
 
 
At discharge 
patients self-
reported 
ACEI/ARBs 
β-blockers 
LLD 
38.2 vs. 40.6 
86.2 vs. 86.6 
84.6 vs. 82.7 
Not reported    Unadjusted 0.05 
0.56 
0.03 
11.5/22 
 
(52%) 
Bennett et al238 
 
Ireland 
Cross-sectional 
 
 
 
1999-2000 
Women=22524 
 
Men=24751 
 
 
Post discharge ACEI 
Aspirin 
β-blockers 
Statins 
 
37.4 vs. 41.3 
67.7 vs. 74.7 
37.0 vs. 43.0 
28.0 vs. 32.0 
 
Not reported Unadjusted Not reported 13/22 
(59%) 
Williams et al215  
 
 
Ireland 
Cross-sectional 
 
 
 
Women=7839 
 
Men=7751 
 
From national 
primary care 
prescribing data 
(GMS) 
ACEI 
Aspirin 
CCB 
β-blockers 
Not reported  0.83 (0.78-0.89) 
0.72 (0.67-0.78) 
0.89 (0.79-0.89) 
0.84 (0.79-0.89) 
Age  P<0.01 
P<0.01 
P<0.01 
P<0.01 
12/22 
 
(54%) 
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1999-2000  Statins 0.97 (0.91-1.05) Not significant 
Simpson et al223 
 
 
Scotland 
Cross-sectional  
 
 
1997-2002 
N=14435 
 
 
Data obtained 
from GP records  
ACEI 
Antiplatelet 
β-blocker 
Statins 
28.1 vs. 36.2 
70.2 vs. 72.3 
44.1 vs. 50.7 
45.0 vs. 54.6 
0.6 (0.5-0.6) 
0.8 (0.8-0.9) 
0.8 (0.8-0.9) 
0.8 (0.7-0.8) 
Age, deprivation 
comorbidities, and practice 
differences  
Not reported  13/22 
(59%) 
Kattainen et 
al245 
 
 
Finland 
cross-sectional 
 
 
2000-2001 
Women=300 
 
Men=300 
Confirmed by 
patients during 
the interview  
ACEI/ARBs 
CCB 
β-blocker 
LLD 
23.0 vs. 23.4 
22.1 vs. 17.7 
65.6 vs. 69.9 
31.0 vs. 36.8  
Not reported  Age p=0.90 
p=0.16 
p=0.29 
p=0.18 
13/22 
 
(59%) 
Opotwasky et 
al219 
 
USA 
Cross-sectional  
 
 
2000-02 
Women=771 
                         
Men= 1098 
Confirmed by 
patients  
Aspirin  62.4 vs. 75.6 0.62 (0.48-0.79) Age, socioeconomic, 
demographic, diabetes, MI, 
asthma, hypertension  
<0.01 17/22 
 
(77.7%) 
Usher et al226 
 
 
 
Ireland  
Cohort 
 
 
 
2001 
Women=4663 
 
Men=4461 
From national 
primary care 
prescribing data 
(GMS 
ACEI 
ARBs  
β-blocker 
CCB  
Statins  
Not reported  0.83 (0.76-0.91) 
1.56 (1.28-1.88) 
0.97 (0.89-1.05) 
0.97 (0.89-1.05) 
1.15 (1.03-1.23) 
Age  P<0.0001 
P<0.0001 
Not significant 
Not significant 
p<0.05 
11/22 
 
(50%) 
DeWilde et al227 
 
England & 
Wales 
Cross-sectional 
 
 
1998 
N=30448 
 
 
 
Prescribing data 
from GP after 
discharge   
Statins 23.5 vs. 33.2 0.94 (0.88-1.00)* 
 
Age, regional health authority, 
time since diagnosis, smoking 
status   
Not reported 11.5/22 
 
(53%) 
Mathur et al222 
 
 
UK 
Cross-sectional‡  
 
2009-10 
N=10933 
 
 
  
Collect the last 
drug record in 
the GP 
ACEI/ARBs 
Aspirin 
β-blockers 
LLD 
71.2 vs. 79.1 
85.9 vs. 88.9 
70.7 vs. 79.1 
91.6 vs. 93.7 
0.66 (0.60-0.73) 
0.74 (0.66-0.83) 
0.64 (0.57-0.72) 
0.77 (0.66-0.90) 
Age, ethnicity, deprivation, 
comorbidity, drug exclusion    
Not reported  15.7/22 
 
(73%) 
Reid F D A228 
 
 
UK 
1998 
 
 
Cross-sectional 
N=760 Confirmed by 
patients 
Statins  Not reported  0.92 (0.63-1.35) Age 0.68 11/22 
(50%) 
Vermeer et al221 
 
Australia  
Cross-sectional 
 
4 months  
Jan-April 2007  
N=169 
 
At discharge 
from medical 
records database 
statins  Not reported  0.30 (0.10-0.9) 
 
Age group, CHD type,  
diabetes, hypertension, current 
smoking, MI, CABG, PCI 
Not reported 16/22 
 
(72%) 
Salomaa et al224 
 
 
Fenland 
Retrospective cohort  
 
 
1995-2003 
Women=16764 
 
Men= 36589 
 
Post discharge 
within 3 months, 
1st CHD 
ACEI 
β-blocker 
LLD 
Not reported  0.94 (0.90-0.98) 
0.96 (0.91-1.00) 
1.02 (0.98-1.06) 
Age, study year, diabetes 
status and university hospital 
district 
Not reported 13.5/22 
(61%) 
70 
 
 
* Unadjusted OR 0.61 (0.58-0.64), ‡ patients with contraindication for each drug were excluded from the analysis, ± First OR for patients with history of ACS/revascularization (39% of sample size) and second without (61%) of 
sample size, ǁ= men vs. women OR 1.42 (95% CI 1.22-1.65; P< 0.0001),  General Medical Services scheme , LLD=Lipid lowering drugs , CABG=Coronary artery bypass graft, PCI=Percutaneous coronary intervention,  
AF=arterial fibrillation, PAD= peripheral arterial disease, DM=diabetes mellitus, CKD=chronic kidney disease, COPD= chronic obstructive pulmonary disease, PUD=peptic ulcer disease, GERD= gastro-esophageal reflux disease, 
GMS=General Medical Services scheme , ADR=adverse dug reaction , LVEF= Left ventricular ejection fraction, PTCA= Percutanous transluminal coronary angioplasty . 
Ye Xin et al247 
 
 
 
 
 
 
USA 
Retrospective cohort 
study 
 
 
 
 
 
2000-03  
Women=6486 
 
Men=11145 
 
Post discharge 
within 6 months, 
1st CHD 
Statins Not reported  0.85 (0.79-0.9) Age, dyslipidaemia, 
hypertension, diabetes, 
psychosis, comorbidity index, 
count of medication , non-
statins LLD, CHD type, enrol 
type, plan type, co-payment, 
cardiologist visit and year of 
CHD hospitalisation  
Not reported 15.5 
 
(70.5%) 
Enriquez et al243 
 
 
 
 
USA 
Cross-sectional  
 
 
 
 
January-march 2005 
Women=151 
 
Men=153 
 
Not reported ACEI 
Aspirin 
β-blockers 
statins 
55.0 vs. 60.1 
85.4 vs. 91.5 
80.8 vs. 77.8 
78.1 vs. 90.8 
1.00 (0.43-1.57) 
0.16 (0.08-0.32) 
0.18 (0.09-0.35) 
0.30 (0.17-0.52) 
Age, HF,  MI, PCI, CABG, 
cerebrovascular disease, 
hypertension, AF, PAD, 
angina, DM CKD, COPD, 
PUD, GERD, drugs and their 
ADR   
Not significant 
0.001 
0.001 
0.001 
12/22 
 
(55%) 
Bongard et al244 
 
 
 
France 
Cross-sectional  
 
 
 
1998-99 
Women=705 
 
Men=1921 
 
Medical records ACEI 
Antiplatelet 
β-blockers 
statins 
44.3 vs. 39.9 
91.5 vs. 93.4 
63.7 vs. 73.4 
40.7 vs. 47.0 
 
1.06 (0.87-1.29) 
1.01 (0.72-1.41) 
0.82 (0.67-1.01) 
1.15 (0.94-1.42) 
Age, year, hospital, diagnosis, 
history of CHD  factors, 
LVEF after acute coronary 
event, PTCA and CABG 
during hospitalisation 
0.58 
0.96 
0.06 
0.17 
15.25 
 
(69.3%) 
Doyle et al246 
 
Ireland  
Prospective  Cross-
sectional 
2003 
Women=386 
Men=979 
 
On time to 
treatment 
Statins±  Not reported 0.51 (0.27-0.98) 
0.74 (0.99-0.55) 
Age (65 years) and total 
cholesterol level 
0.045 
0.043 
11/22 
 
(50%) 
Teeling et al229 
 
Ireland 
Cross-sectional 
 
Jan1998-Dec2002 
N=2399 
 
 
Post discharge Statins  Not reported 0.96 (0.92-1.01) Age  Not significant 10/22 
 
(45.5%) 
Carroll et al242 
 
 
England 
Cross-sectional 
 
 
Sep 2000-May 01 
Women=2787 
 
Men= 3991 
 
Primary care  Aspirin  
Statin 
58.5 vs. 64.8 
38.2 vs. 49.3 
 
0.92 (0.97-0.78) 
0.94 (0.89-1.00) 
Age  Not reported  16/22 
 
(72%) 
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2.4.3 Inequalities by socioeconomic status in prescribing of EBTs for CHD 
 
Unadjusted analyses  
Many studies have shown that the prevalence,
217
 incidence,
248
 mortality and 
morbidity
249,250
 of CHD are commonly associated with low socioeconomic status.
251
 little 
is known however, about the possible socioeconomic inequalities in prescribing EBTs in 
patients with CHD (Table 3). Three studies reported in unadjusted analyses that those 
living in the most deprived areas were less likely to be treated with any EBTs including 
aspirin, ACEI/ARBs, β-blocker, statins, CCB and clopidogrel.252-254 However, the most 
deprived patients were demonstrated to be more likely to be prescribed a nitrate (48.3 vs. 
52.6%).
254
  
One multi-national study examined differences in prescribing by socioeconomic status.
252
 
It included 153,996 individuals (age from 35-75 years) from 17 countries. From 2005 to 
2009, 5650 patients had been diagnosed of CHD. According to the World Bank 
classification, the PURE study classified countries into four categories: low-income 
countries, upper middle-income countries, lower middle-income countries and high-
income countries. Overall, living in the low-income countries was associated with the 
lowest rate of drug use. The rate of EBTs’ prescription declined with a country’s economic 
wealth. For example, the rate of β-blockers’ prescription in high-income countries was 
64.1%, upper middle-income countries 27.1%, lower middle-income countries 20.1%, and 
11.0% (p < 0.0001) in the lower-income countries. Correspondingly, the use of statins was 
70.9%, 21.1%, 4.9% and 4.5% (p < 0.0001).
252
 However, the use of country level data 
means that this study was limited by the ecological fallacy. The ecological fallacy arises 
from the incorrect assumption that associations at a population level are also true at an 
individual level which may not be the case. Therefore we cannot draw any assumption 
about the relationship between socioeconomic status and the relationship with prescribing 
of EBTs from this study at an individual level.  
Adjusted analyses  
Adjusted analyses did not report such consistent findings. The most deprived patients were 
more likely to receive aspirin or an antiplatelet agent (aspirin or clopidogrel).
222,223
 ACEI 
or ARBs were more often prescribed to the most rather than least deprived patients, though 
the difference was not significant.
222,223
 Simpson et al.
223
 reported that the most deprived 
patients were more likely to be prescribed a β-blocker than the least deprived. In another 
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study, after age and sex adjustment, the most deprived were significantly less likely to 
receive β-blockers.255 In a further study, the socioeconomic differences narrowed after 
adjusting for more covariates.
222
 Lower socioeconomic status was associated with lower 
rates of prescribing of statins.
222,223,255
 However, only one study which was adjusted for sex 
and age reported that those who live in the most deprived areas are significantly less 
commonly prescribed statins than whose live in the least deprived areas.
255
 
Few studies examined the relationship between socioeconomic status and the prescribing 
of EBTs following a diagnosis of CHD. Different health systems associated with different 
strategies in providing health care, particularly prescribing medications after a diagnosis of 
a chronic disease such as CHD. In Scotland, medications are provided freely for such 
patients but in some other countries different strategies of payment methods such as co-
payment strategy have been adopted (Table 3). 
 
Limitations in the reporting of the literature 
 The quality of the reporting of studies describing the association between socioeconomic 
status and prescribing of EBTs was assessed using STROBE checklist, and ranged from 
50% to 75%. Only one study did not mention the study design in the title or abstract.
255
 All 
studies described a scientific background and the rationale for the study to be conducted. 
Specific objectives were mentioned in all studies. However, this was not described clearly 
in one study.
254
 Exposures and outcome variables including confounders were not 
described clearly in two studies, 
228,255
 but other studies described these variables in the 
methods. None of the previous studies explained or described the sources of potential bias 
in the methods. Two studies were identified by the authors as suffering from potential 
selection bias
252
 and recall bias.
253
 One study did not describe how they performed the 
statistical analysis of their data.
228
 Further analyses including subgroup analyses, 
interaction or sensitivity analyses were only described in two studies.
222,252
 All studies 
reported the number of eligible individuals included in the analyses. The demographic or 
clinical characteristics were not described in one study.
255
 All previous studies presented 
their results in the format of proportions or odds ratios and none of them conducted 
unadjusted analyses. Moreover, two studies did not describe the limitations of their study.
 
223,254
  
Limitations in the design and analysis of studies included in the literature review 
Although a few studies were identified as examining the association between prescribing 
EBTs and socioeconomic status, a number of limitations were noted. Adjustments for 
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confounders were not comparable as these studies were unadjusted and only reported the 
proportional differences in prescribing EBTs between the social classes.
252,253,254
 Two 
studies that examined prescribing inequalities used patient self-report databases which may 
lack accuracy and have recall bias. In addition, most studies examined prescribing 
inequalities based on one measurement of deprivation, e.g. income.
252,253,254,255,228
 Two 
studies
222,223
 avoided these limitations by adjusting their results for multiple confounders 
and examining socioeconomic status using deprivation measurements based on different 
domains such as income and education. One of these two studies,
222 
however, was limited 
by selection bias as they excluded patients who were unable to tolerate the medication’s 
side effects. 
In summary, there were a number of limitations in the literature surrounding the 
association between socioeconomic status and the prescribing of EBTs in CHD. There was 
also a wide range in the quality of reporting of studies as assessed by the STROBE 
guidelines. Although studies by Mathour et al.
222 
and Simpson et al.
223 
were
 
associated 
with limitations, these well reported and designed studies were adjusted for different 
confounders and used a domain measurement instead of a single measurement. These 
studies generally reported that the most deprived patients were less likely to be prescribed 
EBTs.  
74 
 
Table 3 Inequalities by socioeconomic status in prescribing in EBTs for CHD  
Study Design /year/ 
subject   
 
Reference  Prescribing/ 
Deprivation 
measure 
Medications 
 
Prescribing 
percentage 
Affluent vs. deprived 
OR, 95% CI 
Affluent vs. 
deprived 
Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Yusuf et al252 
 
 
 
17 countries 
Longitudinal cohort 
study 
 
 
2005-2009 
High-income countries 
vs. Low-income 
countries  
 
N=5650 with CHD 
Patients self-
reported  
 
World bank 
classification 
ACEI/ARBs 
Antiplatelet 
CCB 
β-blocker 
Statins  
51.7 vs. 6.50 
64.1 vs. 11.0 
22.4 vs. 7.30 
46.5 vs. 11.1 
70.9 vs. 4.50 
Not reported  Unadjusted <0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
16.5/22  
(75%) 
Niu et al253 
 
 
 
China  
Cross-sectional 
 
 
 
March-June 2006 
High-income vs. Low-
income  
 
N=2278 
 
Confirmed by 
patients  
 
Income 
ACEI/ARBs 
Aspirin  
Clopidogrel 
β-blockers 
Statins 
63.8 vs. 53.6 
87.8 vs. 80.2 
33.3 vs. 13.4 
67.8 vs. 56.2 
68.6 vs. 44.3 
Not reported Unadjusted <0.05 
<0.05 
<0.05 
<0.05 
<0.05 
14.0/22 
 
(63%) 
Munoz et al254 
 
 
 
Spain  
Cross-sectional  
 
 
1999-2000 
Within 6 years prior 
to study conducted 
Social class I&II+ Vs.  
Social class IV-V  
 
N=878 
From medical 
records  
 
Occupational 
measure  
ACEI 
Antiplatelet  
CCB 
β-blockers 
LLD 
Nitrates 
35.0 vs. 28.2 
80.0 vs. 79.6 
35.0 vs. 42.8 
50.0 vs. 36.4 
35.0 vs. 42.8 
48.3 vs. 52.6 
Not reported    Unadjusted 0.39 
0.87 
0.45 
0.12 
0.27 
0.81 
16.5/22 
 
(75%) 
Reid F D A et 
al228 
 
UK 
Cross-sectional  
 
1998 
Non-manual vs. 
manual  
 
N=760 
Confirmed by 
patients 
 
Occupation 
Statins  Not reported  1.24 (0.85-1.82) Sex and age  Not reported  11/22 
(50%) 
Odubanjo et 
al255 
 
 
Ireland  
Cross-sectional 
 
 
 
July 2001-december 
2002 
Relatively affluent 
vs. Relatively deprived 
 
Deprived=66521 
Affluent=28534 
From national 
primary care 
prescribing data 
(GMS) 
 
Income  
β-blockers 
 
statins 
54.0 vs. 49.0 
48.0 vs. 43.0 
1.17 (1.07-1.29) 
 
1.22 (1.11-1.35) 
 
Age and sex  <0.001 
<0.001 
12/22 
(54.5%) 
Simpson et 
al223 
 
 
Scotland  
Cross-sectional  
 
 
 
1997-2002 
Least deprived vs. 
Most deprived 
 
N=14435 
 
Data obtained 
from GP 
records  
 
SIMD 
ACEI* 
Antiplatelet* 
β-blocker* 
Statins* 
Not reported  0.9 (0.71-1.25) 
0.9 (0.71-1.25) 
0.9 (0.71-1.25) 
1.11 (0.9-1.40) 
Sex, age, comorbidities, 
and practice differences  
Not reported  13/22 
(59%) 
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Mathur et al222 
 
 
 
 
UK  
Cross-sectional¶  
 
 
2009-10 
least deprived  vs. 
Most deprived 
 
N=10933 
 
Collect the last 
drug record in 
the GP 
 
Townsend 
score 
ACEI/ARBs 
Aspirin 
β-blockers 
LLD 
74.5 vs. 77.0 
87.6 vs. 89.7 
77.2 vs. 76.2 
93.0 vs. 93.0 
0.90 (0.75-1.09) 
0.83 (0.66-1.04) 
1.11 (0.91-1.33) 
0.97 (0.73-1.28) 
Sex, age, ethnicity, 
comorbidity, drug 
exclusion    
Not 
reported  
15.7/22 
 
(73%) 
 
* OR is only for patients over 75 for year 2002. Result for year 2002. ¶ Patients with contraindication or not tolerated the drug were excluded from the analysis, + Social class I&II= professional and intermediate occupations,  
social class IV-V= unskilled and manual occupation, SIMD= Scottish Index of Multiple deprivation, LLD=Lipid lowering drug
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2.4.4 Trends in prescribing of EBTs for CHD 
Since 1990 the rate of prescribing EBTs has generally improved but the improvement has 
not been the same for all drugs and for some drugs prescription rates have fallen (Table 4). 
The few studies that examined trends in prescribing EBTs all reported that the prescribing 
of aspirin, ACEI, ARBs and β-blockers increased moderately across the study years.256-259 
The majority of previous studies demonstrated the proportion of patients prescribed EBTs 
but only two studies used multivariable models to test the trends in prescribing.  
 
Bennett et al.
256
 examined the trends in prescribing for patients diagnosed with CHD from 
1990 to 2002 using the general medical services prescription database. In this study, 
patients with CHD were identified based on nitrate and aspirin prescription. This study 
showed that prescribing of statins was very low during the early 1990s, which was 
supported by two other studies
257,258
 that used prescribing data between 1994 and 2002. 
Since 1994 the prescribing of statins has increased dramatically. In a multinational 
European study (EUROASPIRE I & II), two cohorts of patients (between 1995 and 1996, 
and 1999 and 2000) diagnosed with CHD were compared with respect to prescribing of 
EBTs after a diagnosis of CHD. Prescriptions after diagnosis were obtained either from 
medical records or patients’ self-reporting. In this study, the prescribing of EBTs increased 
over the time particularly for statins which increased approximately by 40% between 1995 
and 2000.
259
 While statins were the drugs most commonly examined, all drugs classes 
demonstrated a rise in prescribing rates over time with the exception of one study that 
reported a falling rate of prescribing for CCBs. 
256
 
 
In studies that were adjusted for other confounders, this rising rate of statin prescribing was 
still evident.
229,247
 In an age-adjusted study,
229 
it was shown that the prescribing of statins 
significantly increased over the time between 1998 and 2002. Ye Xin et al.
247
 followed 
statin prescriptions for six months after first diagnosis and showed that those more recently 
diagnosed with CHD were more likely to be prescribed statins.
247
 
 
Limitations in the reporting of the literature 
A small number of studies were identified that examined the prescribing trend after 
diagnosis with CHD. The quality of the reporting of studies describing the prescribing 
trends over the time was also assessed by using STROBE checklist and ranged from 50% 
and 75%. All studies provided a clear summary in the abstract including background, 
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methods, results and conclusion. One study indicated the study design in the abstract.
247 
Rayn et al.
258 
did not state a specific objective for their study. The method section in a 
scientific paper should provide a clear description of how the study has been conducted 
including the study design e.g. cross-sectional, prospective or retrospective longitudinal 
cohort study. However only  three studies described that in their methods.
247,256,260 
All 
previous studies described the setting and the date of their study. Eligibility criteria of 
patients’ recruitment was not described in one study.260 Birkhead et al .260 did not describe 
the variables that were included in the analyses clearly. However, this is the only study that 
addressed the potential source of bias in their methods. Two studies did not state how the 
sample size approached the final number that was included in the analyses.
256, 258 
 
 
Statistical methods were described in all studies but Rayn et al.
258
 did not describe how the 
analyses were carried out. Furthermore, none of the previous studies described further 
analyses or explained how missing data were addressed. Four studies did not report the 
number of eligible patients included in the study nor the reasons for those who were 
excluded from the analyses.
229,257,256, 258
 Teeling et al.
229
 did not confirm the number of 
patients prescribed statins. The author, however, just described the trends ratio. All 
previous studies summarised their study key results in the discussion, however, one study 
did not do that.
256 
Although it is important to discuss the study limitations including the 
source of potential bias and confounding that could have affected results, three studies 
failed to discuss their limitations.
256,259,260
 Two studies explained and interpreted the 
outcome and described the reasons for trend improvement.
259,260 
None of the previous 
studies discussed the possibility of their outcome generalisability. Three studies 
acknowledged the financial support for their studies.
 229,257,258
  
 
Limitations in the design and analysis of studies included in the literature review 
A number of gaps and limitations were also identified in the previous literature. Two 
studies did not use updated data which did not represent the current clinical prescribing of 
EBTs. Only two studies described the association between the prescribing of EBTs with 
year using adjusted analyses. One of these adjusted analyses was only adjusted for age. 
Two studies were limited by the validity of the diagnosis of CHD using prescription of 
nitrates or aspirin as a proxy for a  diagnosis of CHD.
229,256 
Selection bias  was identified in 
one study, excluded patients who died during the study.
258
 One study was limited by recall 
bias as noted before in the study by Bennett et al.
256
 No studies reported adjusted rates of 
prescribing of drugs other than statins.  
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In summary, a number of limitations were identified in the previous studies surrounding 
the association between trend and prescribing EBTs after CHD. Also, there was a variation 
in the quality of reporting of studies as assessed using STROBE guidelines. Although the 
study by Birkhead et al.
260
 was not very well reported, this study included a wide specific 
range of EBTs, used electronic data sets collected between 2000 and 2003, and had a large 
sample size. This study demonstrated that the prescribing of EBTs has improved over time.  
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Table 4 Trends in prescribing of EBTs for CHD 
Study Design/year Reference Prescribing Medications Prescribing 
percentage 
OR, 95% CI Adjustment  P values / 
statistical 
significance   
STROBE 
Score 
(%) 
DeWilde et al257 
 
 
UK 
Cross-sectional 
 
 
 
1994-2005 
1994 vs. 2005 
 
 
Men=30000 
 
UK primary care 
database 
ACEI 
Antiplatelet 
β-blockers Statins 
13.5 vs. 57.0  
31.0 vs. 75.0 
29.0 vs.55.0 
4.00 vs. 80.0 
Not reported  Unadjusted Not reported 11.5/22 
 
(53%) 
   
Women= 21000 
 ACEI 
Antiplatelet 
β-blockers Statins 
12.0 vs. 51.0 
37.0 vs. 74.0 
25.0 vs. 48.0 
3.00 vs. 70.0 
    
Bennett et al256 
 
Ireland 
Cross-sectional 
Not report subject 
 
1990-2002 
1990 vs. 2002 
 
 
 
From national 
primary care 
prescribing data 
(GMS) 
ACEI 
β-blockers 
CCB 
Statins* 
8.00 vs. 35.0 
37.0 vs. 55.0 
55.0 vs. 35.0 
6.00 vs. 55.0 
Not reported  Unadjusted Not reported  11/22 
 
(50%) 
Ryan et al258 
 
 
 
England & 
Wales 
Cross-sectional 
 
 
1994-1998  
1994 vs.1998  
 
 
 
Men= 18485 
Obtained from 
GP database 
General practice 
research database 
(GPRD) 
Aspirin 
Statins  
46.3 vs. 61.5  
4.2   vs. 29.0 
Not reported  Unadjusted Not reported  10/22 
 
(45%) 
  Women= 15407  Aspirin  
Statins 
36.0 vs. 53.4 
3.00 vs. 18.9 
    
EUROASPIRE I 
& II259 
 
 
 
 
9 countries 
Retrospective/prospect
ive patients interview 
 
 
1995-1996 
 
1999-2000 
EUROASPIRE I 
Vs. II 
 
 
N=3569 
 
N=3379 
Medical records 
and patients 
ACEI 
Antiplatelet 
β-blockers 
statins 
29.5 vs. 42.7 
81.2 vs. 83.9 
53.7 vs. 66.4 
18.5 vs. 57.7 
Not reported  Unadjusted Not reported  14.2/22 
 
(65%) 
Birkhead et al 260 
 
England & 
Wales  
Observational Study  
 
2000-2003 
2000 vs. 2003 
 
N=156902 
 
At discharge, 
MINAP dataset 
ACEI 
Antiplatelet 
β-blockers 
Statins 
62.4 vs. 72.4 
89.3 vs. 90.2 
76.3 vs. 82.6 
69.6 vs. 83.8 
Not reported  Unadjusted Not reported  12.5/22 
 
(54.5%) 
Ye Xin et al247 
 
 
Retrospective cohort 
study 
 
2001 vs. 2000 
2002 vs. 2000 
2003 vs. 2000 
Post discharge 
within 6 months, 
1st CHD 
Statins Not reported  1.28 (1.17-1.40) 
1.47 (1.34-1.60) 
1.77(1.61-1.94) 
Age, sex, dyslipidaemia, 
hypertension, diabetes, 
psychosis, comorbidity index, 
<0.001 15.5/22 
 
(70.5%) 
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USA 
 
 
 
2000-03  
count of medication , non-
statins LLD, CHD type, enrol 
type, plan type, copayment, 
cardiologist visit and year of 
CHD hospitalisation 
Teeling et al229 
 
 
 
 
Ireland 
Cross-sectional 
 
 
 
 
Jan1998-Dec2002 
1999 vs. 1998 
2000 vs. 1998 
2001 vs. 1998 
2002 vs. 1998 
 
N=344000 
From national 
primary care 
prescribing data 
(GMS) 
 
Statins  Not reported 1.47 (1.36-1.58) 
1.95 (1.82-2.08) 
2.63 (2.46-2.80) 
3.76 (3.52-4.00)  
Age  <0.0001 10/22 
 
(45.5%) 
 
 LLD=Lipid lowering drugs, GMS=General Medical Services prescription database, * The trend starts from 1994, at the time of date study 1990 prescribing of statins was 0.00. 
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2.4.5 Inequalities in prescribing of EBTs for CHD by comorbidities 
The presence of other comorbidities disease in patients with CHD may influence 
prescribing rates of EBTs. A number of studies examined the prescribing of EBTs in 
patients with CHD according to the presence of comorbidities (Table 5). 
Unadjusted analyses  
In unadjusted analyses prescribing rates of aspirin were lower in patients with renal failure 
(RF).
261
 Two studies reported small differences in aspirin (or any antiplatelet agent) 
prescription rates between diabetic and non-diabetic patients.
262-264
 Contrary to this, in one 
study, patients identified as having CHD based on nitrate prescriptions, patients with 
diabetes were significantly more likely to receive aspirin compared to non-diabetics (OR 
1.23; 95% CI 1.09-1.38, p<0.001).
265
 ACEI or ARBs were more frequently prescribed for 
patients with RF or diabetes.
261-265
 The prescriptions of β-blockers were less common 
among patients with diabetes or RF,
261-265
 however, one study reported that patients with 
diabetes were as likely to be prescribed a β-blocker compared to those without.263 In an 
unadjusted study, patients with hypertension (HTN) were more likely to be prescribed a 
statin but no differences were seen in those with diabetes or PAD.
218
 Other studies have 
reported that patients with diabetes are more likely to be prescribed a statin.
262,266
 In 
contrast, prescribing of statins was lower in patients with RF (77.2 vs. 80.6%).
261
 The 
proportion of patients prescribed a CCB was higher for patients with diabetes (40.1 vs. 
35.5%) and RF (29.3 vs. 23.2%).
261,262
 Patients with RF were more likely to be prescribed 
nitrates (53.5 vs. 50.6%), though patients with diabetes were less likely to be prescribed 
nitrates (38.8 vs. 41.5%).
261,264
  
Adjusted analyses  
In adjusted analyses patients with the comorbidities of diabetes or HTN were more likely 
to be prescribed aspirin compared with patients without these comorbidities.
219,222
 
However, patients with RF or asthma were less likely to receive aspirin.
219,267
 Similar to 
unadjusted studies, patients with diabetes were more commonly prescribed 
ACEI/ARBs,
224,266,268,269
 but patients with RF were less likely to be prescribed 
ACEI/ARBs.
225,267
 Vehoke et al.
269
 and Mathur et al.
222
 reported that β-blockers were more 
commonly prescribed for patients with diabetes, though not all studies reported this 
finding.
224
 As expected, β-blockers were less commonly prescribed for patients with 
asthma or chronic obstructive pulmonary disease (COPD).
225
 In conflicting studies statins 
were shown to be less often prescribed for patients with diabetes, RF and HTN,
247
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however, in another study statins were prescribed more frequently in those with diabetes 
and hypertension.
228
 
A number of studies examined the relationship between comorbidities and the prescribing 
of EBTs in those with a diagnosis of CHD. In different observational study designs, the 
majority of previous studies examined the association between diabetes and prescribing 
EBTs in those with a diagnosis of CHD. This may be because it is known that diabetes is a 
strong predictor for poor outcome in CHD. However, there are many other comorbidities 
that may lead to a contraindication in prescribing of cardiovascular secondary prevention 
protective therapy or reduce the likelihood of the medication being prescribed, such as 
asthma or renal failure. Few studies examined comorbidities other than diabetes. 
 
Limitations in the reporting of the literature 
The quality of the reporting for most of the studies in Table 5 has been discussed 
previously with regard to age, sex and socioeconomic status, therefore I will focus on 
studies that have not been discussed yet.
261,263,265,267,269
 The STROBE scores for literature 
that described the association between comorbidities
267
 and the prescribing of EBTs ranged 
from 54% to 66% (Table 5). The abstracts provided a clear summary of what had been 
done including the study design, however, three studies did not use common terms to 
indicate their study design.
261,267,269
 A scientific background was detailed, providing 
information about what had been done previously in all studies except in the reports from 
Lahoz et al.
261
 Pyorala et al.
266
 All previous studies described the study setting, the date of 
recruiting the sample, and the eligibility criteria of patients included in the analyses. 
However, two studies did not describe the variables included in the analyses clearly, 
including the outcomes, exposures and potential confounders.
266,267 
Potential sources of 
bias were not addressed in any of the studies. All studies described their statistical 
methods, but none of them described any further analyses such as examining subgroups 
and interaction, sensitivity analysis or how missing data were addressed. The number of 
patients who were potentially eligible for analysis was not reported in two studies.
265,269
 
Two studies discussed the reasons for excluding patients from their analyses.
263, 267
 Han et 
al.
267
 is the only the study that used a flow diagram to describe eligible patients included in 
the study, and reasons for excluding patients. The number of patients with comorbidities 
who were prescribed any EBTs was not reported in two studies,
261,267
 and unadjusted 
analyses were only reported in one study.
 267
 Three studies failed to discuss their study’s 
limitation and the potential source of bias.
261,263,265
 However, two studies were identified 
with selection bias.
263, 267
 Only one study discussed the generalisability of the study result.  
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Limitations in the design and analysis of studies included in the literature review 
A number of other limitations were identified in the literature. The main issue was that 
studies were limited to examining the association between prescribing of EBTs and only 
one comorbidity such as renal failure or diabetes.
222,224,265,269,270
 The lack of range of 
comorbidities makes assessment of the relative prescribing patterns difficult. Different 
studies with their different eligibility criteria, adjustment for other factors and other biases 
make it hard to compare studies. Studies were limited to examining one or two EBTs only 
and did not examine the range of EBTs indicated for CHD.
218,219,228,247
 The validity of the 
diagnosis of CHD was also poor in some studies that relied on the proxy measure of a 
prescription of nitrates. One study used a prescription of insulin to define the comorbidity 
of diabetes. 
265
 While this may be acceptable for type 1 diabetes where all patients require 
insulin it is not sensitive for type 2 diabetes. This is important as the most common form of 
diabetes in the population with CHD is type 2 diabetes. Furthermore, two studies did not 
describe how the diagnosis of a comorbidity was defined.
265,270
 
 
In summary, there were a number of limitations in the literature surrounding the 
association between comorbidities and prescribing of EBTs in CHD. There was also a wide 
range in the quality of reporting of studies as assessed by the STROBE guidelines. 
Although Vehok et al.
269
 is not the best reported study, this study obtained data from a 
national social insurance database and it examined a wide range of EBTs, using adjusted 
analyses to report the results. This study demonstrated that patients with diabetes generally 
are more commonly prescribed EBTs than those without diabetes.  
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Table 5 Inequalities in prescribing of EBTs for CHD by comorbidities 
Study Design/year/ subject Reference  Prescribing 
 
Medications 
 
Prescribing 
percentage 
OR, 95% CI Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Vehok et al269 
 
 
 
Finland  
Cross-sectional 
 
Men (N)=43501 
 
1997-2002 
DM vs. Not 
 
 
Obtained from data 
after discharge 
 
1st diagnosis 
ACEI 
ARBs  
β-blockers 
LLD 
Not reported 1.10 (1.04-1.17)* 
1.10 (0.99-1.23)* 
1.02 (1.00-1.05)* 
0.94 (0.90-0.98)* 
 
Age, income, myocardial 
infarction and previous use of 
drugs.  
Not reported 14.5/22 
 
(66%) 
 Women (N)=31125 
 
DM vs. Not  
 
 
 ACEI 
ARBs  
β-blockers 
LLD 
Not reported 1.17(1.09-1.26)* 
1.13(1.01-1.26)* 
1.02(0.99-1.05)* 
0.97(0.92-1.02)* 
 Not reported  
Han et al267 
 
 
 
USA 
 Cross-sectional 
 
N=6560 with RF 
 
Jan 2001-Dec 2003 
RF vs. Not 
(in patients with non-
ST segment 
elevation)  
 
At discharge  ACEI 
Aspirin 
β-blockers 
LLD 
59.8 vs. 61.1 
86.9 vs. 90.7 
84.7 vs. 83.8 
79.1 vs. 80.6 
0.76 (0.69-0.83)‡ 
0.82 (0.75-0.89) 
1.01 (0.93-1.10) 
0.93 (0.84-1.04) 
 
Age, sex, BMI, race, family 
history of CAD, HTN, DM, 
smoking status, prior MI, PCI, 
CABG, CHF, positive cardiac 
markers,   
Not reported 14/22 
(61.3%) 
Ye Xin et al247 
 
 
 
 
 
 
USA 
Retrospective cohort 
study 
 
Men (N)=11145 
Women(N)=6486 
 
 
2000-03  
HTN vs. Not 
 
DM  vs. Not 
 
RF  vs. Not 
 
 
Post discharge 
within 6 months,  
 
1st CHD 
Statins Not reported 0.69 (0.90-1.02)¶ 
 
0.99 (0.91-1.08) 
 
0.79 (0.62-1.00) 
 
Age, sex, dyslipidaemia, 
hypertension, diabetes, psychosis, 
comorbidity index, count of 
medication , non-statins LLD, 
CHD type, enrol type, plan type, 
copayment, cardiologist visit and 
year of CHD hospitalisation  
0.16 
 
0.80 
 
0.053 
15.5/22 
 
(70.5%) 
Mathur et al222 
 
 
UK  
Cross-sectional  
N=10933 
 
2009-10 
DM vs. Not 
 
 
 
Collect the last drug 
record in the GP 
 
ACEI/ARBs 
Aspirin 
β-blockers 
LLD 
Not reported 2.92 (2.60-3.28) 
1.43 (1.25-1.63) 
1.90 (1.06-1.33) 
2.84 (2.25-3.58) 
Sex, age, ethnicity, deprivation, 
comorbidity, drug exclusion    
Not reported 15.7/22 
 
(73%) 
Reid F D A et 
al228 
 
 
  UK 
Cross-sectional  
N=760 
 
 
1998 
DM   vs. Not 
HTN vs. Not 
 
 
Confirmed by patients Statins  Not reported 1.23 (0.72-2.12) 
1.09 (0.74-1.59) 
Sex and age Not reported 11/22 
(50%) 
Kassab et al225  
 
Malaysia 
Cross-sectional 
 
 
N=380 
 
2009-10 
RF vs. Not 
 
 
Asthma/COPD vs. 
Not 
 
Clinical records for 
discharge medications 
ACEI/ARBs 
statins 
 
β-blockers 
 
 
Not reported 0.55 (0.3-1.002) 
4.85 (1.5-15.50)   
 
0.07 (0.018-0.27) 
 
 
Age group, sex, CHD subtype, 
diabetes, hypertension, 
hyperlipidaemia, current 
smoking, previous MI,  CABG, 
PCI 
0.049 
0.008 
 
<0.001 
 
 
13.5/22 
 
(60%) 
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Salomaa et al224 
 
Finland 
Cross-sectional  
N=53353 
 
1995-2003 
DM vs. Not 
 
 
 
Within 3 months post 
discharge,  
 
1st CHD 
ACEI 
β-blocker 
LLD 
Not reported 1.89 (1.81-1.99) 
0.83 (0.79-0.88) 
0.82 (0.78-0.86) 
Age, sex, study year, and 
university hospital district 
Not reported 13.5/22 
(61%) 
Opotowsky et 
al219  
 
 
 
USA 
Cross-sectional 
 
N=1869 
 
 
2000-02 
DM vs. Not 
 
Asthma vs. not  
 
HTN vs. Not 
 
Confirmed by patients Aspirin  72.1 vs. 69.8 
 
61.2 vs. 71.9 
 
72.1 vs. 66.1 
1.15 (0.87-1.52)ǁ 
 
0.72 (0.52-1.00)ǁ 
 
1.50 (1.16-1.95)ǁ 
Age, socioeconomic, 
demographic, diabetes, MI, 
asthma, hypertension 
Not reported 17/22 
 
(77.7%) 
Bennett et al265 
 
 
 
Ireland 
Cross-sectional 
 
N=14826 
 
1999-2000 
DM vs. Not 
 
 
 
National primary care 
data base  
GMC 
 
ACEI 
ARBs 
Aspirin 
β-blockers 
statins 
Not reported 3.09 (1.30-1.61) 
1.47 (1.13-1.87) 
1.23 (1.09-1.38) 
0.82 (0.74-0.91) 
1.44 (1.30-1.61) 
Unadjusted  <0.0001 
<0.05 
<0.001 
<0.001 
<0.0001 
13.5/22 
 
(61.3%) 
Pyorala et al266  
(EUROASPIREII
) 
 
 
15 Countries  
Cross-sectional 
 
 
N=5556 
 
1999-2000 
DM vs. Not 
 
 
Patients with 
diabetes=1086 
 
Medical records and 
patients 
ACEI 
ARBs 
Antiplatelet 
CCB 
β-blockers 
statins 
49.2 vs. 35.3 
5.20 vs. 3.20 
83.4 vs. 86.4 
31.4 vs. 24.8 
62.1 vs. 63.0 
54.0 vs. 55.6 
Not reported Age, sex, diagnostic category 
and centre 
<0.001 
0.08 
0.008 
0.005 
0.84 
0.92 
12.5/22 
(57.0%) 
EUROASPIREII) 
 
 
9 Countries 
N=3374 Patients with 
diabetes=740 
 ACEI 
Antiplatelet 
CCB 
β-blockers 
statins 
52.0 vs. 40.0 
82.2 vs. 84.3 
32.0 vs. 24.2 
66.0 vs. 66.5 
56.8 vs. 57.9 
Not reported Unadjusted  Not reported  
EUROASPIRE I 
 
 
9 Countries 
N=3569 
 
 
 
1995-96 
DM vs. Not 
 
Patients with 
diabetes=641 
 
Medical records and 
patients 
ACEI 
Antiplatelet 
CCB 
β-blockers 
statins 
43.2 vs. 26.5 
81.8 vs. 81.0 
40.1 vs. 35.5 
52.0 vs. 54.0 
14.0 vs. 19.5 
Not reported Unadjusted  Not reported  
Maggioni et al218 
 
 
 
  
Italy  
Cross-sectional 
 
 
N=3078 
 
 
Jan-June 2007 
DM vs. Not 
 
HTN vs. Not 
 
PAD vs. Not 
 
 
Discharge records  Statins  Not reported 1.20 (0.95-1.51) 
 
2.30 (1.76-3.02) 
 
1.06 (0.48-2.35) 
Unadjusted  Not reported 14/22 
 
(64%) 
Mostaza-Prieto et 
al263 
 
Cross-sectional 
 
N=6568 
 
DM vs. Not§  
 
Patients with 
RF=2130 
After discharge from 
case note 
ACEI/ARBs 
Antiplatelet/ 
anticoagulant 
β-blocker 
73.8 vs. 61.5 
90.4 vs. 89.2 
 
49.2 vs. 49.4 
Not reported  Unadjusted  <0.001 
NS 
 
NS 
14/22 
 
(63.3%) 
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Spain 
2004 (6 months) LLD 88.4 vs. 86.2 <0.001 
 N=8817 Patients with 
RF=2884 
 CEI/ARBs  
Antiplatelet 
Aspirin  
β-blocker 
CCB 
LLD 
Statins 
73.5 vs. 61.0 
80.2 vs. 80.2 
62.5 vs. 62.3 
45.4 vs. 47.7 
29.8 vs. 21.9 
81.1 vs. 80.3 
79.5 vs. 78.9 
  <0.001 
 
 
0.048 
<0.001  
 
Lahoz et al261 
 
Spain  
Cross-sectional 
 
RF=1766 
 
July-Sep 2004 
RF vs. Not 
 
 
 
Clinical case note at 
discharge time  
ACEI 
ARBs 
Aspirin 
CCB 
β-blockers 
nitrates  
statins 
44.8 vs. 38.5 
73.3 vs. 63.5 
58.7 vs. 63.9 
29.3 vs. 23.2 
41.3 vs. 49.0 
53.5 vs. 50.6 
77.2 vs. 80.6 
Not reported  Unadjusted  Not reported 12/22 
 
(54.5%) 
Sharma et al264 
 
India 
Audit 
 
 
2007-08 
DM vs. Not  Case record form ACEI/ARBs 
Aspirin 
β-blockers 
nitrates  
statins 
86.4 vs. 82.1 
88.7 vs. 88.3 
59.4 vs. 69.2 
38.8 vs. 41.5 
67.1 vs. 59.7 
Not reported  Unadjusted  Not reported  
 
*Result for year 2001-2002, and value are risk ratio. ‡Unadjusted OR 0.92 (0.84-1.00), 0.66 (0.61-0.73), 1.00 (0.92-1.09), 0.87 (0.79-0.96). ¶ Univariate OR 0.89 (0.84-.94; 0.001), 0.79 (0.74-0.85), 0.48 (0.39-0.58) p=0.001, ǁ After 
excluding patients with contraindication 1.45 (0.97-2.16), 0.78 (0.52-1.18), 2.08 (1.48-2.93). §=Exclude patients with contraindication to any of these drugs or patients with adverse effect.
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2.5 Inequalities in prescribing of EBTs for MI  
After experiencing a MI a number of medications have been shown to improve outcomes. 
Unless contraindicated, patients should be discharged from hospital with these medications 
including an antiplatelet agent (aspirin or clopidogrel), an ACEI or ARB, a β-blocker and a 
statin. 
2.5.1 Inequalities by age in prescribing of EBTs for MI 
Unadjusted analyses 
Older patients with MI less commonly undergo cardiac procedures and they receive 
suboptimal treatment with EBTs compared to younger patients.
271,272
 Older patients are 
less commonly treated with β-blockers273,274 and aspirin,275 despite evidence that secondary 
prevention reduces mortality post-MI.
124,127,276
 However, older patients are more likely to 
be prescribed ACEI than younger patients,
277-279
 though some have showed no difference 
(Table 6, unadjusted studies).
280
 In one  study,
279
 age was stratified by sex and there was no 
difference in prescribing of ACEI by age in either sex. β-blockers were less often 
prescribed in older compared to younger patients,
277,279-281
 whereas the opposite was 
reported for the prescription of CCBs.
277,279,281
  Prescribing of statins was lower in older 
compared to younger patients,
277,279,280
 although one study reported that older patients were 
more likely to be prescribed lipid lowering drugs (LLD) than younger patients.
278
  
 
Adjusted analyses 
In adjusted studies older patients were significantly less likely to be prescribed aspirin.
282-
284 
Studies of prescribing of ACEIs or ARBs are conflicting. Some studies reported that 
older patients were more likely to be prescribed an ACEI or ARB,
284-286
 while others 
reported that older patients were less likely to receive an ACEI or ARB.
282,283,287
 The 
studies by Marandi et al
285 
and Winkelmayer et al
288 
are the only two studies to report that 
older patients were more likely to receive β-blockers though the difference was not 
statistically significant. Prescribing of statins was significantly lower among older patients 
in all studies that carried out multivariable adjustment.
282-284,289
 
There are clearly differences in prescribing of EBTs by age, however, studies were limited 
by presenting unadjusted results or only adjusting for a few variables. Other studies 
grouped drugs into less specific groups such as lipid lowering drugs, or examined the 
relationship in patients with a narrow age range. Small sample size may influence some 
studies, as well as short period of follow-up. Limited age grouping in some studies would 
88 
 
not show what is the effective age for prescribing medication. The most recent study was 
conducted between 2007 and 2008, however an earlier one was in 1984.  
 
A number of studies examined the relationship between age and the prescribing of 
evidence based therapies following a diagnosis of CHD. The majority of previous studies 
demonstrated that older age groups were less likely to receive EBTs compared to younger 
age groups (Table 6). However, studies were limited by a number of factors including 
study design, data collection methods, and/or statistical methods. 
 
Limitations in the reporting of the literature 
The score for literature describing the association between age and prescribing EBTs after 
MI ranged from 45% to the highest score 70.4% (Table 6). The study design indicated 
using common terms such as cross-sectional, in the majority of the studies, however, five 
studies did not state the study design either in the title or abstract. 
284,286,290,291,292
 Four 
studies failed to clearly state their objectives.
 293,288,289,294
 The study design was clearly 
presented in most studies, though three studies did not describe it clearly in the 
methods.
283,284,295
 The eligibility criteria of individuals included in the study was not 
mentioned in one study. 
296
 A number of studies did not clearly define and describe how 
their variables were handled. 
293,284,285,290,296
 Although bias is common in the observational 
studies, none of the studies addressed or discussed potential biases in their methods. All 
studies described their statistical methods with the exception of one study. 
293
 Rathore et 
al.
283
 discussed and explained how missing data were handled, however other studies did 
not. None of the studies described any sensitivity analysis. 
 
A number of studies did not define the study cohort clearly, for example, reporting the 
number of potentially eligible individuals, only reporting the number of those who 
survived after discharge.
277,279,280,284,289,290,296,292
 The characteristics of patients included 
were not described in two studies. 
284,294
 Only two studies indicated the number of missing 
data in their results. 
294,281
 Five studies did not report the number of outcome events.
 293,284, 
288, 292, 297
 A clear and full presentation of outcomes including unadjusted results and results 
adjusted for potential confounders can help the reader to compare and judge the magnitude 
and direction of the influence of the confounders. However, only six studies presented 
these results.
293,278,283,288,296,291
 Only three studies discussed their limitations, including the 
potential sources of bias.   
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Limitations in the design and analysis of studies included in the literature review 
A number of gaps were also identified in the previous literature. There are clear differences 
in prescribing of EBTs by age after MI, however, a number of studies were unable to 
adjust the results for confounders or only able to adjust for a few confounders. 
277,279,280,281,285,286,290,294,297
 The majority of American and Canadian studies used 
prescription data between 1987 and 1997, which may not be relevant to current clinical 
practice. Also, these studies were limited to patients in the age group over 64 years old. 
Macchia et al.
282
 and Winkelmayer et al.
288
 overcame that by using a large sample size, 
adjusted result for a wide range of confounders, and examined prescribing of a wide range 
of EBTs, however, their studies only included patients who survived at least 1 and ≥ 120 
days in the year after diagnosis, i.e. both studies suffered from a selection bias. A number 
of studies were able to avoid selection bias, however, they were limited to a few EBTs, 
287,289, 296, 294
 or grouped drugs into less specific groups such as lipid lowering drugs, or 
examined the relationship in patients within a narrow age range. 
 
In summary, there were a number of limitations in the literature surrounding the 
association between sex and prescribing of EBTs in CHD. There was also a wide range in 
the quality of reporting of studies as assessed by the STROBE guidelines. Although some 
studies were well reported, they associated with some limitations such as Rathore et al.
283 
which was exposed to the selection bias. Furthermore, the study by Ohlesson et al.
278
 is a 
well reported study but used unadjusted analyses and was limited to few drug groups. The 
study by Gislason et al.
287
 benefited from a high quality of reporting and had a number of 
strengths over other studies.
 
The authors adjusted for a wide range of confounders, but not 
socioeconomic status, but they did use a nationwide population data set for all hospitals in 
Denmark. This study demonstrated that older patients are less commonly prescribed EBTs 
compared to younger patients. 
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Table 6 Inequalities by age in prescribing of   EBTs after myocardial infarction 
Study Design /subject/year  Age range/  Prescribing 
 
Medications  
 
Prescribing 
percentage 
Eldest vs. youngest 
age group 
OR, 95% CI 
Old vs. young 
Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Martinez  
et al297 
 
 
 
 
Spain 
Retrospective cross-
sectional 
 
N=324 and 190 
(514) 
 
1989-91/ 1994 
< 51 
51-60 
61-70 
71-90 
 
 
At time of discharge 
from hospital discharge 
form  
ACEI 
β-blockers 
 
Not available 1.12 (0.37-3.38) 
0.2 0 (0.10-0.38) 
Unadjusted  Not reported  11/22 
 
(50%) 
Excoffier et al281 
 
 
France 
Cross-sectional 
 
N=2102 
Sep 1993-Jan 95 
≤ 65, 62-75, 
 > 75 
 
 
At discharge from the 
medical chart 
ACEI 
β-blockers 
CCB 
Not available 1.20 (1.11-1.30) 
0.65 (0.59-0.70) 
1.17 (1.08-1.27) 
 
Unadjusted  Not reported 15/22 
 
(68%) 
Austin et al280 
 
 
 
Canada 
Retrospective 
longitudinal cohort  
 
N=8706 
2005-06 
65-69, 70-74,  
75-79, ≥  80 
 
 
Within 90 days post-
discharge 
 
Used linked 
administrative database  
ACEI 
β-blockers 
Statins  
74.6  vs. 81.0 
75.0  vs. 81.5 
71.3  vs. 87.9 
Not reported  Unadjusted  Not reported  12/22 
 
(54.5%) 
Kvan et al277 
 
 
 
Norway 
Retrospective cohort 
A three months period  
 
N=901 
1999/2000 
≥ 80 vs. < 80 
 
 
 
After 6 months  
post  discharge 
treatment obtained from 
the hospital records  
 
ACEI 
Aspirin 
CCB 
β-blockers 
Statins 
48 vs. 32 
72 vs. 86 
15 vs. 13 
67 vs. 85 
9.0 vs. 72 
Not available Unadjusted  Not reported 11/22 
 
(50%) 
Ohlesson et al278 
 
 
 
Sweden  
Retrospective 
longitudinal cohort 
 
N=1364 
2006 
17-59,  
60-69 
70-79 
 
 
Within three months 
post discharge  
1st MI 
ACEI 
LLD 
65 vs. 70 
78 vs. 92 
Not reported Unadjusted  Not reported 15.5/22 
 
(70%) 
Pilote et al279 
 
 
 
 
Canada 
(Ontario) 
 
Cross sectional 
 
N=28647 
 
 
 
1997-2000 
 
65-74, 75-84 
>85 
Men  
 
 
 
Women 
Within 90 days post-
discharge 
 
 
ACEI 
β-blockers  
CCB 
Statins 
 
ACEI 
β-blockers 
CCB 
58.0 vs. 57.0 
48.0 vs. 71.0 
33.0 vs. 29.0 
10.0 vs. 44.0 
   
59.0 vs. 59.0 
49.0 vs. 68.0 
32.0 vs. 34.0 
Not reported  Unadjusted  Not reported  12.5/22 
 
(57%) 
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Statins 9.00 vs. 46.0 
Rathore et al283  
 
 
 
USA 
Cross-sectional  
 
N=96364 
 
1994-96 
65-69, 70-74, 75-
79,80-84,     ≥  85 
 
 
At discharge  
 
1st MI 
ACEI  
Aspirin  
β-blockers 
57.1 vs. 61.6 
73.6 vs. 76.0 
61.8 vs. 55.3 
0.90 (0.86-0.95)* 
0.96 (0.95-0.98) 
0.88 (0.85-0.92) 
Demographic characteristic, medical 
history, admission findings, and 
comorbidities 
0.05 
<0.0001 
0.02 
15.5/22 
 
(70.4%) 
Macchia et al282 
 
 
 
 
Italy 
Three longitudinal 
cohorts  
 
N=21423  
 
2003-04 
2005-06  
2007-08 
>75 vs. ≤ 75‡ 
 
Men  
 
 
Women  
Post-discharge follow 
for one year 
 
 
ACEI/ARBs Aspirin 
β-blockers 
Statins 
 
 
ACEI/ARBs Aspirin 
β-blockers 
Statins 
79.1 vs. 79.3 
78.5 vs. 87.0 
54.6 vs. 73.1 
63.2 vs. 85.6
 
77.3 vs. 81.3 
73.4 vs. 83.2 
54.6 vs. 73.9 
55.1 vs. 81.1 
0.75 (0.67-0.83) 
0.60 (0.54-0.67) 
0.46 (0.42-0.50) 
0.31 (0.28-0.34) 
 
0.59 (0.53-0.65) 
0.45 (0.40-0.49) 
0.43 (0.39-0.46) 
0.22 (0.20-0.24) 
Sex, previous CHD, diabetes, stroke, 
TIA, atrial fibrillation, COPD, 
depression and malignancy 
NA 15/22 
 
(68%) 
Marandi et al285 
 
 
 
 
 
Estonia 
Retrospective 
longitudinal  
Cohort  
 
N=4025 
 
2004-05 
20-39, 40-59, 60-
79, 80-99 
 
 
 
 
One year post discharge 
follow up, 
 
1st MI,  
 
Survived more than 30 
days 
ACEI 
β-blockers 
Statins 
Not reported  5.69 (3.66-8.82)+ 
1.93 (0.58-6.47) 
0.17 (0.02-1.37)+ 
Sex  0.05 
NS 
NS 
13/22 
 
(59%) 
Tran et al286 
 
 
Canada 
Retrospective Cohort 
study 
N=4524 
1994-96 
≥ 65 vs. <65 
 
 
At discharge  ACEI Not reported  1.46 (1.22-1.74) Contraindications to therapy Not reported  12.5/22 
 
(57%) 
Heller et al290 
 
 
 
USA 
Retrospective 
longitudinal Cohort 
 
N=9534 
1994-1997 
65-69, 
70-74,  
75-79, 
80-84, 
≥ 85 
Outpatients prescription  
database  
within 90 days 
 post discharge  
β-blockers Not reported  1.00 
1.09 (0.91-1.30) 
1.07 (0.90-1.27) 
1.01 (0.85-1.21) 
0.84 (0.69-1.01) 
Demographic and year of MI ------- 
0.3 
0.4 
0.8 
0.06 
11.5/22 
 
(52%) 
Rasmussen  
et al289 
 
 
 
Denmark  
 Retrospective 
longitudinal cohort  
 
N=17875 
 
1995-2002 
30-44 
45-54 
55-64 
64-74 
75-84 
≥ 85 
Within 6 months 
 post discharge 
 
Follow statins purchased 
after 
1st MI 
Statins  Not reported  0.89 (0.77-1.03) 
1.22 (1.09-1.37) 
1.00 
0.55 (0.50-0.61) 
0.19 (0.17-0.21) 
0.02 (0.02-0.03) 
Sex, concomitant medications, hospital 
type 
Not reported  15/22 
 
(68%) 
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Winkelmayer et 
al288 
 
 
 
 
Austria  
Cross-sectional 
 
 
 N=4105 
 
 
2004 
70-89 vs. < 50  
 
 
 
 
≥ 90 vs. < 50 
 
Within 120 days post 
discharge 
1st MI 
ACEI/ARBs 
β-blockers 
statins 
 
ACEI/ARBs 
β-blockers 
statins 
Not reported   1.48 (1.19-1.85) 
1.05 (0.83-1.33) 
1.08 (0.86-1.36) 
 
0.73 (0.59-0.90) 
0.62 (0.51-0.76) 
0.39 (0.32-0.47) 
Sex, length of  stay at hospital, 
concomitant medications 
Not reported  12.5/22 
 
(57%) 
Krumholz et al295 
 
  
 
USA 
Retrospective cross-
sectional 
N=45308 
 
1994/1995 
65-74,  
75-84,  
≥ 85 
 
 
At discharge β-blockers 
 
 1.00 
0.92 (0.90-0.94) 
0.76 (0.73-0.79) 
Sex, race, medical history, hospital and 
discharge medications, clinical status, 
hospital complications, hospital 
procedures, length of stay 
Not reported  14/22 
 
(63%) 
Gislason et al287 
 
 
 
 
Denmark 
Retrospective 
longitudinal cohort  
 
N=55315 
 
1995-2002 
30-59 
60-69 
70-79 
≥ 80 
 
 
Within 30 days  
post discharge  
 
1st MI 
ACEI 
β-blockers 
 
27.1 vs. 25.3 
41.9 vs. 71.9 
0.61 (0.57-0.65) 
0.31 (0.29-0.33) 
Sex, calendar year, concomitant 
treatment ( loop diuretic & antidiabetic 
drugs) 
Not reported  15/22 
 
(68%) 
Spencer et 
 al284 
 
USA 
Cross-sectional 
N=5739 
 
1986-1997 
<55, 55-64, 65-
74,  ≥ 75 
 
 
At time of 
 discharge 
ACEI 
Aspirin 
β-blockers 
LLD 
Not reported  1.37 (1.07-1.75) 
0.70 (0.57-0.85) 
0.42 (0.35-0.52) 
0.24 (017-0.34) 
Sex, medical history and clinical 
characteristic  
Not reported  10.5/22 
 
(48%) 
Barakat et  
al296 
 
England  
Prospective  
longitudinal cohort  
N=1225 
1988-1994 
< 60, 60-69 
≥ 75 
 
 
At time of  
discharge  
 
Aspirin  
 
β-blockers 
Not reported  0.88 (0.51-1.50) 
 
0.25 (0.16-0.37) 
Sex, diabetes, previous MI. Q wave 
infarction, left ventricular failure  
0.6 
 
<0.001 
10/22 
 
(45%) 
Rochon et  
al291 
 
 
Canada 
Retrospective 
longitudinal cohort  
N=15542 
 
1993-1995 
66-74, 
75-84, 
 ≥ 85 
 
 
Within a year after 
hospital discharge 
(administrative 
database) 
β-blockers 
 
 1.00 
1.5 (1.4-1.6)± 
2.8 (2.5-3.2) ± 
Sex, Charlson comorbidity score, 
contraindication, residence of long 
term facilities 
 
Not reported 
 
 
 
14.5/22 
 
(66%) 
Carey et al294, 
 
 
 
 
UK 
Retrospective 
longitudinal cohort 
 
N=9367 
 
 
1997-2006 
30-49 
50-59 
60-64 
65-69 
70-74 
75-79 
80-84 
Within 6 months post 
discharge, obtained from 
primary care database  
1st MI 
Statins 81.1 
84.3 
79.0 
78.6 
72.6 
66.3 
57.7 
0.96 (0.93-1.00)* 
1.00 
0.94 (0.90-0.94) 
0.93 (0.90-0.96) 
0.86 (0.83-0.89) 
0.78 (0.75-0.82) 
0.68 (0.64-0.72) 
Sex and practice Not reported 14.5/22 
 
(66%) 
93 
 
 Avanzini et al292 
 
 
 
 
 
Italy 
Retrospective 
longitudinal cohort 
  
N=9452 
N=10407 
N=16958 
1984-1993 
>70 vs. ≤ 70  
 
GISSI-1  
GISSI-2 
GISSI-3 
Post discharge, data 
from  
 
β-blockers Not reported -------------------- 
------------------- 
0.25 (0.18-0.35) 
0.50 (0.42-0.59) 
0.45 (0.40-0.50) 
Sex, comorbidities, AMI characteristic 
at admission, procedure complications, 
treatment at discharge 
-------------- 
-------------- 
< 0.01 
< 0.01 
< 0.01 
 
11.5/22 
 
(52%) 
Whincup et al293 
 
 
Britain  
Cross-sectional survey  
N=286 
 
1998-2000 
< 60, 60-69, 
≥  70 
  
 
Post discharge, general 
practice records and 
patients questionnaire  
LLD 7.00 vs. 49.0 0.18 (0.05-0.62) Previous revascularisation,  
age at last diagnosis, year of last 
diagnosis, manual social classes, 
smoking and geographical residence  
0.06 10/22 
 
(45%) 
  
* Risk ratio, ‡ OR Reference is men ≤ 75 (younger) for both men and women age >75,  + Reference is age group (40-59).  ± Indicated that older patients at higher risk of not receiving a β-blocker.
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2.5.2 Inequalities by sex in prescribing of EBTs for MI 
Unadjusted analyses 
Prescribing rates of EBTs for secondary prevention following a MI vary by sex, with 
women being prescribed EBTs at a lower rate than men. In unadjusted analyses women 
were less likely to receive a prescription for aspirin after a MI than men (Table 7, 
unadjusted).
298-302
 Only one study suggested an opposite trend with women aged less than 
65 years being more likely to be prescribed aspirin than men of the same age.
303
 Studies of 
prescribing rates of ACEI conflicted, some reporting no difference by sex, however 
280,298,300,302
 others reported that men received ACEIs more often than women.
278,299,301,303
 
One study reported that women were more likely to be prescribed an ACEI.
297
 Women 
were less commonly prescribed β-blockers,298-301,304 however, two studies reported a non-
significant trend towards women being more likely to be prescribed a β-blocker than 
men,
302,303
 and one reported no difference.
280
 Three studies examined the sex differences in 
prescribing of CCBs. In a Scottish study,
304
 women were more likely to be prescribed a 
CCB than men (30.8% vs. 26.4%), a finding replicated in two studies from Japan.
301,303
 
The proportion of women prescribed a statin was lower than men in two studies.
280,302
 
Conversely, women were more likely to be prescribed a lipid lowering drug in studies from 
Japan,
301,303
 but not in studies from Canada
300
 and Sweden.
278
 
 
Adjusted analyses 
In multivariable analyses (Table 7, adjusted studies), women were less likely to receive 
aspirin compared to men. One age adjusted study reported that women and men were 
almost equally likely to be prescribed an ACEI,
305
 though all other studies reported that 
women were less likely to be prescribed an ACEI or ARBs than men.
282,284,287,305-308
 Most 
studies reported that women were less likely to be prescribed β-blockers.282-284,287,289,305-310 
However, a study by Rathore et al.
311
 included patients diagnosed with MI between 1994 
and 1996 and examined the difference in those older than 64 years. This study showed no 
difference in the prescribing of β-blockers by sex. Heller et al.290 reported that after 
adjustment for demographics and year of MI, women were significantly more likely to 
receive β-blockers than men (OR 1.12; 95%CI 1.01-1.24, p=0.03). In Scotland, Weir et 
al.
310
 examined 865 patients with a first MI and found that men were significantly more 
likely to be prescribed a β-blocker than women (OR 1.59; 95%CI 1.21-2.10) but the 
difference disappeared after adjustment (OR 0.98; 95% CI 0.70-1.37). Griffith et al.
306
 
reported that after adjusting for confounders, women were significantly (p=0.05) more 
likely to be prescribed β-blockers than men. In the GISSI trials312 women were more likely 
95 
 
to receive β-blockers, however, the difference was attenuated with time. Two studies 
reported that women were more likely to be prescribed CCBs than men, though this did not 
reach statistical significance.
284,305
 In general, statins were less likely to be prescribed for 
women compared to men, however, two studies reported that women were more likely to 
be prescribed a statin.
305,306
   
 
Limitations in the reporting of the literature 
The quality of the reporting of these studies was assessed by using STROBE checklist and 
ranged from 41% to 70%. In this section I will discuss the studies that examined sex 
inequalities in prescribing of EBTs which I did not discuss in the previous section 2.4.1.
298-
303,305-307,309-311
 The quality of reporting for these studies ranged from 41% to the highest 
score 63.6%. Three studies did not indicate the study design in their study title or abstract.
 
299,301,302
 The study background was described clearly in almost all studies but one study 
did not explain the scientific background clearly.
301
 Specific study objectives were not 
stated in three studies.
298,299,302 
Criteria of eligibility was not described and discussed in 
four studies.
299,300, 302,310
 Four studies did not define the variables included in their study 
clearly, including  outcome variables and confounding variables.
301,302,305,307
 No study 
adequately described or discussed potential sources of bias. All studies described the 
statistical methods used for analyses.  
 
All studies reported the number of potential and eligible participants in their studies with 
the exception of one.
311
 Only one study discussed and described the reasons for patient 
exclusions.
 306
 Two studies did not described the cohort characteristic.
 302,311
Three studies 
described the missing data of included participants.
300,307,309
 The number of outcome events 
was summarised clearly in the majority of studies, though it was not reported in three 
studies.
 307,309,311
 Six studies presented the unadjusted and adjusted analyses in their results, 
however, other studies either presented unadjusted or adjusted results. One study discussed 
the limitations including potential sources of bias.
305 
Four studies did not interpret their 
results clearly.
300, 305, 307, 311
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Limitations in the design and analysis of studies included in the literature review 
A number of gaps and limitations were also identified in the previous literature. Since the 
prescribing of EBTs is the main focus in these studies, many of the studies were limited to 
one or two drugs.
 298,309-311 
 A number of studies used data for patients diagnosed between 
1988 and 1997 and therefore prescribing may not represent current clinical practice.
 
298,305,309,310 
The study by Griffith et al.
306
 conducted in the Southwest of Scotland, had a 
number of strengths including the study design, a prospective cohort, which enabled EBTs 
to be collected at time of discharge, examined prescribing inequalities for almost all 
recommended EBTs and adjusted for a wide range of confounders that were included in 
the analyses. Its only weakness was its relatively small sample size though this is 
inevitable in a study that collects such detail. Unfortunately, they did not clearly describe 
whether they excluded patients who did not survive 30 days. A number of conducted 
studies used primary or secondary care data sets making the generalisability of results 
difficult. The age of patients included in the study was not mentioned in two studies. 
Finally, one study was subject to selection bias as they did not include patients who did not 
survive more than 30 days.
307
    
 
In summary, there were a number of limitations in the literature surrounding the 
association between sex and prescribing of EBTs in MI. There was also a wide range in the 
quality of reporting of studies as assessed by the STROBE guidelines. Few studies 
achieved a quality score of over 63.6%, however, these studies were associated with a 
number of limitations that have already has discussed above such as selection bias and a 
small sample size. The study by Gislason et al.
287
 had a number of strengths over other 
studies.
 
This study adjusted for a wide range of confounders, although not socioeconomic 
status, and used nationwide population data sets for all hospitals in Denmark, making 
results generalisable. In general women were less likely to receive appropriate EBTs 
following MI than men. 
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Table 7 Inequalities by sex in prescribing of EBTs after myocardial infarction 
Study Design/year subject   Prescribing Medications Prescribing 
percentage 
Women vs. men 
OR, 95% CI 
Women vs. men 
Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Martinez  
et al297 
 
Spain 
Retrospective cross-
sectional 
 
1989-91/ 1994 
324 and 190 
 
N=514 
At time of discharge 
from hospital chart 
ACEI 
 
Not reported  4.45 (2.16-9.14) Unadjusted Not reported  11/22 
 
(50%) 
Austin et al280 
 
 
 
Canada 
Retrospective 
population cohort  
 
 
2005-06 
Age ≥ 65 
 
N=8706 
Within 90 days post-
discharge 
 
 
ACEI 
β-blockers 
Statins  
78.5 vs. 78.5 
78.1 vs. 78.4 
76.7 vs. 82.0 
Not reported  Unadjusted Not reported  12/22 
 
(54.5%) 
Sadowska et 
al302  
 
 
 
Poland 
Retrospective cross-
sectional 
 
 
 
2005-06 
N=420  
 
(Cardiology  centre) 
At time of discharge 
from data centre 
ACEI 
Aspirin 
Clopidogrel 
β-blockers 
Statins Nitrates  
90.4  vs. 90.9 
89.2  vs. 94.1 
16.9  vs. 28.7 
81.9  vs. 77.6 
78.9  vs. 85.8 
54.8  vs. 49.2 
Not reported  Unadjusted 0.84 
0.06 
0.005 
0.28 
0.06 
0.26 
8.5/22 
 
(39%) 
Hirakawa et 
al301 
 
 
Japan  
Prospective cross-
sectional  
 
 
2001-2003 
< 65 
 
Women= 169 
Men=  1246 
 
At time of discharge 
Detailed chart 
review & 
questionnaire  
ACEI 
Aspirin 
CCB 
β-blockers 
LLD 
Nitrates 
42.6 vs. 46.6 
80.5 vs. 89.6 
14.8 vs. 18.6 
4.14 vs.  7.7 
43.2 vs. 35.8 
46.7 vs. 49.8 
Not reported  Unadjusted NS 
< 0.01 
NS‡ 
NS 
NS 
NS 
11/22 
 
(50%) 
  ≥ 65 
 
Women=616 
Men=1240 
 ACEI 
Aspirin 
CCB 
β-blockers 
LLD 
Nitrates 
34.7 vs. 41.7 
72.4 vs. 81.2 
14.3 vs. 16.5 
5.40 vs. 5.97  
26.6 vs. 22.4 
44.8 vs. 49.8 
  < 0.01 
< 0.01 
NS 
NS 
< 0.05 
< 0.05 
 
Barakat et al298 
 
England  
Retrospective cohort 
study 
 
1988-97 
Women=463 
Men=1274 
 
At time of discharge   ACEI  
Aspirin 
β-blockers 
 
34.3 vs. 32.9 
90.0 vs. 92.9 
31.6 vs. 44.9 
Not reported  Unadjusted NS 
0.08 
< 0.001 
12/22 
 
(54.5%) 
Di Cecco et al300 
 
 
 
Canada  
Audit  
 
 
 
 
≥ 60 
 
Women=81 
 
Men= 142 
Chart review   ACEI  
Anticoagulant  
Aspirin  
β-blockers 
LLD 
57.0 vs. 56.0  
17.0 vs. 11.0 
77.0 vs. 82.0 
72.0 vs. 75.0 
33.0 vs. 48.0 
Not reported  
 
 
 
 
Unadjusted Not reported 
 
 
 
 
11.5/22 
 
(52%) 
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2000  Nitrates  77.0 vs. 66.0 
Clarke et al299 
 
UK 
Retrospective cross-
sectional 
 
1998-90 
Women=424 
 
Men= 997 
 
At time of discharge Aspirin 
 
β-blockers 
 
75.0 vs. 79.7   
28.7 vs. 42.2  
Not reported  
 
Unadjusted < 0.01 
 
< 0.01 
11.5/22 
 
(52%) 
Hirakawa et 
al303 
 
 
 
Japan 
Retrospective cross-
sectional 
 
 
 
1995-97 
< 65  
 
Women= 143 
 
Men=  822 
 
At time of discharge 
Detailed chart 
review & 
questionnaire 
ACEI 
Aspirin 
CCB 
β-blockers 
LLD 
Nitrates 
33.5 vs. 40.1 
71.3 vs. 64.1 
51.1 vs. 46.8 
7.70 vs. 5.23 
17.5 vs. 12.4 
39.8 vs. 38.2 
Not reported  Unadjusted NS 
NS 
NS 
NS 
NS 
NS 
11/22 
 
(50%) 
  ≥ 65 
 
Women=319 
 
Men=661 
 
 ACEI 
Aspirin 
CCB 
β-blockers 
LLD 
Nitrates 
31.7 vs. 30.5 
68.5 vs. 67.7 
35.3 vs. 38.4 
3.60 vs. 2.72  
8.95 vs. 5.57 
31.4 vs. 32.5 
  < 0.01 
< 0.01 
NS 
NS 
< 0.05 
< 0.05 
 
Ohlesson et al278 
 
 
Sweden  
Retrospective cohort 
 
 
2006 
N=1364 
 
 
Within three months 
post discharge  
1st MI 
Income  
ACEI 
LLD 
63.0 vs. 72.0 
82.0 vs. 87.0 
Not reported Unadjusted Not reported 15.5/22 
 
(70%) 
Macchia et al282 
 
 
Italy 
Three cohorts  
 
2003-04 
2005-06  
2007-08 
 
Age ≤ 75 
 
N=21423  
Post-discharge 
follow for one year 
ACEI/ARBs 
Aspirin 
β-blockers 
Statins 
81.3 vs. 79.3 
83.2 vs. 87.0 
73.9 vs. 73.1 
81.1 vs. 85.6 
0.94 (0.84-1.04) 
0.72 (0.65-0.81) 
0.99 (0.90-1.08) 
0.70 (0.63-0.78) 
Age,  previous CHD, diabetes, 
stroke, TIA, atrial fibrillation, 
COPD, depression and 
malignancy 
Not reported  15/22 
 
(68%) 
Heller et al290 
 
 
 
 
USA 
Retrospective Cohort 
study 
 
 
 
1994-1997 
≥ 65 
 
N=9534 
Outpatients 
prescription database 
with 90 days post 
discharge  
 
β-blockers 
 
Not available 1.12 (1.01-1.24) 
 
 
Demographic and year of MI 0.03 11.5/22 
 
(52%) 
Rasmussen  
et al289 
 
 
 
 
Denmark  
 Retrospective cohort  
 
 
 
 
1995-2002 
 1995-97 
 
1998-99 
 
2000-02 
 
N=17875 
Within 6 months 
post discharge 
Follow statins 
purchased  
 
1st MI 
Statins  Not reported  1.29 (1.18-1.45) 
 
1.26 (1.18-1.38) 
 
0.95 (0.88-1.03) 
Age, concomitant medications, 
hospital type 
Not reported  15/22 
 
(68%) 
Winkelmayer et 
al288 
 
Retrospective cohort  
 
2004 
N=4105 Within 120 days post 
discharge 
 
ACEI/ARBs 
β-blockers 
statins 
Not reported  0.93 (0.80-1.09) 
0.87 (0.74-1.03) 
0.90 (0.77-1.06) 
Age, length of  stay at hospital, 
concomitant medications 
Not reported  12.5/22 
 
(57%) 
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Austria  1st MI   
Gislason et al287 
 
Denmark  
Retrospective cohort  
 
1995-2002 
Men vs. women  
 
 
N=55315 
Within 30 days  
post discharge  
 
1st MI 
ACEI 
β-blockers 
 
28.8 vs. 29.8 
52.2 vs. 62.6 
0.85 (0.82-0.89) 
0.80 (1.21-1.30) 
Age, calendar year, 
concomitant treatment  
(loop diuretic & antidiabetic 
drugs) 
<0.001 15/22 
 
(68%) 
Spencer et al284 
 
 
USA 
Cross-sectional 
 
 
 
1986-1997 
N=5739 At time of 
 discharge 
ACEI 
Aspirin 
CCB 
β-blockers 
LLD* 
Not reported  0.86 (0.74-1.01) 
0.86 (0.78-1.01) 
1.06 (0.92-1.20) 
0.83 (0.73-0.94) 
0.92 (0.73-1.16) 
Age, medical history and 
clinical characteristic  
Not reported  10.5/22 
 
(48%) 
Griffith et al306  
 
 
Southwest 
Scotland  
Prospective cohort 
 
1994-2000 follow up 
to end of 2001 
Women= 458 
 
Men= 821 
 
At time of discharge  
 
1st MI 
ACEI 
Aspirin 
β-blockers 
Statins 
49.6 vs. 52.0 
86.7 vs. 90.3 
38.0 vs. 48.8 
23.8 vs. 23.8 
0.85 (0.66- 1.08)+ 
0.90 (0.62- 1.32) 
0.78 (0.60- 1.00) 
1.48 (1.10- 1.98) 
Age, smoking, comorbidity, 
previous angina, 
revascularisation 
PAD, DM, HTN, and social 
deprivation 
0.18 
0.60 
0.05 
0.001 
9/22 
 
 
(41%) 
Sial et al309 
 
 
USA 
Retrospective cross-
sectional 
 
1990-1991 
N=444 At time of discharge 
from medical records 
β-blockers 
 
Not reported  0.52 (0.30- 0.88) Age, race, comorbidities, other 
medications, MI characteristic, 
physician  
Not reported  13.7/22 
 
(62%) 
Rathore et al311 
 
USA  
Retrospective cross-
sectional 
 
1994-96 
≥ 65 
 
N=169079 
At time of discharge 
from medical records 
database  1st MI 
Aspirin  
β-blockers 
 
 
Not reported 0.98 (0.96-0.99) 
1.00 (0.97-1.02) 
Age, illness severity, doctor 
speciality, live rural area, US 
census region of residency   
Not reported  12.5/22 
 
(57%) 
Hanrratty et 
al305 
 
 
 
 
England  
Prospective cohort 
study 
 
 
 
 
Sep-Nov 1995 
Women=850 
 
Men=1303 
 
At time of discharge  ACEI 
Anticoagulant 
Aspirin 
CCB 
β-blockers 
Nitrates 
Statins  
Not reported 1.01 (0.82-1.26) 
1.40 (0.97-2.03) 
0.91 (0.68-1.23) 
1.25 (0.96-1.63) 
0.84 (0.67-1.07) 
0.85 (0.69-1.06) 
1.37 (0.92-2.03) 
Age  0.91 
0.07 
0.55 
0.09 
0.15 
0.15 
0.12 
11/22 
 
(50%) 
Williams et al307 
 
 
Wales  
Retrospective cross-
sectional 
 
Jan, Feb, July and Aug 
1999 
Women=438 
 
Men= 819 
 
Case notes   
 
Exclude patients 
died within 30 days 
ACEI 
Aspirin 
β-blockers 
Statins  
Not reported 0.83 (0.63-1.10) 
0.93 (0.65-1.32) 
0.97 (0.73-1.28) 
0.98 (0.74-1.30) 
Age Not reported  10/22 
 
(45.5%) 
Carey et al294  
 
 
 
 
UK 
Retrospective cohort 
 
N=9367 
 
1997-2006 
Women=3107 
 
Men=6210 
 
Within 6 months 
post discharge, 
obtained from 
primary care 
database  
1st MI 
Statins 72.0 vs. 75.9 1.01 (0.98-10.3)ǁ 
 
Age, and practice Not reported 14.5/22 
 
(66%) 
100 
 
 
*LLD=Lipid lowering drug, ‡ Not significant, ǁ Risk ratio, ¶ Unadjusted OR 0.62 (0.48-0.82), + Unadjusted ACEI (OR 0.91, 0.72-1.14), aspirin (OR 0.70, 0.49-1.00), blockers (OR 0.64, 0.51-0.81), statins (OR 1.00, 0.76-  
1.30).
Avanzini et al312 
 
Italy 
Retrospective 
cohort  
 
1984-1993 
GISSI-1 (N=9452) 
GISSI-2 (N=10,407) 
GISSI-3 (N=16,958) 
Post discharge, data 
from  
 
β-blockers Not reported 1.15 (0.93-1.24) 
1.06 (0.92-1.22) 
1.03 (0.93-1.14) 
Age, comorbidities, AMI 
characteristic at admission, 
procedure complications, 
treatment at discharge 
No significant 11.5/22 
 
(52%) 
Weir et al310 
 
 
 
Scotland  
Retrospective cohort  
 
 
1994-1995 
Age 30 -93  
 
N=865 
 
Post discharge, use 
record linkage 
database 
1st MI 
 
 
β-blockers Not reported  1.02 (073-1.42)¶ Age, deprivation, obstructive 
airway disease, diabetes 
mellitus, PAD, prior beta 
blockers, prior of CCB, ACEI, 
alpha blockers, thiazide 
diuretic, loop diuretic, nitrates, 
antiplatelet drug, lipid 
lowering drug, steroid.  
Not reported  14/22 
 
(63.5%) 
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2.5.3 Inequalities by socioeconomic status in prescribing of EBTs for MI 
   
The association between the prescribing of EBTs and socioeconomic status has only been 
examined in a few studies (Table 8).  
 
Unadjusted analyses 
In an unadjusted analyses Hawkins et al.
313
 reported that the most deprived were more 
likely to be prescribed aspirin, though this difference became non-significant over time 
(RR 1.28; 95% CI 1.08-1.53) in 1999 and (RR 1.01; 95% CI 0.76-1.34) in 2007. In the 
same study ACEI/ARBs were prescribed similarly for the most and least deprived.
313
 
Although this study was not adjusted, it has a number of strengths such as large sample 
size obtained from the general practice database, including all EBTs, and it used a 
deprivation measurement based on different domains. In contrast, a Swedish study
278
 using 
routinely collected regional data reported that the least deprived were more likely to be 
prescribed an ACEI than the most deprived (66.0 vs. 74.0). No studies reported a 
significant difference in prescribing rates of β-blockers between the most and least 
deprived groups.
278,313
 Hawkins et al.
313
 reported that statins were less commonly 
prescribed for the most versus the least deprived patients post-MI but this was not 
statistically significant (RR 0.67; 95% CI 0.45-1.01).  
 
Adjusted analyses and limitations of the published literature 
In the multivariable adjusted analyses examining the relationship between socioeconomic 
status and the prescription of aspirin, more deprived patients were not significantly less 
likely to be prescribed aspirin (OR 0.98; 95% CI 0.96-1.00). However, this study used a 
single deprivation measurement and only included patients aged ≥ 65 years in the study.311 
Reid et al.
314
 reported that the least deprived were more likely to be prescribed an ACEI. 
Conversely, prescribing of β-blockers was higher among the least deprived patients after 
adjustment.
311,314
 Although these studies adjusted their results for a wide range of 
confounders and examined prescribing inequalities for more than one drug, they were 
subject to a number of limitations such as limiting the study to patients aged ≥ 65 years,311 
excluding patients who did not survive more than 120 days  leading to selection bias, 
314
 
and using one measure to determine socioeconomic deprivation.
311,314
 Carey et al.’s294 
study avoided these limitations using a measurement based on different domains of 
deprivation, though it was adjusted for only a few confounders. This study reported no 
difference in statin prescribing rates by socioeconomic status.
294
 Reid et al.
314
 reported that 
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statins were significantly more likely to be prescribed for men with high income than those 
with lower income.  
 
Limitations in the reporting of the literature 
The quality of the reporting of these studies was assessed by using STROBE checklist and 
ranged from 45% to 70%. All studies indicated their study design using common terms 
either in the title or in the abstract. Three studies did not state their objectives.
293,294,314
 The 
study design was not described clearly in the methods for one study. 
311
 One study did not 
report the eligibility criteria for patients included in their analyses.
313
 Two studies did not 
describe the statistical methods included in the analyses.
293,313
 All studies reported the 
number of individuals included in the study and those included in the analyses, however 
one study did not.
313
 Three of the six studies did not describe the demographic 
characteristics of the patients.
 294,311,313
 Only one study described and discussed the 
potential sources of bias in the limitation section. 
278
  
 
In summary, there were a number of limitations in the literature surrounding the 
association between socioeconomic and prescribing of EBTs in MI. There was also a wide 
range in the quality of reporting of studies as assessed by the STROBE guidelines. One 
study achieved a quality score of over 70%.  In those studies that did adjust their analyses 
the most deprived individuals were less likely to receive appropriate EBTs following a MI. 
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Table 8 Inequalities by socioeconomic status in prescribing of EBTs after myocardial infarction 
Study Design /year/  
 
Reference/ 
subject  
Prescribing/ 
Deprivation 
measure 
Medications 
 
Prescribing 
percentage 
Affluent vs. deprived 
OR, 95% CI 
Affluent vs. deprived 
Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Ohlesson et 
al278 
 
 
 
 
Sweden  
Retrospective cohort 
 
 
 
 
2006 
high income 
 vs. Low income 
 
Age 40-100 
 
N=1364 
Within three 
months post 
discharge  
1st MI 
Income  
ACEI 
LLD 
74.0 vs. 66.0 
91.0 vs. 82.0 
Not reported Unadjusted Not reported 15.5/22 
 
(70%) 
Hawkins et 
al313 
 
 
UK 
Cross-sectional 
 
 
1999  
Less deprived  
vs. Most deprived 
 
N=32976 
General practice 
research 
database 
ACEI/ARBs 
Aspirin 
β-blockers 
statins  
17.5 vs. 18.8 
33.7 vs. 43.3 
32.1 vs. 32.9 
45.2 vs. 30.3 
0.92 (0.73-1.19)‡ 
1.28 (1.08-1.53) 
0.98 (0.52-1.82) 
1.49 (0.99-2.22) 
Unadjusted Not reported  13.5/22 
 
(61%) 
 2007  IMD* ACEI/ARBs 
Aspirin 
β-blockers 
statins 
56.1 vs. 57.3 
63.5 vs. 64.3 
49.7 vs. 52.7 
74.6 vs. 67.8 
0.98 (0.76-1.26) 
1.01 (0.76-1.34) 
0.94 (0.72-1.25) 
1.10 (0.85-1.41) 
   
Rathore et 
al311 
 
 
USA  
Retrospective cross-
sectional 
 
 
1994-96 
Affluent vs. deprived  
 
≥  65 
 
N=169079 
At time of 
discharge  
 
Household 
income 
Aspirin  
β-blockers 
 
 
Not reported 1.02 (1.00-1.04) 
1.05 (1.01-1.09) 
Age, illness severity, doctor 
speciality, live rural area, US 
census region of residency   
Not reported 12.5/22 
 
(57%) 
Whincup et 
al293 
 
 
 
 
 
UK  
Cross-sectional 
survey  
 
 
 
 
1998-2000 
Non-manual 
vs. Manual 
 
N=286 
 
Men  
Post discharge, 
general practice 
records and 
patients 
questionnaire 
 
Occupation  
LLD 49.0 vs. 49.0 1.45 (0.82-2.56) Previous revascularisation,  
age at last diagnosis, year of 
last diagnosis, manual social 
classes, smoking and 
geographical residence  
0.2 10/22 
 
(45%) 
Carey et al294 
 
 
 
 
UK 
Retrospective cohort 
 
 
 
 
1997-2006 
Least deprived vs. 
Most deprived 
 
Women=3107 
 
Men=6210 
Within 6 months 
post discharge, 
primary care 
database  
1st MI 
IMD* 
Statins 72.0 vs. 75.9  1.01 (0.98-1.03)ǁ 
 
Age, sex and practice Not reported 14.5/22 
 
(66%) 
Reid RJ et 
al314  
 
Cross-sectional 
 
 
High income vs. low 
income 
 
Within 120 days 
post discharge  
 
ACEI 
β-blockers 
Statins  
Not reported 1.37 (1.24-1.51) 
1.50 (1.35-1.68) 
1.71 (1.53-1.90) 
Age using 5 years age bands, 
urban residence and general 
health status  
Not reported 15.2/22 
 
(69%) 
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Canada 
 
 
1999-2006 
Men 
 
 
N=28216 
administrative 
database  
  Women Income ACEI 
β-blockers 
Statins 
 1.04 (0.89-1.20) 
1.25 (1.06-1.47) 
1.32 (1.12-1.54) 
   
 
 
* Index of Multiple deprivation, ‡ Rate ratio, ǁ Risk ratio 
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2.5.4 Trends in prescribing of EBTs for MI 
Several studies have reported that the use of EBTs for secondary prevention post-MI has 
improved over the last decade (Table 9). Prescribing of EBTs at discharge or shortly after 
discharge has been examined in a number of studies. 
 
Unadjusted analyses 
Prescribing of aspirin or any antiplatelet agent at any time point post discharge increased 
over time in the studies.
282,284,315-319
 Only one study reported that prescribing of aspirin 
declined at time of discharge, though the sample size was very small in this study 
compared to other studies.
297
 Prescribing of ACEI/ARBs similarly improved over time. 
Since the 1990s the prescribing of β-blockers has improved.282,284,297,315-320 The largest 
increases in prescribing were seen with statins.
282,284,315,316,319
 Although all above studies 
were unadjusted, they have a number of strengths. Almost all of these studies included all 
recommended EBTs after MI, however, a few did not. Long time periods of the trend were 
examined in the majority of these studies, which helps to demonstrate how far prescribing 
EBTs has improved.  A recent report published in 2014 by British Heart Foundation 
(BHF), reported that the prescription used in the prevention and treatment of 
cardiovascular diseases in England, Wales and Scotland increased over the time.
321
   
 
Adjusted analyses 
Few studies used multivariable analyses to examine the prescribing trends for EBTs after 
MI. Of the studies that did adjust for other confounders they all reported that prescribing 
rates improved over time for all of the above drugs. However, they only adjusted for a 
limited number of covariates or were limited to one or two drugs. One study
322
 with a large 
sample size, included all patients diagnosed with MI from age 35 years and above, and 
examined prescribing trends for all recommended EBTs. This study, however, adjusted for 
limited confounders and was not specific for statins examining all lipid lowering drugs. 
This study showed that prescribing EBTs increased significantly from 1991 to 2002 for all 
secondary prevention therapies.    
Limitations in the reporting of the literature 
A number of studies were identified that examined the trends in prescribing after diagnosis 
with MI. In this section, I will focus my discussion on the studies that explicitly examined 
trends in prescribing of EBTs after MI.
315-320, 322-323 
The quality of the reporting of studies 
describing the prescribing trends over the time was assessed using the STROBE checklist 
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and ranged from 36% to 74%. Two studies did not indicate the study design using common 
terms in the title or abstract.
318,320
 The majority of studies provided a clear summary in the 
abstract including background, methods, results and conclusion.
315-319,322-323 
Study 
objectives were not described clearly in three studies.
315,320,323
  Study design was not 
clearly described in one study.
323 
The eligibility criteria of patients for inclusion in the 
study was not described in three studies.
317,318,320 
The outcome, exposure and potential 
predictors were not described clearly in one study.
320
  
 
Statistical methods were described in all but one study not.
 320
 Furthermore, none of the 
studies described any further analyses or explained how missing data were addressed. All 
studies reported the number of eligible patients included in the study. Four studies did not 
describe the reasons for those who were excluded from the analyses.
 315-317,320
 The number 
of outcome events was not indicated in five studies.
315,319,324,323
 Three studies presented the 
unadjusted and adjusted analyses in their results.
318,319,324
 Other studies, however, either 
presented unadjusted or adjusted results. Two studies failed to discuss the source of the 
potential bias in their limitations.
322,324 
 
 
Limitations in the design and analysis of studies included in the literature review 
A number of gaps and limitations were identified in the literature. Few studies examined 
prescribing trends using all EBTs and most limited their analyses to select groups of drugs. 
The majority of previous studies reported unadjusted analyses and therefore results were 
not adjusted for potential confounders. The results of some studies may not represent 
current clinical practice as they measured the trends using older data sets. De Ruijter et 
al.
320 
did not explain how the practices included in the study were selected. In addition, this 
study examined prescribing at three different points but did not clarify whether they 
avoided double counting of individuals between periods. Selection bias was identified in 
two studies.
322,324
  
 
In summary, a number of limitations were identified in the previous studies of trends in 
prescribing EBTs after MI. There was variation in the quality of reporting of studies as 
assessed using STROBE guidelines. There was, however, a general consensus in the 
literature that the prescribing of EBTs has improved over time.  
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Table 9 Trends in prescribing of EBTs after myocardial infarction 
Study Design/year Reference/ 
Subject 
Prescribing Medications Prescribing 
percentage 
OR, 95% CI Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Spencer et al284 
 
 
 
USA 
Cross-sectional 
 
 
 
1986-1997 
1986 vs. 1997 
 
N=5739 
 
At time of 
 discharge 
ACEI 
Aspirin 
β-blockers 
CCB 
LLD* 
0.00 vs. 40.0‡ 
15.0 vs. 77.0 
35.0 vs. 70.0 
50.0 vs. 15.0 
1.00 vs. 20.0 
Not reported  Unadjusted Not reported  10.5/22 
 
(48%) 
Perschbacher et 
al318 
 
USA  
Cross-sectional 
 
1979-1998 
1979 vs. 1998 
 
N= 2093 
At time of 
discharge, medical 
records database 
ACEI 
Aspirin 
β-blockers 
0.00 vs. 39.0 
10.0 vs. 88.0 
25.0 vs. 73.0 
Not reported  Unadjusted Not reported  13/22 
(59%) 
De Ruijter et 
al320 
 
Netherlands 
Cross-sectional 
 
2000-2007 
2000 vs. 2007 
 
N=800 
Post discharge, 
obtained from 
medical records of 
GP 
ACEI 
β-blockers 
Statins 
30.0 vs. 47.0 
40.0 vs. 58.0 
44.0 vs. 71.0 
Not reported  Unadjusted Not reported  8/22 
 
(36%) 
Gasse et al316 
 
 
Denmark  
Retrospective 
longitudinal cohort  
 
1997-2003 
1997 vs. 2003 
 
N=11927 
 
Within 6 months 
post discharge  
ACEI/ARBs 
Aspirin 
β-blockers 
Statins 
35.0 vs. 52.7 
38.0 vs. 83.0 
74.0 vs. 76.2 
17.0 vs. 70.5 
Not reported  Unadjusted Not reported 15/22 
 
(68%) 
Masoudi et al317 
 
 
USA  
Retrospective cohort  
 
 
1992-2001 
1992 vs. 2001  
 
N=20550 
At time of 
discharge, used 
patients Medical 
records 
ACEI 
Aspirin 
β-blockers 
47.3 vs. 64.6 
66.0 vs. 79.4 
33.1 vs. 71.4 
Not reported  Unadjusted < 0.001 
< 0.001 
< 0.001 
11.5/22 
 
(52%) 
Macchia et al282 
 
 
Italy 
Three cohorts  
 
2003-04 
2005-06  
2007-08 
2003 vs. 2007 
 
N=21423 
 
 
Within 1 year after 
discharge 
ACEI/ARBs 
Aspirin 
β-blockers 
Statins 
73.1 vs. 82.1 
76.4 vs. 85.7 
59.3 vs. 71.2 
67.0 vs. 80.6 
Not reported  Unadjusted Not reported  15/22 
 
(68%) 
Setoguchi et al324 
 
 
USA 
Retrospective cohort 
study  
 
1995-2004 
1995 vs. 2004 
 
N=21484 
Within 30 days  
post discharge  
ACEI/ARBs 
Antiplatelet 
β-blocker 
Statins 
39.2  vs. 50.0 
2.60  vs. 50.9 
41.5  vs. 71.6 
7.60  vs. 50.7 
Not reported  Unadjusted <0.0001 
<0.0001 
<0.0001 
<0.0001 
13.7/22 
 
 
(62%) 
Austin et al315 
 
 
Canada  
Cross-sectional  
 
 
1992-2005 
1992 vs. 2005 
Age ≥ 65 years   
 
N=132778 
Within 90 days post 
discharge from 
Ontario MI 
database,1st MI 
ACEI/ARBs 
β-blocker 
statins 
 
42.0 vs. 78.4 
42.6 vs. 78.1 
4.20 vs. 79.2 
 
Not reported Unadjusted < 0.001  12.5/22 
 
(57%) 
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Barron et al323 
 
USA 
Cross-sectional 
 
1994-1996 
1994 vs. 1996  
 
N=190015 
At discharge, from 
national registry for 
MI2  
ACEI 25.0 vs. 30.7 Not reported Unadjusted Not reported 12/22 
 
(54.5%) 
Setguchi et al319 
 
USA 
Retrospective cohort      
 
1995-2004 
1995 vs. 2004  
 
N=19368 
Within 90 days post 
discharge  
ACEI/ARBs 
β-blockers 
Statins 
46.0 vs. 58.0 
47.0 vs. 80.0 
11.0 vs. 61.0 
Not reported Unadjusted <0.001 
<0.001 
<0.001 
13/22 
 
(59%) 
Martinez  
et al297 
 
Spain  
Retrospective cross-
sectional 
 
1989-91/ 1994 
1989 vs. 1994 
  
 
324 and 190 
At discharge  ACEI 
β-blocker 
Aspirin 
CCB 
14.0 vs. 23.0 
62.0 vs. 63.0 
75.0 vs. 71.0 20.0 
vs. 17.0 
Not reported  Unadjusted Not reported  11/22 
 
(50%) 
Aventine et al292 
 
 
Italy 
Retrospective cohort  
 
 
 
1984-1993 
1984 vs. 1993 
 
N=36817 
 
Post discharge, data 
from  
GISSI-1 
GISSI-2 
GISSI-3 
β-blockers 8.50 vs. 31.4 5.73 (5.23-6.26) Age, sex, comorbidities, AMI 
characteristic at admission, 
procedure complications, 
treatment at discharge  
Not reported  11.5/22 
 
(52%) 
Heller et al290 
 
 
 
 
 
USA 
Retrospective Cohort 
study 
 
 
 
 
1994-1997 
1994 
1995 
1996 
1997 
 
N=9534 
 (≥ 65) 
Outpatients 
prescription 
database with 90 
days post discharge  
 
β-blockers 
 
Not reported  1.00 
1.36 (1.20-1.53) 
1.72 (1.50-1.97) 
2.33 (2.03-2.67) 
 
 
Demographic and year of MI --------- 
0.0001 
0.0001 
0.0001 
11.5/22 
 
(52%) 
Gislason et al287 
 
Denmark  
Retrospective cohort  
 
 
1995-2002 
1995 vs. 2002 
 
 
N=55315 
Within 30 days  
post discharge  
 
1st MI 
ACEI 
β-blockers 
 
 24.5 vs. 35.5 
 38.1 vs. 67.9  
1.86 (1.73-2.01) 
3.84 (3.58-4.13) 
Age, sex, calendar year, 
concomitant treatment  
(loop diuretic & antidiabetic 
drugs) 
<0.001 15/22 
 
(68%) 
Carey et al294  
 
 
 
UK 
Retrospective cohort 
 
N=9367 
 
1997-2006 
1997-1998 
1999-2000 
2001-2002 
2003-2004 
2005-2006 
Within 6 months 
post discharge, from 
primary care 
database, 
1st MI 
Statins  1.00 
1.34 (1.31-1.47)* 
1.68 (1.58-1.79) 
1.93 (1.81-2.07) 
1.97 (1.84-2.11) 
Age, sex and practice Not reported 14.5/22 
 
(66%) 
Hardoon et al322 
 
 
UK 
Retrospective cohort 
N=10,352 
 
1991-2002 
 1991 vs. 2002 
 
 
≥ 35 years 
Within 90 days post 
discharge, general 
practice (GP) 
database  
ACEI 
Antiplatelet 
β-blocker 
LLD 
11.0 vs. 71.0  
46.0 vs. 86.0 
26.0 vs. 68.0 
3.00 vs. 79.0 
1.28 (1.26-1.30) 
1.20 (1.17-1.23) 
1.23 (1.20-1.26) 
1.79 (1.73-1.85) 
Age, sex, and GP Not reported  16/22 
 
(74%) 
  Men=6586  ACEI 
Antiplatelet 
β-blocker 
LLD 
11.6 vs. 72 .7 
47.7 vs. 87.1 
32.9 vs. 73.3 
3.90 vs. 83.1 
1.30 (1.27-1.32) 
1.20 (1.18-1.22) 
1.22 (1.20-1.24) 
1.83 (1.78-1.89) 
 < 0.001 
< 0.001 
< 0.001 
< 0.001 
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  Women=3766  ACEI 
Antiplatelet 
β-blocker 
LLD 
10.2 vs. 67.1 
42.3 vs. 83.5 
12.8 vs. 59.7 
1.28 vs. 71.7 
1.25 (1.22-1.28) 
1.20 (1.17-1.23) 
1.24 (1.21-1.27) 
1.72 (1.66-1.79) 
 < 0.001 
< 0.001 
< 0.001 
< 0.001 
 
Gale C et al325 
 
England and 
Wales 
Cross-sectional 
 
N=612995 
2003 vs. 2010 
<55 
>85 
 
<55 
>85 
 
<55 
>85 
 
<55 
>85 
 
<55 
>85 
At time of 
discharge, obtained 
from electronic data 
base 
 
 
 
Aspirin  
 
 
ACEI 
 
 
β-blockers 
 
 
Clopidogrel  
 
 
Statins  
 
95.8 vs. 82.5 
81.1 vs. 71.6 
 
81.4 vs. 76.5 
57.4 vs. 55.9 
 
85.5 vs. 75.3 
49.1 vs. 56.7  
 
56.1 vs. 97.3  
28.1 vs. 89.1  
 
94.2 vs. 82.4 
61.3 vs. 68.6 
 
0.20 (0.19-0.22)* 
0.59 (0.55-0.63) 
 
1.35 (1.27-1.42) 
1.06 (1.01-1.12) 
 
0.52 (0.49-0.55) 
1.35 (1.29-1.43) 
 
28.48 (20.64-39.69) 
81.31 (59.06-112.26) 
 
0.29 (0.26-0.31) 
1.38 (1.31-1.46) 
 Not reported 16/22 
 
(74%) 
 
*Relative risk, ‡ result approximated from a figure.
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2.5.5 Prescribing of EBTs for MI by comorbidities 
Prescribing of EBTs post-MI may be influenced by the presence of concomitant disease. 
One study reported that aspirin was less commonly prescribed in patients with end stage 
renal disease (ESRD) post MI.
326
 Prescribing rates of ACEIs were lower among patients 
with the comorbidities of diabetes mellitus, HF, cancer, stroke, chronic kidney disease 
(CKD) and RF.
280
 Similar trends have been reported for β-blockers and statins.280,326,327  
A number of studies examined the effect of comorbidities using adjusted multivariable 
analyses and reported that the presence of concomitant disease was associated with a lower 
rate of prescribing of EBTs (Table 10). Aspirin was prescribed less commonly among 
patients with diabetes than without.
328
 ACEI/ARBs were prescribed more commonly in 
patients with respiratory disease, diabetes and HF.
287,288,328
 However, rates of prescribing 
of ACEI/ARBs were lower in those with CKD and RF.
308
 The most widely studied group 
of drugs was β-blockers. The presence of a number of comorbidities (asthma, COPD, 
diabetes, PAD, HF and atrial fibrillation) was associated with lower rates of prescribing of 
β-blockers.287,288,290,309,310,328 Two comorbidities were associated with higher rates of 
prescribing of β-blockers, these were hypertension309 and CKD.308 One study,308 reported 
that statins were more commonly prescribed in patients with CKD.  Other studies, 
however, reported that statins were less likely to be prescribed in the presence of 
comorbidities.
288,308,328
 
 
Limitations in the reporting of the literature 
Few studies examined the relationship between comorbidities and the prescribing of EBTs 
following a diagnosis of MI. The STROBE scores for literature that described the 
association between comorbidities and prescribing of EBTs after MI ranged from 45% to 
68% (Table 10). Four studies did not mention their study design either in the title or in the 
abstract.
290,326,327,328 
Four authors did not state their study objectives.
287,288,308,328 
One study 
did not report the eligibility criteria for patients included in their analyses.
310 
The outcome, 
exposure, predictors and potential confounders variables were not defined clearly in one 
study.
310
 No studies discussed or identified potential sources of bias, though all studies 
reported how the statistical analysis was conducted. One study described a subgroup 
analysis.
308
 Four studies did not report the number of individuals included in the study and 
the patient population was not clearly described in other studies.
280,326,327,290, 309,328
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The rationale of excluding participants from a study was explained in four 
studies.
287,288,326,328 
Two studies did not describe the baseline characteristics of the included 
population.
326,328
 Missing variables were only reported in one study.
309
 Four studies 
presented the unadjusted and adjusted analyses in their results.
288,308, 309,310.  
Other studies, 
however, either presented unadjusted or adjusted results. Three studies discussed the 
limitations including the source of potential biases.
288,308,326
 
 
Limitations in the design and analysis of studies included in the literature review 
A number of gaps and limitations were also identified in the previous literature. Three 
studies were subject to bias. Norhammar et al.
328
 obtained comorbidity diagnosis from 
patients and is therefore subject to “recall bias”. They also excluded patients aged 80 years 
and older. Winkelmayer et al.
308
 excluded patients who did not survive more than 30 days 
after diagnosis “survivor bias” and Berger et al.326 excluded patients younger than 65 years  
selection bias. Limiting the study sample to one area, or one hospital will limit the 
generalisability of the results to the whole population. Younis et al.
327
 examined the 
association between comorbidities and prescribing EBTs after MI in a small sample 
recruited from one hospital. A number of studies were limited to one disease such as RF or 
diabetes.
326-328
 
  
In summary, there were a number of limitations in the literature surrounding the 
association between comorbidities and prescribing of EBTs in MI. There was also a wide 
range in the quality of reporting of studies as assessed by the STROBE guidelines. Only a 
few studies achieved a quality score of over 70%. The presence of comorbidities was 
generally associated with lower rates of prescribing of EBTs. 
 
 
 
112 
 
Table 10 Inequalities in prescribing of EBTs after MI by comorbidities 
Study Design/year/ Subject Reference/ 
 
Prescribing 
 
Medications 
 
Prescribing 
percentage 
OR, 95% CI Adjustment  P values / 
statistical 
significance   
STROBE  
Score (%) 
Berger et al326 
 
 
USA 
Retrospective cohort  
 
N=146765 
 
1994-1996 
ESRD vs. No  
 
ESRD=1025       
 
≥ 65 
Not reported  ACEI 
Aspirin 
β-blockers 
27.6 vs. 37.2 
62.0 vs. 78.9 
37.7 vs. 45.8 
 
Not reported  Unadjusted Not reported   
Austin et al280 
 
 
 
Canada 
Retrospective 
population cohort  
 
N=8706 
 
2005-06 
DM vs. No DM 
 
Age ≥ 65  
 
HF vs. No HF 
 
 
 
 
Cancer vs. No cancer 
 
Stroke 
 
 
 
CKD  
Within 90 days 
post-discharge 
 
Used linked 
administrative 
database  
ACEI 
β-blockers 
Statins  
 
ACEI 
β-blockers 
Statins 
 
ACEI 
β-blockers 
Statins 
 
ACEI 
β-blockers 
Statins 
 
ACEI 
β-blockers 
Statins 
69.7 vs. 79.0 
79.4 vs. 78.2 
77.9 vs. 79.6 
77.0 vs. 79.0 
75.5 vs. 79.2 
71.8 vs. 82.1 
 
64.9 vs. 78.9 
72.1 vs. 78.5 
64.1 vs. 80.0 
 
75.0 vs. 78.6 
75.4 vs. 78.4 
75.8 vs. 79.6 
 
59.7 vs. 80.3 
75.8 vs. 78.5 
74.6 vs. 80.0 
Not reported  Unadjusted Not reported  12/22 
 
(54.5%) 
Younis et al327 Retrospective cross-
sectional 
 
N=400 
1995-1999 
DM vs. not 
 
DM=201 
At discharge 
obtained from the 
case sheet 
1st MI 
β-blockers 23.4 vs. 52.3 Not reported  Unadjusted Not reported  10/22 
 
(45.5%) 
Norhammar 
et al328 
 
Sweden 
Retrospective 
longitudinal cohort 
N=25633 
1995-1998 
DM vs. Not 
 
DM=5193 
< 80 years 
At discharge, 
Medical records 
database (RIKS-
HIA) 
ACEI 
Aspirin 
β-blockers 
Statins 
50.0 vs. 34.0 
80.0 vs. 84.0 
75.0 vs. 80.0 
25.0 vs. 28.0 
1.45 (1.33-1.58) 
0.97 (0.87-1.08) 
0.97 (0.87-1.07) 
0.88 (0.80-0.97) 
Adjusted different confounders, 
however not particularly 
mentioned 
Not reported  10/22 
 
(45.5%) 
Heller et al290 
 
 
 
Retrospective 
longitudinal cohort 
study 
 
AF vs. No AF 
 
HF vs. No HF 
 
Outpatients 
prescription 
database with 90 
days post discharge  
β-blockers 
 
Not reported  0.86 (0.76-0.97) 
 
0.52 (0.47-0.58) 
 
Demographic and year of MI   0.01 
<0.01 
<0.01 
<0.01 
11.5/22 
 
(52%) 
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USA 
 
N=9534 
 
 
1994-1997 
COPD vs. No 
 
Asthma vs. No 
 
≥ 65 
0.49 (0.44-0.56) 
 
0.32 (0.22-0.47) 
 
Winkelmayer 
et al288 
 
Austria  
Retrospective cohort  
 
N=4105 
2004 
Asthma/COPD vs. No  
 
 
Within 120 days 
post discharge 
1st MI 
ACEI/ARBs 
β-blockers 
statins 
 
Not reported  1.07 (0.86-1.34) 
0.67 (0.55-0.83) 
0.87 (0.71-1.07) 
 
Age, sex, length of  stay at 
hospital, concomitant medications 
Not reported  12.5/22 
 
(57%) 
Gislason et 
al287 
 
 
 
Denmark  
Retrospective 
longitudinal cohort  
 
N=55315 
 
1995-2002 
DM vs. No DM 
 
 
HF vs. No HF 
 
 
Within 30 days  
post discharge  
 
1st MI 
ACEI 
β-blockers 
 
ACEI 
β-blockers 
Not reported  1.48 (1.40-1.58) 
0.79 (0.74-0.84) 
 
3.32 (3.19-3.47) 
0.71 (0.68-0.74) 
Age, sex, calendar year, 
concomitant treatment  
( loop diuretic & antidiabetic 
drugs) 
Not reported  15/22 
 
(68%) 
Sial et al309 
 
 
 
USA 
Cross-sectional 
 
N=444 
 
1990-1991 
COPD vs. Non 
 
HTN vs. Non 
 
HF vs. Non 
At time of 
discharge from 
medical records 
β-blockers 
 
Not reported  0.21 (0.07- 0.60) 
 
1.86 (1.11- 3.12) 
 
0.46 (0.27-0.79) 
Gender, age, race, comorbidities, 
other medications, MI 
characteristic, physician  
Not reported  13.7/22 
 
(62%) 
Wei et al310 
 
 
 
 
 
 
Scotland  
Retrospective 
longitudinal cohort  
 
 
N=865 
 
 
1994-1995 
OAD vs. Not 
 
DM   vs. Not 
 
HF    vs. Not 
 
PAD vs. Not 
Age 30 -93 
Post discharge, use 
record linkage 
database 
1st MI 
 
 
β-blockers Not reported  0.30 (0.15-0.60)* 
 
0.93 (0.57-1.65) 
 
0.33 (0.19-0.60) 
 
0.64 (0.31-1.32) 
Age, sex, deprivation, obstructive 
airway disease, diabetes mellitus, 
PAD, prior beta blockers, prior 
use of CCB, ACEI, alpha 
blockers, thiazide diuretic, loop 
diuretic, nitrates, antiplatelet drug, 
lipid lowering drug, steroid.  
Not reported  14/22 
 
(63.5%) 
Winkelmayer 
et al308 
 
 
USA 
Retrospective 
longitudinal cohort 
 
N=21484 
1995-2004 
CKD vs. Not 
 
CKD=3645 
 
≥ 65 
Within 30 days 
post discharge  
ACEI/ARBs 
β-blockers 
Statins  
38.0 vs. 45.0 
55.0 vs. 58.0 
28.0 vs. 26.0 
0.78 (0.75-0.82)+ 
1.00 (0.96-1.03) 
1.02 (0.96-1.08) 
Demographic, discharge year, 
comorbidities, health service 
measure, in-hospital procedures 
 15/22 
 
(68%) 
  ESRD vs. Not 
 
ESRD=436 
 ACEI/ARBs 
β-blockers 
Statins 
28.0 vs. 45.0 
57.0 vs. 58.0 
22.0 vs. 26.0 
0.57 (0.49-0.66) 
0.94 (0.86-1.04) 
0.83 (0.70-0.99) 
   
 
* Unadjusted OR: OAD 0.24 (0.15-0.39), DM 0.83 (0.51-1.35), HF 0.27 (0.16-0.46), PAD 0.52 (0.28-0.94), + Risk ratio, 
   OAD=obstructive airway disease, HF=heart failure, PAD=peripheral vascular disease, DM=diabetes mellitus,   
   RIKS-HIA= Register of information and knowledge about Swedish heart intensive care admissions, ESRD=End stage renal disease, CKD=chronic kidney disease 
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2.6 Inequality in prescribing of EBTs for Angina 
Patients who are diagnosed with angina usually have frequent episodes of chest pain which 
can be treated using nitrate sublingually or nitrate spray such as glyceryl trinitrate (GTN). 
Other treatments that are recommended by the guidelines include β-blockers, CCBs, 
ACEIs, aspirin and statins. The literature surrounding the prescribing of these medications 
in patients with angina will be discussed here.   
2.6.1 Inequalities by age in prescribing of EBTs for angina 
Unadjusted analysis 
Two unadjusted studies (Table 11) reported the association between age and prescribing of 
EBTs in patients with angina. Murphy et al.
329
 reported that the proportion of patients 
prescribed aspirin, ACEI/ARBs, CCBs and nitrates was higher among older patients 
compared to younger patients. In contrast, prescribing of β-blockers was higher among 
younger patients.
329
 This study included a wide range of EBTs, age grouping, large sample 
size and datasets that represent the Scottish population. Beaulieu et al.
330
 in a study from 
Canada with a large sample size, wide range of ages (although limited to a few EBTs and 
to older ages) reported that older patients were less commonly prescribed β-blockers or any 
lipid lowering drugs.
330
 This study used an out-patient pharmaceutical database. 
Clopidogrel was more often prescribed in young patients although prescription rates were 
very low in all ages.
329
 Statins were less likely to be prescribed in older patients.
329
 
Adjusted analysis 
Bennett et al.
238
 identified a cohort of patients who were prescribed a nitrate (as a proxy for 
a diagnosis of angina) and reported that older age was significantly associated with lower 
rates of prescribing of aspirin, β-blockers and statins but higher rates of ACEI prescriptions 
(OR 1.65; 95% 1.35-1.79, p <0.001). This study has a number of strengths such as 
including most recommended EBTs, a large sample size and wide range of age groups, and 
included all patients diagnosed with angina at any point  during their life (i.e. no age 
specificity), although this was adjusted for fewer confounders.  Whincup et al.
293
 examined 
the difference in prescribing of all lipid lowering drugs (LLD i.e. not specific for statins) in 
very limited sample and again reported that older patients were less likely to be prescribed 
a LLD than younger patients. 
 
Only a small number of studies examined the relationship between age and the prescribing 
of EBTs following a diagnosis of angina. The majority of studies demonstrated that older 
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age groups were less likely to receive most EBTs compared to younger age groups (Table 
11). However, studies were limited by a number of factors such as study design, data 
collection methods, and/or statistical methods. 
 
Limitations in the reporting of the literature 
The STROBE checklist score for the literature describing the association between age and 
prescribing EBTs ranged from 45% to 63.5% (Table 11). The study design was indicated 
using common terms such as cross-sectional in all studies. Two studies did not describe 
their study objectives.
293,329
 All authors described their study design clearly in the methods. 
The eligibility criteria were described in all studies.  Variables included in the analyses 
were not described clearly in one study.
 293
 Although, all studies described how their 
sample was collected, one study failed to describe the statistical methods. 
293
  
 
One study did not define the study cohort clearly.
238
 Though all studies did not explain the 
reason for non-participation. The participant characteristics were not described in one 
study.
238  . No studies reported the degree of missing data in their results.  Two studies did 
not report the number of outcome events.
293,238
 A clear and full presentation of outcomes 
including unadjusted results and results adjusted for potential confounders was only 
presented by one study.
293
 Two studies discussed their limitations.
329,330
   
   
Limitations in the design and analysis of studies included in the literature review 
A number of gaps were also identified in the previous literature as have been already 
discussed in part above. There are clear differences in prescribing of EBTs by age after 
angina diagnosis. Two studies, however, were unable to adjust the results for 
confounders.
329,330
 Even though many studies did adjust for confounders, the biggest 
limitation was that they did not adjust for a wide range of confounders that may explain the 
unadjusted association between prescribing and age. All studies used single resources for 
data, i.e. primary care or secondary care data sets.  
 
In summary, there were a number of limitations in the literature surrounding the 
association between age and prescribing of EBTs in angina. There was also a wide range in 
the quality of reporting of studies as assessed by the STROBE guidelines. Although 
Beaulieu et al.
330
 adjusted for a few confounders, it included the most recommended EBTs, 
had a large sample size and wide range of age groups. The study by Murphy et al.
329
 
although unadjusted examined a wide range of EBTs, over broad ages in fairly big sample 
116 
 
size and in datasets that represent the Scottish population. Both studies demonstrated that 
older patients were less commonly prescribed β-blockers and statins. 
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Table 11 Inequalities by age in prescribing of EBTs for angina 
Study Design /year Age range/ 
subject 
Prescribing 
 
Medications 
 
Prescribing 
percentage 
Eldest vs. youngest 
age group 
OR, 95% CI 
Old vs. young 
Adjustment P values / 
statistical 
significance   
STROBE 
Score (%) 
Murphy et al329 
 
 
 
Scotland 
Cross-sectional 
 
N=9508  
 
2001-2002 
< 45, 45-54, 55-
64, 65-74, 75-84, 
≥ 85 
Primary care 
practice database 
CMR 
ACEI/ARBs 
Aspirin  
β-blockers 
CCB 
Clopidogrel 
Nitrates 
Statins 
26.2 vs. 20.9 
65.6 vs. 50.5 
34.1 vs. 46.1 
36.2 vs. 22.3 
2.60 vs. 3.40 
59.1 vs. 43.7 
9.30 vs. 38.3 
Not reported Unadjusted Not reported 14/22 
 
(63.5%) 
Beaulieu et al330 
 
 
 
Canada  
Cross-sectional 
 
N=11141 
 
1996-1997 
65-69, 70-74, 
≥ 75  
Outpatients 
pharmaceutical 
database  
Antiplatelet  
β-blockers 
LLD 
Not reported Not significant 
0.71 (0.64-0.79) 
0.28 (0.25-0.31) 
Unadjusted Not reported 14/22 
 
(63.5%) 
Bennett et al238  
 
 
 
 
Ireland  
Retrospective  
cross-sectional 
 
N=47275 
 
1999-2000 
44-45, 55-64, 65-
69, 70-74,      ≥  
75 
 
Post discharge, 
GP prescription 
database 
ACEI  
Aspirin  
β-blockers 
Statins 
Not reported 1.65 (1.35-1.79) 
0.79 (0.72-0.85) 
0.42 (0.39-0.46) 
0.24 (0.22-0.25) 
Age, sex, health region < 0.001 
< 0.001 
0.02 
13 
 
(59%) 
Whincup et al293 
 
 
 
 
UK  
Cross-sectional 
survey  
 
N=286 
 
1998-2000 
< 60, 60-69, 
≥  70 
  
Post discharge, 
general practice 
records and 
patients 
questionnaire  
LLD* 7.00 vs. 49.0 0.18 (0.05-0.62) Previous revascularisation, 
age at last diagnosis, year of last 
diagnosis, manual social classes, 
smoking and geographical 
residence 
0.04 10 
 
(45%) 
 
*One third of prescriptions were statins, LLD= not specific lipid lowering drug including statins and fibrate.
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2.6.2 Inequalities by sex in prescribing of EBTs for angina 
Unadjusted analyses 
A number of studies examined the association between sex and prescribing of EBTs for 
angina (Table 12). Use of aspirin was higher among men than women,
331-333
 however, one 
unadjusted study reported that women were significantly more likely to be prescribed an 
antiplatelet agent.
330
 Two studies reported that the likelihood of being prescribed a β-
blocker was higher among men than women.
332,333
 Beaulieu et al.
330
 reported that the odds 
of being prescribed a β-blocker was significantly higher among women compared to men. 
One study examined the difference in prescribing CCBs and reported that men were more 
likely than women to be prescribed a CCB.
333
 Daly et al.
332
 reported that the proportion of 
men to be prescribed a statin was higher than women.  
 
Adjusted analyses 
Bennett et al.
238
 reported that aspirin was significantly more likely to be prescribed for men 
compared to women. Crilly et al.
334
 found that there were no sex differences in prescribing 
aspirin, however, this study included a relatively small sample size, and was adjusted for 
few confounders. Patients selection in this study was based on nitrate prescription, leading 
to potential selection bias. Murphy et al.
329
 in a large study and adjusting for more 
confounders including socioeconomic status reported that women were significantly less 
likely to receive antiplatelet agents (aspirin and clopidogrel) compared to men. Two 
studies examined the prescribing of ACEI/ARBs and reported that men were significantly 
more likely to receive these drugs than women.
238,329
 Similar results were reported for β-
blockers and statins.
238,329
 Furthermore, women were significantly less likely to receive a 
CCB. Women were also less likely to be prescribed a nitrate though this was not 
significant after adjustment.
329
 
 
Limitations in the reporting of the literature 
Only a few studies examined the relationship between sex and the prescribing of evidence 
based therapies following a diagnosis of angina. The majority of studies demonstrated that 
women were less likely to receive most EBTs compared to men (Table 12). The STROBE 
checklist used to assess the reporting qualities for the studies examined the prescribing 
inequalities based on sex difference. The score for literature described the association 
between sex and prescribing EBTs in those with angina ranged from 41% to the highest 
score 66% (Table 12). A balanced summary including background, aims, methods and 
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results was provided in all studies except one.
331 
Two studies failed to explain the scientific 
background
331,333 
and three studies did not describe their objectives.
329,332,333 
All authors 
described their study design, eligibility criteria, and cohort setting clearly in the methods. 
Variables included in the analyses were not described clearly in one study.
331 
The potential 
source of bias was only discussed in one study.
333
 However, all studies described how the 
sample was collected. All studies described the statistical methods. None of the studies 
described further analyses including sensitivity tests.  
 
One study did not define the study cohort clearly,
238
 and only one study explained the 
reason for non-participation.
334 
One study did not describe the characteristics of the 
cohort,
238  and none described the missing data. Two studies did not report the number of 
outcome events.
238,333
 Only two studies accounted for confounders.
332,334
 Three studies 
discussed their limitations
329,330,333
 and two studies included potential sources of bias in the 
limitations and discussion.
 332,334
  
 
Limitations in the design and analysis of studies included in the literature review 
The main limitation of the literature was the failure to adjust for confounders in most 
studies.
330-333
 In one of the studies that did adjust, selection bias (due to the definition of a 
case in the cohort) potentially limits the generalisability of results. 
334
 
 
In summary, there were a number of limitations in the literature surrounding the 
association between sex and prescribing of EBTs in angina. There was also a wide range in 
the quality of reporting of studies as assessed by the STROBE guidelines. A few studies 
achieved a quality score of over 66%.  These studies demonstrated that women patients are 
generally less commonly prescribed most EBTs than men. 
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Table 12 Inequalities by sex in prescribing of EBTs for angina 
Study Design/year Reference/ subject   Prescribing Medications Prescribing 
percentage 
Women vs. men 
OR, 95% CI 
Women vs. Men 
Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Beaulieu et al330 
 
Canada  
Cross-sectional 
 
 
1996-1997 
N=11141 
 
Outpatients 
pharmaceutical 
database  
Antiplatelet  
β-blockers 
LLD 
Not reported 1.43 (1.32-1.55) 
1.15 (1.06-1.25) 
Not significant 
 
Unadjusted  Not reported 14/22 
 
(63.5%) 
Scirica et al333 
 
 
USA 
Cross-sectional 
 
 
1995-96 
Women=1160 
 
Men=1788 
 
At time of discharge Aspirin 
β-blockers 
CCB 
Nitrates 
63.0 vs. 72.0 
42.0 vs. 43.0 
35.0 vs. 31.0 
45.0 vs. 47.0 
Not reported 
 
 
 
Unadjusted  Not reported 
 
12/22 
 
(54.5%) 
Daly et al332 
 
 
 
Europe  
Cross-sectional 
 
 
 
March-Dec 2000 
N=3379 
 
At time attending 
physician from 
electronic case 
record forms 
Aspirin  
β-blockers 
Statins 
73.0 vs. 81.0 
65.0 vs. 67.0 
45.0 vs. 51.0 
Not reported Unadjusted  < 0.001 
< 0.001 
   0.021 
13.5/22 
 
(61%) 
Bouvy et al331 
 
 
 
Netherland  
Retrospective cross-
sectional 
 
 
1996 
N=346 
 
General practice  Aspirin  33.0 vs. 66.1 Not reported Unadjusted  Not reported 9/22 
 
(41%) 
Bennett et al238  
 
 
 
 
Ireland  
Retrospective  
cross-sectional 
 
N=47275 
 
1999-2000 
Women=22524 
 
Men=24751 
 
 
Post discharge, GP 
prescription database 
ACEI  
Aspirin  
β-blockers 
Statins 
Not reported 0.82 (0.79-0.85) 
0.74 (0.71-0.77) 
0.87 (0.83-0.90) 
1.01 (0.97-1.05) 
Age, health region Not reported  13/22 
 
(59%) 
Crilly et al334 
 
 
 
 
 
England 
Retrospective Cross-
sectional 
 
 
 
 
Sep-Dec 2001 
Women=552 
 
Men=610 
 
Primary care, 
Liverpool primary 
care data project 
Aspirin  
β-blockers 
Statins 
81.0 vs. 86.0 
28.0 vs. 38.0 
53.0 vs. 56.0 
0.75 (0.53-1.03) 
0.69 (0.53-0.90) 
1.08 (0.85-1.38) 
Age, duration of angina, and 
previous MI 
Not reported  14.5/22 
 
(66%) 
121 
 
 
 
*Aspirin and clopidogrel  
LLD= Not specific lipid lowering drug including statins and fibrate.
 
Murphy et al329 
 
 
 
Scotland 
Cross-sectional 
 
N=9508 
 
2001-2002 
Women vs. men Primary care practice 
database 
ACEI/ARBs 
Antiplatelet*  
β-blockers 
CCB 
Nitrates 
Statins 
Not reported 0.69 (0.63-0.76) 
0.82 (0.74-0.90) 
0.86 (0.78-0.93) 
0.85 (0.78-0.93) 
0.96 (0.88-1.04) 
0.83 (0.76-0.91) 
Practice, age, deprivation 
category, comorbidity,  
<0.001 
<0.001 
<0.001 
<0.001 
   0.31 
<0.001 
14/22 
 
(63.5%) 
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2.6.3 Inequalities by socioeconomic status in prescribing of EBTs for angina 
Two cross-sectional studies examined the association between socioeconomic status and 
prescribing of EBTs for angina.
293,329
 In a cross-sectional study conducted in Scotland 
between 2001 and 2002, Murphy et al.
329
 investigated prescribing EBTs for those 
diagnosed with angina in a primary care setting. In adjusted analyses (for practice, age, 
deprivation category, comorbidity), the same study reported that patients residing in more 
deprived areas were significantly more likely to be prescribed ACEI/ARBs (OR 1.51; 
95%CI 1.23-1.85, p<0.001), CCB (OR 1.25; 95%CI 1.04-1.48, p=0.015), or nitrates (OR 
1.25; 95%CI 1.05-1.50, p<0.012) than those from the least deprived areas. However, there 
were no differences in prescribing β-blockers, statins, or antiplatelet agent. Whincup et 
al.’s293 study was conducted between 1998 and 2000, and used general practice records in 
Britain. This study was limited to one therapeutic group (LLD) and recruited a small 
sample size of men aged between 60 and 75 years. This study used an occupation-based 
measure of deprivation.  Patients in the non-manual class received more prescriptions of 
LLD compared to patients in the manual class (28% vs. 21%). After adjustment for 
covariates (previous revascularisation, age, year of last diagnosis, smoking status and 
geographic residence), manual social class was associated with lower odds of prescribing 
LLD (OR 0.75; 95% CI 0.42-1.32, p=0.32) compared to non-manual social class. The 
limitations of these studies and quality of reporting of these studies have been discussed 
previously.  
2.6.4 Trends over time in prescribing of EBTs for angina 
Trends over time in the prescribing of EBTs for angina have not been well studied. Smith 
et al.
335
 examined the prescribing rate of EBTs for a small sample (885) of patients 
hospitalised due to unstable angina from 1990 to 1995, which may not be relevant to 
current clinical practices and patients with stable chronic angina. Out-patient pharmacy 
records were used to identify elderly patients who filled a prescription within 90 days after 
hospital discharge, however, those who did not were excluded leading to selection bias. 
Furthermore, they only included the first diagnosis of unstable angina. Prescribing rates 
over time showed modest increases for aspirin (from 73.0% to 74.1%) and for β-blockers 
(33.3% to 36.4%). However, prescribing of ACEI/ARBs increased from 18.4% to 29.0% 
(p <0.01) and from 12.1% to 26.5% (p >0.01) for dihydropyridine CCBs, respectively. 
Conversely, the prescribing of nitrates declined significantly over the study period (81.0% 
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to 72.2%, p < 0.05), and declined for non-dihydropyridine CCBs mainly diltiazem (from 
56.9% to 40.1%, p <0.01).          
The quality of reporting for this study was assessed using the STROBE checklist and it 
scored 12/22 (54.5%). This study did not describe a clear background, statistical methods, 
and interpretations. 
2.6.5 Prescribing of EBTs for angina by comorbidities 
The influence of concomitant comorbidities on the prescribing of EBTs for angina was 
examined in one study. Beaulieu et al.
330
 described the association of comorbidities 
(COPD, HF and DM) in prescribing EBTs for patients with stable angina aged ≥ 65 years. 
Prescribing of EBTs was obtained from an out-patient pharmaceutical database for all 
prescriptions prescribed by either a general practitioner or cardiologist. The study only 
reported the significant results for each of the studied medications. Furthermore, it 
examined general groups of therapies (antiplatelet agents and LLD) instead of specific 
effective known drugs, e.g. aspirin, clopidogrel and statins. In a multivariable analyses, 
prescribing of EBTs was significantly lower among patients with COPD for β-blockers 
(OR 0.20; 95% CI 0.16-0.24), for antiplatelet agents (OR 0.73; 95% CI 0.62-0.86) and for 
LLD (OR 0.69; 95% CI 0.57-0.84). Patients with HF were less likely to receive β-blockers 
(OR 0.58; 95% CI 0.51-0.65), antiplatelet agents (OR 0.86; 95% CI 0.77-0.97) and LLDs 
(OR 0.60; 95% CI 0.52-0.70). Patients with diabetes, however, were more likely to be 
prescribed an antiplatelet agent (OR 1.13; 95% CI 1.01-1.26). The limitations of this study 
have been discussed previously. 
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2.7 Inequalities in prescribing of EBTs for PAD   
2.7.1 Inequalities by age in prescribing of EBTs for PAD 
Two studies described age differences in the prescribing of EBTs for patients diagnosed 
with PAD. Paquet et al.,
336
 a Canadian study that had a fairly large sample (n=5062) 
between 1997 and 2007 and included a population-based cohort of patients ≥ 50 years with 
PAD, reported that age did not influence the prescribing of antiplatelet agents within 90 
days following discharge. However, the proportion of patients prescribed an ACEI was 
higher among younger patients (50-64 years) compared to older patients aged ≥ 80 years 
(44.0% vs. 40%, p <0.05). Furthermore, the proportion of patients prescribed statins was 
higher in younger patients (57% vs. 33%, p< 0.005). In a cross-sectional study that was 
conducted in China,  Jing et al.
337
 examined the association between age and the 
prescribing of statins in patients with a history of atherosclerotic disease including PAD. In 
the same study, only 89 patients with PAD were included and interviewed. Using an 
unadjusted analysis, they reported that increasing age was associated with higher rates of 
being prescribed a statin. For example, 38% of patients aged between 70 to 80 years were 
prescribed a statin compared to 13% of those patients aged between 50 and 59 years.  
 
The quality of reporting for these studies was assessed using the STROBE checklist and 
was found to be 14.5/22 (66%) for Paquet et al.
336
 and 11/22 (50%) for the Jing et al.
337
 
study. Neither of these studies stated the study design either in the title or abstract. Jing et 
al.
337
 did not mention their study objectives and did not describe clearly the variables 
included in the study. Although recall bias was evident in the Jing et al.
337
  study, sources 
of potential bias were not described in either study. These studies described the statistical 
methods used in the analyses, however, they did not describe any further analyses. The 
number of eligible patients included in the study was indicated in both studies. In their 
study, Jing et al.,
337
 however, did not explain the reasons for those who were excluded 
from the analyses. Finally, both studies failed to discuss their study limitations and give an 
explicit overall interpretation of results.     
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2.7.2 Inequalities by sex in prescribing of EBTs for PAD 
A few studies described sex inequalities in prescribing of EBTs for patients with PAD 
(Table 13). All studies only reported the proportional differences in prescribing 
medication. Furthermore, three studies were small in sample size.
337,338,339
  Antiplatelet 
agents were prescribed more frequently for women compared to men though the difference 
was not statistically significant.
336
 Klein-Weigel et al.
338
 examined the use of aspirin and 
clopidogrel separately and reported that the rate of prescribing clopidogrel was 
significantly greater for women compared to men (p=0.03), but no significant difference in 
aspirin use was observed. Also, it was reported that women were more frequently 
prescribed ACEI and slightly less frequently ARBs than men. In another study, the 
prescription of ACEIs was significantly (p <0.005) higher in men compared to women.
336
 
Men were also more likely to be prescribed a β-blocker than women. Moreover, a large 
study reported that men were more likely to be prescribed statins,
336
 though two small 
studies found the opposite.  
 
 
Four studies examined the relationship between sex and the prescribing of EBTs following 
a diagnosis of PAD.  Generally, women were less likely to receive most EBTs compared to 
men (Table 13). The STROBE score for literature ranged from 45% to 66% (Table 13). 
The study design was not indicated in all studies. Only one study described their study 
objectives.
336 
All authors described their study design, eligibility criteria and cohort setting 
clearly in the methods. Variables included in the analyses were not described clearly in 
three studies.
337,338,339
 The potential sources of bias were not discussed in all studies, 
although one study was clearly subject to influence by recall bias.
 337
 All studies described 
the statistical methods, however, none of them described further analyses including 
sensitivity tests. All studies defined the study cohort clearly, however, only one study 
explained the reason for non-participation.
336 The participants’ characteristics were 
described in all studies but none indicated the number of missing data in their results.  One 
study did not report the number of outcome events.
339
 No studies presented an adjusted 
analysis. Two studies discussed their general limitations, though all failed to discuss the 
sources of potential bias.  
 
In summary, there were a number of limitations in the literature surrounding the 
association between sex and prescribing of EBTs in PAD. The most important limitation 
126 
 
was the lack of adjustment of the results. In general women were less likely to be 
prescribed EBTs.  
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Table 13 Inequalities by sex in prescribing of EBTs for PAD 
Study Design/year Reference/ subject   Prescribing Medications Prescribing 
percentage 
Women vs. men 
OR, 95% CI 
Women vs. men 
Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Paquet et al336  
 
 
 
 
Canada   
Retrospective cohort  
 
  
 
1997-2007 
Women=2610 
 
Men=3352 
Post discharge 
within 90 days  
ACEI  
Antiplatelet  
Statins 
39.3 vs. 44.5 
72.3 vs. 71.1 
39.3 vs. 44.5 
Not reported Unadjusted  < 0.005 
Not 
significant 
< 0.005 
14.5/22 
 
(66%) 
Klein-Weigel et 
al338 
 
 
 
 
Germany  
Retrospective cross-
sectional 
 
 
 
 
Jan 2007-June 2008 
Women=143 
 
Men=121 
 
Discharge  
medications 
documented in case 
records forms 
ACEI 
ARBs 
Aspirin 
Anticoagulant 
β-blockers 
Clopidogrel 
Statins 
54.5 vs. 52.9 
11.9 vs. 13.2 
89.5 vs. 91.7 
4.90 vs. 9.10 
33.6 vs. 44.6 
74.1 vs. 61.2 
72.0 vs. 71.2 
Not reported Unadjusted  0.80 
0.80 
0.60 
0.20 
0.07 
0.03 
0.70 
11/22 
 
(50%) 
Jing et al337  
 
 
 
China 
Retrospective cross-
sectional 
 
 
June 2007-Oct 09 
N=89 
 
Post discharge/ 
Diagnosis  
Statins  40.0 vs. 16.0 Not reported Unadjusted  Not reported 11/22 
(50%) 
McDermott et 
al339 
 
 
USA 
Randomised control 
trial  
 
 
Feb2006-Sep 09 
N=311 
 
Not reported  LLD 73.7 vs. 79.5 Not reported Unadjusted  Not reported 10/22 
(45%) 
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2.7.3 Inequalities by socioeconomic status in prescribing of EBTs for PAD 
One study examined the association of socioeconomic status with prescribing of  EBTs in 
patients with PAD.
340
 This study defined the socioeconomic status according to the median 
income of the patients. This study used the zip code of the residence to categorise 
participants into five quintiles. In the unadjusted analysis, patients in the lowest 
socioeconomic quintile were significantly less commonly prescribed statins (risk ratio 
[RR] 0.84, 95% CI 0.83-0.86; p< 0.0001). However, the difference between 
socioeconomic status and prescribing of statins was attenuated (RR 0.99, 95% CI 0.99-
1.01; p=0.77) after adjustment for practice, age, sex, history of MI, revascularisation in the 
previous 12 months, insurance, HF, diabetes, stroke, tobacco use and dyslipidaemia. 
Similarly, prescribing of an antiplatelet agent (aspirin and/or clopidogrel), was less likely 
in the lowest socioeconomic quintile (unadjusted RR 0.93; 95% CI 0.91-0.94; p< 0.0001). 
After adjustment, the difference was not significant (RR 0.99; 95% CI 0.99-1.01, p=0.87). 
The quality of reporting for this study was assessed using the STROBE checklist and it 
scored 13/22 (59%). This study did not state a specific study’s objectives, did not describe 
the potential source of bias, and did not give the reasons for non-participation at each 
stage.    
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2.7.4 Trends over time in prescribing of EBTs for PAD  
A few studies examined the trends over time in prescribing of EBTs after a diagnosis with 
PAD. All of these studies reported the proportional difference in prescribing EBTs (Table 
14). Two studies included the four main drugs used as secondary prevention after PAD 
diagnosis, however, these studies did not report a significance test for their results.
316,341 
Prescribing of antiplatelet agents significantly improved in two studies.
336,342
 Prescribing of 
ACEI and β-blockers also significantly improved over time in two studies. The degree of 
significance, however, was not reported in the other studies. The main limitation for these 
studies was that they all used unadjusted analyses to report prescribing improvements after 
diagnosis with PAD. One study used population cohort patients over 64 years, and limited 
their analysis to statins.
343
 
 
Limitations in the reporting of the literature 
The quality of the reporting of studies described the prescribing trends over the time was 
assessed by using the STROBE checklist and ranged from 50% to 73% (Table 14). Two 
studies did not indicate the design of the study.
336,342 
All authors described their study 
eligibility criteria, and cohort setting clearly in the methods. Variables included in the 
analyses were not described clearly in one study.
343 
The potential source of bias was 
discussed in one study.
341
  All studies described the statistical  methods and only one study 
described further analyses including a sensitivity test.
342
  
 
The study cohort was described clearly in all studies. Two studies explained the reasons for 
non-participation.
336,342 
The participants characteristics were described in all studies. 
 
However, none of the studies indicated the extent of missing data in their results.  Two 
studies did not report the number of outcome events.
343,342
 A clear and full presentation of 
outcomes including unadjusted results and results adjusted for potential confounders were 
not discussed in three studies.
336,343,342
 Three studies discussed the general limitations  but 
only one study discussed the sources of potential bias. Two studies discussed and gave 
explicit explanations for the results.
 342,341
   
 
In summary, there were a number of limitations in the literature surrounding the trends 
over time and prescribing of EBTs in PAD. There was also a wide range in the quality of 
reporting of studies as assessed by the STROBE guidelines. Two studies achieved a quality 
score of over 73%.
341,342
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Table 14 Trends in prescribing of EBTs for PAD 
Study Design/year Reference/ 
Subject 
Prescribing Medications Prescribing 
percentage 
OR, 95% CI Adjustment  P values / 
statistical 
significance   
STROBE 
Score (%) 
Gasse et al316 
 
 
 
Denmark  
Retrospective cohort  
 
N=3424 
 1997-2003 
1997 vs. 2003 
 
 
 
 
Within 6 months 
post diagnosis 
ACEI/ARBs 
Aspirin 
β-blockers 
Statins 
14.0 vs. 28.0 
23.0 vs. 41.0 
9.00 vs. 15.0 
3.00 vs. 22.0 
Not reported  Unadjusted  Not reported 15/22 
(68%) 
Subherwal et 
al342 
 
Denmark  
Retrospective cohort  
 
 N=34160 
2000-2007 
2000 vs. 2007 
 
≥ 40  
Within 3 months 
post diagnosis 
ACEI 
Antiplatelet  
Statins  
11.0 vs. 17.0 
29.0 vs. 59.0 
9.00 vs. 56.0 
Not reported Unadjusted  <0.0001 
<0.0001 
<0.0001 
16/22 
(73%) 
Paquet et al336 
 
 
 
 
Canada   
Retrospective cohort  
 
 N=5962 
1997-2007 
1997 vs. 2006 Post discharge 
within 90 days  
ACEI  
Antiplatelet  
Statins 
38.0 vs. 49.0 
67.0 vs. 80.0 
38.0 vs. 67.0 
Not reported Unadjusted  < 0.005 
< 0.005 
< 0.005 
10/22 
(45%) 
Al-Omran et 
al343 
 
Canada 
Retrospective cross-
sectional 
 
N=23886 
1995-2004 
1995 vs. 2004 
 
≥ 65 
Post discharge, 
obtained from 
ODB* 
Statins  6.80 vs. 43.3 Not reported Unadjusted  < 0.01 14.5/22 
(66%) 
Feringa et al341 
 
 
Netherland  
Prospective cohort  
 
N=2420 
 
Jan 1983-Jan2005 
1983-89 vs. 2000-
04 
Post discharge/ 
diagnosis, obtained 
from hospital 
records and patients   
ACEI 
Aspirin  
β-blockers 
Statins  
12.0 vs. 30.0 
15.0 vs. 27.0 
17.0 vs. 40.0 
 13.0 vs. 32.0 
Not reported Unadjusted  Not reported 16/22 
(73%) 
 
*ODB= Ontario Drug Benefit database. 
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2.7.5 Prescribing of EBTs for PAD by comorbidities 
Jing et al.
337
 examined the influence of concomitant hypertension and diabetes mellitus 
on the prescribing of statins for patients with PAD. They reported that compared to 
patients without hypertension, those with hypertension were less likely to receive a 
statin (13% hypertension vs. 28% no hypertension). Similarly, patients with diabetes 
were less likely to receive a statin (20% vs. 24%).  
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Summary  
This literature review showed that inequality in prescribing of evidence based therapies 
for CHD (including MI and angina), MI separately, angina separately and PAD may 
exist for age, sex and socioeconomic groups and be influenced by other chronic 
concomitant disease. Furthermore, prescribing of EBTs has improved over time. In 
general, older age and female sex were associated with less prescribing of evidence 
EBTs. Most of the previous studies, however, focused on CHD and MI. Most studies 
focused on inequality in prescribing EBTs for age and sex. But different methods and 
designs have been used in the previous studies making comparison difficult.  
The majority of prior studies examined prescribing inequalities using either a primary 
or secondary care database, which may mean that the results do not generalise to the 
other populations. Administrative databases were used in a number of studies allowing 
large sample sizes but not all studies were of sufficient size to make firm conclusions. 
A major limitation that was common to many of the studies was a lack of adjustment 
for confounders. This was the consistent limitation in the studies. Furthermore, of the 
studies that did adjust, a number did not adjust their results for socioeconomic status.  
A number of studies only examined one or a few select drugs. This was evident for all 
conditions. This makes comparison of the relative prescribing inequalities between 
drugs difficult, e.g. are statins less likely to be prescribed in the elderly than aspirin in 
the elderly.  
In this thesis, I will fill these gaps using a linked database of primary and secondary 
care records to identify patients, whether the first diagnosis was in hospital or by their 
GP records, and examine their prescription history. I will also examine various 
confounding variables including age, sex, socioeconomic status, comorbidities and 
calendar year, which will be studied in a consistent manner using one population-based 
data set. I will also examine a wide range of EBTs recommended for the treatment of 
MI, angina and PAD.  
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3.0 Aims and objectives  
 
Aims  
1. To describe the evidence based pharmacological therapies prescribed to patients 
diagnosed with MI, angina and PAD in Scotland. 
2. To describe the factors associated with rates of prescribing of evidence based 
therapies including age, sex, socioeconomic status, and comorbidities after first 
presentation of MI, angina and PAD. 
3. To describe trends over time in the prescribing of evidence based therapies for 
MI, angina and PAD over the period of the study.   
 
Objectives 
Multiple cardiovascular diseases will be identified. Each of the following objectives 
will be examined in relation to CHD (including angina and MI) and PAD.  
 To describe the baseline characteristics and incidence rate for patients 
diagnosed with MI, angina, PAD and PAD/CHD 
 To describe the rate of prescribing EBTs before, within 30 days and at any time 
after first diagnosis of MI, angina, PAD and PAD/CHD 
 To describe the effect of age, sex, socioeconomic status and comorbidities on 
prescribing rate of EBTs within 30 days after first diagnosis of MI, angina, PAD 
and PAD/CHD 
 To examine the independent effect of age, sex, socioeconomic status and 
comorbidities in prescribing EBTs within 30 days after first diagnosis of MI, 
angina, PAD and PAD/CHD   
 To describe trends over time of prescribing EBTs within 30 days after first 
diagnosis of MI 
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 To examine whether the trends in prescribing differ by age, sex, socioeconomic 
status and comorbidities.  
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4.0 Methods  
4.1 Data sources 
The data used for analysis were extracted from a primary care database (The 
Continuous Morbidity Record) and a secondary care database (The Scottish Morbidity 
Records). 
4.1.1 Electronic health records 
Electronic health record (EHR) is a systematic digital format records system that can be 
shared across different health care settings adopting a longitudinal collection of 
electronic health information about an individual patient or population.
344
 A wide range 
of data can be shared using EHR across different health care settings. These data may 
include demographics, medical history, medication and  allergies, immunization status, 
laboratory test results, radiology images, vital signs, personal statistics such as age and 
weight, and billing information.
345
 Generally, health care system is organised in 
different ways in different countries, however, generally it split into different settings 
including primary, secondary and tertiary care. Different health care professionals 
including physicians, nurses, radiologists, pharmacists, laboratory technicians and 
radiographers use EHR as well as administrative staff.
345
 One of the advantages of 
electronic records over paper records is the decrease of errors due to handwriting 
problems and ease of physical storage requirements. Moreover, electronic records 
simultaneously affect other error-reducing technologies by rendering them coherent. 
Another significant additional advantage of delivering a longitudinal record by EHR 
models is the ability to track all medical interactions by a particular patient and provide 
comprehensive data across populations.
346,347
  Many potential benefits for patients and 
providers of EHRs can be gained, including reduction in medical errors, delivery of 
more efficient health care, reduced costs, streamlined clinical workflow, better disease 
management, improved quality, and improved data tracking and accessibility.
270
 
Furthermore, health care researchers can potentially benefit from widespread EHR 
adoption. Observational data from clinical practice, obtained by EHR data 
“observational data from clinical practice” have implications in many aspects of 
research. Understanding practice patterns, assessing outcomes, evaluating quality 
indicators, and developing effective quality improvement interventions are some 
examples of these implications.
348
 Furthermore, EHRs can serve care organizations, 
insurance companies and other payers. This is particularly important with the growing 
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concern over the cost and quality of medical care.
349
 Moreover, accessing records by 
patients  reviewing lab results, scheduling appointments online, referring back to their 
discharge and follow-up instructions and even communicating with their physician or 
nurse practitioner via e-mail are all made possible with the use of EHRs. Consequently, 
these capabilities would enhance the ability for patients to become actively involved in 
managing their own care. Furthermore, the use of EHRs would result in improving 
efficiency within health care as well as decreasing costs. This is mainly due to 
preventing duplicate tests from being ordered as well as the ability of accessing a 
complete medical record.
350
 
 
Continuous Mortality Records database (CMR), which collects data from the primary 
care setting, and Scottish Morbidity Records (SMR) which collect data from the 
secondary care setting, are the two main data sets in Scotland. They are mainly handled 
by the information service division (ISD). These databases are comprised of a range of 
data including patients’ demography and treatments (which will be discussed in detail 
in the method chapter).    
 
4.1.2 The General Practice Administration System for Scotland  
Based on a software that was originally developed by Dr David Ferguson, The General 
Practice Administration System for Scotland (GPASS) was introduced in 1984 as a 
clinical record and practice administration software package. This relatively simple 
system was initially based on the routine administrative functions of the practice.  After 
a year and a half 85 general practices with approximately 750,000 patients in Scotland 
had installed the system. It was a practical system, requiring little knowledge of 
computing, other than elementary keyboard skills. Furthermore, within ten years 
(between 1988 and 1999) 80% of general practices, covering some 4,133,000 of the 
5,102,400 registered patients in Scotland, had used the GPASS system.
351,352
 The 
routine information included in the GPASS are: details of patient registration and 
identification, details regarding repeat prescription which recorded the interval between 
review consultations as well as  some details with regard to up to 9 authorised drugs per 
patient, some data related to generic drug preparations (unless commanded during data 
entry to authorise a specific proprietary preparation for an individual patient), 
additional morbidity factors including  smoking and blood pressure. A system that 
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enables patients to be flagged for drug trials using seven markers for each practice, 
dates related to routine major procedures such as most recent cervical smear test, 
records of blood pressure measurements, health visitor markers, e.g. for immunisations, 
and nurse markers such as  injection therapies.
351,353,354 
 
GPASS Data Evaluation Project (GDEP) was introduced in 1988 at the Department of 
General Practice and Primary Care, the University of Aberdeen. This project 
approached those responsible for GPASS with the concept of the Electronic 
Questionnaire (EQ). It aimed at interrogating the GPASS patient data files and store 
anonymised and aggregated data on floppy disc. These data can be returned by 
participating practices for analysis and feedback. In June 1988, the first version of EQ 
was released and it enabled each practising GP to obtain information that reflected a 
practice level summary of clinical, prescribing and administrative data.  This data is 
available on the practice computer and it goes beyond specific information about 
individual patients.
351,355
  
By April 1991, the EQ system had attracted, 328 GPASS general practices with 
1,954,759 patients that were receiving feedback.
351,356
  The number had increased to 
460 practices with 2,400,000 patients by 1998.  
Further development enabled collecting anonymous morbidity and drug data at patient 
and postcode level so that at the time of each diagnosis or prescription for individual 
patients the data was collected from the entire practice database. By doing this, the 
geographical, locality and regional analysis of data and linkage of morbidity and 
prescribing information have been achieved.
351,357
  
4.1.3 Continuous Morbidity Record (CMR) 
Almost all residents in Scotland are registered with a primary care practitioner and 
health care is provided free of charge. Individuals of any age can register and attend a 
primary health care practice at any point in time. Access to secondary care services is 
obtained through referral from primary care or by emergency admission. In the initial 
CMR dataset, patients’ information was collected by GPs, i.e. in participating general 
practices.  
The conception of CMR came about in 1995 as a reply for the recommendations for 
recording more detailed morbidity data for every GP consultation. These 
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recommendations were suggested by the University Department of General Practice in 
Aberdeen and the Information and Statistics Division (ISD) of the Scottish Office. This 
conception of CMR was introduced as a result of refinements made to GPASS software 
which was increasingly used by GPs as noted above. Data collected by this system was 
comprehensive and included symptoms, diagnoses, health promotion, illness 
prevention, and screening and administration activity.
351,352
  Using ‘Read Codes’, each 
doctor/patient contact was coded and recorded in GPASS.  As patient records used with 
the consultation were largely paper based, data operators supported by ISD, funded by 
the CMR project and employed within each participating CMR practice, coded and 
entered data directly into the clinical system after the patient contact had been 
completed. These data operators meant that potential drawbacks existed, however, as 
data collected by CMR practices lacked standardised criteria and this was largely 
discussed through internal validation. 
In general, the CMR project aimed to support existing data collection systems that 
already existed within primary care (EQ) and secondary care (SMR). In 1998, CMR 
was recognised as a national dataset.
329,358,359
 In 2002, 55 practices were participating. 
In 1999, the introduction of New GPASS’ software (a Microsoft Windows based 
version of GPASS) enabled the CMR database to be carried out centrally by the data 
collection systems of ISD. 
A positive feature of CMR is that clinicians recorded an additional code for every 
morbidity contact that identified whether the presenting condition is a first occurrence, 
a persistent problem with previous recent contacts, or a re-occurrence (defined as a 
subsequent presentation after a quiescent interval). This ‘modifier’ code can be used to 
separate disease workload from period prevalence and incidence. 
In April 2003, CMR was superseded by Practice Team Information (PTI). By February 
2010, 62 practices contributed in PTI which covered around 6% of the Scottish 
population (Appendix 3). Between 2003 and 2006, PTI information was collected by 
GPs, practice nurses, district nurses and health visitors in a general practice or a 
patient’s home. However, by 2007 data were only collected by GPs and practice 
nurses.
360,361
 These primary care data are representative of the Scottish primary care 
population in terms of age, sex, deprivation and urban/rural mix. Information from 
primary care obtained by practitioners at patients’ face-to-face consultations are entered 
in the CMR record, including: unique Patient identifier, modifier (described below), 
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date of birth, date of consultation, sex, type of encounter, post code, clinician ID and 
diagnosis. 
Each diagnosis is given a modifier that indicates whether the condition is new (first 
time diagnosis), recurrent or persistent. A diagnosis is recorded using a Read code, 
which was developed as a medical term thesaurus.
362
 It is used as a national coding 
system in primary care. Read codes comprise five alphanumeric characters. They start 
with broad classification and then narrow to become more specific. For example, 
‘G….’ denotes circulatory system disease, ‘G3…’ denotes ischaemic heart disease, 
‘G30..’ denotes acute MI, ‘G301.’ denotes acute MI not otherwise specified and 
‘G3011’ denotes acute anteroseptal infarction. The encounter type identifies whether 
the contact took place at a home visit, in out of hours or a surgery/clinic.
358,361,362
 
Prescribed medications are also recorded in the CMR by general practitioners. Entering 
a new prescription or a repeat prescription is freely inputted without guidance and as a 
consequence the prescribed drug can be recorded automatically as various trade or 
generic names that are registered in the British National formulary (BNF). Recorded 
information for a drug includes drug name, dose, date of prescription, date of first time 
prescribed (start date) and date of discontinuation (end date).
358,363
  
The included practices were located throughout Scotland (Appendix 3) with the highest 
concentration of practices and population in the central area of Scotland. Between April 
1996 and April 1999 the number of practices increased from 47 (267,146 registered 
patients) to 60 (364,346 registered patients).
358,361
 The decline in the recruitment of 
CMR practices was largely due to the release of several new GPASS versions.  
4.1.3.1 Data Quality 
ISD operates a continuous quality assurance system for completeness and accuracy of 
data entry into the CMR database. Completeness is assessed quarterly and it is 
measured by comparing the number of consultations on the CMR database in a week to 
the recorded contacts for the same week. Accuracy is assessed by comparing the 
clinical notes with the Read codes held on the CMR database for a random sample for 
80 contacts in each practice. In 1999-2000 the completeness of capture of contacts was 
91% and the accuracy of Read coding was 91%. Sensitivity of the CMR database has 
been tested in a survey that compared electronic data of chronic diseases with the paper 
records of 50 patients in each CMR practice. This survey demonstrated that 
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approximately 100% sensitivity was achieved. Furthermore, the sensitivity of repeat 
prescribing was found to be nearly 100%.
361,364
  
4.1.3.2 Validity of the CMR datasets 
Although no sensitivity analysis has been carried out specifically on CMR practices, a 
study by Whitelaw et al.
365
 showed that, in a sample of 5,567 patients who were 
registered in 41 out of the 410 GPASS practices that contributed to the EQ dataset in 
April 1992, a 75% sensitivity over 19 conditions was observed when comparing data 
recorded on the computer with patient notes. A sensitivity of nearly 100% was found 
for repeat prescriptions.  A series of quality assurance exercises undertaken more 
recently by ISD in 2001 have been reassuring in terms of data accuracy.
351
  
The practices included in the CMR are broadly representative of the Scottish 
population in relation to age, sex and socioeconomic status.
366
 The age and sex 
structure of the cohort population matches the age and sex structure of the Scottish 
population. The distribution of socioeconomic status is similar to the Scottish 
population. In an assessment of the dataset, 91.5% were not in deprived areas versus 
88.5% of the whole population of Scotland. Therefore deprived patients were slightly 
under-represented in the cohort but not significantly so. The CMR practices reflect the 
rural and urban mix of Scotland. They are located across Scotland including the islands 
(Appendix 3) and are therefore representative of the geographical distribution of the 
population of Scotland. For example 10.8% of patients are in rural communities 
compared to 8.5% of the whole Scottish population.
366
 There were no specific criteria 
required to become a CMR practice. There was no specific requirement to be of a 
certain standard to join the CMR. Experience in coding was not necessary as a coder 
was employed by the Information and Statistics Division (ISD) to provide coding 
support to the practice. The training of the coders was undertaken and maintained by 
ISD. 
A number of factors may influence the performance of the practice and lead to a 
potential source of bias. Single-handed practices did not participate in CMR (Dr Colin 
Simpson, ISD Custodian of datasets, personal communication) therefore the inability to 
account for this is not a potential source of bias in the analysis though the results may 
not be applicable to single-handed practices. However, prior studies have shown that 
there is no difference in standards between single-handed practices and other practices 
with multiple partners, therefore the lack of single-handed practices is unlikely to make 
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the results of these analyses biased.
367,368
 Indicators of quality of a practice are the 
Practices Accreditation (PA) and Quality Practice Award (QPA) standards as well as 
being a training practice; however, data on these characteristics are not recorded in 
CMR. (James McNally, Health and Social care pathway, ISD NHS National Services 
Scotland, and Paula L McClements, ISD NHS National Services Scotland, personal 
communication). Therefore analyses will be corrected for clustering to account for 
these potential differences in the absence of practice level data on quality indicators. 
4.1.3.3 Organisation and extraction of the CMR data 
Information extraction from the CMR is carried out through the use of an electronic 
questioner (EQ) software programme and data stored in Rich Text Formatted files.  
These are converted and stored in a Microsoft Access™ database, which is a relational 
database system. Microsoft Access™ uses Standard Query Language (SQL) queries to 
extract data from long lists of information into smaller and easier understandable tables. 
These are the patient table, the clinical events table and the prescribing table. All tables 
include the unique practice and patient identifiers. The patient table includes date of 
birth, sex, registration status (i.e. whether temporary, full registered or deregistered), 
and post code of residence. The clinical events table includes Read codes for every 
identified diagnosis, date of diagnosis, modifier code (to discriminate whether first, 
recurrent or persistent), and encounter number. The prescribing table includes 
information of the name, dose, quantity and frequency on every drug prescribed, start 
and end dates, and whether the drug was prescribed as repeat or acute script (Script 
type).
358,361
 
4.1.4 Scottish Morbidity Record (SMR)  
Secondary care data in Scotland is collected as a series of records at the individual 
level. The main record type denotes the general type of healthcare received during a 
hospital episode. They include outpatient attendances (SMR00), all discharges from 
acute hospitals (SMR01), maternity units (SMR02), psychiatric units (SMR04), 
neonatal units (SMR11) and geriatric long stay inpatients (SMR50). This study covers 
the analysis of SMR01 data.   
The SMR01 is a scheme of episode-based patient records which relate to all inpatient 
or day case discharges from non-obstetric and non-psychiatric wards across Scotland’s 
hospitals. A stay in hospital (continuous inpatient stay) can consist of one or more 
episodes. A new episode is generated if a patient changes specialty within a hospital or 
  
142 
 
moves between hospitals. The SMR01 record contains data from the case notes. These 
data include patients’ principal diagnosis and up to five comorbidities or secondary 
diagnoses, up to four operations, identifiable information, administrative details 
including hospital and consultant in charge, demographic information. These 
comorbidities are recorded if they affect the management of the patient or are 
associated with the main condition or are chronic conditions.  At discharge from each 
episode, principal diagnosis and comorbidities are assigned using codes from the World 
Health Organisation (WHO) International Classification of Diseases (ICD) system. The 
ICD coding system is a standard diagnostic tool for epidemiology, health management 
and clinical purposes. It is divided into several chapters and each disease given a 
numeric code comprised of three or four digits. Three digits are used to define major 
headings and the fourth digit to give more specificity of the diagnosis. For example, for 
MI the ICD-9 code is 410 (three digits) and more specifically 410.0 is MI of the 
anterior wall. In the tenth revision the coding system was revised using alphanumeric 
codes so that MI is I21 (three “digits”) and anterior wall infarction is I21.1 (four 
“digits”). Up to five digits are used in ICD coding but for practical purposes up to four 
are used commonly. All linkages with SMR data include as many digits as are coded in 
the database, be that 3 or 4 or 5.  Diseases were coded using the ninth revision (ICD-9) 
up to March 31
st
 1996 and the tenth revision (ICD-10) thereafter. 
The General Register Office for Scotland records the causes of death (GROS) for all 
Scottish residents.
361,369
 The codes used to classify deaths are allocated using ICD 
system. Classification of the cause of death is based on information collected on the 
medical certificate of cause of death which contains information on the underlying 
cause of death and up to three other causes considered to have contributed to the death. 
Linking individual patients records together was first demonstrated in 1968.
361
 In 
Scotland, secondary care records and death registration records belonging to the same 
patients have been linked together in the Scottish Record linkage system since 
1970.
370,371
 This system aimed to bring all records centrally stored in ISD into one 
dataset. Since 1980, the linked dataset holds hospital discharge records for non-
psychiatric, non-obstetric specialist (SMR01) together with Scottish Cancer Registry 
records (SMR06) and Registrar General’s death records. 
To provide profiles for each individual patient the probability matching record was 
used to link records from individual hospital episodes from different SMR schemes 
together with records from the Registrar General. Methods of probability matching 
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have been developed and refined in Oxford, Scotland and Canada since the early 1970s, 
and are used by the Record Linkage System to allow for inaccuracies in identifying 
information. After linking records together, two records are compared using identifying 
items such as surname, first initial, sex, month and day of birth, and postcode. The 
decision is made as to whether they belong to the same patient. A computer algorithm 
calculates a score for each pair of records that is proportional to the likelihood that they 
belong to the same patients. The huge volume of data would mean that it would be 
impossible to compare every record with all the other records and blocking is used to 
cut down the number of comparisons required. Only those records that have a 
minimum level of agreement in identifying items are compared. Probability matching 
then allows mathematically precise assessment of the implications of the levels of 
agreement and disagreement between records.
361,372,373
 
The process of linkage is complex and more details can be found in an overview by 
Jaro.
372
 The mathematical basis of the linking algorithms is outside of the scope of this 
thesis. However these are detailed by Jaro. In essence however, firstly blocks are 
formed for matching as described above. Weights and computed probabilities are then 
computed so that the two records match. A matrix of all matching variables, age, sex, 
postcode etc. is made and a linear sum made, above which a match is deemed to have 
been made. This process also looks for duplicates using the same algorithm. 
4.1.4.1 Quality of the data 
The linkage process is largely automatic as a threshold score based on probability 
matching dictates the decision as to whether the records belong together. Clerical 
checking has shown that the accuracy of probability matching is 98%.
361,374
 In ISD the 
Quality Assessment and Accreditation (QAA) unit monitor the quality of SMR data, by 
assessing accuracy, completeness, consistency and fitness for purpose. QAA performs 
routine validation of a sample of SMR01 records where data held on the sampled 
records are compared with information contained in the medical case notes.  Between 
2000 and 2002, assessment and accuracy of a 2% sample of SMR01 data demonstrated 
that the accuracy for recording of clinical data at the three-digit level was 88% for the 
main diagnosis, falling to 81% at the four-digit level.
375
 A recent assessment report 
(May 2012) of SMR01 data showed a similar accuracy of recording clinical data 
regarding the main condition at the three-digit level and four-digit level (described 
above 4.1.3).
376
 The accuracy of AMI, angina and chest pain coded as a principal 
diagnosis was shown to be 86%, 88% and 93% respectively. The accuracy of AMI 
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coded as a principal diagnosis had been shown to be 97% in the1996/97 audit.
377
 The 
accuracy of coding when the PAD is the main diagnosed condition is from 90 to 
100%.
378
   
4.1.4.2 Quality outcome framework  
General practice scheme has an essential public health role to improve the population 
health care.
379
 A number of countries introduced pay-for-performance to approach 
better care for chronic disease in the primary care.
380
 In the United kingdom (UK), a 
new contract for general practice known as Quality and Outcome Framework (QOF) 
was established in 2004, which includes the pay-for-performance elements.
379
 The 
QOF is a voluntary incentive program for general practices in the UK.
381 
The QOF 
measures a general practice’s achievement against a number of evidence-based 
indicators that are designed to encourage good practice.
382
 The QOF comprised of five 
main components “domains” including: clinical, public health, public health additional 
services, patient experience, quality and productivity. Each of these domains consists of 
a number of measures “indicator”, and payment for the general practice based on their 
level of achievement against those indicators. In the 2013/14 revision, the QOF 
measured achievement against 121 indicators, practices scored points on the basis of 
achievement against each indicator, up to a maximum of 900 points.
383
 Indicators are 
distributed on the main five domains as follow: 
 Clinical domain, comprised of 93 indicators across 20 clinical areas (e.g. 
chronic kidney disease, HF, hypertension) worth up to a maximum of 610 
points, 
 
 Public health domain, comprised of 9 indicators (worth up to 113 points) across 
four clinical areas – blood pressure, CVD (primary prevention), obesity and 
smoking, 
 
 Public health additional services domain, comprised of 9 indicators (worth up to 
44 points) across four service areas – cervical screening, child health 
surveillance, contraception and maternity services, 
 
 Quality and productivity domain, comprised of 9 indicators (worth up to 100 
points) as a service area in its own right (previously part of the now retired 
organisational domain), 
 
 Patient experience domain, comprised of one indicator (worth up to 33 points) 
that relates to length of consultations. 
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A study used data collected from the first two years of QOF. This study showed an 
increase in pre-target improvements in the quality of care for asthma and diabetes.
379,384
 
Campbell et al.
379,385
 reported that the rate of improvement for heart disease has 
significantly declined below the improvement rates of the years before introducing the 
QOF (p= 0.02). 
Furthermore, this study found that the total quality score for year 2007 was similar to 
that in year 2005. A systematic review of the literature demonstrated that a modest 
improvement in diabetes care has been indicated since the introduction of the QOF.
386
 
For those conditions covered by the QOF, there is evidence of excessive or 
inappropriate prescriptions or referrals.
387,388
 In a study of 147 practices in the UK, 
diabetes care was found to be steadily improving, but it was not possible to associate 
this with the QOF, however, this could be due to other factors such as the 
implementation of guidelines and the National Service Framework which may also 
contribute to improvements.
389
 Financial encouragement has shown that the rate of 
cervical cancer screening in general practices has improved after implementation of the 
pay-for-performance scheme.
390
     
4.1.4.3 Organisation and extraction of the data 
The linked data is stored as a conventional flat file of records. The records for each 
individual are stored adjacently in chronological order and marked with a unique 
personal identifier. Different types of record are stored in their original unlinked format 
and are preceded by several fields of linkage information. The dataset is complex and 
requires tailored FORTRAN programs to access the data. The staff in ISD use 
FORTAN programming to produce specific datasets.
351
 
4.1.5 Measurement of Socioeconomic Deprivation  
Socioeconomic Deprivation (SED) can be measured by a variety of available methods 
including the use of a single measurement such as income, education and occupation. 
Occupation based indicators of socioeconomic status are commonly used. They can 
represent the socioeconomic status by demonstrating a person’s place in society related 
to their social standing, income and intellect. Furthermore, occupation can characterise 
working relationships between employers and employees.
391
 In the Registrar’s General  
social class scheme occupations are classified into six categories and ranked from 
highest “professional I class” which includes doctors, lawyers, to “intermediate II”, 
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“skilled non-manual III-N”, “skilled manual III-M”, “partly skilled IV” to the lowest 
social class, “unskilled V” which includes jobs such as porters and labourers. This 
classification can also be narrowed to two categories, non-manual and manual, I-IIIN 
vs. IIIM-V.
392,393
 The most important strength of occupational measurements is their 
availability in different routine data such as the census and death registration. However, 
they cannot be used for those who are not currently employed and as the head of the 
household occupation is used to decide on the classification for a household it may not 
reflect the occupational class of all members of the house such as women.
392,393
  
Income is another indicator that can be used to measure socioeconomic status. Income 
is the best single indicator to determine an individual’s living standards.391 However, 
income is relative and can be influenced by the education attainment and occupation. 
Furthermore, it is a sensitive question that many participants may refuse to provide 
information on when asked and is therefore prone to bias.
391
 The policy of a health care 
system may limit the use of income as a socioeconomic status measure, for example in 
countries with free access to health care it may not be as good a determinant of health 
care use as in countries with no free health care system.
393
 Furthermore, income (as 
obtained from a job) may not fully encapsulate the income of a house or individual as 
other sources of income such as state benefits are not usually taken into account. 
Education is a commonly used measure of socioeconomic status in epidemiological 
studies.
391,393
 Education level is not such a sensitive question, so a higher proportion of 
participants are likely to respond to this question compared with questions on income. 
Education is easy to measure as years to complete education, or categorised by 
education level such as primary or high school, low or higher education. Level of 
education can be influenced by birth cohorts and access to free education. Therefore, 
the social and behavioural correlates of education may be influenced by age.
391,393
         
More complex measurements based on different domains can be used to measure 
socioeconomic status. The UK has a long history in constructing this type of 
measurements including: the Townsend Scale,
394
 Carstairs Index,
395
 the Index of 
multiple deprivation (IMD),
396
 and Scottish index of multiple deprivation (SIMD).
397,398
 
The Townsend and Carstairs measures are based on data collected by census, however 
the IMD and SIMD, using the routinely collected data, are regularly updated.
398
 For the 
purpose of this thesis I will discuss the Scottish index of multiple deprivation below.  
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Scottish Index of Multiple Deprivation 
The Scottish Index of Multiple Deprivation (SIMD) is an area based measurement that 
is used in Scotland to identify small area concentrations of multiple deprivation across 
Scotland.
399 
In August 2003, a report from the Scottish Centre for Research on Social 
Justice called “Measuring Deprivation in Scotland: Developing a Long-Term Strategy” 
was published by the Scottish Executive.
400,401
 A wide range of recommendations for 
the short, medium and long term measurement of deprivation were established. The 
recommendations in the long term strategy report to build on the Scottish Indices of 
Deprivation (SID) 2003 were executed by the Scottish Executive in order to deliver the 
Scottish Index of Multiple Deprivation (SIMD) 2004.
400,402
 
In the first published SIMD in 2004, all Scotland is divided into 6,505 small areas, 
which are known as data zones.
403
 In each data zone, the median population is 769 
individuals. The most deprived 976 data zones are the 15% most deprived in Scotland 
which tend to be the focus of policies and funding. A range of administrative systems 
and the Scottish Census of Population have been used as the source of the data for the 
SIMD 2004. Six domains including current income, employment, health, education, 
skills and training, and telecommunication formed the SIMD 2004. The relative weight 
and number of indicators for each domain are: 
 Income (7 indicators, given 28% of the total weighting),  
 Employment (3 indicators, 28%), 
 Health (7 indicators, 14%),  
 Education, skills and training (5 indicators, 14%), 
 Geographic Access to Services (8 indicators, 9%),  
 Crime (6 indicators, 5%) and  
 Housing (2 indicators, 2%). 
All together, they provide a comprehensive picture of deprivation within each data zone 
across Scotland, measuring both individual and area characteristics.
403,404
 Each domain 
is comprised of and measured using different indicators. For example the housing 
deprivation domain is measured by two indicators obtained from the 2001 census: 1) 
Persons in households which are overcrowded and 2) Persons in households without 
central heating. Scores from each domain are combined into an overall score using 
weights. This is further expressed as a rank, where 1 is the most deprived data zone in 
Scotland and 6505 is the least deprived data zone. These scores are then grouped into 
quintiles or deciles. A final score is ultimately produced by adding together the 
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household populations that experience each type of deprivation represented by the 
indicators.
403,404
 Because the SIMD is based on census data it can be applied to older 
data such as that used in this thesis. 
In 2006, the second version of SIMD was published.
405
 The new 2006 SIMD included a 
new public transport sub-domain in the geographic access to services domain and a 
new crime domain, which is a collection of selected recorded crimes linked to 
deprivation. The SIMD 2006 is therefore based on 37 indicators in seven domains as 
well as data from 2004 or 2005 with their relevant denominators. Furthermore, two 
SIMD versions were published in 2009 and 2012 and both used the same domains as 
2006.  
The degree of deprivation in one data zone compared to another cannot be determined 
by the SIMD. However, Scotland’s most deprived small areas on the overall index and 
each individual domain can be identified by the SIMD. This can be commonly 
achieved by applying a cut off such as 10%, 15% or 20%. This cut off should, however, 
be informed by whether it aims to target areas with the very highest concentrations of 
deprivation or to be wider ranging. The figure provided by SIMD is a relative measure 
of deprivation.  This means that the main output from SIMD – the SIMD ranks – can be 
used to compare data zones by providing a relative ranking from the most deprived 
(rank 1) to the least deprived (rank 6,505). 
One theoretical criticism of SIMD is that because it includes a health domain, its use in 
studying deprivation patterns in health is invalid because the SIMD and the health 
indicator being studied are not independent of each other. However, the health domain 
is weighted to account for a relatively small part of the overall SIMD (14% of SIMD 
2009 and 2012), and analyses of health inequalities using SIMD 2004 were found to 
give similar results whether the health domain was included or excluded, because that 
domain was so highly correlated with the overall index (Catherine Dickie, Office of the 
Chief Statistician and Performance, Scottish Executive, personal communication). 
Therefore on the advice of the Scottish Executive Office of the Chief Statistician and 
Performance, the health domain was not removed from the SIMD score.   
   
  
149 
 
4.2 Permission, governance, security and extraction of data for present 
study 
The Privacy Advisory Committee (PAC) was established in 1990 to provide ISD and 
Registrar General with independent advice on the processing of the personal data for 
which these organisations are responsible. It also advises other divisions of NHS 
National Services Scotland (NNS) as required. PAC was established as an advisory 
committee for NNS in 2007. PAC’s views are particularly sought in relation to any 
request of process to information that would involve the release of data that are, or have 
the potential to be, person-identifiable, and in respect of any new record linkage.  
PAC aims to advise on the protection of the privacy of patient information while at the 
same time recognising the need for legitimate access to information held in data sets by 
research workers and those involved in health administration for well-defined and bona 
fide purposes, subject to appropriate safeguards to maintain confidentiality. 
An application to use personal health information was submitted to the PAC to get a 
data set for current research project and approved. This application included 
information about: 
1- The team that will be involved in the study including all persons responsible for the 
design and analysis of the study, a principal contact person, information about the 
custodian, and the principal co-workers,  
2- General description of the study including the study background, aims, objectives, 
and methods, 
3- Requested data including all information that the researcher needs in the study such 
as age, sex and diagnosis, 
4- Information governance during the study.  
 In collaboration with Dr Colin Simpson (ISD custodian of datasets) the datasets were 
extracted for the purposes of this study. Each patient record contains information on 
date of birth, sex, general practice identifier, patient identifier, date of diagnosis, ICD 
code or Read code, prescribed drug, date of prescription, SIMD score, comorbidities, 
date of deaths. Patients’ personal information was fully anonymised (i.e. no name, 
address, postcode, practice identifier). The data was stored on a password protected, 
encrypted computer in a locked room in the university of the Glasgow.  
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4.3 Organizing data for analyses  
4.3.1 Prior to data analysis 
Prior to starting the data analysis many steps were conducted including manipulation of 
the datasets and merging dataset files together. The datasets are patients diagnosed in 
primary care, patients diagnosed in secondary care, prescriptions, deaths and SIMD 
scores. SIMD is categorised from one (least deprived quintile) to ten (most deprived 
quintile). Manipulating data includes creation of new variables for disease (MI, angina, 
isolated PAD and PAD/CHD), variables for medications used in the management of 
these diseases and which are recommended by guidelines, variables to identify first 
date of a disease diagnosis either at the hospital or at the general practitioner clinic 
(GP), variables to identify every time point when each patient was prescribed an 
evidence based drug, and creating comorbidity variables. To identify first time of 
diagnosis the Read codes for primary care, and the ICD9 and ICD10 for secondary care 
were used. Age was stratified into five groups (< 55, 55-64, 65-74, 75-84, and ≥ 85 
years). British national formulary (BNF) codes were used to identify the evidence 
based medications that are used in the management of MI, angina and PAD.    
Linking the CMR to SMR  
The data were extracted from the practices including Read codes, prescribing and 
demographics, and linked using probabilistic methods using the identifiers Community 
Health Index Number (CHI), date of birth, sex and postcode to the SMR01, which 
means that the linkage was of high quality. The same practices were included over time 
to minimise the effect of any changes in prescribing or expertise between practices or 
effect of entering or leaving the CMR which may have biased the results.  
4.3.2 Identifying patients with disease  
In this study all patients with a first diagnosis of MI, angina, isolated PAD and 
PAD/CHD from 1
st
 January 1997 to 31
st
 December 2005 were identified. A first 
diagnosis was defined as a first hospitalisation OR first recording of the diagnosis in 
primary OR secondary care during the time of study. This was achieved in the merged 
file of datasets that included all patients diagnosed in the primary or secondary care, by 
sorting the records by patient ID and then date of the record. The first date in which a 
diagnosis was recorded was considered the first diagnosis for each patient regardless of 
whether that was a record from primary or secondary care.  
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Data from primary care included 40 practices that contributed in the CMR project from 
1997-2005. The number of these practices was consistent for all study years. Patients 
with a first diagnosis in primary care were identified using the Read codes. In this 
dataset, modifiers were ignored as their quality is variable (personal communication, Dr 
Colin Simpson, ISD custodian of the datasets). The information on the GP’s 
consultation involved in the CMR project (including the diagnosis and modifier code), 
is handed to the data operator who enters the information immediately onto GPASS. It 
is not required that the data operator enter the previous diagnostic information into the 
datasets. Therefore prior diagnoses or problems are not always entered and therefore 
the modifier for code is not entered on every occasion leading to its variable quality. 
This does mean that some lifetime morbidity that a patient may have had, which is not 
an active disease during the study period, will not have been included in these analyses.  
However, in order to achieve best practice, GPs have been encouraged to enter 
summarised information of patients onto the GPASS system. Again this is variable in 
practice. This means that some information on chronic morbidity conditions may have 
been entered into the database with a modifier code. However, its use is not consistent 
enough to permit accurate use and therefore it was not used at any point in the analyses.  
 Patients diagnosed within secondary care were identified by ICD9 for cases prior to 
2000, thereafter ICD10 (Appendix 4). In the secondary care diagnostic dataset, patients 
may have been admitted due to a different cause, but the condition of interest, i.e. MI, 
angina or PAD could be one of a patient’s comorbidities. Therefore, these conditions 
were included in the analyses even if they were not the main cause for hospital 
admission. Furthermore, only the first diagnosis was included in the analyses which 
means that the case recurrence was excluded, i.e. individual cases were included just 
once in the analyses and there was no duplication. Comorbidities (coronary obstructive 
pulmonary disease (COPD), asthma, hypertension, atrial fibrillation, diabetes, cancer, 
HF, renal failure and stroke) were defined as any concomitant recorded diagnosis 
occurring within the previous five years. These comorbidities were considered if the 
date of diagnosis was identified within five years before the date index for the first 
diagnosis of MI, angina or PAD. The five years period was used for consistency. In the 
analyses of patients with PAD/CHD, PAD was considered as a principal disease and 
then patients were followed to identify whether they had complications with CHD.  
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Patient selection bias 
Patients who were identified with MI, angina or PAD in the primary or secondary care 
and had survived 30 days after diagnosis were included in this study. However, those 
who did not survive 30 days were excluded which means that this study is exposed to 
selection bias. A sensitivity analysis was undertaken to identify the number/proportion 
of those who died within 30 days after first diagnosis and had at least one prescription 
of EBTs.  
4.3.3 Identification of medications 
Common clinical guidelines were reviewed to identify EBTs for each individual 
disease. These guidelines include the Scottish Intercollegiate Guidelines Network 
(SIGN) guideline which is the principal guideline for Scotland, the National Institute 
for Health and Clinical Excellence (NICE) guideline, the European Society of 
Cardiology (ESC) guideline and the American College of Cardiology foundation and 
American Heart Association (ACC/AHA) guideline. Recommended medications in 
these guidelines were defined as EBTs and used to examine inequalities in prescribing 
for age, sex, socioeconomic deprivation and comorbidities.  
Patients diagnosed at hospital usually need to visit their GP to get a prescription within 
a month after hospital discharge. To establish the 30 days prescription, the times 
between first diagnosis in the primary care or date of discharge in the secondary care 
and prescription for EBTs were calculated. Prescribed medications within 30 days and 
at any time point were extracted from the primary care database. Any patients 
identified with a prescription for EBTs were introduced at one time in the study which 
means that there were no multiple observations for the same patients and there was no 
cumulative effect on the analysis. Medications were prescribed either in trade varied 
names or generic name therefore BNF and electronic medicines compendium (eMC) 
have been used to identify medications prescribed with trade name. All medications 
were then classified into their pharmacological groups according to the BNF coding 
system (Appendix 5), for example 2.5.5 including drugs affecting the renin-angiotensin 
system, 2.4 beta blockers. A medication was counted as having been prescribed if a 
prescription was issued within the 30 day period. As many general practitioners will 
supply a 30 day batch of medications it was assumed that patients who received a 
prescription before day 30 were still receiving it. While I cannot separate out those who 
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stopped medications, the aim was to document the intent to prescribe appropriate EBTs 
for each condition 
4.4  Statistical analysis 
The incidence of first diagnosis of MI, angina and PAD was calculated for sex, age and 
socioeconomic status. Incidence is the number of patients who present with illnesses 
for a first time (i.e. newly diagnosed) during a specified time. The rate of incidence was 
calculated per 1000 using the following formula: 
Incidence= new cases occurring during a given time period   X 1000 
                    Population at risk during the same time period 
   
 
The population at risk was the total registered practices population for the years 
studied.   
Percentage of prescribed EBTs was calculated for the first 30 days and at any time 
point after first diagnosis. Percentage of prescribed EBTs before first diagnosis was 
also calculated. Chi-square test was used to identify the association between 
prescribing an EBTs and other variables including age, sex, socioeconomic status and 
comorbidities.  
Multivariable logistic regression for those subsets of patients who did not die within 30 
days after first diagnosis was conducted to examine the independent effects of age, sex, 
socioeconomic status, years and comorbidities on prescribing EBTs within 30 days 
after first diagnosis. Adjustment was performed on the basis of available data. 
Unadjusted results were not presented as they would be confounded in this 
observational cohort.  In this study a sensitivity test was conducted to identify the 
number of patients who died within 30 days and had a prescription of EBTs. A higher 
ratio of patients who died within 30 days before getting a prescription of EBTs has 
been identified compared to those who had a prescription and died within 30 days. 
Therefore, to avoid overestimation I decided to exclude patients who died within 30 
days after first diagnosis.     
The odds ratios were adjusted for age group, sex, socioeconomic status, year, 
comorbidities including diseases which may affect prescribing for MI, angina or PAD 
(COPD/asthma, AF, hypertension, diabetes, cancer, renal failure, HF, PAD, stroke, 
angina), a drug prescribed prior to the first diagnosis and clustering of practices. 
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A statistical test for interaction with study year was performed for associations with 
significant P values. The rationale for this was to assess whether any identified 
inequality was narrowing or widening over the study period. 
4.4.1 Slope index of inequalities (SII) and relative index of inequalities (RII) 
The slope index of inequality (SII) represents the linear regression coefficient that 
shows the relation between the level of health or the frequency of a health problem in 
each socioeconomic category and the hierarchical ranking of each socioeconomic 
category on the scale.
406-408
 It is an absolute summary measure of inequality, and can be 
used to measure health inequalities based on socioeconomic status. The approach 
involves calculating the mean health status of each socioeconomic group and then 
ranking classes by their socioeconomic status (not by their health).
406
 The SII is 
sensitive to the mean rate of health in the population, therefore, another useful index is 
the relative index of inequality (RII) which is not sensitive to the mean rate of health in 
the population. RII can be calculated by dividing the SII by the mean rate or frequency 
of population health or the health outcome in the population.
407-410
    
 
4.4.2 Goodness of fit 
Goodness of fit or “accuracy of the model” in statistics is a term used to describe how 
well the logistic regression model agrees with the observed data. There are two 
essential components for the accuracy of mode calibration and discrimination. The 
Hosmer and Lemeshow test evaluates whether the logistic regression model is well 
calibrated so that probability predictions from the model reflect the occurrence of 
events in the data. A significant p value, usually <0.05, indicates that the model is not 
well calibrated i.e. that the fit is not good.  Discrimination is a measure to describe the 
ability of the model to separate subjects having the event from subjects not having the 
event. For this test from the logistic regression model I predicted the probability of 
being prescribed the EBT and the predictions were then ranked and split into fifths. 
Within each of the fifths the observed number prescribed EBT was compared to the 
predicted by multiplying the average probability in that group by the number of people 
in that group. If a model is well calibrated there should be good agreement between 
these numbers. The receiver operating characteristic (ROC) curve is the most 
commonly used measurement for discrimination. The minimum value for the ROC is 
0.5 (no discrimination) and the maximum value is 1.0. The values of ROC from 0.7 to 
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0.8 are considered as acceptable discrimination, values of 0.8 to 0.9 to show excellent 
discrimination, and values ≥ 0.9 to show outstanding discrimination of the model.411,412 
In this thesis the Hosmer and Lemeshow test and ROC curves were used to examine the 
magnitude of the goodness of fit for the logistic regression models that examined the 
odds of being prescribed EBTs in patients who  survived 30 days after first diagnosis of 
MI, angina, PAD and PAD/CHD. 
The SII and the RII were conducted in this study and used to measure the relation 
between the prescribing of EBTs after 30 days of hospital discharge or diagnosis of MI, 
angina or PAD, also the ROC to examine the accuracy of the logistic regression model.  
 
The presence of missing data was examined in this study, however there was no 
missing data for all of the variables included in the study. 
4.4.3 Tests of linearity 
Linear associations with age and year were tested using the contrast command in Stata. 
These are presented below for MI (Table 15), angina (Table 16), PAD (Table 17) and 
PAD with CHD (Table 18). As a non-linear trend was observed for many of the drugs 
the variables were categorised and treated as a categorical variable. Age was 
categorised into the groups <55, 55-64, 65-74, 75-85 and >=85 years. Year was 
categorised per year i.e. 1997-2005.  
Table 15 Tests of linear trend by age and year in prescribing evidence based therapies for MI 
 
ACEI/ARBs β-Blockers CCB Statins aspirin clopidogrel 
oral 
anticoagulant 
Age <0.001 0.01 0.75 <0.001 0.03 0.35 0.04 
Year <0.001 <0.001 0.06 <0.001 0.01 <0.001 0.26 
  
Table 16 Tests of linear trend by age and year in prescribing evidence based therapies for Angina 
 ACEI/ARBs β-Blockers CCB Nitrates Statins aspirin clopidogrel 
Other 
antianginal 
Age  0.53 <0.001 0.83 0.78 <0.001 0.003 0.87 0.27 
Year <0.001 <0.001 0.005 <0.001 0.004 <0.001 <0.001 0.15 
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Table 17 Tests of linear trend by age and year in prescribing evidence based therapies for isolated 
PAD 
 
 
ACEI/ARBs β-Blockers CCB PVD Statins aspirin clopidogrel 
oral 
anticoagulant 
Age  
 
0.73 0.003 0.21 <0.001 <0.001 0.01 0.05 0.94 
Year 
 
0.21 0.78 0.13 0.01 0.07 0.002 0.93 0.95 
 
Table 18 Tests of linear trend by age and year in prescribing evidence based therapies for PAD 
with CHD 
 ACEI/ARBs β-Blockers CCB PVD Statins aspirin clopidogrel 
oral 
anticoagulant 
Age  0.70 0.92 0.20 0.11 0.81 0.21 0.30 0.02 
Year 0.67 0.37 0.05 0.23 0.02 0.01 0.06 0.63 
 
4.4.4 Multiple testing and clustering 
Multiple testing  
To answer the research questions of this thesis many statistical analyses were 
conducted. A potential danger of carrying out multiple statistical tests is that the chance 
of detecting a spurious finding (i.e. finding p<0.05 when in fact the null hypothesis is 
true) is considerably increased. This is particularly the case when focusing on results of 
significant associations for hypotheses that were not pre-specified.
413
 I will only look at 
those associations that directly address the research questions that were defined a priori. 
The issue of preserving an overall significance level by using a multiple comparisons 
procedure such as Bonferroni is controversial in epidemiology. It is justified not to do 
such procedures because it can lead to a lack of power in detecting real associations and 
the null hypothesis becomes that all null hypotheses for each single test are 
simultaneously true, which is not of interest.
414
 Therefore, in this study I will not 
conduct a formal multiple comparisons procedure but will mention in the discussion 
that there is a chance that any of the statistically significant associations found might be 
spurious because of multiple testing. 
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Clustering  
In all regression models, cluster standard errors have been used (with the GP practice 
used as the clustering variable). This allows the standard errors, and therefore the 
confidence intervals, to be corrected for any lack of independence imposed by the 
hierarchical structure of the data. 
Hierarchical model “multilevel analysis” is a statistical method of analysis which can 
be used to analyse hierarchical or multilevel data. The data in this model are organized 
into a tree like structure (my data would have two levels, patients (level 1) nested 
within practices (level 2). Hierarchical analysis models allow the variance seen at 
multiple levels to be quantified, while also allowing estimation of covariate effects at 
every level of the hierarchy. The aim of my thesis was not specifically to look at 
geographical variation in EBT prescribing and obtain practice specific estimates. 
Therefore, I decided to account for the hierarchical structure in the data using cluster 
standard errors in the regression models rather than with multilevel analysis 
methodology. 
All analyses were undertaken using Stata (versions 12, Stata cooperation, College 
Station, Texas, USA). Statistical significance was assessed at the conventional level of 
5% (P<0.05). Results are presented with SD for means, and 95% confidence intervals 
for proportions and ratios.  
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5.0 Results  
The Scottish primary and secondary care database contained health care records for 
238,064 individuals for the period 1997-2005 (approximately 6% of the Scottish 
population).  
5.1 Myocardial Infarction (MI) 
Baseline demographic characteristics  
A total of 5162 individuals were identified as having a diagnosis of MI. In the study 
cohort, 1803 patients identified with first MI in the primary care and 3359 patients in 
the secondary care (Figure 1). Of these, 875 patients (261 from the primary care and 
596 from the secondary care) did not survive 30 days after hospital discharge and were 
excluded. In this study, 4305 (83.4%) patients who survived 30 days after first 
diagnosis were eligible to be included in the study. Of these, 1542 (35.8%) patients 
were identified in the primary care and 2763 (64.2%) patients in the secondary care. 
Table 19 summarises the characteristics of these patients and the subset of patients who 
survived 30 days after the first recorded diagnosis. Approximately 60% of the MI 
patients are men and the largest proportion were aged between 65 and 74 years. 
Patients residing in the most deprived areas (quintile 10) made up a higher percentage 
of patients in the dataset than those residing in areas from the least deprived area 
(quintile 1). The most prevalent comorbidities were hypertension (33.1%), angina 
(22.7%) and HF (22.2%). 
Table 20 shows the incidence of MI per 1000 population. The incidence rate was higher 
in men, 3.85 per 1000, than in women, 2.62 per 1000. The incidence of MI displays a 
clear age gradient, from 1.08 per 1000 in those aged less than 45 years compared to 
19.78 per 1000 in patients aged 85 years and over. The incidence rate of MI also 
increased with increasing levels of socioeconomic deprivation from 2.08 per 1000 in 
the least deprived quintile to 3.87 per 1000 in the most deprived quintile. The most 
recent study year, 2005, had a lower incidence rate of MI than the first study year, 
1999, incidence seemed to reach its peak in 2002/2003.  
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Figure 1 Flow diagram showing the selection of patients with a first diagnosis of MI  
                  Primary care                                                           Secondary care  
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Table 19 Baseline demographic characteristics 
 Survived 30 days 
(n=4305)§ 
Patients died within 30 
days after 1
st
 diagnosis 
(n=857)* 
All patients 
(n=5162) 
Male sex  
2628 (61.0%) 420 (49.0%) 3048 (59.0%) 
SD/variance 0.5/0.2 0.5/0.3 0.5/0.2 
Age (years):    
< 55 977 (22.7%) 45 (5.2%) 1022 (19.8%) 
55 – 64 979 (22.7%) 84 (9.8%) 1063 (20.6%) 
65 – 74 1175 (27.3%) 200 (23.3%) 1375 (26.6%) 
75 – 84 877 (20.4%) 323 (37.7%) 1200 (23.3%) 
85+ 297 (6.9%) 205 (23.9%) 502 (9.7%) 
Socioeconomic 
deprivation 
   
Q1 Least deprived 309 (7.2%) 58 (6.7%) 367 (7.1%) 
Q2 233 (5.4%) 31 (3.6%) 264 (5.1%) 
Q3 427 (9.9%) 88 (10.2%) 515 (9.9%) 
Q4 406 (9.4%) 88 (10.2%) 494 (9.5%) 
Q5  453 (10.5%) 87 (10.1%) 540 (10.4%) 
Q6 650 (15.1%) 150 (17.5%) 800 (15.5%) 
Q7 501 (11.6%) 104 (12.1%) 605 (11.7%) 
Q8 459 (10.6%) 87 (10.1%) 546 (10.5%) 
Q9 513 (11.9%) 99 (11.5%) 612 (11.8%) 
Q10 Most deprived 354 (8.2%) 65 (7.5%) 419 (8.1%) 
Year     
1997 422 (9.8%) 89 (10.4%) 511 (9.9%) 
1998 474 (11.0%) 97 (11.3%) 571 (11.1%) 
1999 461 (10.7%) 104 (12.1%) 565 (10.9%) 
2000 460 (10.7%) 106 (12.3%) 566 (11.0%) 
2001 516 (12.0%) 93 (10.8%) 609 (11.8%) 
2002 532 (12.4%) 98 (11.4%) 630 (12.2%) 
2003 545 (12.7%) 103 (12.0%) 648 (12.6%) 
2004 471 (10.9%) 96 (11.2%) 567 (11.0%) 
2005 424 (9.8%) 71 (8.3%) 495 (9.6%) 
Comorbidities    
COPD/Asthma 529 (12.3%) 145 (17.0%) 674 (13.1%) 
Atrial fibrillation  424 (9.8%) 119 (14.0%) 543 (10.5%) 
Hypertension 1401 (32.5%) 306 (35.7%) 1707 (33.1%) 
Diabetes  426 (9.9%) 90 (10.5%) 516 (10.0%) 
Cancer 250 (5.8%) 98 (11.4%) 348 (6.7%) 
Renal failure 108 (2.5%) 89 (10.4%) 197 (3.8%) 
Heart failure 863 (20.0%) 285 (33.2%) 1148 (22.2%) 
PAD 331 (7.7%) 106 (12.3%) 437 (8.5%) 
Stroke  373 (8.7%) 152 (17.7%) 525 (10.2%) 
Angina  1002 (23.3%) 170 (19.8%) 1172 (22.7%) 
 
 * Only 34 (4.0%) patients died within 30 days and had a prescription, § No missing data  
 
    COPD=Chronic obstructive pulmonary disease, PAD=Peripheral arterial disease 
 
 
 
 
 
  
161 
 
 
Table 20 Rate per (1000) of incident myocardial infarction  
 
Total population registered with 
GPs 
Patients with MI Rate 
Sex     
Men 792651 3048 3.85 
Women 807959 2114 2.62 
 Age     
<45 950345 1022 1.08 
45-64 410998 1063 2.59 
65-74 133058 1375 10.33 
75-84 80828 1200 14.85 
85+ 25381 502 19.78 
Socioeconomic    
Q1 305557 637 2.08 
Q2 358497 999 2.79 
Q3 401492 1341 3.34 
Q4 305760 1154 3.77 
Q5 266735 1031 3.87 
Years     
1999 227690 565 2.48 
2000 226503 566 2.50 
2001 225806 609 2.70 
2002 227146 630 2.77 
2003 228766 648 2.83 
2004 232554 567 2.44 
2005 232343 495 2.13 
 
Prescribing of evidence based therapies before and after first recorded diagnosis  
 
Table 21 shows prescribing of EBTs before and after the first recorded diagnosis of MI. 
Almost a third (30.3%) of patients were prescribed aspirin before first diagnosis of MI. 
After a first diagnosis, prescribing of aspirin increased to 42.8% (within 30 days) and to 
83.1 % at any time after. A similar pattern was observed for ACEI/ARBs: 19.0% to 
30.2% (within 30 days), β-blockers 24.1% to 35.5%, statins 15.6% to 36.1% and 
clopidogrel 2.6% to 11.6%.   However, prescribing of calcium channel blockers (CCB) 
declined 22.1% to 9.0%.         
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Table 21 Evidence based therapies prescribing for patients with incident diagnosis of myocardial 
infarction 
Medicine Prescribed drug before 
1
st
 diagnosis 
Prescribed drug after 
1
st
 diagnosis at any 
time 
Prescribed drug within 
30 days after 1
st
 
diagnosis* 
ACEI/ARBs 19.0% 72.4% 30.2% 
β-blocker 24.1% 72.4% 35.5% 
CCB 22.1% 36.4% 9.0%  
Statins 15.6% 83.5% 36.1% 
Aspirin 30.3% 83.1% 42.8%  
Clopidogrel 2.6% 29.3% 11.6% 
Oral anticoagulant 3.9% 91.4% 3.3% 
 
 
* This percentage is for patients alive 30 days after the 1
st
 diagnosis, ACEI=Angiotensin converting 
enzyme inhibitor, ARBs=Angiotensin receptor blockers, CCB=calcium channel blockers.   
 
 
5.1.1 Differences in prescribing of evidence based therapies for MI   
5.1.1.1 Age differences in prescribing of evidence based therapies  
Patients aged between 55 and 64 years received proportionally more prescriptions of 
ACEI/ARBs, β-blockers, statins, aspirin and clopidogrel compared with the other age 
groups (Figure 2). Prescribing of oral anticoagulants and CCBs was highest for 75 to 84 
year olds. In general the proportion prescribed a drug decreased as age increased. 
However, for CCBs and oral anticoagulants, prescribing increased as age increased 
(except in the oldest group). The percentages of prescribing EBTs for age group 55-64 
were 45.8%, 42.2% and 41.1% for aspirin, statins and β-blockers, respectively (Table 
25). After risk adjustment using multivariable analysis, there were statistically 
significant differences in the odds of prescribing between the age groups – ACEI/ARBs 
(p<0.001), β-blockers (p<0.001), statins (p<0.001), aspirin (p=0.002), and clopidogrel 
(p=0.01), (Table 1 appendix 6). 
Compared to the youngest age group (<55 years), the eldest patient group (≥ 85 years) 
were significantly less likely to be prescribed ACEI/ARBs (OR 0.46; 95% CI 0.32-
0.67), β-blockers (OR 0.38; 95% CI 0.26-0.54), statins (OR 0.21; 95% CI 0.11-0.32), 
aspirin (OR 0.66; 95% CI 0.47-0.92), clopidogrel (OR 0.51; 95% CI 0.31-0.85), and 
oral anticoagulants (OR 0.33; 95% CI 0.10-1.07). There were no significant differences 
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in prescribing EBTs between patients younger than 55 years and those aged between 55 
years and 74 years. However, significant differences in prescribing EBTs were 
identified in age group 75 to 84 years compared to <55 years for β-blockers (OR 0.64; 
95% CI 0.51-0.80), statins (OR 0.54; 95% CI 0.43-0.68), and clopidogrel (OR 0.67; 
95% CI 0.51-0.88) (Figure 3).   
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                                      Figure 2 Plot of age and prescription rate for evidence based therapies within 30 days after a first myocardial infarction 
                
 
                                                 ACEI=Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAC= Oral anticoagulant
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Figure 3 Forest plot of odds ratio of age and prescribing evidence based therapies within 30 days 
after first myocardial infarction 
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Patients aged <55 years are the reference category. Odds ratio adjusted for sex, socioeconomic status, year of 
diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal 
failure,  heart failure, and stroke, peripheral arterial disease, angina, clustered practices, and whether the drug was 
previously prescribed. 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel 
blockers, OAC=Oral anticoagulant 
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5.1.1.2 Sex differences in prescribing of evidence based therapies  
Prescribing of ACEI/ARBs, β-blockers, statins, aspirin and clopidogrel was higher in 
men compared with women, whereas women received more prescriptions for CCBs 
and oral anticoagulants than men (Figure 4). The values of the percentages shown in 
Figure 1 are in Table 25. β-blockers were prescribed for 38.2% of men versus 31.4% of 
women, statins 38.4% for men vs. 32.6% for women, aspirin 44.2% for men vs. 40.5% 
for women. As can be seen in Figure 5 (and Table 2 appendix 6), after adjustment using 
multivariable analysis compared to women, there was a trend towards men being more 
likely to be prescribed ACEI/ARBs (OR 1.12; 95% CI 0.91-1.39, p=0.27), CCB (OR 
1.02; 95% CI 0.81-1.28, p=0.90), statins (OR 1.09; 95% CI 0.94-1.25, p=0.20), aspirin 
(OR 1.09; 95% CI 0.96-1.24, p=0.15), and clopidogrel (OR 1.09; 95% CI 0.88-1.36, 
p=0.41), although these were not statistically significant. Men were, however, 
statistically significantly more likely than women to receive β-blockers (OR 1.18; 95% 
CI 1.04-1.33, p=0.01). There was a trend towards men being less likely to be prescribed 
an oral anticoagulant than women (OR 0.79; 95% CI 0.55-1.15, p=0.29). 
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                          Figure 4 Plot of sex and prescribing of evidence based therapies after a first diagnosis myocardial infarction 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAC= Oral anticoagulant
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Figure 5 Forest plot of odds ratio of sex and prescribing evidence based therapies within 30 days 
after first myocardial infarction 
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Women are the reference category. Odds ratio adjusted for age group, socioeconomic, year of 
diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, 
cancer, renal failure, heart failure, stroke, peripheral arterial disease, angina, clustered practices, 
and whether the drug was previously prescribed. 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= 
Calcium channel blockers, OAC=Oral anticoagulant 
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5.1.1.3 Socioeconomic differences in prescribing of evidence based therapies  
There were only minor differences in the prescribing of EBTs between the 
socioeconomic groups (Figure 6). These were not consistent or statistically 
significantly different. The multivariable analyses showed that after adjustment 
clopidogrel was significantly more likely to be prescribed for patients in decile 4 than 
most deprived patients in decile 1 (OR 1.57; 95% CI 1.02-2.53; 0.04), however there 
was no evidence of differences in the odds of prescribing between the socioeconomic 
deprivation groups (Figure 7).   
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  Figure 6 Plot of socioeconomic deprivation and prescribing of evidence based therapies after a first myocardial infarction 
 
Q1= Least deprived, Q10=Most deprived, ACEI=Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAC= Oral anticoagulant
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Figure 7 Forest plot of odds ratio of socioeconomic deprivation and prescribing evidence based therapies within 30 days after first myocardial 
infarction 
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Quintile 1 (Q1) least deprived is a reference. Odds ratio adjusted for sex, age group, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, 
cancer, renal failure, heart failure, and stroke, peripheral arterial disease, angina, clustered practices, and whether the drug was previously prescribed. 
                            SED=Socioeconomic deprivation ACEI=Angiotensin converting enzyme inhibitors, ARBs=Angiotensin receptor blockers, CCB=Calcium channel blockers, OAC=Oral anticoagulants.
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5.1.1.4 Trends of prescribing evidence based therapies from 1997 to 2005   
Figure 8 shows the trends in prescribing of EBTs within 30 days after first diagnosis of 
MI over the 9 years of the study. Prescribing of most EBTs increased steadily over the 
period of study, by contrast, prescriptions of CCBs and oral anticoagulants changed 
little over time (Figure 8, Table 25). From 1997 to 2005, prescribing of EBTs within 30 
days after a first diagnosis of MI increased for ACEI/ARBs (from 12.3% to 46.5%), β-
blockers (from 19.2% to 43.4%), statins (from 9.7% to 54.7%), aspirin (from 28.9% to 
53.3%), and clopidogrel (from 2000 to 2005, from 3.0% to 35.1%). There were no 
increases in prescribing of CCBs (from 6.6% to 8.7%) or oral anticoagulants (from 
0.7% to 5.0%). After risk adjustment using multivariable analysis, there were 
statistically significant differences in the odds of prescribing between the years of the 
study – ACEI/ ARBs (p<0.001), β-blockers (p<0.001), statins (p<0.001), aspirin 
(p<0.001) and clopidogrel (p<0.001). Compared to prescribing in 1997, patients in 
2005 were significantly more likely to be prescribed ACEI/ARBs (OR 5.25, 95% CI 
3.40-8.11), β-blockers (OR 3.60, 95% CI 2.49-5.20), statins (OR 11.11, 95% CI 6.70-
18.42), aspirin (OR 2.81, 95% CI 1.90-4.15) and oral anticoagulants (OR 5.91, 95% CI 
1.15-30.37). However, there was no evidence of change over time for CCBs (OR 0.88, 
95% CI 0.50-1.57) (Figure 9 and Table 4 appendix 6).             
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     Figure 8 Trends over the time in prescribing of evidence based therapies trends (1997-2005) after a first myocardial infarction 
 
          ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAC= Oral anticoagulant
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Figure 9 Forest plot of odds ratio of trends over time (1997-2005) and prescribing evidence based therapies within 30 days after first myocardial infarction 
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Year 1997 is the reference. Adjusted for sex, age group, socioeconomic status, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure,   heart failure, and stroke, peripheral arterial 
disease, angina, clustered practices, and whether the drug was previously prescribed. **2000 is the reference for clopidogrel. Clopidogrel divided by 10 for years 2003-05  
                  ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAC=Oral anticoagulant 
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5.1.1.5 Association between comorbidity and prescribing of evidence based 
therapies   
Prescribing of EBTs was generally higher among patients with hypertension than those 
without hypertension (Figure 10 c). However, other concomitant diseases were 
associated with different patterns of prescribing particular drugs (Figures 10a-10j). 
Asthma/COPD was associated with a lower rate of β-blocker prescribing than no 
asthma/COPD, 38.2% vs. 16.6%, respectively, Table 25. Atrial fibrillation (AF) was 
associated with lower use of aspirin 32.5% than those without AF 43.9%. However, 
patients with AF received more prescriptions of oral anticoagulant 17.9% than those 
without AF 1.8%. Patients with renal failure were often prescribed β-blockers, those 
with HF or PAD were more often prescribed ACEI/ARBs.  
As can be seen in Table 22, after adjustment using multivariable analysis, there were 
some statistically significant differences in the odds of prescribing a therapy in the 
presence of certain comorbidities. Patients with COPD/asthma were significantly less 
likely to receive β-blockers (OR 0.33; 95% CI 0.25-0.42), but more likely to receive 
CCBs (OR 2.17; 95% CI 1.65-2.86) than patients without COPD/asthma. Patients with 
AF were significantly less likely to receive aspirin (OR 0.61; 95%CI 0.50-0.75), or 
clopidogrel (OR 0.59; 95%CI 0.41-0.84), though they were more likely to be 
prescribed oral anticoagulants (OR 6.71; 95% CI 3.60-12.50) than patients without AF. 
Patients with hypertension were more likely to receive most EBTs than patients without 
hypertension. Patients with diabetes were less likely to receive statins (OR 0.71; 95% 
CI 0.59-0.85) than those without diabetes. Patients with HF were significantly more 
likely to be prescribed ACEI/ARBs (OR 1.94; 95% CI 1.57-2.40) than patients without 
HF. Patients with stroke were less likely to be prescribed most EBTs, however, they 
were more likely to receive oral anticoagulants (OR 1.86; 95% CI 0.97-3.57) than those 
without stroke. Patients with angina were more likely to be prescribed CCBs (OR 1.41; 
95% CI 1.10-1.81) than those without angina. 
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                        Table 22 Association between comorbidities and prescribing of evidence based therapies within 30 days after a first myocardial infarction 
Adjusted OR, 
95% CI, 
p value 
 
ACEI/ABs β-blockers CCB Statins Aspirin Clopidogrel 
Oral-
anticoagulant 
COPD 
0.99 (0.78-1.25), 
0.90 
0.33 (0.25-0.42), 
0.01 
2.17 (1.65-2.86), 
0.01 
0.87 (0.70-1.08), 
0.21 
1.07 (0.89-1.29), 
0.45 
0.80 (0.60-1.04), 
0.16 
0.37 (0.17-0.78), 
0.01 
AF 
0.81 (0.63-1.02), 
0.08 
0.60 (0.46-0.78), 
0.01 
0.68 (0.48-0.96), 
0.03 
0.83 (0.65-1.07), 
0.16 
0.61 (0.50-0.75), 
0.01 
0.59 (0.41-0.84), 
0.01 
6.71 (3.60-12.50), 
0.01 
 HYP 
1.11 (0.95-1.29), 
0.15 
1.20(1.02-1.41), 
0.02 
1.29 (1.02-1.63), 
0.03 
1.23 (1.04-1.47), 
0.02 
1.19 (1.03-1.37), 
0.01 
1.40 (1.01-1.83), 
0.02 
0.66 (0.48-0.91), 
0.01 
Diabetes 
0.96 (0.77-1.19), 
0.73 
0.79(0.65-0.98), 
0.03 
0.79 (0.53-1.18), 
0.26 
0.71 (0.59-0.85), 
0.01 
0.80 (0.67-0.96), 
0.02 
0.86 (0.65-1.16), 
0.41 
1.06 (0.61-1.86), 
0.81 
Cancer 
0.85 (0.62-1.16), 
0.33 
0.79 (0.63-0.99), 
0.04 
0.78 (0.48-1.26), 
0.32 
0.96 (0.72-1.27), 
0.80 
0.97 (0.74-1.28), 
0.87 
0.88 (0.51-1.62), 
0.73 
0.89 (0.47-1.67), 
0.72 
Renal failure 
0.53 (0.32-0.89), 
0.02 
0.64 (0.42-0.98), 
0.04 
1.06 (0.55-2.04), 
0.84 
0.69 (0.44-1.08), 
0.12 
0.85 (0.54-1.33), 
0.48 
1.14 (0.69-1.95), 
0.60 
0.28 (0.05-1.52), 
0.14 
HF 
1.94 (1.57-2.40), 
0.01 
0.87 (0.70-1.09), 
0.24 
0.67 (0.51-0.90), 
0.01 
1.07 (0.88-1.30), 
0.48 
1.16 (0.96-1.40), 
0.12 
0.81 (0.66-1.04), 
0.13 
1.63 (0.90-2.95), 
0.11 
PAD 
1.24 (0.92-1.68), 
o.15 
0.81 (0.64-1.02), 
0.08 
0.94 (0.67-1.33), 
0.76 
1.07 (0.79-1.45), 
0.63 
0.89 (0.66-1.19), 
0.46 
1.06 (0.69-1.95), 
0.70 
1.16 (0.55-2.44), 
0.70 
 Stroke 
0.73 (0.59-0.92), 
0.01 
0.53 (0.42-0.67), 
0.01 
1.33 (0.88-2.00), 
0.17 
0.63 (0.50-0.80), 
0.01 
0.64 (0.50-0.83), 
0.01 
0.65 (0.40-1.07), 
0.10 
1.86 (0.97-3.57), 
0.06 
Angina 
0.91 (0.76-1.07), 
0.25 
0.97 (0.79-1.19), 
0.82 
1.41 (1.10-1.81), 
0.01 
1.08 (0.87-1.33), 
0.46 
0.92 (0.77-1.11), 
0.43 
0.92 (0.66-1.35), 
0.80 
0.76 (0.47-1.23), 
0.27 
 
*   Adjusted for sex, age group, socioeconomic status, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure, heart 
failure, and stroke, peripheral arterial disease, angina, clustered practices, and whether the drug was previously prescribed. **2000 is the reference for clopidogrel, 
  
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers.
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          Figure 10 Plot of comorbidities and prescribing of evidence based therapies within 30 days after first MI 
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                                         5g                                                                                   5h                                                                    5i 
             
                                       5j 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, BB=beta blockers, CCB= Calcium channel blockers, COPD=chronic obstructive pulmonary 
disease, OAC=oral anti-coagulants
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
p
e
r
c
e
n
ta
g
e
 
EBTs 
Heart failure NO heart failure 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
P
e
r
c
e
n
ta
g
e
 
EBTs 
PAD NO PAD 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
P
e
r
c
e
n
ta
g
e
 
EBTs 
Stroke NO stroke 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
p
e
r
c
e
n
ta
g
e
 
EBTs 
Angina NO Angina 
  
179 
 
5.1.1.6 Testing for interactions with year 
Where statistically significant findings were found in sections 5.1.1.1–5.1.1.3 and 
5.1.1.5, the interaction between that variable and year was tested (Table 23). It can be 
seen that the only statistically significant interaction was observed between age and 
year for ACEI/ARBs (p=0.03). To examine the nature of this interaction the adjusted 
ORs for age group are shown for each year in Table 24, and the unadjusted prescribing 
rates for ACEI/ARBs by age group and year are shown in Figure 11. It is clear that 
there is no overall trend and the interaction result will have been strongly influenced by 
1999 where the association between age and prescribing of ACEI/ARBs is the opposite 
of that seen for all other years. The rationale for this was to assess whether any 
identified inequality was narrowing or widening over the study period. 
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Table 23 Interaction between year of diagnosis and selected variables and therapies. Variables and 
medications selected on the basis of significant multivariable associations. 
Factors Medication P value 
Age group   
 ACEI/ARBs 0.03 
 β-blocker 0.65 
 Statins 0.70 
 Aspirin 0.63 
 Clopidogrel 0.28 
   
Sex   
 β-blocker  0.46 
Socioeconomic deprivation    
 Oral anticoagulant 0.70 
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Table 24 Adjusted Odds ratio of the prescribing of ACEIs/ARBs and age stratified by year of diagnosis of myocardial infarction 
 1997 1998 1999 2000 2001 2002 2003 2004 2005 
<55 
0.70 (0.15-
3.14), 0.64 
0.16 (0.02-
1.36), 0.09 
2.58 (0.94-
7.09), 0.07 
0.39 (0.13-
1.09), 0.07 
0.55 (0.23-
1.29), 0.17 
0.32 (0.13-
0.75), 0.01 
0.25 (0.09-
0.68), 0.01 
0.58 (0.23-
1.41), 0.23 
0.36 (0.15-
0.89), 0.03 
55-64 
0.94 (031- 
2.87), 0.92 
1.05 (0.35-
3.20), 0,92  
0.42 (0.13-
1.32), 0.14 
0.88 (0.33-
2.47), 0.81 
0.53 (0.19-
1.47), 0.22 
0.95 (0.34-
2.61), 0.92 
0.56 (0.21-
1.52), 0.26 
0.53 (0.19-
1.48), 0.23 
0.57 (0.21-
1.59), 0.28 
65-74 
0.57 (20-   
1.61), 0,29 
1.75 (0.61-
4.96), 0.29 
0.46 (0.15-
1.36), 0.16 
0.82 (0.32-
2.12), 0.70 
0.87 (0.34-
2.22), 0.77 
1.06 (0.41-
2.73), 0.89 
1.22 (0.47-
3.14), 0.66 
0.66 (0.25-
1.74), 0.41 
1.27 (0.48-
3.38), 0.62 
75-84 
1.33 (0.40-
4.41), 0.74 
0.74 (0.22-
2.48), 0.63 
0.28 (0.08-
0.98), 0.05 
0.74 (0.23-
2.30), 0.60 
0.34 (0.12-
1.04), 0.06 
0.87 (0.28-
2.67), 0.80 
0.91 (0.30-
2.79), 0.88 
0.38 (0.12-
1.21), 0.10 
1.57 (0.49-
4.97), 0.44 
≥85 
0.23 (0.02-
3.11), 0.27 
4.27 (0.32-
56.1), 0.27 
0.27 (0.04-
1.64), 0.16 
1.80 (0.29-
11.1), 0.52 
1.26 (0.23-
7.05), 0.79 
2.16 (0.38-
12.5), 0.38 
2.77 (0.46-
16.7), 0.26 
1.20 (0.21-
6.89), 83 
1.90 (0.33-
10.8), 0.46 
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Figure 11 Years trends of prescribing ACEI/ARBs based on age     
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Table 25 Prescribing of evidence based therapies within 30 days after first MI for patients who survived the first 30 days after a first diagnosis (N=4305) 
 
ACEI/ARBs β-blocker CCB Statins Aspirin Clopidogrel Oral anticoagulant 
N=4305 1299 (30.1%) 1530 (35.5%) 386 (9.0%) 1555 (36.1%) 1841 (42.8%) 498 (11.6%) 143 (3.3%) 
Male (n=2628) 823 (31.3%)* 1004 (38.2%) 225 (8.6%) 1008 (38.4%) 1161 (44.2%) 325 (12.4%) 77 (2.9%) 
Female (n=1677) 467 (28.0%) 526 (31.4%) 161 (9.6%) 547 (32.6%) 680 (40.5%) 173 (10.3%) 67 (4.0%) 
Age (years)        
< 55 (n=977) 279 (28.6%) 397 (40.6%) 65 (6.7%) 401 (41.0%) 432 (44.2%) 124 (12.7%) 20 (2.0%) 
55 – 64 (n=979) 330 (33.7%) 402 (41.1%) 82 (8.4%) 413 (42.2%) 448 (45.8%) 137 (14.0%) 28 (2.9%) 
65 – 74 (n=1175) 375 (31.9%) 431 (36.7%) 116 (9.9%) 446 (38.0%) 522 (44.4%) 130 (11.1%) 45 (3.8%) 
75 – 84 (n=877) 256 (29.2%) 243 (27.7%) 101 (11.5%) 253 (28.8%) 340 (38.8%) 84 (9.6%) 45 (5.1%) 
85+ (n=297) 59 (19.9%) 57 (19.2%) 22 (7.4%) 42 (14.1%) 99 (33.3%) 23 (7.7%) 6 (2.0%) 
Socioeconomic 
deprivation 
       
Q1 (n=309) 80 (25.9%) 109 (35.2 %) 26 (8.4%) 95 (30.7%) 124 (40.1%) 28 (9.1%) 11 (3.6%) 
Q2 (n=233) 79 (33.9%) 83 (35.6%) 19 (8.1%) 93 (39.9%) 93 (39.9%) 27 (11.6%) 6 (2.6%) 
Q3 (n=427) 122 (28.5%) 156 (36.5%) 36 (8.3%) 156 (36.5%) 182 (42.6%) 49 (11.5%) 14 (3.3%) 
Q4 (n=406) 146 (35.9%) 156 (38.4%) 34 (8.4%) 151 (37.2%) 177 (43.6%) 53 (13.1%) 6 (1.5%) 
Q5 (n=453) 140 (30.9%) 166 (36.6%) 31 (6.8%) 176 (38.8%) 198 (43.7%) 52 (11.5%) 23 (5.1%) 
Q6 (n=650) 190 (29.2%) 234 (36.0%) 61 (9.3%) 225 (34.6%) 282 (43.4%) 73 (11.2%) 21 (3.2%) 
Q7 (n=501) 140 (27.9%) 158 (31.5%) 46 (9.2%) 176 (35.1%) 203 (40.5%) 56 (11.2%) 22 (4.4%) 
Q8 (n=459) 145 (31.6%) 161 (35.1%) 49 (10.7%) 165 (35.9%) 197 (42.9%) 59 (12.8%) 18 (3.9%) 
Q9 (n=513) 156 (30.4%) 169 (38.2%) 47 (9.2%) 197 (38.4%) 234 (45.6%) 60 (11.7%) 14 (2.7%) 
Q10 (n=354) 101 (28.5%) 111 (31.3%) 37 (10.4%) 121 (34.2%) 151 (42.4%) 41 (11.6%) 9 (2.5%) 
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Year ACEI/ARBs β-blocker CCB Statins Aspirin Clopidogrel Oral anticoagulant 
1997 (n=422) 52 (12.3%) 81 (19.2%) 28 (6.6%) 41 (9.7%) 122 (28.9%) 0 (0.0%) 3 (0.7%) 
1998 (n=474) 72 (15.2%) 118 (24.9%) 28 (5.9%) 95 (20.0%) 165 (34.8%) 0 (0.0%) 13 (2.7%) 
1999 (n=461) 86 (18.7%) 148 (32.1%) 37 (8.0%) 128 (27.8%) 194 (42.1%) 0 (0.0%) 15 (3.3%) 
2000 (n=460) 129 (28.0%) 173 (37.6%) 47 (10.2%) 143 (31.1%) 199 (43.3%) 14 (3.0%) 12 (2.6%) 
2001 (n=516) 175 (33.9%) 208 (40.3%) 58 (11.2%) 182 (35.3%) 210 (40.7%) 34 (6.6%) 22 (4.3%) 
2002 (n=532) 208 (39.1%) 210 (39.5%) 55 (10.3%) 231 (43.4%) 251 (47.2%) 73 (13.7%) 18 (3.4%) 
2003  (n=545) 194 (35.6%) 202 (37.1%) 54 (9.9%) 239 (43.9%) 245 (45.0%) 91 (16.7%) 17 (3.1%) 
2004  (n=471) 186 (39.5%) 206 (43.7%) 42 (8.9%) 264 (56.1%) 229 (48.6%) 137 (29.1%) 23 (4.9%) 
2005 (n=424) 197 (46.5%) 184 (43.4%) 37 (8.7%) 232 (54.7%) 226 (53.3%) 149 (35.1%) 21 (5.0%) 
Comorbidities        
COPD/Asthma         
 
Yes   (529) 173 (32.7%) 88 (16.6%) 90 (17.0%) 187 (35.3%) 238 (45.0%) 63 (11.9%) 11 (2.1%) 
No (3776) 1126 (29.8%) 1442 (38.2%) 296 (7.8%) 1368 (36.2%) 1603 (42.5%) 435 (11.5%) 133 (3.5%) 
Atrial fibrillation         
 
Yes (424) 132 (31.1%) 105 (24.8%) 35 (8.3%) 134 (31.6%) 138 (32.5%) 37 (8.7%) 76 (17.9%) 
No (3881) 1167 (30.1%) 1425 (36.7%) 351 (9.0%) 1421 (36.6%) 1703 (43.9%) 461 (11.9%) 68 (1.8%) 
Hypertension         
 
Yes (1401) 530 (37.8%) 564 (40.3%) 195 (13.9%) 587 (41.9%) 644 (46.0%) 229 (16.3%) 52 (3.7%) 
No (2904) 769 (26.9%) 966 (33.3%) 191 (6.6%) 968 (33.3%) 1197 (41.2%) 269 (9.3%) 92 (3.2%) 
Diabetes         
 
Yes (426) 154 (36.2%) 138 (32.4%) 42 (9.9%) 147 (34.5%) 169 (39.7%) 54 (12.7%) 24 (5.6%) 
No (3879) 1145 (29.5%) 1392 (35.9%) 344 (8.9%) 1408 (36.3%) 1672 (43.1%) 444 (11.4%) 120 (3.1%) 
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 ACEI/ARBs β-blocker CCB Statins Aspirin Clopidogrel Oral anticoagulant 
Cancer          
 Yes (250) 74 (29.6%) 71 (28.4%) 20 (8.0%) 85 (34.0%) 104 (41.6%) 30 (12.0%) 11 (4.4%) 
No (4055) 1225 (30.2%) 1459 (36.0%) 366 (9.0%) 1470 (36.3%) 1737 (42.8%) 468 (11.5%) 133 (3.3%) 
Renal failure         
 Yes (108) 31 (28.7%) 28 (25.9%) 13 (12.0%) 32 (29.6%) 42 (38.9%) 16 (14.8%) 4 (3.7%) 
No (4197) 1268 (30.2%) 1502 (35.8%) 373 (8.9%) 1523 (36.3%) 1799 (42.9%) 482 (11.5%) 140 (3.3%) 
Heart failure (HF)        
 Yes (863) 365 (42.3%) 268 (31.1%) 69 (8.0%) 310 (35.9%) 379 (43.9%) 95 (11.0%) 59 (6.8%) 
No (3442) 934 (27.1%) 1262 (36.7%) 317 (9.2%) 1245 (36.2%) 1462 (42.5%) 403 (11.7%) 85 (2.5%) 
PAD        
 Yes (331) 127 (38.4%) 100 (30.2%) 45 (13.6%) 132 (39.9%) 135 (40.8%) 48 (14.5%) 18 (5.4%) 
No (3974) 1172 (29.5%) 1430 (36.0%) 341 (8.6%) 1423 (35.8%) 1706 (42.9%) 450 (11.3%) 126 (3.2%) 
Stroke        
 Yes (373) 101 (27.1%) 85 (22.8%) 49 (13.1%) 103 (27.6%) 124 (33.2%) 34 (9.1%) 25 (6.7%) 
No  (3932) 1198 (30.5%) 1445 (36.7%) 337 (8.6%) 1452 (36.9%) 1717 (43.7%) 464 (11.8%) 119 (3.0%) 
Angina        
 
Yes (1002) 315 (31.5%) 367 (36.6%) 155 (15.5%) 391 (39.0%) 420 (41.9%) 119 (11.9%) 31 (3.1%) 
No  (3303) 984 (29.8%) 1163 (35.2%) 231 (7.0%) 1164 (35.2%) 1421 (43.0%) 379 (11.5%) 113 (3.4%) 
 
* Proportions for each cell represent the number of those who prescribed an EBT e.g. ACEI/ARBs for each category e.g. men.  For example, the proportion for men who are prescribed 
ACEI/ARBs within 30 days after 1st diagnosis is 823, the total men who survived 30 days after 1st diagnosis 2628 (prescribed and not prescribed ACEI/ARBs): 823/2628 x 100=31.3%. For the 
same drug and category, those not prescribed ACEI/ARBs 1805: 1805/2628 x 100=68.7%.   
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5.1.1.7 Slope index of inequalities (SII) and relative index of inequalities 
(RII) 
In this study SII and RII are used to measure the socioeconomic relationship between 
the prescribing of EBTs within 30 days after hospital discharge of MI.    
 
As can be seen in Tables 26 and 27, both the absolute and relative index of inequalities 
are small in magnitude across the classes of EBTs (values close to 0 and 1, 
respectively) and not statistically significant, indicating no inequality in the prescribing 
of EBTs in terms of socioeconomic deprivation. These findings are similar to the 
logistic regression models above.  
Table 26 RII for myocardial infarction 
 RII (95% CI) P value 
ACEI/ARBs 0.95 (0.71-1.26) 0.7 
β-blockers 0.95 (0.73-1.23) 0.7 
CCB 1.19 (0.85-1.66) 0.3 
Statins 1.02 (0.80-1.29) 0.8 
Aspirin 1.06 (0.79-1.41) 0.7 
Clopidogrel 1.11 (0.78-1.57) 0.5 
Oral anticoagulant 1.09 (0.59-2.00) 0.7 
RII=Relative index of inequality 
 
Table 27 SII for myocardial infarction  
 SII (95% CI) P value 
ACEI/ARBs -0.02 (-0.11-0.07) 0.6 
β-blockers -0.03 (-0.12-0.07) 0.5 
CCB -0.001 (-0.03-0.02) 0.9 
Statins -0.01 (-0.09-0.07) 0.8 
Aspirin 0.02 (-0.1-0.14) 0.7 
Clopidogrel 0.003 (-.02-0.03) 0.8 
Oral anticoagulant 0.002 (-0.01-0.02) 0.8 
SII=Slope index of inequality 
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5.1.1.8 Goodness of fit tests for MI 
As can be seen in Table 28, the majority of ROC values ranged between 0.7 and 0.8 
which shows acceptable discrimination, however, the ROC value for aspirin showed 
that the discrimination of the model was poorer for this medication. When the Hosmer-
Lemeshow test was examined the model was well calibrated for each of the 
medications with the exception of CCBs. However, the calibration results were 
sensitive to the number of groups chosen. With 10 groups, evidence of poor fit was also 
seen for ACEI/ARBs, β-blockers and clopidogrel. 
 
Table 28 ROC and Hosmer-Lemeshow 
 
ROC 
P value 
Hosmer-Lemeshow 
group (5) 
P value 
Hosmer-Lemeshow 
group (10) 
P value  
ACEI/ARBs 0.71 0.14 0.01 
β-blockers 0.69 0.13 0.01 
CCB 0.78 0.01 0.03 
Statins 0.72 0.14 0.41 
Aspirin 0.61 0.48 0.11 
Clopidogrel 0.84 0.23 0.01 
Oral anticoagulant 0.84 0.37 0.70 
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5.1.2 Summary 
5.1.2.1Incidene of myocardial infarction  
The information services division (ISD) Scotland, a division of National Services 
Scotland that provides health information, health intelligence and statistical services, 
recently reported that the crude incidence rate per 100000 population for MI has 
declined over the years 2002-2012.
415
 The rate reported for ISD Scotland for new 
hospitalised cases of MI in 2002/03 (266.8 per 100000), 2003/04 (252.7 per 10000), 
and 2004/05 (243.7 per 100000) and 2005/06 (299.1 per 100000) were similar to the 
results in my study (page 110).       
5.1.2.3 Age differences in prescribing evidence based therapies after a first 
MI         
I have shown that there was a clear association between age and the prescribing of 
EBTs after a first diagnosis of MI. In general, previous studies showed that the 
prescribing of EBTs declined as age increases with differences being particularly 
evident in those aged more than 85 years.
284-286,285,288
 
 
Older patients were significantly less likely to receive prescriptions for ACEI/ARBs, β-
blockers, statins, aspirin and clopidogrel, which has been reported 
previously.
282,283,287,289-291,294-296,312
 A few other studies showed different trends in 
prescribing EBTs regarding age, particularly in prescribing ACEI/ARBs.
284-286,288
 
Significant differences in prescribing EBTs in the elderly aged ≥ 85 years may be 
explained by the lack of evidence of the efficacy of many of these therapies specifically 
in these age group.
416
  
5.1.2.2 Sex differences in prescribing of evidence based therapies after a 
first MI 
I found that prescribing of EBTs was higher in men than women but was only 
statistically significantly different for β-blockers. Similar to previous studies, the 
adjusted odds of prescribing ACEI/ARBs was higher among men compared to 
women.
284,287,288
 Only one study has shown that men and women were equally likely to 
be prescribed ACEI/ARBs, however, the association was only adjusted for age.
305
 The 
finding that men had statistically significantly higher odds of being prescribed β-
blockers than women matches results from three other studies.
 287, 284, 309 
 However, only 
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one study adjusted for a few covariates (demographics and year of MI) and examined 
the difference in patients aged ≥ 65 only. 290 Two studies reported that there was no 
difference in prescribing of β-blockers by sex after a MI.283,310 Contrary to this study, 
one study found a higher odds of prescribing of CCB in women compared to men.
305
 
Only one study has demonstrated that the prescribing of statins was significantly lower 
among women compared to men,
282
 one small study found that women were 
significantly more likely to receive prescriptions for statins than men (OR1.48.0; 95% 
CI 1.10-1.98).
306
 Prescribing of aspirin was similar in men and women in keeping with 
prior studies.
282,284,305,306
 No prior studies have examined differences in prescribing of 
clopidogrel and oral-anticoagulants.      
5.1.2.4 Socioeconomic status differences in prescribing of evidence based 
therapies after a first MI 
This study found no evidence for significant differences in prescribing by 
socioeconomic deprivation status. It seems plausible to attribute this finding to the fact 
that Scotland has a free health care system which includes medications for chronic 
disease. This is supported by a cross-sectional  study in Scotland
223
 which used similar 
data sets and found no significant difference in prescribing of secondary prevention 
therapies in patients with CHD. However, studies conducted in the USA and Canada, 
where they have different health care systems than Scotland, displayed the effect of 
socioeconomic status.
 311,314
    
5.1.2.5 Trends over time in prescribing of evidence based therapies after a 
first MI  
Prescribing increased over the study period for all EBTs with the exception of CCBs. 
This is in agreement with previous studies that show that prescribing of secondary 
prevention post MI was associated with a reasonable improvement in the last couple of 
decades. The drug associated with the highest improvement was statins (OR 11.11; 
95%CI 6.70-18.42). In this study prescribing was still considered suboptimal and needs 
to be encouraged. Compared to other studies the proportion of prescribing of 
ACEI/ARBs was almost similar to mine. The trends of prescribing β-blockers is lower 
in this study compared to some other previous studies, which potentially can be 
explained by increased prevalence of COPD or asthma.
319, 317, 316, 318,284, 322
 However, 
compared to studies using multivariable analysis, only one study showed higher odds of 
prescribing β-blockers (OR 5.73; 95%CI 5.23-6.26) compared to this study.312  
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5.1.2.6 Comorbidities and their relation to prescribing of evidence based 
therapies after a first MI 
In these analyses, several comorbidities influenced the prescribing of EBTs after a MI. 
One previous study showed
288
 that the odds of prescribing ACEI/ARBs are higher 
among patients with than those without COPD/asthma, however this was not 
significant. Prescribing of ACEI/ARBs was statically significant in patients with 
diabetes,
287,328
 HF,
287
 than those without relevant disease. Though, in this study 
prescribing for ACEI/ARBs was only significantly higher in patients with than without 
HF.  Lower prescribing of EBTs in concomitant disease can be attributed to the 
contraindications. For example, prescribing of β-blockers is similar to previous studies 
low in patients with COPD or asthma.
290,288 Furthermore, there was a high prevalence 
of older patients who are more likely to have more comorbidities. The severity of renal 
failure can influence the prescribing of EBTs for patients with renal disease. I found 
similar trends in the prescribing of EBTs in patients with renal failure to previous 
studies. Patients with renal failure received fewer prescriptions of β-blockers and 
statins.
308
 Clinical trials have demonstrated that oral anticoagulants, e.g. warfarin are 
more effective to prevent vascular events in patients with AF which explains why oral 
anticoagulant use is higher than use of aspirin and clopidogrel in patients with AF. 
 
Summary  
Prescribing of EBTs within 30 days after a first MI has improved over time, however, it 
remains suboptimal. Prescribing of statins has increased greatly since 1997 and the 
influence of age, sex and comorbidities was evident. Differences in prescribing of 
EBTs by age were evident though differences by sex were only evident for β-blockers. 
Differences in prescribing EBTs due to socioeconomic status were not significant 
which may be attributable to the equity of access of the Scottish health system.  
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5.2 Angina 
Baseline demographic characteristics  
A total of 7309 individuals were identified as having a diagnosis of angina. In the study 
cohort, 6574 patients were diagnosed with angina in the primary care and 735 patients 
in the secondary care (Figure 12). Of these, 99 patients (38 from the primary care and 
61 from the secondary care) did not survive 30 days after first diagnosis and were 
excluded from the analysis. In this study, 7210 (64.2%) patients who survived 30 days 
after first diagnosis were eligible to be included in the study. Of these, 6536 (90.7%) 
patients were identified in the primary care and 674 (9.3%) patients identified in the 
secondary care.    
Table 29 summarises the characteristics of these patients and the subset of patients who 
survived 30 days after the first recorded diagnosis. It can be seen that approximately 
55% of the angina patients were men and the largest proportion were aged between 65 
and 74 years. Patients residing in areas among the most deprived quintile of 
socioeconomic deprivation had a higher percentage of patients than those residing in 
areas from the least deprived quintile, but the largest numbers were in the third and 
fourth deprivation groups. The most prevalent comorbidities were hypertension 
(32.2%), COPD/asthma (12.2%) and HF (11.8%). Table 30 shows the incidence of 
angina per 1000 population. The incidence rate was higher in men, 5.11 per 1000, than 
in women, 4.04 per 1000. The incidence of angina had a clear age gradient from 1.56 
per 1000 in those aged less than 45 years compared to 17.61 per 1000 in those aged 75-
84 years., There was then a decline for patients aged 85 years and more, 13.99 per 
1000. The incidence rate of angina increased with increasing socioeconomic 
deprivation status from 2.93 per 1000 in the least deprived quintile to 5.67 per 1000 in 
the most deprived quintile. Over the year angina incidence declined to reach the lowest 
rate in 2005.  
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              Figure 12  Flow chart showing the selection of  patients with a first diagnosis of angina  
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Table 29 Baseline demographic characteristics 
 
Survived 30 days 
(n=7210) § 
Patients died within 30 
days after 1
st
 diagnosis 
(n=99)* 
 
 
All patients 
(n=7309) 
 
Male sex  3990 (55.3) 57 (57.6%) 4047 (55.4%) 
SD/variance 0.5/0.2 0.5/0.2 0.5/0.2 
Age (years):    
< 55  1479 (20.5%) 3 (3.0%) 1482 (20.3%) 
55 – 64  1965 (27.3%) 11 (11.1) 1976 (27.0%) 
65 – 74  2056 (28.5%) 17 (17.2%) 2073 (28.4%) 
75 – 84  1381 (19.2%) 42 (42.4%) 1423 (19.5%) 
85+  329 (4.6%) 26 (26.3%) 355 (4.9%) 
Socioeconomic 
deprivation 
   
 Q1 Least deprived 452 (6.2%) 5(5.1%) 452 (6.2%) 
Q2 426 (5.9%) 8 (8.1%) 426 (5.9%) 
Q3 770 (10.6%) 12 (12.1%) 770 (10.6%) 
Q4 634 (8.7%) 15 (15.1%) 634 (8.7%) 
Q5  753 (10.4%) 11 (11.1%) 753 (10.4%) 
Q6 1106 (15.3%) 14 (14.1%) 1106 (15.3%) 
Q7 838 (11.6%) 7 (7.1%) 838 (11.6%) 
Q8 738 (10.2%) 10 (10.1%) 738 (10.2%) 
Q9 877 (12.2%) 10 (10.1%) 877 (12.1%) 
Q10 Most deprived 616 (8.5%) 7 (7.1%) 616 (8.5%) 
Year    
1997 972 (13.5%) 9 (9.1%) 981 (13.4%) 
1998 1081 (15.0%) 8 (8.1%) 1089 (14.9%) 
1999 984 (13.6%) 15 (15.1%) 999 (13.7%) 
2000 952 (13.2%) 17 (17.1%) 969 (13.3%) 
2001 834 (11.6%) 14 (14.1%) 848 (11.6%) 
2002 788 (10.9%) 10 (10.1%) 798 (10.9%) 
2003 583 (8.1%) 7 (7.1%) 590 (8.1%) 
2004 564 (7.8%) 11 (11.1%) 575 (7.9%) 
2005 452 (6.3%) 8 (8.1%) 460 (6.3%) 
Comorbidities    
COPD/Asthma 877 (12.2%) 20 (20.2%) 897 (12.2%) 
Atrial fibrillation  497 (6.9%) 12 (12.2%) 509 (7.0%) 
Hypertension 2365 (32.8%) 31 (31.3%) 2396 (32.2%) 
Diabetes  411 (5.7%) 13 (13.1%) 424 (5.8%) 
Cancer 414 (6.1%) 24 (24.2%) 465 (6.4%) 
Renal failure 55 (0.8%) 12 (12.1%) 67 (0.9%) 
Heart failure 824 (11.4%) 39 (39.3%) 863 (11.8%) 
PAD 460 (6.4%) 17 (17.1%) 477 (6.5%) 
Stroke  478 (6.6%) 20 (20.1%) 498 (6.8%) 
 
* Only 34 (4.0%) patients died within 30 days and had a prescription, § No missing data  
    COPD=Chronic obstructive pulmonary disease, PAD=Peripheral arterial disease 
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Table 30  Rate per (1000) of incident angina  
 
Total population registered with 
GPs 
Patients with angina Rate 
Sex     
Men 792651 4047 5.11 
Women 807959 3262 4.04 
 Age       
<45 950345 1482 1.56 
45-64 410998 1976 4.81 
65-74 133058 2073 15.58 
75-84 80828 1423 17.61 
85+ 25381 355 13.99 
Socio-economic      
Q1 305557 895 2.93 
Q2 358497 1426 3.98 
Q3 401492 1887 4.70 
Q4 305760 1589 5.20 
Q5 266735 1512 5.67 
Years       
1999 227690 999 4.39 
2000 226503 969 4.28 
2001 225806 848 3.76 
2002 227146 798 3.51 
2003 228766 590 2.58 
2004 232554 575 2.47 
2005 232343 460 1.98 
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Prescribing of evidence based therapies before and after first recorded diagnosis  
Table 31 shows prescribing of EBTs before and after the first recorded diagnosis of 
angina.  More than a third, 39.7% and 37.3%, of patients were prescribed aspirin and 
nitrates before a first diagnosis of angina, respectively. After a first diagnosis, 
prescribing of EBTs within 30 days declined slightly for most of EBTs, though for 
clopidogrel it increased from 3.5% to 4.9%, and for other anti-anginal treatment 
(nicorandil and ivabradine) from 2.3% to 3.7%.  Prescribing of EBTs increased at least 
by double for all secondary prevention EBTs at any time point after first diagnosis.    
 
 
Table 31 Evidence based therapies prescribing for patients with incident diagnosis of angina 
Medicine Prescribed drug before 1
st
 
diagnosis 
Prescribed drug after 
1
st
 diagnosis at any time 
Prescribed drug 
within 30 days after 
1
st
 diagnosis 
ACEI/ARB 
 
22.3% 58.7% 15.3% 
β-blockers 
 
33.2% 72.4% 30.5% 
CCB 
23.2% 54.1% 16.1% 
Nitrates 
37.3% 81.6% 36.0% 
Statins 
 
22.1% 83.8% 23.7% 
Aspirin 
 
39.7% 85.2% 34.1% 
Clopidogrel 
3.5% 22.8% 4.9% 
Other anti-anginal drugs 
2.3% 22.6% 3.7% 
 
* This percentage is for patients alive 30 days after the 1
st
 diagnosis, ACEI=Angiotensin converting   
enzyme inhibitor, ARBs=Angiotensin receptor blockers, CCB=calcium channel blockers. 
Other anti-angina (Nicorandil and ivabradine)   
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5.2.1 Differences in prescribing of evidence based therapies for angina 
5.2.1.1 Age differences in prescribing of evidence based therapies  
Generally, older patients received proportionally less prescription of EBTs than 
younger patients (Figure 13 and Table 36). Patients aged less than 55 years received 
more prescriptions of statins (28.5%), clopidogrel (6.2%) and other anti-anginal 
treatments (5.0%) than other age groups. Patients aged between 55 and 64 years 
received more prescriptions of β-blockers (34.7%) than all other age groups. 
Prescribing of ACEI/ARBs and CCBs was highest for age (from 65 to 74, from 16.8% 
and 17.4%, respectively). Patients aged ≥ 85 years had the highest percentage of 
nitrates prescribed (38.6%). After adjustment using multivariable analysis, there were 
statistically significant differences in the odds of prescribing between the age groups 
for β-blockers (p<0.001), nitrates (p=0.03), statins (p<0.001), aspirin (p=0.01), and 
clopidogrel (p=0.02), (Table 5 appendix 6). As can be seen in Figure 14, compared to 
youngest age group (> 55 years), the eldest patient group (≥ 85 years) were 
significantly less likely to be prescribed β-blockers (OR 0.34; 95% CI 0.25-0.46), 
statins (OR 0.19; 95% CI 0.12-0.33) and clopidogrel (OR 0.39; 95% CI 0.19-0.77). 
However, nitrates were more likely to be prescribed for patients ≥ 85 years than those 
aged < 55 years (OR 1.29; 95% CI 1.05-1.59). Aspirin was significantly more likely to 
be prescribed to age groups 55-64 years (OR 1.20; 95% CI 1.05-1.37) and 65-74 years 
(OR 1.16; 95% CI 1.02-1.32) as compared to those aged < 55 years. Significant 
differences were identified in age groups 65-74 and 75-84 years compared to <55 years 
for nitrates (OR 1.21; 95% CI 1.04-1.40 and OR 1.21; 95% CI 1.06-1.39, respectively). 
Prescribing of β-blockers (with exception for age group 55-64 years), statins and 
clopidogrel declined as age increased.    
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              Figure 13 Plot of age and prescription rate for evidence based therapies within 30 days after a first angina 
                               
            ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAA= Other antianginal.
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Figure 14 Forest plot of odds ratio of age and prescribing evidence based therapies within 30 days 
after first diagnosis of angina 
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Patients aged <55 years are the reference category. Odds ratio adjusted for sex, socioeconomic status, year of 
diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal 
failure, heart failure, and stroke, peripheral arterial disease, clustered practices, and whether the drug was previously 
prescribed. 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel 
blockers, OAA=Other antianginal 
  
  
199 
 
5.2.1.2 Sex differences in prescribing of evidence based therapies  
Prescribing of ACEI/ARBs, β-blockers, statins, aspirin and clopidogrel was higher in 
men compared with women, whereas women received more prescriptions for CCBs 
(Figure 15). There was no difference in prescribing of nitrates and other anti-anginal 
treatments between men and women. ACEI/ARBs were prescribed for 16.6% vs. 
13.8% for women, β-blockers 32.1% for men vs. 28.4% for women, statins 26.0% for 
men vs. 20.9% for women (Table 36). After adjustment using multivariable analysis 
compared to women, men were significantly more likely to receive ACEI/ARBs (OR 
1.26; 95% CI 1.05-1.47, p=0.005) than women. Furthermore, men had higher odds of 
being prescribed all other medications such as clopidogrel (OR 1.27; 95% CI 0.98-1.64, 
p=0.06), however the associations were not statistically significant (Figure 16 and 
Table 6 appendix 7). 
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Figure 15 Plot of sex and prescribing of evidence based therapies after a first angina 
     
                  ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAA=Other antianginal
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Figure 16 Forest plot of odds ratio of sex and prescribing evidence based therapies within 30 days 
after first diagnosis of angina 
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Women are the reference category. Odds ratio adjusted for age group, socioeconomic, year of 
diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, 
cancer, renal failure, heart failure, stroke, peripheral arterial disease, clustered practices, and 
whether the drug was previously prescribed. 
 
 ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB=                     
Calcium channel blockers, OAA=Other antianginal 
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5.2.1.3 Socioeconomic differences in prescribing of evidence based therapies  
For the most part, there were only minor differences in the prescribing of EBTs 
between socioeconomic deprivation groups (Figure 17). However, the proportion of β-
blockers and statins prescribing is higher in quintile 1 than the other quintiles, 
particularly quintile 10. Table 36 shows the proportion differences in prescribing of 
EBTs between the deprivation quintiles. As can be seen, there are minor differences 
between the groups. The multivariable analyses (Figure 18) showed that after 
adjustment there was no evidence of differences in the odds of prescribing most of 
EBTs between the socioeconomic deprivation groups, however, β-blockers were 
significantly less likely to be prescribed for patients in quintile Q9 compared to the 
least deprived areas quintile Q1 (OR 0.76; 95% CI 0.57-0.99), (Table 7 appendix 6).   
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Figure 17 Plot of socioeconomic status and prescribing of evidence based therapies after a first angina  
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Figure 18 Forest plot of odds ratio of socioeconomic deprivation and prescribing evidence based therapies within 30 days after first diagnosis of angina 
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Quintile 1 (Q1) least deprived is a reference. Odds ratio adjusted for sex, age group, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure, heart failure, 
and stroke, peripheral arterial disease, clustered practices, and whether the drug was previously prescribed.  
SED=Socioeconomic deprivation ACEI=Angiotensin converting enzyme inhibitors, ARBs=Angiotensin receptor blockers, CCB=Calcium channel blockers, OAA=Other antianginal.  
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5.2.1.4 Trends of prescribing evidence based therapies from 1997 to 2005   
Figure 19 shows the trend in prescribing of EBTs within 30 days after first diagnosis of 
angina over the study period. Prescribing of most EBTs increased steadily over the period. 
Prescribing of statins shows the greatest absolute increase from 1997 to 2005, followed by 
β-blockers. From 1997 to 2005, prescribing within 30 days after first diagnosis of angina 
increased for ACEI/ARBs (from 6.6% to 28.8% ), β-blockers (from 14.0% to 44.5%), 
CCB (from 11.6% to 16.8%), nitrates (from 27.3% to 42.7%), statins (from 6.9% to 
47.3%), aspirin (from 17.7% to 47.1%), clopidogrel (0.00% to 18.4%) and other anti-
angina treatments (from 0.9% to 10.2%) Table 36. After adjustment using multivariable 
analysis (Figure 20), there were statistically significant differences in the odds of 
prescribing between the years of the study – with p<0.001 for all EBT classes. Compared 
to prescribing in 1997, patients in 2005 were significantly more likely to be prescribed 
ACEI/ARBs (OR 3.71; 95% CI 2.46-5.58), β-blockers (OR 4.75; 95% CI 3.26-6.73), 
nitrates (OR 1.77; 95% CI 1.32-2.38), statins (OR 8.11; 95% CI 5.89-11.15), aspirin (OR 
2.99; 95% CI 2.24-4.00), and other anti-angina treatment (OR 7.69; 95% CI 3.03-19.5). 
Although the odds of prescribing CCBs in 2005 was not statistically different to 1997 (OR 
1.31; 95% CI 0.95 to 1.79), the overall trend across all the study years was significant (p < 
0.001) (Figure 20 and Table 8 appendix6). 
  
206 
 
Figure 19 Trends over the time in prescribing of evidence based therapies trends (1997-2005) after a first angina  
   
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers 
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Figure 20 Forest plot of odds ratio of trends over time (1997-2005) and prescribing evidence based therapies within 30 days after first diagnosis of 
angina 
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Year 1997 is the reference. Adjusted for sex, age group, socioeconomic status, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure,   heart 
failure, and stroke, peripheral arterial disease, clustered practices, and whether the drug was previously prescribed. **2000 is the reference for clopidogrel. Clopidogrel divided by 10 for years 2003-05  
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAA= Other antianginal.
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5.2.1.5 Association between comorbidity and prescribing of evidence based 
therapies   
Prescribing of EBTs was mostly higher in patients with COPD/asthma than those 
without COPD/asthma (Figure 21 a), and generally higher among patients with than 
without hypertension (Figure 21 c). Prescribing of EBTs was generally lower among 
patients with cancer than those without cancer (Figure 21 e).  
From Table 36, it can be seen that 12.0% of patients with COPD/asthma received β-
blockers compared to 33.0% of those without COPD/asthma, 21.5% with AF received 
ACEI compared with 14.9% without AF. Patients with HF was associated with higher 
use of ACEI/ARBs (34.6%) compared with 12.9% in those without HF. Prescribing of 
β-blockers was lower among those with PAD (21.7%) compared to 31.1% in those 
without PAD, 23.8% with stroke received β-blockers compared with 30.9% in those 
without stroke.  
After adjustment using multivariable analysis (Table 32), patients with asthma/COPD 
were much less likely to receive β-blockers (OR 0.29; 95% CI 0.23-0.37), though they 
were more likely to receive CCB (OR 1.57; 95% CI 1.21-2.03) than those without 
COPD. Patients with AF were less likely to be prescribed nitrates (OR 0.78; 95% CI 
0.61-1.01) and aspirin (OR 0.63; 95% CI 0.49-0.81) than those without AF. Patients 
with diabetes were less likely to be prescribed β-blockers (OR 0.73; 95% CI 0.56-0.91), 
statins (OR 0.72; 95% CI 0.58-91) than those without diabetes. Patients with cancer 
were less likely to receive a CCB (OR 0.62; 95% CI 0.45-0.87), and other anti-angina 
treatments (OR 0.40; 95% CI 0.16-0.95) than those without cancer. Prescribing of 
ACEI/ARBs was significantly lower (OR 0.34; 95% CI 0.19-0.63) among patients with 
renal failure than those without renal failure. Patients with HF were significantly less 
likely to be prescribed β-blockers (OR 0.78; 95% CI 0.63-0.93) and CCB (OR 0.71; 
95% CI 0.56-0.91) but significantly more likely to be prescribed ACEI/ARBs (OR 
1.75; 95% CI 1.43-2.14). Patients with PAD were significantly less commonly 
prescribed ACEI/ARBs (OR 0.67; 95% CI 0.51-0.89), β-blockers (OR 0.60; 95% CI 
0.47-0.77) than patients without PAD. Patients with stroke were less likely to receive β-
blockers (OR 0.71; 95% CI 0.58-0.82) and aspirin (OR 0.76; 95% CI 0.63-0.91) than 
patients without stroke. 
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Table 32 Association between comorbidities and prescribing of evidence based therapies within 30 days after a first angina  
Adjusted OR, 
95% CI,  
P value 
 
ACEI/ARBs Beta blocker CCB Nitrates Statins Aspirin Clopidogrel 
Other anti-
angina 
COPD 
0.91 (0.69-1.21), 
0.56 
0.29 (0.23-0.37), 
0.01 
1.57 (1.21-2.03), 
0.01 
1.13 (0.99-1.30), 
0.06 
0.87 (0.73-1.04), 
0.14 
0.93 (0.75-1.16), 
0.75 
1.02 (0.70-1.49), 
0.90 
1.22 (0.80-1.88), 
0.34 
AF 
0.97 (0.70-1.33), 
0.85 
0.89 (0.72-1.13), 
0.36 
0.90 (0.68-1.19), 
0.47 
0.78 (0.61-1.01), 
0.06 
0.88 (0.68-1.15), 
0.37 
0.63 (0.49-0.81), 
0.01 
0.87 (0.57-1.33), 
0.54 
1.05 (0.64-1.73), 
0.90 
HYP 
1.19 (1.04-1.36), 
0.01 
1.06 (0.91-1.21), 
0.34 
1.11 (0.94-1.31), 
0.21 
1.10 (0.99-1.22), 
0.05 
1.01 (0.88-1.14), 
0.82 
1.11 (0.99-1.24), 
0.05 
0.91 (0.69-1.19), 
0.50 
1.16 (0.90-1.49), 
0.23 
Diabetes 
0.96 (0.68-1.35), 
0.95 
0.73 (0.56-0.91), 
0.02 
0.99 (0.78-1.25), 
0.91 
1.05 (0.83-1.31), 
0.60 
0.72 (0.58-0.91), 
0.01 
0.78 (0.63-0.95), 
0.02 
0.90 (0.50-1.60), 
0.72 
1.46 (0.80-2.65), 
0.22 
Cancer 
0.67 (0.48-0.94), 
0.03 
0.92 (0.75-1.13), 
0.45 
0.62 (0.45-0.87), 
0.01 
0.90 (0.72-1.12), 
0.40 
0.84 (0.64-1.11), 
0.24 
0.84 (0.69-1.04), 
0.13 
0.69 (0.38-1.25), 
0.22 
0.40 (0.16-0.95), 
0.04 
Renal failure 
0.34 (0.19-0.63), 
0.01 
0.78 (0.42-1.39), 
0.45 
0.93 (0.38-2.27), 
0.86 
0.88 (0.49-1.57), 
0.74 
0.73 (0.36-1.46), 
0.42 
1.10 (0.69-1.75), 
0.61 
2.17 (0.90-5.23), 
0.07 
2.35 (0.81-6.77), 
011 
HF 
1.75 (1.43-2.14), 
0.01 
0.78 (0.63-0.93), 
0.02 
0.71 (0.56-0.91), 
0.01 
0.93 (0.82-1.05), 
0.31 
0.86 (0.71-1.04), 
0.16 
0.92 (0.78-1.07), 
0.33 
0.71 (0.52-0.96), 
0.03 
0.99 (0.61-1.60), 
0.94 
PAD 
0.67 (0.51-0.89), 
0.01 
0.60 (0.47-0.77), 
0.01 
1.09 (0.83-1.43), 
0.51 
0.80 (0.64-1.01), 
0.07 
0.80 (0.64-0.99), 
0.05 
0.82 (0.63-1.09), 
0.20 
0.96 (0.64-1.45), 
0.90 
0.95 (0.50-1.83), 
0.90 
Stroke 
0.74 (0.53-1.03), 
0.08 
0.71 (0.58-0.82), 
0.01 
1.01 (0.77-1.31), 
0.10 
0.87 (0.72-1.04), 
0.20 
0.87 (0.69-1.09), 
0.28 
0.76 (0.63-0.91), 
0.01 
1.25 (0.86-1.83), 
0.22 
0.87 (0.45-1.68), 
0.70 
 
* Adjusted for sex, age group, socioeconomic status, year of diagnosis, chronic obstructive pulmonary disease (COPD), asthma, atrial fibrillation (AF), hypertension (HTN), 
diabetes, cancer, renal failure,  heart failure (HF), and stroke, peripheral arterial disease (PAD), angina, and whether the drug was previously prescribed. 
  
            ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers 
              
              NB: comparator for all comorbidities is No disease 
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            Figure 21 Plot of comorbidities and prescribing of evidence based therapies 
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ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, BB=beta blockers, CCB= Calcium channel blockers, COPD=chronic obstructive pulmonary 
disease, OAA=other anti-angial.
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5.2.1.6 Interactions by year of diagnosis  
Where statistically significant findings were found in sections 5.2.1.1–5.2.1.3, the 
interaction between that variable and year was tested (Table 33). It can be seen that the 
only statistically significant interaction was observed between sex and year for 
ACEI/ARBs (p=0.04). To examine the nature of this interaction the adjusted ORs for age 
group and sex are shown for each year in Table 34 and Table 35, and the unadjusted 
prescribing rates for ACEI/ARBs by sex and year are shown in Figure 22. It is clear that 
there is no overall trend and the interaction result will have been influenced by 1999 and 
2004 where the association between sex and prescribing of ACEI/ARBs is the opposite of 
that seen for all.  
 
Table 33 Interaction between year of diagnosis and selected variables and therapies. Variables and 
medications selected on the basis of significant multivariable associations. 
Factors Medication P for interaction 
Age group   
 Beta blocker <0.001 
 Nitrates 0.18 
 Statins 0.19 
 Aspirin 0.30 
 Clopidogrel 0.98 
Sex   
 ACEI/ARBs 0.03 
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Table 34 Adjusted Odds ratio of the prescribing of β-blockers and age stratified by year of diagnosis of angina 
 1998 1999 2000 2001 2002 2003 2004 2005 
<55 
0.16 (0.02-
1.27), 0.08 
0.08 (0.02-
0.35), 0.02 
0.41 (0.17-
0.96), 0.04 
0.61 (0.29-
0.31), 0.21 
0.49 (0.22-
1.08), 0.08 
0.47 (0.13-
1.66), 0.24 
0.52 (0.17-
1.57), 0.25 
0.18 (0.06-
0.57), 0.01 
55-64 
0.78 (0.39-
1.59), 0.51  
1.67 (0.87-
3.19), 0.87 
1.55 (0.79-
3.02), 0.19 
1.12 (0.57-
2.20), 0.73 
1.34 (0.67-
2.69), 0.40 
0.50 (0.24-
1.04), 0.07 
1.02 (0.48-
2.14), 0.95 
1.69 (0.77-
3.69), 0.19 
65-74 
1.06 (0.51-
2.20), 0.87 
1.53 (0.78-
3.01), 0.78 
1.29 (0.65-
2.56), 0.45 
0.99 (0.50-
1.97), 0.98 
1.23 (0.60-
2.51), 0.56 
0.49 (0.23-
1.05), 0.07 
0.80 (0.37-
1.72), 0.58 
1.24 (0.57-
2.67), 0.58 
75-84 
0.81 (0.35-
1.85), 0.61 
1.25 (0.58-
2.70), 0.58 
1.09 (0.51-
2.36), 0.81 
0.82 (0.38-
1.78), 0.62 
1.23 (0.55-
2.74), 0.60 
0.83 (0.36-
1.90), 0.66 
0.65 (0.27-
1.53), 0.32 
0.91 (0.38-
2.18), 0.84 
 
 
Table 35 Adjusted Odds ratio of the prescribing of ACEIs/ARBs and sex stratified by year of diagnosis of angina 
 1997 1998 1999 2000 2001 2002  2003 2004 2005 
Male vs. 
female  
1.03 (0.59-
1.77), 0.91 
1.35 (0.82-
2.22), 0.23 
0.70 (0.45-
1.08), 0.11 
1.03 (0.67-
1.58), 0.87 
1.44 (0.94-
2.22), 0.09 
1.90 (1.23-
2.92), 0.01 
1.95 (1.20-
3.16), 0.01 
0.93 (0.56-
1.54), 0.80 
1.33 (0.79-
2.24), 0.28 
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       Figure 22 Years trends of prescribing ACEI/ARBs based on sex        
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Table 36 Prescribing of evidence based therapies within 30 days after angina for patients who survived the first 30 days after a first diagnosis (N=7210) 
 ACEI/ARB β-blocker CCB Nitrates Statins Aspirin Clopidogrel 
Other anti-
anginal 
 N=7210 1106(15.3%) 2196 (30.5%) 1158 (16.1%) 2593 (36.0%) 1710 (23.7%) 2461 (34.1%) 354 (4.9%) 268 (3.7%) 
Male (n=3990) 661 (16.6%)* 1281(32.1%) 622 (15.6%) 1437(36.0%) 1036 (26.0%) 1390 (34.8%) 231 (5.8%) 153 (3.8%) 
Female (3220) 445 (13.8%) 915 (28.4%) 536 (16.6%) 1156 (35.9%) 674 (20.9%) 1071 (33.3%) 123 (3.8%) 115 (3.6%) 
Age (years)         
< 55 (n=1479) 198 (13.4%) 496 (33.5%) 206 (13.9%) 493 (33.3%) 421 (28.5%) 475 (32.1%) 92 (6.2%) 74 (5.0%) 
55 – 64 (n=1965) 285 (14.5%) 681 (34.7%) 316 (16.1%) 685 (34.9%) 553 (28.1%) 707 (36.0%) 109 (5.5%) 69 (3.5%) 
65 – 74 (n=2065) 346 (16.8%) 617 (30.0%) 358 (17.4%) 773 (37.6%) 502 (24.4%) 734 (35.7%) 93 (4.5%) 75 (3.6%) 
75 – 84 (n=1381) 228 (16%) 356 (25.8%) 231 (16.7%) 515 (37.3%) 215 (15.6%) 428 (31.0%) 52 (3.8%) 41 (3.0%) 
85+ (n=329) 49 (14.9%) 46 (14.0%) 47 (14.3%) 127 (38.6%) 19 (5.8%) 117 (35.6%) 8 (2.4%) 9 (2.7%) 
Deprivation         
Q1 (n=452) 65 (14.3%) 161 (35.6%) 77 (17.0%) 174 (38.5%) 115 (25.4%) 148 (32.7%) 28 (6.2%) 21 (4.6%) 
Q2 (n=426) 79 (18.5%) 148 (34.7%) 67 (15.7%) 150 (35.2%) 118 (27.7%) 151 (35.4%) 29 (6.8%) 19 (4.4%) 
Q3 (n=770) 107 (13.9%) 229 (29.7%) 124 (16.1%) 271 (35.2%) 166 (21.5%) 235 (30.5%) 43 (5.6%) 29 (3.7%) 
Q4 (n=634) 99 (15.6%) 203 (32.0%) 119 (18.7%) 232 (36.6%) 138 (21.7%) 224 (35.3%) 27 (4.2%) 21 (3.3%) 
Q5 (n=753) 122 (16.2%) 249 (33.1%) 114 (15.1%) 280 (37.2%) 185 (24.5%) 272 (36.1%) 32 (4.2%) 29 (3.8%) 
Q6 (n=1106) 180 (16.3%) 324 (29.1%) 196 (17.7%) 410 (37.1%) 276 (24.9%) 383 (34.6%) 56 (5.1%) 34 (3.1%) 
Q7 (n=838) 144 (17.2%) 250 (29.8%) 107 (12.7%) 288 (34.4%) 192 (22.9%) 286 (34.1%) 33 (3.9%) 28 (3.3%) 
Q8 (n=738) 114 (15.4%) 216 (29.2%) 117 (15.8%) 248 (33.6%) 180 (24.4%) 246 (33.3%) 36 (4.8%) 25 (3.4%) 
Q9 (n=877) 114 (13%) 257 (29.3%) 143 (16.3%) 318 (36.3%) 201 (22.9%) 298 (33.9%) 38 (4.3%) 38 (4.3%) 
Q10 (n=616) 82 (13.3%) 159 (25.8%) 94 (15.2%) 222 (36.0%) 139 (22.5%) 218 (35.4%) 32 (5.2%) 24 (3.9%) 
 
  
216 
 
Year ACEI/ARB β-blocker CCB Nitrates Statins Aspirin Clopidogrel 
Other anti-
anginal 
1997 (n=972) 64 (6.6%) 136 (14.0%) 113(11.6%) 265 (27.3%) 67 (6.9%) 172 (17.7%) 0 (0.0%) 9 (0.9%) 
1998 (n=1081) 85 (7.9%) 182 (16.8%) 145 (13.4%) 288 (26.6%) 126 (11.7%) 250 (23.1%) 0 (0.0%) 17 (1.6%) 
1999 (n=984) 100 (10.2%) 250 (25.4%) 157 (16.0%) 326 (33.1%) 178 (18.1%) 311 (31.6%) 9 (0.9%) 14 (1.4%) 
2000 (n=952) 139 (14.6%) 319 (33.5%) 164 (17.2%) 348 (36.6%) 216 (22.7%) 346 (36.3%) 8 (0.8%) 27 (2.8%) 
2001 (n=834) 153 (18.3%) 317 (38.0%) 167 (20.0%) 336 (40.3%) 200 (24.0%) 330 (39.6%) 30 (3.6%) 26 (3.1%) 
2002 (n=788) 162 (20.6%) 283 (35.9%) 149 (18.9%) 336 (42.6%) 223 (28.3%) 323 (41.0%) 58 (7.4%) 36 (4.6%) 
2003 (n=583) 145 (24.9%) 259 (44.4%) 99 (17.0%) 267 (45.8%) 223 (38.3%) 265 (45.5%) 67 (11.5%) 38 (6.5%) 
2004 (n=564) 128 (22.7%) 249 (44.1%) 88 (15.6%) 234 (41.5%) 263 (46.6%) 251 (44.5%) 99 (17.6%) 55 (9.8%) 
2005 (n=452) 130 (28.8%) 201 (44.5%) 76 (16.8%) 193 (42.7%) 214 (47.3%) 213 (47.1%) 83 (18.4%) 46 (10.2%) 
Comorbidities 
        
COPD/Asthma         
 
Yes (877) 157 (17.9%) 106 (12.2%) 207 (23.6%) 350 (39.9%) 206 (23.5%) 304 (34.7%) 52 (5.9%) 47 (5.4%) 
No (6333) 949 (15.0%) 2090 (33.0%) 951 (15.0%) 2243 (35.4%) 1504(23.7%) 2157 (34.1%) 302 (4.8%) 221 (3.5%) 
Atrial fibrillation         
 
Yes ( 497) 107 (21.5%) 134 (27.0%) 72 (14.5%) 62 (32.6%) 99 (19.9%) 135 (27.2%) 21 (4.2%) 19 (3.8%) 
No (6713) 999 (14.9%) 2062 (30.7%) 1086(16.2%) 2431 (36.2%) 1611 (24.0%) 2326 (34.6%) 333 (5.0%) 249(3.7%) 
Hypertension         
 
Yes(2365) 584 (24.7%) 870 (36.8%) 507 (21.4%) 930 (39.3%) 654 (27.7%) 912 (38.6%) 142 (6.0%) 115 (4.9%) 
No (4845) 522 (10.8%) 1326 (27.4%) 651 (13.4%) 1663 (34.3%) 1056 (21.8%) 1549(32.0%) 212 (4.4%) 153 (3.2%) 
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* Proportions for each cell represent the number of those who are prescribed an EBT e.g. ACEI/ARBs for each category e.g. men.  For example, the proportion for men who are prescribed ACEI/ARBs 
within 30 days after 1st diagnosis is 661, the total male survived 30 days after 1st diagnosis 3990 (prescribed and not prescribed ACEI/ARBs): 661/3990 x 100=16.6%. For the same drug and category, those 
not prescribed ACEI/ARBs 3329: 3329/3990 x 100=83.4%.   
ACEI= Angiotensin converting enzyme inhibitor, ARBs=Angiotensin receptor blockers, CCB= calcium channel blockers, COPD= Chronic obstructive pulmonary disease, PAD=Peripheral arterial     
disease. 
 ACEI/ARB β-blocker CCB Nitrates Statins Aspirin Clopidogrel 
Other anti-
anginal 
Diabetes         
 
Yes (411) 12 (30.0%) 117 (28.5%) 82 (20.0%) 163 (39.7%) 118 (28.7%) 140(34.1%) 27 (6.6%) 31 (7.5%) 
No (6799) 983(14.5%) 2079 (30.6%) 1076 (15.8%) 2430 (35.7%) 1592 (23.4%) 2321 (34.1%) 327 (4.8%) 237 (3.5%) 
Cancer         
 
Yes (414) 60 (13.6%) 119 (27.0%) 53 (12.0%) 156 (35.4%) 84 (19.0%) 138 (31.3%) 17 (3.9%) 9 (2.0%) 
No (6796) 1046 (15.5%) 2077 (30.7%) 1105 (16.3%) 2437 (36.0%) 1626 (24.0%) 2323 (34.3%) 337 (5.0%) 259 (3.8%) 
Renal failure         
 
Yes (55) 11 (20.0%) 13 (23.6%) 10 (18.2%) 19 (34.5%) 13 (23.6%) 20 (36.4%) 5 (9.1%) 5 (9.1%) 
No (7155) 1095(15.3%) 2183 (30.5%) 1148 (16.0%) 2574 (36.0%) 1697 (23.7%) 2441 (34.1%) 349 (4.9%) 263 (3.7%) 
Heart failure         
 
Yes (824) 285 (34.6%) 194 (23.5%) 119 (14.4 %) 302 (36.7%) 182 (22.1%) 278 (33.7%) 41 (5.0%) 44 (5.3%) 
No (6386) 821 (12.9%) 2002 (31.3%) 1039 (16.3%) 2291 (35.9%) 1528 (23.9%) 2183 (34.2%) 313(4.9%) 224 (3.5%) 
PAD         
 
Yes (460) 86 (18.7%) 100 (21.7%) 98 (21.3%) 153 (33.3%) 113 (24.6%) 155 (33.7%) 33 (7.2%) 22 (4.8%) 
No (6750) 1020 (15.1%) 2096 (31.1%) 1060 (15.7%) 2440 (36.1%) 1597 (23.7%) 2306 (34.2%) 321 (4.8%) 246 (3.6%) 
Stroke         
 
Yes (478) 85 (17.8%) 114 (23.8%) 85 (17.8%) 167 (34.9%) 108 (22.6%) 158 (33.1%) 29 (6.1%) 17 (3.6%) 
No (6732) 1021 (15.2%) 2082 (30.9%) 1073 (15.9%) 2426 (36.0%) 1602 (23.8%) 2303 (34.2%) 325 (4.8%) 251 (3.7%) 
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5.2.1.7 Slope index of inequalities (SII) and relative index of inequalities 
(RII) 
In this study SII and RII were used to measure the socioeconomic relationship between 
the prescribing of EBTs within 30 days after hospital diagnosis angina.    
As can be seen in Tables 37 and 38, inequality in prescribing β-blockers through the 
socioeconomic deprivation quintiles is evident after first diagnosis of angina. This can 
be seen clearly as the p value for RII and SII were statistically significant at 0.02 and 
0.001, respectively. However, for the other EBTs both the absolute and relative index 
of inequalities are small in magnitude across the classes (values close to 0 and 1, 
respectively) and not statistically significant, indicating not much evidence of 
inequality in the prescribing of EBTs in terms of socioeconomic deprivation.  
 
Table 37 Relative index of inequality (RII) 
 RII (95% CI) P value 
ACEI/ARBs 0.95 (0.82-1.11) 0.6 
β-blockers 0.85 (0.75-0.96) 0.02 
CCB 0.89 (0.71-1.21) 0.3 
Nitrates  0.96 (0.81-1.13) 0.6 
Statins 0.89 (0.76-1.06) 0.2 
Aspirin 1.04 (0.92-1.16) 0.5 
Clopidogrel 0.8 (0.58-1.11) 0.2 
Other anti-angina 0.85 (0.56-1.28) 0.45 
 
Table 38 Slope index of inequality (SII) 
 SII (95% CI) P value 
ACEI/ARBs 0.001 (-0.02-0.02) 0.9 
β-blockers -0.07 (-0.11- -0.04) 0.001 
CCB -0.02 (-0.05-0.01) 0.2 
Nitrates  -0.01 (-0.07-0.05) 0.6 
Statins -0.01 (-0.04-0.01) 0.3 
Aspirin 0.01 (-0.03-0.05) 0.7 
Clopidogrel -0.006 (-0.04-0.001) 0.1 
Other anti-angina -0.004 (-0.01-0.01) 0.4 
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5.2.1.8 Goodness of fit tests for angina 
As can be seen in Table 39, the majority of ROC values ranged between 0.7 and 0.8 
which demonstrates acceptable discrimination. As was seen for MI, the ROC value was 
low for aspirin and, in addition, for nitrates. The Hosmer-Lemeshow test suggested that 
the calibration of the model was not good for all medications with the exception of 
CCB, clopidogrel and other anti-angina medications. Sensitivity analyses using 10 
groups for the test confirmed that the models were not well calibrated for most EBMs.  
Table 39 ROC and Hosmer-Lemeshow 
 
ROC 
P value 
Hosmer-Lemeshow 
group (5) 
P value  
Hosmer-Lemeshow 
group (10) 
P value  
ACEI/ARBs 0.85 <0.001 <0.001 
β-blockers 0.75 <0.001 <0.001 
CCB 0.76 0.20 0.23 
Nitrates  0.61 <0.001 <0.001 
Statins 0.80 <0.001 <0.001 
Aspirin 0.66 <0.001 <0.001 
Clopidogrel 0.88 0.60 0.56 
Other anti-angina  0.83 0.31 0.20 
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5.2.2 Summary  
5.2.2.1 Incidence of angina   
The Murphy et al. study
329
 is the only study that estimates angina incidence rate in 
Scotland. This study used the primary care data base for 55 GPs (2001/02) across 
Scotland. Generally it reported that the incidence of angina was higher in men than in 
women and increased with increasing age (for < 45 years 0.1/1000 vs. ≥ 75 years 
5.2/1000) and socioeconomic deprivation (least deprived 0.8/1000 vs. most deprived 
2.2/1000), which was similar to this study. Compared with this study, the Murphy 
study showed lower incidence rate of angina in the matched year 2001/2002 (1.6 per 
1000 vs. 3.7 per 1000), however, the present study included all patients diagnosed in 
primary and secondary care. 
5.2.2.2 Age differences in prescribing of evidence based therapies after a 
first angina         
I have shown that age had a clear influence on the prescribing of EBTs after a first 
diagnosis of MI. This study showed that older patients received significantly fewer 
prescriptions for β-blockers, statins and clopidogrel. In addition, age was associated 
with lower odds of being prescribed ACEI/ARBs and CCB. This is supported by prior 
studies that reported the similar finding that older patients received significantly fewer 
prescriptions of β-blockers, statins or lipid lowering drugs (LLD).238,293 However, 
Bennett et al.
238
 showed a conflicting result for prescribing ACEI/ARBs to this study, 
however this study adjusted for sex and health region. Unadjusted studies also similarly 
demonstrated that older patients were less commonly prescribed β-blockers, statins or 
LLD.
329,330
 Older patients may come with different comorbidities, deterioration in 
organ function, e.g. renal function. These can be age related factors that may influence 
prescribing of EBTs.  Furthermore, the lower use of EBTs may be due to physicians’ 
perception that these medications are less effective and less cost effective among older 
patients.         
5.2.2.3 Sex differences in prescribing of evidence based therapies after a 
first angina 
I found that the prescribing of EBTs was higher in men compared to women but was 
only statistically significantly different for ACEI/ARBs. This finding is similar to a 
prior study which reported that men were significantly more likely to be prescribed 
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ACEI/ARBs than women.
238
 Furthermore, Murphy et al.’s study,329 using the Scottish 
primary care database (CMR), reported that women were significantly less likely to 
receive ACEI/ARBs compared to men. In this study, difference of prescribing β-
blockers was statistically insignificant for men and this finding was reported in two 
prior studies.
238,334
 Murphy et al.’s study, showed that women, compared to men, were 
significantly less likely to be prescribed β-blockers (OR 0.86, 95% CI 0.78-0.93), CCB 
(OR 0.85, 95% CI 0.78-0.93), and statins (OR 0.83, 95% CI 0.76-0.91). Similar to MI, 
discrepancy of prescribing EBTs after angina according to sex is evident. This can be 
due to age as women are approximately 10 years older than men in angina incidence. It 
is known that angina is commonly diagnosed in GP, so practitioners may believe that 
women diagnosed with angina less commonly have other serious cardiovascular 
disease. Generally women have less access to health services.     
5.2.2.4 Socioeconomic status association in prescribing of evidence based 
therapies after a first angina 
In this study I found no evidence for significant differences in prescribing by 
socioeconomic deprivation status. It seems plausible to attribute this finding to the fact 
that Scotland has a free health care system that includes medications for chronic 
disease. Simpson et al.
223
 used similar data sets and found no significant difference in 
prescribing secondary prevention in patients with CHD. A cross-sectional study
293
 
conducted in Britain used the occupation definition to examine the difference in 
prescribing LLD. It included only 286 men diagnosed with angina. Compared to non-
manual workers, those who do manual work received less LLD (39.0% vs. 44.0%). 
After adjustment for covariate, manual workers had lower odds of being prescribed 
LLD (OR 0.75; 95% CI 0.42 to 1.32). However, in the Murphy et al. study, most 
deprived patients were significantly more likely to be prescribed ACEI/ARBs, β-
blockers, and CCB.         
5.2.2.5 Trends over time in prescribing of evidence based therapies after a 
first angina 
Prescribing has increased over the study period for all EBTs. Only one study
335
 has 
been found that examined the trends of prescribing EBTs after angina diagnosis over 5 
years. It used unadjusted analysis to determine the change in the trends over 5 years for 
885 patients diagnosed with angina. It also showed an increase in the percentage rate of 
prescribing ACEI/ARB, β-blocker, aspirin, however, this was contradicted in nitrates 
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(from 81.0% in 1990 to 72.2% in 1995). Furthermore, it showed increase for 
dihydropyridine CCB (from 12.1% to 26.5%), but not for non-dihydropyridine (from 
56.9% to 40.1%). In this study, prescribing for ACEI/ARBs, aspirin, β-blockers and 
nitrates is associated with better improvement than the previous one.        
5.2.2.6 Comorbidities association in prescribing evidence based therapies 
after first angina 
In this analysis, several of concomitant diseases have been included in the analysis to 
identify their influence in prescribing EBTs after angina. Only one previous study 
examined the influence of comorbidities in prescribing EBTs after angina. It showed 
that, from unadjusted analysis, the prescribing of antiplatelet (exception for patients 
with diabetes), β-blockers and LLD were significantly lower in patients with 
COPD/asthma, HF and diabetes than those without relevant disease. Prescribing of 
antiplatelet was significantly higher among patients with than without diabetes 
(unadjusted OR 1.13; 95%CI 1.01-1.26).
330
  
 
Summary  
Prescribing EBTs within 30 days after first angina improved over the time period; 
however, it remains low. Prescribing of statins was associated with a great increase 
since 1997 and the influence of age, sex and comorbidities existed. Differences in 
prescribing of EBTs were only significant in ACEI/ARBs for sex; however, age 
differences were significant for all EBTs. Differences in prescribing EBTs due to 
socioeconomic status were not significant, which may be attributable to the equity of 
access of the Scottish health system. 
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5.3 Isolated PAD 
Baseline demographic characteristics  
A total of 3532 individuals were identified as having a diagnosis of PAD. In the study 
cohort, 2581 patients identified with first PAD in the primary care and 951 patients in 
the secondary care (Figure 23). Of these, 147 patients (20 from the primary care and 
127 from the secondary care) did not survive 30 days after hospital discharge and 
excluded. In this study, 3,385 (95.8%) patients survived 30 days after first diagnosis 
were eligible to be included in the study. Of these, 2561 (75.6%) patients had first 
diagnosis in the primary care and 824 (24.3%) patients had first diagnosis in the 
secondary care. Table 40, summarises the characteristics of these patients and the 
subset of patients who survived 30 days after the first recorded diagnosis. It can be seen 
that men had a slightly higher proportion of incident PAD (53.5%) than women. The 
largest proportion was aged between 65 and 74 years. Patients residing in the most 
deprived area (quintile 5) had a higher percentage of patients in the dataset compared to 
those residing in areas from the least deprived area (quintile 1), but the largest numbers 
are in the third and fourth deprived quintile groups. The most prevalent comorbidities 
were hypertension (31.2%), COPD/asthma (12%) and stroke (9.7%).  
 
Table 41 shows the incidence of PAD per 1000 population. The incidence rate was 
higher in men, 2.37 per 1000, than in women, 2.05 per 1000. The incidence of PAD 
increased with age from 0.58 per 1000 in those aged less than 45 years compared to 
10.36 per 1000 in those in aged 85 years and over. The incidence rate of PAD increased 
with increasing socioeconomic deprivation status from 1.30 per 1000 in the least 
deprived quintile to 2.92 per 1000 in the most deprived quintile. The rate of PAD 
incidence has declined gradually from 2.05 per 1000 in 1999 to 1.18 per 1000 in 2005. 
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Figure 23 Flow chart to show the selection of patients with a first diagnosis of PAD 
                 Primary care                                                            Secondary care  
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Table 40 Baseline demographic characteristics 
 
Within 30 days 
(n=3385)
§
  
Patients died within 
30 days after 1
st
 
diagnosis (n=147)* 
 
All patients 
(n=3582) 
Male sex 1812 (53.5%) 63 (42.8%) 1875 (53.1%) 
SD/variance  1.15/1.33 0.95/0.91 1.17/1.37 
Age (years):    
< 55  551 (16.3%) 2 (1.4%) 553 (15.7%) 
55 – 64  780 (23.0%) 9 (6.1%) 789 (22.3%) 
65 – 74  1024 (30.3%) 28 (19.1%) 1052 (29.8%) 
75 – 84  819 (24.2%) 56 (38.1%) 875 (24.8%) 
85+   211 (6.2%) 52 (35.3%) 263 (7.4%) 
Socioeconomic deprivation    
Q1 least deprived 210 (6.2 %) 6 (4.1%) 216 (6.1%) 
Q2 172 (5.1%) 8 (5.4%) 180 (5.1%) 
Q3 372 (10.9%) 17 (11.6%) 389 (11.0%) 
Q4 249 (8.7%) 21 (14.3%) 315 (8.9%) 
Q5 335 (9.9%) 11 (7.5%) 346 (9.8%) 
Q6 490 (14.5%) 21 (14.3%) 511 (14.4%) 
Q7 421 (12.4%) 17 (11.6%) 438 (12.4%) 
Q8 345 (10.2%) 14 (9.5%) 359 (10.1%) 
Q9 460 (13.6%) 21 (14.3%) 481 (13.6%) 
Q1 most deprived 0 286 (8.5%) 11 (7.5%) 297 (8.41%) 
Year     
1997  370 (10.9%) 8 (5.4%) 378 (10.7%) 
1998  403 (11.9%) 13 (8.8%) 416 (11.8%) 
1999  453 (13.4%) 14 (9.5%) 467 (13.2%) 
)) 2000  432 (12.8%) 15 (10.2%) 447 (12.7%) 
2001  400 (11.0%) 23 (15.6%) 423 (12.0%) 
2002  386 (11.4%) 24 (16.3%) 410 (11.6%) 
2003  357 (10.5%) 21 (14.3%) 378 (10.7%) 
2004  324 (9.6%) 51 (10.2%) 339 (9.6%) 
2005  260 (7.7%) 14 (9.5%) 274 (7.8%) 
Comorbidities    
COPD/Asthma 398 (11.8%) 27 (18.4%) 425 (12%) 
Atrial fibrillation  156 (4.6%) 28 (19.1%) 184 (5.2%) 
Hypertension 1055 (31.2%) 46 (31.3%) 1101 (31.2%) 
Diabetes  267 (7.9%) 16 (10.8%) 283 (8.0%) 
Cancer 267 (7.9%) 32 (21.7%) 299 (8.5%) 
Renal failure 57 (1.7%) 19 (12.9%) 76 (2.2%) 
Heart failure 165 (4.9%) 30 (20.4%) 195 (5.5%) 
Stroke  306 (9.0%) 38 (25.8%) 344 (9.7%) 
*Only 10 (6.8%) patients died within 30 days and had a prescription, § No missing data  
  
COPD=Chronic obstructive pulmonary disease 
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Table 41 Rate per (1000) of incident isolated PAD 
 
Total population registered with 
GPs 
Patients with PAD Rate 
Sex     
Men 792651 1875 2.37 
Women 807959 1657 2.05 
 Age       
<45 950345 553 0.58 
45-64 410998 789 1.92 
65-74 133058 1052 7.91 
75-84 80828 875 10.83 
85+ 25381 263 10.36 
Socio-economic      
Q1 305557 397 1.30 
Q2 358497 701 1.96 
Q3 401492 857 2.13 
Q4 305760 799 2.61 
Q5 266735 778 2.92 
Years       
1999 227690 467 2.05 
2000 226503 447 1.97 
2001 225806 423 1.87 
2002 227146 410 1.81 
2003 228766 378 1.65 
2004 232554 339 1.46 
2005 232343 274 1.18 
 
GPs=General practitioners  
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Prescribing of EBTs before and after first recorded diagnosis  
 
Table 42 shows prescribing of EBTs before and after the first recorded diagnosis of 
PAD. More than a quintile (23.0%) of patients were prescribed aspirin before first 
diagnosis of PAD and almost a quintile (18.7%) were prescribed β-blockers. After a 
first diagnosis, prescribing within 30 days was at a lower percentage than before the 
first diagnosis for all classes apart from aspirin and oral anti-coagulants. However, 
prescribing at any time after first diagnosis of PAD increased for all classes.  
 
Table 42 Evidence based therapies prescribing for patients with incident diagnosis of PAD 
Medicine Prescribed drug 
before 1
st 
 
diagnosis 
Prescribed drug 
after 1st diagnosis 
at any time 
Prescribed drug 
within 30 days after 
1
st
 diagnosis
*
 
ACEI/ARB 16.5% 43.0% 8.9% 
β-blockers 18.7% 29.0% 5.8% 
CCB 16.4% 36.7% 9.5% 
PVD 2.8% 11.0% 4.1% 
Statins 10.8% 59.8% 10.9% 
Aspirin 23.0% 63.7% 19.2% 
Clopidogrel 1.1% 11.9% 1.2% 
Oral anti-coagulant 3.8% 8.8% 2.2% 
 
* This percentage is for patients alive 30 days after the 1
st
 diagnosis, ACEI=Angiotensin 
converting enzyme inhibitor, ARBs=Angiotensin receptor blockers, CCB=Calcium channel blockers. 
PVD=peripheral vasodilator 
 
5.3.1 Differences in prescribing of evidence based therapies for PAD 
5.3.1.1 Age differences in prescribing of evidence based therapies  
Figure 24 shows that patients in age groups 65-74 and 75-84 years received 
proportionally more prescriptions of ACEI/ARBs, β-blockers, CCBs, peripheral 
vasodilator (PVD) and aspirin. Prescribing of statins was highest among age group 65-
74 years and lowest among those aged 85 years and over. However, older patients 
received more prescriptions of clopidogrel than others. The percentage of prescribing 
for patients in age group 65-74 years was 11.0% and 7.2% for ACEI/ARBs and β-
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blockers, respectively (Table 45). Proportions of prescribing CCB (12.6%), PVD 
(5.3%), and oral anticoagulants (2.8%) were higher for patients in age group 75-84 
years. After adjustment using multivariable analysis there were statistically significant 
differences in the odds of prescribing between the age groups for β-blockers (overall p 
value = 0.02), statins (0.001), aspirin (0.05). Compared to those younger than 55 years, 
elderly patients (≥ 85 years) were significantly less likely to receive ACEI/ARBs (OR 
0.36; 95%CI 0.17-0.78), and statins (OR 0.06; 95%CI 0.01-0.28). The clearest age 
gradient in the adjusted results was seen for ACEI/ARBs, with odds of prescribing 
falling as age increases (Figure 25 and Table 9 appendix 6). 
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Figure 24 Plot of age and prescription rate of evidence based therapies within 30 days after a first peripheral arterial disease   
 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD=peripheral vasodilator, OAC=Oral anticoagulant
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Figure 25 Forest plot of odds ratio of age and prescribing evidence based therapies within 30 days 
after first diagnosis of peripheral arterial disease. 
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Patients aged <55 years are the reference category. Odds ratio adjusted for sex, socioeconomic status, year of diagnosis, chronic 
obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure, heart failure, and stroke, 
clustered practices, and whether the drug was previously prescribed. 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAC= 
Oral anticoagulants. 
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5.3.1.2 Sex differences in prescribing of evidence based therapies  
Prescribing of EBTs was higher in women compared with men apart for oral 
anticoagulants. However, the difference in the percentages of prescribing EBTs was 
modest for most classes (Figure 26). CCBs were prescribed for 8.9% of men vs. 10.3% 
of women, statins 9.5% of men vs. 12.5% of women (Table 45). After adjustment using 
multivariable analysis, compared to women (Figure 27), men were significantly less 
likely to receive statins (OR 0.73; 95% CI 0.59-0.91, p=0.004) than women, which is 
the largest observed difference between men and women. Furthermore, men had lower, 
but not statistically significant, odds of being prescribed all other medications, apart 
from β-blockers, CCBs and PVD (Table 10 appendix 6). 
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                        Figure 26 Plot of sex and prescribing of evidence based therapies after a first peripheral arterial disease  
 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD= peripheral vasodilator, OAC=Oral 
anticoagulants.
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Figure 27 Forest plot of odds ratio of sex and prescribing evidence based therapies within 30 days 
after first diagnosis of peripheral arterial disease 
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Women are the reference category. Odds ratio adjusted for age group, socioeconomic, year of diagnosis, 
chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure, 
heart failure, stroke, clustered practices, and whether the drug was previously prescribed. 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium 
channel blockers, OAC= Oral anticoagulants.  
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5.3.1.3 Socioeconomic differences in prescribing of evidence based therapies  
Figure 28 shows the differences in prescribing EBTs according to socioeconomic 
status. Variations in prescribing EBTs between the deprivation quintiles were similar 
across the classes of EBTs. As can be seen in Table 45, those living in the most 
deprived areas (Q10) received less prescriptions than those living in the least deprived 
areas (Q1) for ACEI/ARBs (4.9% vs. 9.1%), β-blockers (4.2% vs. 7.6%), CCBs (9.1% 
vs. 11.9%), statins (9.1% vs. 11.9%) and aspirin (14.3% vs. 22.4%). In contrast, they 
received more prescription of PVD (5.6% vs. 1.4%), clopidogrel PVD (1.4% vs. 0.5%) 
than those living in quintile Q10. The multivariable analyses showed that, compared to 
those patients living in the least deprived areas (Q1), patients residing in more deprived 
areas were  more likely to be prescribed PVD, apart from Q2, Q5 and Q6 (Figure 29). 
However, they were significantly less likely to be prescribed aspirin (OR 0.55, 95% 
CL0.37-0.83). There was no evidence of differences in the odds between the 
socioeconomic deprivation groups for the other classes of EBT (Figure 29 and Table 
11, appendix 6). 
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   Figure 28 Plot of socioeconomic status and prescribing evidence based therapies after a first peripheral arterial disease  
 
    ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD=peripheral vasodilator, OAC=Oral anticoagulant
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Figure 29 Forest plot of odds ratio of socioeconomic deprivation and prescribing evidence based therapies within 30 days after first diagnosis of peripheral arterial disease 
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Quintile 1 (Q1) least deprived is a reference. Odds ratio adjusted for sex, age group, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure, heart failure, and 
stroke, clustered practices, and whether the drug was previously prescribed. Upper 95% CI for PAD has configured in the plot “see appendix. SED=Socioeconomic deprivation ACEI=Angiotensin converting enzyme inhibitors, 
ARBs=Angiotensin receptor blockers, CCB=Calcium channel blockers, OAC= oral anticoagulant.  
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5.3.1.4 Trends of prescribing evidence based therapies from 1997 to 2005   
Figure 30 shows trends of prescribing EBTs within 30 days after first diagnosis of PAD 
over the 9 years of the study. Prescribing of EBTs has increased slightly from 1997 to 
2005 for most classes. However, marked increases in the prescribing of aspirin and 
statins were observed over the study period. As can be seen in Table 45, from 1997 to 
2005, prescribing of EBTs within 30 days after a first PAD increased for ACEI/ARBs 
from 4.5% to 14.6%, for CCB from 6.5% to 16.5%. As already stated, the highest 
increase among prescribing EBTs was for statins from 1.1% to 31.2% and aspirin from 
7.8% to 30.4%. After adjustment using multivariable analysis (Figure 31), there were 
statistically significant differences in the odds of prescribing between the years of the 
study for PVD (overall p<0.001), statins (p<0.001), aspirin (p<0.001) and clopidogrel 
(0.02). Compared to prescribing in 1997, patients in 2005 were significantly more 
likely to be prescribed PVD (OR 4.71; 95% CI 1.98 to 11.21), statins (OR 20.22; 95% 
CI 8.7-46.9), and aspirin (OR 4.06; 95% CI 2.62-6.29). The clearest gradient over time 
in the adjusted results was seen for statins, with odds of prescribing increasing steadily 
over the study period (Figure 31 and Table 12 appendix 6). 
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Figure 30 Trends over the time in prescribing of evidence based therapies trends (1997-2005) after a first peripheral arterial disease    
         
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD=peripheral vasodilator, OAC=Oral anticoagulant 
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Figure 31 Forest plot of odds ratio of trends over time (1997-2005) and prescribing evidence based therapies within 30 days after first diagnosis of peripheral arterial disease 
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Year 1997 is the reference. Adjusted for sex, age group, socioeconomic status, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure,   heart failure, and stroke, peripheral arterial 
disease, clustered practices, and whether the drug was previously prescribed. **2000 is the reference for clopidogrel. Upper 95% CI for years 2002-05 has configured for statins see table in appendix.  
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAC= oral anticoagulant. 
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5.3.1.5 Association between comorbidity and prescribing of evidence based 
therapies 
Prescribing of EBTs was generally higher among patients with hypertension than those 
without hypertension (Figure 32c), almost as in patients with diabetes (Figure 32d) and 
patients with stroke (Figure 32h). As can be seen in Table 45, patients with 
COPD/asthma associated with higher proportion of prescriptions for statins (13.1%) 
than those without COPD/asthma. Patients with AF had higher percentage for 
ACEI/ARBs (20.1% vs. 8.3%). Patients with hypertension had higher percentage for 
ACEI/ARBs (21.8%) than patients without hypertension (3.0%). Patients with diabetes 
had higher percentage for ACEI/ARBs (24.0%) than those without diabetes (7.6%).  
Patients with stroke had higher percentage for aspirin (29.7% vs. 18.2%). After 
adjustment using multivariable analysis, patients with AF were more likely to be 
prescribed oral anticoagulants (OR 3.39; 95% CI 1.63-7.04), though they were 
significantly less likely to have received aspirin (OR 0.46; 95% CI 0.27-0.79) (Table 
43). Patients with hypertension were less likely to be prescribed PVD (OR 0.66; 95% 
CI 0.36-1.21). Patients with diabetes were less likely to receive CCB (OR 0.54; 95% CI 
0.34-0.83) than those without diabetes. Patients with renal failure were significantly 
less likely to be prescribed ACEI/ARBs (OR 0.32; 95% CI 0.12-0.85) than those 
without renal failure. 
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       Figure 32 Plot of comorbidities and prescribing of evidence based therapies  
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                                                            32g                                                                                                32h  
                            
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, BB= beta blocker PVD= Peripheral 
vasodilator, OAC=Oral anti-coagulant 
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Table 43 Association between comorbidities and prescribing evidence based therapies within 30 days after a first peripheral arterial disease    
Adjusted OR, 
95% CI 
ACEI/ARBs β-blocker CCB PVD Statins Aspirin Clopidogrel 
Oral 
anticoagulant 
COPD 
1.12 (0.73-1.69), 
0.60 
0.60 (0.28-1.27), 
0.18 
1.21 (0.76-1.91), 
0.41 
1.01 (0.62-1.63), 
0.96 
1.18 (0.85-1.64), 
0.30 
0.87 (0.70-1.09), 
0.25 
1.57 (0.74-3.32), 
0.23 
1.80 (0.93-3.48), 
0.08 
AF 
1.83 (0.95-3.51), 
0.07 
1.20 (0.57-2.51), 
0.62 
0.72 (0.44-1.15), 
0.17 
0.37 (0.11-1.29), 
0.15 
0.75 (0.37-1.51), 
0.43 
0.46 (0.27-0.79), 
0.01 
1.06 (0.39-2.87), 
0.90 
3.39 (1.63-7.04), 
0.01 
HTN 
1.92 (1.28-2.88), 
0.01 
1.01 (0.62-1.63), 
0.96 
2.32 (1.63-3.29), 
0.01 
0.66 (0.36-1.21), 
0.25 
1.65 (1.32-2.06), 
0.01 
1.11 (0.91-1.36), 
0.30 
1.35 (0.68-2.68), 
0.38 
0.90 (0.43-1.89), 
0.80 
Diabetes 
1.08 (0.64-1.81), 
0.76 
1.09 (0.66-1.81), 
0.72 
0.54 (0.34-0.83), 
0.01 
0.84 (0.34-2.08), 
0.76 
0.75 (0.52-1.09), 
0.13 
0.68 (0.48-0.97), 
0.03 
0.61 (0.19-1.96), 
0.40 
1.51 (0.61-3.68), 
0.40 
Cancer 
1.21 (0.75-1.95), 
0.43 
1.12 (0.61-2.04), 
0.70 
0.82 (0.51-1.34), 
0.44 
0.77 (0.42-1.43), 
0.50 
0.67 (0.42-1.06), 
0.10 
0.82 (0.59-1.13), 
0.24 
1.67 (0.77-3.62), 
0.19 
1.68 (0.90-3.15), 
0.10 
Renal failure 
0.32 (0.12-0.85), 
0.02 
1.75 (0.76-4.01), 
0.18 
0.94 (0.36-2.44), 
0.90 
0.53 (0.09-2.92), 
0.50 
0.79 (0.33-1.92), 
0.61 
0.90 (0.47-1.73), 
0.76 
1.14 (0.38-3.46), 
0.80 
1.09 (0.21-5.56), 
0.91 
HF 
1.04 (0.56-1.94), 
0.88 
0.98 (0.41-2.35), 
0.97 
0.92 (0.45-1.85), 
0.81 
1.08 (0.47-2.49), 
0.83 
0.93 (0.48-1.81), 
0.84 
1.27 (0.92-1.77), 
0.14 
1.21 (0.33-4.42), 
0.76 
0.91 (0.36-2.30), 
0.84 
Stroke 
1.47 (0.90-2.39), 
0.12 
1.14 (0.65-2.01), 
0.63 
0.74 (0.48-1.14), 
0.18 
0.45 (0.16-1.24), 
0.17 
1.18 (0.74-1.86), 
0.47 
1.15 (0.87-1.53), 
0.30 
1.81 (0.56-5.81), 
0.31 
0.76 (0.40-1.44), 
0.41 
* Adjusted for sex, age group, socioeconomic, year, chronic obstructive pulmonary disease (COPD), asthma, atrial fibrillation (AF), hypertension (HTN), diabetes, cancer, 
renal failure, heart failure (HF), and stroke, whether the drug was previously prescribed. 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers 
NB: comparator for all comorbidities is No disease. 
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5.3.1.6 Interactions by year of diagnosis 
Where statistically significant findings were found in sections 5.3.1.1 – 5.3.1.3, the 
interaction between that factor and year was tested (Table 44).  It can be seen that there 
was no significant interactions between sex, age groups, socioeconomic deprivation 
and year. This indicates that there was little evidence to support the hypothesis that the 
effects of sex, age and socioeconomic deprivation were modified by study year. 
 
Table 44 Interaction between year of diagnosis and selected variables and therapies. Variables and 
medications selected on the basis of significant multivariable associations.   
Factors Medication P for interaction 
Age group   
  β-blocker 0.80 
 Statins 0.24 
 Aspirin 0.95 
Sex   
 Statins  0.62 
Socioeconomic deprivation    
 Peripheral vasodilator 0.99 
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              Table 45 Prescribing evidence based therapies within 30 days after PAD for patients who survived the first 30 days after a first diagnosis (N=3385) 
 ACEI/ARBs β-blockers CCB PVD Stains Aspirin Clopidogrel 
Oral anti 
coagulant 
N=3385 300 (8.9%) 197 (5.8%) 323 (9.5%) 138 (4.1%) 369 (10.9%) 651 (19.2%) 41(1.2%) 75   (2.2%) 
Male (n=1812) 152 (8.4%) 96 (5.3%) 16 (8.9%) 70 (3.9%) 172 (9.5%) 329 (18.2%) 21(1.2%) 43 (2.4%) 
Female (n=1573) 148(9.4%) 101 (6.4%) 162 (10.3%) 68 (4.3%) 197 (12.5%) 322 (20.5%) 20 (1.3%) 32 (2.0%) 
Age (years) 
        
< 55  (n=551) 30 (5.4%) 32 (5.8%) 23 (4.2%) 14 (2.5%) 65 (11.8%) 77 (14.0%) 4 (0.7%) 12 (2.2%) 
55 – 64 (n=780) 69 (8.8%) 29 (3.7%) 64 (8.2%) 28 (3.6%) 91 (11.7%) 137 (17.6%) 9 (1.2%) 15 (1.9%) 
65 – 74 (n=1024) 113 (11.0%) 74 (7.2%) 118 (11.5%) 47 (4.6%) 135 (13.2%) 225 (22.0%) 16 (1.6%) 20 (2.0%) 
75 – 84 (n=819) 76 (9.3%) 55 (6.7%) 103 (12.6%) 43 (5.3%) 76 (9.3%) 174 (21.2%) 8 (1.0%) 23 (2.8%) 
85+ (n=211) 12 (5.7%) 7 (3.3%) 15 (7.1%) 6 (2.8%) 2 (0.9%) 38 (18.0%) 4 (1.9%) 5 (2.4%) 
Deprivation         
Q1 (n=210) 21 (10.0%) 16 (7.6%) 25 (11.9%) 3 (1.4%) 25 (11.9%) 47 (22.4%) 1 (0.5%) 4 (1.9%) 
Q2 (n=172) 14 (8.1%) 4 (2.3%) 13 (7.5%) 5 (2.9%) 19 (11.1%) 26 (15.1%) 4 (2.3%) 7 (1.2%) 
Q3 (n=372) 35 (9.4%) 34 (9.1%) 53 (14.2%) 17 (4.6%) 38 (10.2%) 78 (20.9%) 0 (0.0%) 2 (1.8%) 
Q4 (n=249) 42 (14.3%) 10 (3.4%) 27 (9.2%) 13 (4.4%) 33 (11.2%) 64 (21.7%) 6 (2.0%) 11 (3.7%) 
Q5 (n=335) 30 (8.9%) 23 (6.8%) 41 (12.2%) 19 (5.6%) 39 (11.6%) 72 (21.5%) 4 (1.2%) 7 (2.1%) 
Q6 (n=490) 47 (9.6%) 36 (7.3%) 48 (9.8%) 25 (5.1%) 58 (11.8%) 104 (21.2%) 7 (1.4%) 8 (1.6%) 
Q7 (n=421) 29 (6.9%) 20 (4.7%) 28 (6.6%) 14 (3.3%) 50 (11.9%) 66 (15.7%) 6 (1.4%) 11 (2.6%) 
Q8 (n=345) 32 (9.3%) 17 (4.9%) 28 (8.1%) 11 (3.2%) 41 (11.9%) 76 (22.0%) 3 (0.8%) 7 (2.0%) 
Q9 (n=460) 36 (7.8%) 25 (5.4%) 34 (7.4%) 15 (3.3%) 40 (8.7%) 77 (16.7%) 6 (1.3%) 13 (2.8%) 
Q10 (n=210) 14 (4.9%) 12 (4.2%) 26 (9.1%) 16 (5.6%) 26 (9.1%) 41 (14.3%) 4 (1.4%) 5 (1.7%) 
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ACEI/ARBs β-blockers CCB PVD Stains Aspirin Clopidogrel 
Oral anti 
coagulant 
Year         
1997 (n=370) 13(3.5%) 13(3.5%) 24 (6.5%) 8 (2.2%) 4 (1.1%) 29 (7.8%) 0 (0.0%) 8 (2.2%) 
1998 (n=403) 18(4.5%) 9 (2.2%) 23 (5.7%) 8 (2.0%) 8 (2.0%) 44 (10.9%) 0 (0.0%) 4 (1.0%) 
1999 (n=453) 26 (5.7%) 27 (6.0%) 43(9.5%) 10 (2.2%) 27 (6.0%) 75 (16.6%) 0(0.0%) 7 (1.5%) 
2000 (n=432) 36 (8.3%) 21(4.9%) 45 (10.4%) 20 (4.6%) 31(7.2%) 87 (20.1%) 6 (1.4%) 13 (3.0%) 
2001 (n=400) 45 (11.3%) 22 (5.5%) 43 (10.8%) 26 (6.5%) 34 (8.5%) 74 (18.5%) 5 (1.3%) 6 (1.5%) 
2002 (n=386) 36 (9.3%) 22(5.7%) 36 (9.3%) 23 (6.0%) 52 (13.5%) 101 (26.2%) 2 (0.5%) 10 (2.6%) 
2003 (n=357) 48 (13.4%) 37 (10.4%) 38 (10.6%) 12 (3.4%) 69 (19.3%) 78 (21.8%) 10 (2.8%) 10 (2.8%) 
2004 (n=324) 40 (12.3%) 24 (7.4%) 28 (8.6%) 14 (4.3%) 63 (19.4%) 84 (25.9%) 9 (2.8%) 11(3.4%) 
2005 (n=260) 38 (14.6%) 22 (8.5%) 43 (16.5%) 17 (6.5%) 81 (31.2%) 79 (30.4%) 8 (3.1%) 6 (2.3%) 
Comorbidities          
COPD/Asthma         
 
Yes (398) 42 (10.6%) 9 (2.3%) 43(10.8%) 19 (4.8%) 52 (13.1%) 73 (18.3%) 9 (2.3%) 15 (3.8%) 
No (2978) 258 (8.7%) 188 (6.3%) 280 (9.4%) 119 (4.0%) 317 (10.6%) 578 (19.4%) 32 (1.1%) 60(2.0%) 
Atrial fibrillation         
 
Yes (156) 32 (20.5%) 16 (10.3%) 19 (12.2%) 3 (1.9%) 14 (9.0%) 25 (16.0%) 4 (2.4%) 29 (18.6%) 
No (3229) 268 (8.3%) 181 (5.6%) 304 (9.4%) 135 (4.2%) 355 (11.0%) 626 (19.4%) 37 (1.1%) 46 (1.4%) 
Hypertension          
 
Yes (1055) 230 (21.8%) 127 (12.0%) 225 (21.3%) 37 (3.5%) 198 (18.8%) 266 (25.2%) 21 (2.0%) 28 (2.7%) 
No (2330) 70 (3.0%) 70 (3.0%) 98 (4.2%) 101 (4.3%) 171 (7.3%) 385 (16.5%) 20 (0.9%) 47 (2.0%) 
Diabetes         
 
Yes (267) 64 (24.0%) 24 (9.0%) 27 (10.1%) 9 (3.4%) 52 (19.5%) 54 (20.2%) 5 (1.9%) 12 (4.5%) 
No (3118) 236 (7.6%) 173 (5.5%) 296 (9.5%) 129 (4.1%) 317 (10.2%) 597 (19.1%) 36 (1.2%) 63 (2.0%) 
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   * Proportions for each cell represent the number of those who are prescribed an EBT e.g. ACEI/ARBs for each category e.g. men.  For example, the proportion for men who are prescribed  
ACEI/ARBs within 30 days after 1st diagnosis is 152, the total men survived 30 days after 1st diagnosis 1812 (prescribed and not prescribed ACEI/ARBs): 152/1812 x 100=8.4%. For the same 
drug and category, those not prescribed ACEI/ARBs 1660: 1660/1812 x 100=91.6%.   
  
 
 
ACEI/ARBs β-blockers CCB PVD Stains Aspirin Clopidogrel Oral anti coagulant 
Cancer         
 Yes (267) 29 (10.9%) 16 (6.0%) 26 (9.7%) 9 (3.4%) 22 (8.2%) 48 (18.0%) 5 (1.9%) 10 (3.7%) 
 No (3118) 271 (8.7%) 181 (5.8%) 297 (9.5%) 129 (4.1%) 347 (11.1%) 603 (19.3%) 36 (1.2%) 65 (2.1%) 
Renal failure          
 Yes (57) 7 (12.3%) 9 (15.8%) 9 (15.8%) 1 (1.8%) 8 (14.0%) 11 (19.3%) 1 (1.8%) 4 (7.0%) 
No (3328) 293 (8.8%) 188 (5.6%) 314 (9.4%) 137 (4.1%) 361 (10.8%) 640 (19.2%) 40 (1.2%) 71 (2.1%) 
Heart failure (HF)         
 Yes (165) 34 (20.6%) 10 (6.1%) 18 (10.9%) 6 (3.6%) 16 (9.7%) 39 (23.6%) 4 (2.4%) 12 (7.3%) 
 No (3220)  266 (8.3%) 187 (5.8%) 305 (9.5%) 132 (4.1%) 353 (11.0%) 612 (19.0%) 37 (1.1%) 63 (2.0%) 
Stroke          
 
Yes (306) 52 (17.0%) 30 (9.8%) 31 (10.1%) 6 (2.0%) 55 (18.0%) 91 (29.7%) 8 (2.6%) 11 (3.6%) 
No (3079) 248 (8.1%) 167 (5.4%) 292 (9.5%) 132 (4.3%) 314 (10.2%) 250 (18.2%) 33 (1.1%) 64 (2.1%) 
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5.3.1.7 Slope index of inequalities (SII) and relative index of inequalities (RII) 
In this study the SII and RII were used to measure the socioeconomic relationship between 
the prescribing of EBTs within 30 days after hospital diagnosis of PAD.    
 
As can be seen in Table 46, the relative index of inequalities are small in magnitude across 
the classes of EBTs (values close to 0 and 1, respectively) and not statistically significant, 
which indicates not much evidence of inequality in the prescribing of EBTs in terms of 
socioeconomic deprivation. However, the absolute index of inequalities (Table 47) shows 
significant p value for CCB and aspirin, which indicate association between prescribing these 
drugs and socioeconomic deprivation.  
 
Table 46 Relative risk of inequality (RII) for PAD 
 RII (95% CI) P value 
ACEI/ARBs 0.77 (0.54-1.11) 0.2 
β-blockers 0.91 (0.61-1.51) 0.8 
CCB 0.96 (0.71-1.31) 0.8 
PAV 1.10 (0.43-2.80) 0.8 
Statins 0.87 (0.69-1.10) 0.3 
Aspirin 0.80 (0.62-1.04) 0.1 
Clopidogrel 1.09 (0.42-2.91) 0.9 
Oral anticoagulant  1.15 (-0.62-2.13) 0.6 
 
Table 47 Slope index of inequality (SII) for PAD  
 SII (95% CI) P value 
ACEI/ARBs -0.03 (-0.07-0.003) 0.07 
β-blockers -0.02 (-0.04-0.01) 0.2 
CCB -0.03 (-0.04- -0.01) 0.006 
PVD 0.002 (-0.03-0.04) 0.9 
Statins -0.02 (-0.04- 0.0004) 0.06 
Aspirin -0.05 (-0.09- -0.01) 0.01 
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5.3.1.8 Goodness of fit tests for PAD 
The model discrimination for EBTs used for PAD was generally good (see Table 48). 
Similarly, the calibration of the model as assessed by the Hosmer-Lemeshow test was also 
good and better than MI or angina. However, the calibration results were sensitive to the 
number of groups chosen. With 10 groups, evidence of poor fit was seen for more EBM 
classes (CCB, statins and aspirin).   
Table 48 ROC and Hosmer-Lemeshow 
 
ROC 
P value 
Hosmer-Lemeshow 
group (5) 
P value  
Hosmer-Lemeshow 
group (10) 
P value  
ACEI/ARBs 0.92 0.03 0.13 
β-blockers 0.93 0.53 0.77 
CCB 0.87 0.06 0.02 
PVD 0.73 0.75 0.80 
Statins 0.86 0.21 0.01 
Aspirin 0.72 0.07 0.03 
Clopidogrel 0.86 0.32 0.09 
Oral anticoagulant 0.87 0.21 0.22 
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5.4 PAD with CHD 
Baseline demographic characteristics  
A total of 1351 individuals were identified as having a diagnosis of PAD with CHD 
(PAD/CHD). In the study cohort, 481 patients identified as having first diagnosed in the 
primary care and 510 patients in the secondary care (Figure 33). Of these, 83 patients (4 from 
the primary care and 79 from the secondary care) did not survive 30 days after hospital 
discharge and were excluded. In this study, 1268 (93.8%) patients who survived 30 days after 
first diagnosis were eligible to be included in the study. Of these, 837 (66.0%) patients were 
identified in the primary care and 431 (34.0%) patients identified in the secondary care.  
Table 49 summarises the characteristics of these patients and the subset of patients who 
survived 30 days after the first recorded diagnosis, n = 1268 (93.8%). Approximately 60% of 
the PAD/CHD patients were men and the largest proportion were aged between 65 and 74 
years. Patients residing in areas among the most deprived quintile (quintile 10) made a higher 
percentage of the dataset than those residing in areas from the least deprived area (quintile 1), 
but the largest numbers were in the third and fourth deprived quintile groups. The most 
prevalent comorbidities were hypertension (42.0%) and HF (26.6%).  
 
Table 50 shows the incidence of PAD/CHD per 1000 population. The incidence rate was 
higher in men, 1.06 per 1000, than in women, 0.63 per 1000. The incidence of PAD/CHD 
increased with age from 0.13 per 1000 in those aged less than 45 years compared to 3.59 per 
1000 in those aged 85 years and over. However, the highest rate was among those aged 
between 75 and 84 years, 6.07 per 1000. In general, the incidence rate of PAD/CHD 
increased as socioeconomic deprivation status increased from 0.5 per 1000 in the least 
deprived quintile to 1.13 per 1000 in the most deprived quintile. The most recent study year, 
2005, reported a lower incidence rate of PAD/CHD, 0.52 per 1000, than the first study year, 
1999, 0.73 per 1000, though incidence rate reached its peak in 1999/2000, 0.80 per 1000.  
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              Figure 33 Flow chart demonstrates patients with a first diagnosis of PAD/CHD 
             Primary care                                                                 Secondary care 
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Table 49 Baseline demographic characteristics   
 
Within 30 days 
(n=1268) 
Patients died within 30 
days after 1
st
 diagnosis 
(n=83) 
 
All patients 
(n=1351) 
Male sex 
 
796 (62.8%) 45 (54.2%) 841 (62.3%) 
SD/Variance 1.05/1.12 0.87/0.76 1.07/1.14 
Age (years):    
< 55  119 (9.4%) 1 (1.2%) 120 (8.9%) 
55 – 64  298 (23.0%) 4 (4.8%) 302 (22.4%) 
65 – 74  418 (33.0%) 19 (23.0%) 437 (32.3%) 
75 – 84  362 (28.5%) 39 (47.0%) 491 (29.7%) 
85+  71 (5.6%) 20 (24.1%) 91 (6.7%) 
Deprivation    
Q1 Least deprived 71 (5.6%) 6 (7.2%) 77 (5.7%) 
Q2 69 (5.4%) 5 (6.0%) 74 (5.4%) 
Q3 116 (9.1%) 7 (8.4%) 123 (9.1%) 
Q4 112 (8.8%) 5 (6.0%) 117 (8.6%) 
Q5  130 (10.2%) 9 (10.8%) 139 (10.2%) 
Q6 194 (15.3%) 13 (15.6%) 207 (15.3%) 
Q7 142 (11.2%) 10 (12.0%) 152 (11.2%) 
Q8 149 (11.7%) 7 (8.4%) 156 (11.5%) 
Q9 158 (12.4%) 13 (15.6%) 171 (12.6%) 
Q 10 Most deprived 127 (10.0%) 8 (9.6%) 135 (9.9%) 
Year    
1997 111 (8.8%) 5 (6.02%) 116 (8.6%) 
1998 135 (10.6%) 5 (6.02%) 140 (10.4%) 
1999 161 (12.7%) 5 (6.02%) 166 (12.3%) 
2000 170 (13.4%) 12 (14.4%) 182 (13.5%) 
2001 138 (10.9%) 9 (10.8%) 147 (10.9%) 
2002 152 (12.0%) 12 (14.4%) 164 (12.1%) 
2003 157 (12.4%) 12 (14.4%) 169 (12.5%) 
2004 136 (10.7%) 11 (13.2%) 147 (10.9%) 
2005 108 (8.5%) 12 (14.4%) 120 (8.9%) 
Comorbidities    
COPD/Asthma 202 (15.9%) 22 (26.5%) 224 (16.6%) 
Atrial fibrillation  179 (14.1%) 21 (25.5%) 200 (14.8%) 
Hypertension 536 (42.3%) 31 (37.1%) 567 (42.0%) 
Diabetes  170 (13.4%) 12 (14.5%) 182 (13.5%) 
Cancer 105 (8.3%) 13 (15.6%) 118 (8.7%) 
Renal failure 49 (3.9%) 19 (22.8%) 68 (5.0%) 
Heart failure 320 (25.2%) 40 (48.2%) 360 (26.6%) 
Stroke  184 (14.5%)  17 (20.5%) 201 (14.9%) 
COPD=Chronic obstructive pulmonary disease 
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Table 50 Rate per (1000) of incident PAD with CHD  
 
Total population registered with 
GPs 
Patients with 
PAD/CHD 
Rate 
Sex     
Men 792651 841 1.06 
Women 807959 510 0.63 
 Age       
<45 950345 120 0.13 
45-64 410998 302 0.73 
65-74 133058 437 3.28 
75-84 80828 491 6.07 
85+ 25381 91 3.59 
Socio-economic      
Q1 Least deprived  305557 152 0.50 
Q2 358497 139 0.39 
Q3 401492 345 0.86 
Q4 305760 310 1.01 
Q5 Most deprived 266735 301 1.13 
Years       
1999 227690 166 0.73 
2000 226503 182 0.80 
2001 225806 147 0.65 
2002 227146 164 0.72 
2003 228766 169 0.74 
2004 232554 147 0.63 
2005 232343 120 0.52 
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Prescribing of EBTs before and after first recorded diagnosis  
Table 51 shows prescribing of EBTs before and after the first recorded diagnosis of 
PAD/CHD.  The percentage of patients prescribed aspirin before first diagnosis of PAD/CHD 
was 64.0%, β-blockers 47.5%, CCB 44.3%, and statins 42.1%. After a first diagnosis, 
prescribing within 30 days was at a lower percentage than before diagnosis. However, 
prescribing at any time after diagnosis was at a higher level than before for all EBTs. 
 
Table 51 Evidence based therapies prescribing for patients with incident diagnosis of PAD/CHD   
Medicine Prescribed drug 
before 1st  diagnosis 
Prescribed drug after 
1st diagnosis 
at any time 
Prescribed drug 
within 30 days after 
1
st
 diagnosis* 
 ACEI/ARB 38.6% 69.0% 20.1% 
 β-blockers 47.5% 61.8% 20.5% 
CCB 44.3% 57.6% 20.5% 
PVD 3.1% 9.0% 3.2% 
Statins 42.1% 84.6% 27.1% 
Aspirin 64.0% 82.7% 30.4% 
Clopidogrel 6.1% 21.4% 3.7% 
Oral anti-coagulant 9.0% 31.1% 4.2% 
 
* This percentage is for patients alive 30 days after the 1
st
 diagnosis, ACEI=Angiotensin  
converting   enzyme inhibitor, ARBs=Angiotensin receptor blockers, CCB=calcium channel blockers. 
PVD=peripheral vasodilator 
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5.4.1 Differences in prescribing of evidence based therapies for PAD/CHD  
5.4.1.1 Age differences in prescribing of evidence based therapies  
Figure 34 shows that patients aged less than 55 years received proportionally more 
prescriptions of CCB and statins than the other age groups. Patients aged from 55-64 years 
received more prescriptions of β-blockers. Prescribing of ACEI/ARBs and aspirin was higher 
for age group 65-74 years than other groups. Patients aged between 75 and 84 years had the 
highest percentage of PVD and oral anticoagulants prescriptions than other age groups. 
Patients aged ≥ 85 years received proportionally more prescriptions of clopidogrel. The 
values of the percentages shown in Figure 34 are in Table 53. For example, proportion of 
prescribing CCBs for age group less than 55 years was 26.1% and 33.6% for statins 
compared to the other groups (Table 54). Age group 55-64 years received more prescriptions 
for β-blockers (25.8%). Proportions of prescribing ACEI (20.1%), aspirin (33.3%) were 
higher for patients in the age group 75-84 than others. Higher proportions for PVD (4.7%) 
and oral anticoagulants (6.6%) were for the age group between 75 and 84 years.  
After adjustment using multivariable analysis compared to the youngest group <55, the eldest 
age group (≥ 85 years) were significantly less likely to receive oral anticoagulants (OR 0.07; 
95%CI 0.01-0.75). The eldest patients had higher odds of being prescribed PVD (OR 3.50; 
95%CI 0.22-53.88) and clopidogrel (OR 5.26; 95%CI 0.75-36.7); however, they had lower 
odds of being prescribed all other medications compared to the youngest patients (Figure 35 
and Table 13 appendix 6).  
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Figure 34 Plot of age and prescription rate for evidence based therapies within 30 days after a first PAD/CHD   
 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD=Peripheral vasodilator, OAC=Oral anticoagulant 
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Figure 35 Forest plot of odds ratio of sex and prescribing evidence based therapies within 30 days after 
first diagnosis of peripheral arterial disease with CHD 
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Patients aged <55 years are the reference category. Odds ratio adjusted for sex, socioeconomic status, year of diagnosis, 
chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure, heart failure, 
and stroke, clustered practices, and whether the drug was previously prescribed. Upper 95% CI for PVD has configured see 
table in the appendix.  
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, 
OAC= Oral anticoagulants. 
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5.4.1.2 Sex differences in prescribing of evidence based therapies  
Prescribing of EBTs was higher in men compared with women for most EBT classes. 
Prescribing of ACEI/ARBs, β-blockers, statins, aspirin, clopidogrel and oral anticoagulant 
was higher in men compared with women, whereas women received more prescriptions for 
CCBs and PVD than men (Figure 36). The values of the percentages shown in Figure 36 are 
found in Table 54. ACEI/ARBs were prescribed for 19.3% of men vs. 16.1% for women, β-
blockers 21.9% of men vs. 18.2% of women, statins 29.1% of men vs. 23.5% of women, 
aspirin 31.3% of men vs. 23.5% of women. After adjustment using multivariable analysis 
compared to women, there was a trend towards men being more likely to be prescribed β-
blockers (OR 1.31; 95% CI 0.97-1.75, p=0.04), clopidogrel (OR 1.55; 95% CI 0.71-3.38, 
p=0.2), but these were not statistically significant. Men were statistically more likely to 
receive statins (OR 1.39; 95% CI 1.01-1.93, p=0.04). In contrast, they had lower odds to 
receive CCBs (OR 0.94; 95% CI 0.66-1.35, p=0.7) and PVD (OR 0.57; 95% CI 0.28-1.16, 
p=0.12) (Figure 37 and Table 14 appendix 6).  
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          Figure 36 Plot of sex and prescribing of evidence based therapies after a first PAD/CHD   
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Figure 37 Forest plot of odds ratio of sex and prescribing evidence based therapies within 30 days after 
first diagnosis of peripheral arterial disease with CHD 
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Women are the reference category. Odds ratio adjusted for age group, socioeconomic, year of diagnosis, 
chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal 
failure, heart failure, stroke, clustered practices, and whether the drug was previously prescribed. 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium 
channel blockers, OAC= Oral anticoagulants.  
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5.4.1.3 Socioeconomic differences in prescribing of evidence based therapies  
Figure 38 shows the differences in prescribing of EBTs between the socioeconomic status 
groups. Small variations in the prescribing of EBTs between the deprivation groups were 
identified. Patients residing in the least deprived areas (Q1) received fewer prescriptions than 
those residing in the most deprived areas (Q10) for ACEI/ARBs (16.3% vs. 22.9%) and 
aspirin (27.3% vs. 32.4%) (Table 53). Generally, patients residing in the most deprived area 
(Q5) associated with higher percentage of EBTs prescriptions, particularly statins (28.9%) 
and aspirin (30.7%) than the least deprived area. 
The multivariable analyses showed that after adjustment there was only evidence of 
differences in the odds of prescribing between the socioeconomic deprivation groups for 
ACEI/ARBs (0.03) (Table 54). Compared to those patients residing in the least deprived 
areas (Q1), patients living in the most deprived areas had lower odds of being prescribed β-
blockers (OR 0.88; 95% CI 0.48-1.59), CCB (OR 0.54; 95% CI 0.25-1.18) and PVD (OR 
0.69; 95% CI 0.13-3.57) although all these associations were not statistically significant 
(Figure 39 and Table 15, appendix 6).  
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                    Figure 38 Plot of socioeconomic status and prescribing of evidence based therapies after a first PAD/CHD   
 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD=Peripheral vasodilator 
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 Figure 39 Forest plot of odds ratio of socioeconomic deprivation and prescribing evidence based therapies within 30 days after first diagnosis of peripheral 
arterial disease/CHD 
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Quintile 1 (Q1) least deprived is a reference. Odds ratio adjusted for sex, age group, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure, 
heart failure, and stroke, clustered practices, and whether the drug was previously prescribed. Upper 95% CI for clopidogrel and OAC has configured in the plot “see appendix. SED=Socioeconomic deprivation 
ACEI=Angiotensin converting enzyme inhibitors, ARBs=Angiotensin receptor blockers, CCB=Calcium channel blockers, OAC= oral anticoagulant.  
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5.4.1.4 Trends of prescribing EBTs from 1997 to 2005   
Figure 40 shows trends of prescribing EBTs within 30 days after first diagnosis of PAD/CHD 
over the 9 years of the study. Although there is an overall increase in the trend of prescribing 
EBTs, there were variations in the association. Prescribing of clopidogrel, PVD and oral 
anticoagulants all slightly increased from 1997 to 2005. Aspirin and statins were associated 
with higher increases during the study period than other drugs. Although prescribing had 
generally increased, it declined between 2004 and 2005 for statins, β-blockers, CCB and 
clopidogrel. The trends of prescribing EBTs shown in Figure 40 are presenting as 
percentages in Table 54.  For instance, there were increases in prescribing for ACEI/ARBs 
from 5.4% to 29.6%, β-blockers from11.7% to 27.8%, CCBs from10.8% to 21.3%, PVD 
from 0.0% to 4.6%, statins from 6.3% to 36.1%, aspirin from13.5% to 37.0%, and oral-
anticoagulants from 3.6% to 3.7%. Compared to prescribing in 1997, patients in 2005 were 
significantly more likely to be prescribed ACEI/ARBs (OR 3.17; 95% CI 1.11-7.12), aspirin 
(OR 2.51; 95% CI 1.19-5.28) and clopidogrel (OR 13.6; 95% CI 1.65-11.2) (Figure 41 and 
Table 16, appendix 6). 
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   Figure 40 Trends over the time in prescribing of evidence based therapies trends (1997-2005) after first PAD/CHD   
                 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD=Peripheral vasodilator,   
OAC=Oral anticoagulant 
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 Figure 41 Forest plot of odds ratio of trends over time (1997-2005) and prescribing evidence based therapies within 30 days after first diagnosis of peripheral arterial 
disease/CHD. 
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Year 1997 is the reference. Adjusted for sex, age group, socioeconomic status, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure,   heart failure, and stroke, 
peripheral arterial disease, clustered practices, and whether the drug was previously prescribed. **2000 is the reference for clopidogrel. For clopidogrel result see table in the appendix.  
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, OAC= oral anticoagulants
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5.4.1.5 Association between comorbidity and prescribing     
Figure 42b shows a stark difference in the prescribing of oral anti-coagulants for patients 
with and those without AF. Prescribing of EBTs was generally higher among patients with 
hypertension than those without hypertension (see Figure 42c). However, prescribing EBTs 
was generally lower among patients with cancer than those without cancer (see Figure 42e). 
Other concomitant diseases were associated with different patterns in the prescribing of 
EBTs.  
Compared to patients without COPD/asthma, patients with COPD/asthma had lower 
percentage of prescriptions for β-blockers (10.4% vs. 22.4%). Patients with AF had a higher 
percentage for oral anticoagulant (71.3% vs. 2.0%), but lower for aspirin (32.1% vs. 19.6%) 
than those without AF. The largest difference between patients with hypertension compared 
to those without hypertension was for ACEI/ARBs (24.8% vs. 22.9) (Table 53).  
As can be seen in Table 52, after adjustment using multivariable analysis there were some 
statistically significant differences in the odds of prescribing and whether certain 
comorbidities were present or not. Patients with COPD/asthma were significantly less likely 
to receive β-blockers (OR 0.60; 95% CI 0.36-0.99). Patients with AF were more likely to be 
prescribed oral anticoagulants (OR 4.46; 95% CI 1.72-11.16), though they were significantly 
less likely to be prescribed aspirin (OR 0.50; 95% CI 0.31-0.81). Patients with hypertension 
were significantly more likely to be prescribed ACEI/ARBs (OR 1.53; 95% CI 1.05-2.29) 
and β-blockers (OR 1.39; 95% CI 1.01-1.92) than those without hypertension. Patients with 
diabetes were less likely to receive oral anticoagulant (OR 0.25; 95% CI 0.07-0.82) than 
those without diabetes. Patients with renal failure were significantly less likely to be 
prescribed CCB (OR 0.11; 95% CI 0.02-0.49) than those without renal failure.  
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                            Figure 42 Plot of comorbidities and prescribing of evidence based therapies  
                                                            42a                                                                                       42b                                                                                 42c 
          
                                            42d                                                                        42e                                                                            42f 
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                                                 42i                                                                                                    42j 
                      
COPD= chronic obstructive pulmonary disease, ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel 
blockers, BB= beta blocker PVD= Peripheral vasodilator, OAC=Oral anticoagulant 
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  Table 52 Association of comorbidities with prescribing EBTs for patients diagnosed with PAD/CHD (OR, 95% CI)   
Adjusted OR, 
95% CI, 
 p value 
ACEI/ARBs β-blocker CCB PVD 
 
Statins 
Aspirin 
 
Clopidogrel 
Oral anti-
coagulant 
 COPD 
1.31 (0.88-1.95), 
0.17 
0.60 (0.36-0.99), 
0.05 
1.12 (0.72-1.74), 
0.61 
1.91 (0.91-4.00), 
0.08 
1.01 (0.67-1.52), 
0.95 
1.09 (0.76-1.56), 
0.62 
2.22 (1.01-4.94), 
0.05 
0.81 (0.31-2.09), 
0.66 
AF 
0.82 (0.53-1.26), 
0.37 
0.75 (0.44-1.25), 
0.27 
1.23 (0.78-1.95), 
0.36 
0.41 (0.11-1.47), 
0.17 
0.91 (0.59-1.39), 
0.66 
0.50 (0.31-0.81), 
0.01 
8.70 (0.37-2.03), 
0.75 
4.46 (1.72-11.6), 
0.01 
HYP 
1.53 (1.05-2.22), 
0.03 
1.39 (1.01-1.92), 
0.05 
1.14 (0.81-1.60), 
0.44 
0.55 (0.26-1.12), 
0.10 
1.16 (0.82-1.62), 
0.38 
0.93 (0.70-1.25), 
0.66 
1.21 (0.59-2.47), 
0.58 
1.09 (0.57-2.06), 
0.79 
Diabetes 
0.81 (0.53-1.21), 
0.30 
1.03 (0.68-1.56), 
0.87 
1.05 (0.68-1.62), 
0.80 
0.11 (0.02-0.45), 
0.01 
0.77 (0.51-1.16), 
0.22 
1.07 (0.76-1.52), 
0.66 
0.75 (0.27-2.06), 
0.58 
0.25 (0.07-0.82), 
0.02 
Cancer 
0.57 (0.32-1.02), 
0.06 
1.17 (0.68-2.01), 
0.55 
0.56 (0.30-1.06), 
0.08 
0.85 (0.29-2.48), 
0.77 
1.18 (0.82-1.69), 
0.36 
0.67 (0.43-1.06), 
0.09 
0.16 (0.01-2.18), 
0.17 
1.67 (0.64-4.35), 
0.28 
Renal failure 
0.29 (0.11-0.72), 
0.01 
0.52 (0.21-1.31), 
0.16 
0.11 (0.02-0.49), 
0.01 
1.14 (0.23-5.47), 
0.80 
0.45 (0.22-0.92), 
0.03 
0.39 (0.21-0.74), 
0.01 
1.22 (0.29-5.07), 
0.77 
4.99 (1.38-17.9), 
0.01 
HF 
1.19 (0.84-1.68), 
0.31 
0.87 (0.57-1.33), 
0.54 
0.80 (0.54-1.16), 
0.24 
1.32 (0.66-2.62), 
0.42 
1.17 (0.85-1.61), 
0.33 
1.21 (0.92-1.59),  
0.15 
1.11 (0.46-2.62), 
0.81 
1.14 (0.48-2.70), 
0.75 
Stroke 
0.91 (0.55-1.51), 
0.73 
0.69 (0.43-1.11), 
0.12 
1.11 (0.71-1.75), 
0.63 
1.65 (0.64-4.22), 
0.30 
1.19 (0.78-1.82), 
0.40 
1.01 (0.68-1.46), 
0.99 
1.14 (0.42-3.08), 
0.80 
1.46 (0.69-3.08), 
0.31 
 
  * Adjusted for sex, age group, socioeconomic status, year of diagnosis, chronic obstructive pulmonary disease (COPD), asthma, atrial fibrillation (AF), 
     hypertension (HTN), diabetes, cancer, renal failure, heart failure (HF), and stroke, whether the drug was previously prescribed. 
  
     ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers 
    
     NB: comparator for all comorbidities is No disease 
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5.4.1.6 Interactions by year of diagnosis 
Where statistically significant findings were found in sections 5.4.1.1–5.4.1.3, the 
interaction between that factor and year was tested (Table 53). It can be seen that there was 
no significant interactions between sex, age groups, deprivation and year.  
 
 
Table 53 Interaction between year of diagnosis and selected variables and therapies. Variables and 
medications selected on the basis of significant multivariable associations. 
Factors Medication P for interaction 
Age group   
 Oral anticoagulant 0.99 
   
   
Sex   
 Statins  0.51 
Socioeconomic deprivation   
 ACEI/ARBs 0.64 
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Table 54 Prescribing evidence based therapies within 30 days for patients who survived the first 30 days after a first diagnosis PAD/CHD (n=1268)   
 ACEI/ARB 
 
β-lockers 
 
CCB PVD Statins 
 
Aspirin 
 
Clopidogrel Oral anti 
coagulant 
N (n=1268) 230 (18.1%) 260 (20.5%) 260 (20.5%) 41 (3.2%) 343 (27.1%) 385 (30.4%) 47 (3.7%) 53 (4.2%) 
Male (n=796) 154 (19.3%) 174 (21.9%) 160 (20.1%) 20 (2.5%) 232 (29.1%) 249 (31.3%) 30 (3.8%) 40 (5.0%) 
Female (n=472) 76 (16.1%) 86 (18.2%) 100 (21.2%) 21 (4.4%) 111 (23.5%) 136 (28.8%) 17 (3.6%) 13 (2.8%) 
Age (years)           
< 55 (n=119) 17 (14.3%) 29 (24.4%) 31 (26.1%) 1 (0.8%) 40 (33.6%) 30 (25.2%) 3 (2.5%) 5 (4.2%) 
55 – 64 (n=298) 55 (18.5%) 77 (25.8%) 55(18.5%) 7 (2.3%) 94 (31.5%) 88 (29.5%) 13 (4.4%) 15 (5.0%) 
65 – 74 (n=418) 84 (20.1%) 89 (21.3%) 88 (21.1%) 13 (3.1%) 130 (31.1%) 139 (33.3%) 10 (2.4%) 8 (1.9%) 
75 – 84 (n=362) 62 (17.1%) 57 (15.7%) 79 (21.8%) 17 (4.7%) 70 (19.3%) 115 (31.8%) 14 (3.9%) 24 (6.6%) 
85+ (n=71) 12 (16.9%) 8 (11.3%) 7 (9.9%) 3 (4.2%) 9 (12.7%) 13 (18.3%) 7 (9.9%) 1 (1.4%) 
Deprivation         
Q1 (n=71) 10 (14.1%) 14 (19.7%) 16 (22.5%) 3 (4.1%) 18 (25.3%) 19 (26.7%) 1 (1.4%) 2 (2.8%) 
Q2 (n=69) 14 (20.3%) 14 (20.3%) 13 (18.8%) 3 (4.3%) 18 (26.1%) 19 (27.5%) 1 (1.4%) 1 (1.4%) 
Q3 (n=116) 23 (19.8%) 24 (20.7%) 22 (18.9%) 2 (1.7%) 33 (28.4%) 36 (31.0%) 4 (3.4%) 5 (4.3%) 
Q4 (n=112) 21 (18.7%) 30 (26.8%) 20 (17.8%) 2 (1.7%) 26 (23.2%) 39 (34.8%) 3 (2.6%) 3 (2.6%) 
Q5 (n=130) 32 (24.6%) 32 (24.6%) 20 (15.4%) 5 (3.8%) 38 (29.2%) 39 (31.0%) 7 (5.3%) 7 (5.3%) 
Q6 (n=194) 29 (14.9%) 26 (13.4%) 38 (19.6%) 11 (5.6%) 49 (25.2%) 41 (21.1%) 10 (5.1%) 12 (6.2%) 
Q7 (n=142) 21 (14.8%) 32 (22.5%) 38 (26.7%) 3 (2.1%) 40 (28.2%) 51 (35.9%) 4 (2.8%) 7 (4.9%) 
Q8 (n=149) 31 (20.8%) 26 (17.4%) 33 (22.1%) 3 (2.01%) 38 (25.5%) 49 (32.8%) 5 (3.3%) 4 (2.6%) 
Q9 (n=128) 33 (20.9%) 33 (20.9%) 32 (20.2%) 5 (3.2%) 45 (28.5%) 53 (33.5%) 8 (5.1%) 4 (2.5%) 
Q10 (n=127) 41 (32.3%) 29 (22.8%) 28 (20.1%) 4 (3.2%) 38 (28.9%) 39 (30.7%) 4 (3.1%) 8 (6.3%) 
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Year  ACEI/ARB 
 
β-lockers 
 
CCB PVD Statins 
 
Aspirin 
 
Clopidogrel Oral-anti 
coagulant 
1997 (n=111) 6 (5.4%) 13 (11.7%) 12 (10.8%) 0 (0.0%) 7 (6.3%) 15 (13.5%) 0 (0.0%) 4 (3.6%) 
1998 (n=135) 17 (12.6%) 12 (8.9%) 20 (14.8%) 2 (1.5%) 19 (14.1%) 25 (18.5%) 0 (0.0%) 6 (4.4%) 
1999 (n=161) 20 (12.4%) 33 (20.5%) 46 (28.6%) 5 (3.1%) 33 (20.5%) 47 (29.2%) 1 (0.6%) 8 (5.0%) 
2000 (n=170) 27 (15.9%) 26 (15.3%) 36 (21.2%) 11 (6.5%) 34 (20.0%) 56 (32.9%) 0 (0.0%) 5 (2.9%) 
2001 (n=138) 29 (21.0%) 33 (23.9%) 32 (23.2%) 5 (3.6%) 41 (29.7%) 57 (41.3%) 2 (1.4%) 9 (6.5%) 
2002 (n=152) 36 (23.7%) 32 (21.1%) 30 (19.7%) 7 (4.6%) 56 (36.8%) 45 (29.6%) 7 (4.6%) 7 (4.6%) 
2003 (n=157) 34 (21.7%) 38 (24.2%) 31 (19.7%) 2 (1.3%) 53 (33.8%) 52 (33.1%) 13 (8.3%) 7 (4.5%) 
2004 (n=136) 29 (21.3%) 43 (31.6%) 30 (22.1%) 4 (2.9%) 61 (44.9%) 48 (35.3%) 15 (11.0%) 3 (2.2%) 
2005 (n=108) 32 (29.6%) 30 (27.8%) 23 (21.3%) 5 (4.6%) 39 (36.1%) 40 (37.0%) 9 (8.3%) 4 (3.7%) 
Comorbidities          
COPD/Asthma         
 
Yes (202) 48 (23.8%) 21 (10.4%) 49 (24.3%) 10 (5.0%) 54 (26.7%) 67 (33.2%) 9 (4.5%) 9 (4.5%) 
No (1066) 182 (17.1%) 239 (22.4%) 211 (19.8%) 31 (2.9%) 289 (27.1%) 318 (29.8%) 38 (3.6%) 44 (4.1%) 
Atrial fibrillation         
 
Yes (179) 41 (22.9%) 30 (16.8%) 35 (19.6%) 3 (1.7%) 42 (23.5%) 35 (19.6%) 9 (5.0%) 
31 (17.3%) 
 
No (1089) 189 (17.4%) 230 (21.1%) 225 (20.7%) 38 (3.5%) 301 (27.6%) 350 (32.1%) 38 (3.5%) 22 (2.0%) 
Hypertension         
 
Yes (536) 133 (24.8%) 131 (24.4%) 132 (24.6%) 15 (2.8%) 163 (30.4%) 171 (31.9%) 22 (4.1 %) 22 (4.1%) 
No (732) 97 (13.3%) 129 (17.6%) 128 (17.5%) 26 (3.6%) 180 (24.6%) 214 (29.2%) 25 (3.4%) 31(4.2%) 
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* Proportions for each cell represent the number of those who are prescribed an EBT e.g. ACEI/ARBs for each category e.g. men.  For example, the proportion for men who are prescribed 
ACEI/ARBs within 30 days after 1st diagnosis is 154, the total men who survived 30 days after 1st diagnosis 796 (prescribed and not prescribed ACEI/ARBs): 154/796 x 100=19.3%. For the same 
drug and category, those not prescribed ACEI/ARBs 642: 642/796 x 100=80.7%.   
 
 
 
ACEI/ARB 
 
β-lockers 
 
CCB PVD Statins 
 
Aspirin 
 
Clopidogrel Oral-anti 
coagulant 
Diabetes         
 Yes (170) 41 (22.9%) 30 (16.8%) 35 (19.6%) 3 (1.7%) 42 (23.5%) 35 (19.6%) 9 (5.0%) 31 (17.3%) 
 
 No (1116) 189 (17.4%) 230 (21.1%) 225 (20.7%) 38 (3.5%) 301 (27.6%) 350 (32.1%) 38 (3.5%) 22 (2.0%) 
Cancer         
 
Yes (105) 15 (14.3%) 24 (22.9%) 16 (15.2%) 3 (2.9%) 28 (26.7%) 26 (24.8%) 1 (1.0%) 6 (5.7%) 
No (1163) 215 (18.5%) 236 (20.3%) 244 (21.0%) 38 (3.3%) 315 (27.1%) 359 (30.9%) 46 (4.0%) 47 (4.0%) 
Renal failure         
 
Yes (49) 7 (14.3%) 7 (14.3%) 2 (4.1%) 0 (0.0%) 10 (20.4%) 10 (20.4%) 3 (6.1%) 4 (8.2%) 
No (1219) 223 (18.3%) 253 (20.8%) 258 (21.2%) 41 (3.4%) 333 (27.3%) 375 (30.8%) 44 (3.6%) 49 (4.0%) 
Heart failure (HF)         
 Yes (320) 92 (28.8%) 49 (15.3%) 54 (16.9%) 12 (3.8%) 87 (27.2%) 102 (31.9%) 16 (5.0%) 26 (8.1%) 
No (948) 138 (14.6%) 211 (22.3%) 206 (21.7%) 29 (3.1%) 256 (27.0%) 283 (29.8%) 31 (3.3%) 27 (2.8%) 
Stroke         
 Yes (184) 31 (16.8%) 28 (15.2%) 40 (21.7%) 9 (4.9%) 52 (28.3%) 57 (31.0%) 9 (4.9%) 14 (7.6%) 
No (1084) 199 (18.4%) 232 (21.4%) 220 (20.3%) 32 (3.0%) 291 (26.8%) 328 (30.3%) 38 (3.5%) 39 (3.6%) 
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5.4.1.7 Slope index of inequalities (SII) and relative index of inequalities (RII) 
In this study SII and RII were used to measure the socioeconomic relationship between the 
prescribing of EBTs within 30 days after hospital discharge of PAD/CHD.    
 
As can be seen in Tables 55 and 56, most of the absolute and relative index of inequalities 
are small in magnitude across the classes of EBTs (values close to 0 and 1, respectively) 
and not statistically significant, indicating not much evidence of inequality in the 
prescribing of EBTs in terms of socioeconomic deprivation. However, ACEI/ARBs are 
statistically significant in the absolute and relative index of inequality, which indicates 
inequality in prescribing this drug group. 
Table 55 Relative index of inequality (RII) for PAD/CHD 
 RII (95% CI) P value 
ACEI/ARBs 1.59 (1.07-2.37) 0.02 
β-blockers 0.94 (0.63-1.41) 0.8 
CCB 1.09 (0.76-1.55) 0.6 
PAV 0.8 (0.32-2.07) 0.6 
Statins 1.14 (0.81-1.61) 0.4 
Aspirin 1.20 (0.92-1.56) 0.2 
Clopidogrel 1.65 (0.74-3.62) 0.2 
Oral anticoagulant 1.31 (0.44-3.94) 0.6 
 
Table 56 Slope index of inequality (SII) for PAD/CHD  
 SII (95% CI) P value 
ACEI/ARBs 0.08 (0.02-0.15) 0.01 
β-blockers -0.01 (-0.1-0.06) 0.7 
CCB 0.03 (-.04-0.11) 0.4 
PVD 0.01 (-0.02-0.04) 0.5 
Statins 0.01 (-0.08-0.11) 0.7 
Aspirin 0.05 (-0.01-0.12) 0.1 
Clopidogrel 0.02 (-0.03-0.06) 0.4 
Oral anticoagulant 0.01 (-0.03-0.63) 0.5 
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5.4.1.8 Goodness of fit tests for PAD/CHD 
As can be seen in Table 57, the majority of ROC values for the EBTs ranged between 0.7 
and 0.9 which shows acceptable and good discrimination. The Hosmer-Lemeshow test p 
value was >0.05 for all medications indicating good model fit for all of the medications for 
those with PAD and CHD. Furthermore, sensitivity analyses (using 10 groups for the test) 
showed good model fit as well. 
 
 Table 57 ROC and Hosmer-Lemeshow 
 
ROC 
P value 
Hosmer-Lemeshow 
group (5) 
P value  
Hosmer-Lemeshow 
group (10) 
P value  
ACEI/ARBs 0.85 0.40 0.85 
β-blockers 0.82 0.87 0.89 
CCB 0.83 0.41 0.24 
PVD 0.85 0.74 0.66 
Statins 0.83 0.42 0.30 
Aspirin 0.72 0.19 0.50 
Clopidogrel 0.91 0.24 0.40 
Oral anticoagulant 0.90 0.25 0.14 
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5.4.2 Summary 
5.4.2.1 Incidence of peripheral arterial disease  
A study from Edinburgh
417
 was conducted in 1988 and randomly recruited 1592 subjects 
aged 55-74 years from 10 general practices. Patients were followed up prospectively to 5 
years. The Edinburgh artery study was associated with higher incidence rate of intermittent 
claudication (15.5/1000) compared to the most matched year of this study “1999” 
(2.05/1000).  
 
5.4.2.2 Age differences in prescribing EBTs after a first PAD, PAD/CHD         
In the isolated PAD group, prescribing of β-blockers, statins and aspirin was significantly 
influenced by age. However, with CHD it was only significant for oral anticoagulants. Two 
studies, using unadjusted analysis, examined age differences in prescribing EBTs for PAD. 
The Paquet et al. study
336
 showed higher proportion of ACEI, antiplatelet and statins 
among young compared to old patients, however, another study (n=89)
337
 had a conflicting 
result for statins (old 33% vs. 13.0% for young). In this study the percentage of prescribing 
statins was higher among young than old patients, whereas it was similar for ACEI/ARBs. 
5.4.2.3 Sex association in prescribing EBTs after first PAD, PAD/CHD 
In this study, for most EBT classes, the odds of prescribing for patients with isolated PAD 
are lower in men than in women, but were only statistically significant for statins (OR 
0.73; 95% CI 0.57 to 0.95, p=0.01). In contrast, in patients diagnosed with CHD, men were 
associated with higher odds of being prescribed most EBTs than women, Table 24 and 
Table 33. Men with CHD were significantly more often prescribed statins than women 
(OR 1.41; 95% CI 1.02-1.93, p=0.03). In the earlier sections for MI and angina men were 
more likely to receive EBTs which can explain the difference here between isolated and 
non-isolated PAD. Few studies, using unadjusted analysis, examined sex differences in 
prescribing EBTs for PAD.
338,339
 In this study, the proportion of prescribing EBTs in 
patients with isolated PAD was higher among women than men, except for anticoagulants. 
Three studies were congruent with this study and showed that prescribing of statins or LLD 
was higher among women than men,
338,339
 however, one reported that men had higher 
proportions of statin prescriptions than women.
336
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5.4.2.4 Socioeconomic status association in prescribing EBTs after first PAD, 
PAD/CHD 
This study found that there was evidence for significant differences in prescribing PVD by 
socioeconomic deprivation status for isolated PAD and in prescribing ACEI/ARBs for 
PAD/CHD. Although the percentage differences in prescribing PVD for isolated PAD 
were small, it was relatively significant (0.03) after adjustment. On the other hand, there 
was no evidence for significant differences in prescribing by socioeconomic deprivation 
status for other EBTs. Only one study,
340
 using adjusted analysis, matched these results and 
showed no significant difference in prescribing antiplatelet and statins between low and 
high socioeconomic status. However, unadjusted RR showed that the risk of being 
prescribed antiplatelet and statins was significantly lower among low than high 
socioeconomic status. 
5.4.2.5 Trends of prescribing EBTs after a first PAD, PAD/CHD over time 
Prescribing was increased over the study period for all EBTs in both isolated PAD or in 
PAD/CHD. In this study, prescribing of ACEI/ARBs and β-blockers for PAD was lower 
than two previous studies,
316,341
 however it was higher for statins.
316,336,341
 One study 
showed a higher increase of statins prescriptions over the years than this study.
343
 
Subherwal et al.’s study342 described prescribing of cardioprotective medication in patients 
diagnosed with PAD alone, PAD with CHD and CHD alone. Trends of prescribing (within 
the first 3 months after diagnosis for Subherwal et al.’s study and within 30 days after 
diagnosis for this study) over the period for both studies were increased in all study groups. 
In my study the use of statins in isolated PAD group increased from 1.1% in 1997 to 
31.2% in 2005 (30.1% change over the years, P<0.001), and in the PAD/CHD group from 
6.3% in 1997 to 36.1% in 2005 (29.8% change over the years, P=0.006). In the Subherwal 
et al. study prescribing of statins for isolated PAD increased from 9% in 2000 to 56% in 
2007 (47% change, P<0.0001), and approximately from 28% in 2000 to 72% for 
PAD/CHD. 
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5.4.2.6 Comorbidities association in prescribing EBTs after first PAD, 
PAD/CHD   
In my analyses, several concomitant diseases have been included to identify their influence 
in prescribing EBTs after angina. Only one previous study examined the influence of 
comorbidities in prescribing EBTs after PAD. It showed that, from unadjusted analysis, the 
percentage of prescribing for statins was higher in patients with hypertension and diabetes 
than those without relevant disease. Concomitant CHD with other comorbidities in patients 
recently diagnosed with PAD can alter the choice of drug, such as β-blockers, which was 
significant in patients with CHD (OR 1.39; 95% CI 1.01-1.93), however, it disappeared in 
isolated PAD (OR 1.00; 95% CI 0.69-1.45). 
Summary  
Prescribing EBTs within 30 days after a first PAD and PAD/CHD improved over the time, 
however it remains suboptimal. Sex differences in prescribing EBTs associated with 
conflicting results between isolated and concomitant CHD analysis. Influence of 
socioeconomic status has been seen with PAD analysis; however, this was not found in MI 
and angina patient groups. Prescribing of statins and aspirin are associated with greatest 
increases since 1997. Concomitant CHD may influence the choice of drug in PAD 
treatment.
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6.0 Overall discussion 
Summary of key findings 
Several studies have investigated the prescribing of EBTs after a diagnosis of MI. These 
studies show conflicting results for the nature of the association between prescribing EBTs 
and age, sex, socioeconomic status and comorbidities. However, all studies have 
demonstrated that prescribing of EBTs has improved over time. This is the first study to 
examine the association between prescribing EBTs and age, sex, socioeconomic status, 
comorbidities and trends over time in one single population. This study also adjusted for 
many covariates and prescribing for all recommended, evidence-based, secondary 
prevention was examined. Prescribing within 30 days post MI was examined to ensure that 
all patients had enough time to collect their prescriptions from their GPs. I also examined 
prescribing after a first event so as to get clarity about prescribing for a particular episode 
and avoid confusion as to whether recommended treatments might have been given for 
another event.  
This study aimed to describe the associations between prescribing EBTs (within 30 days 
after first diagnosis with MI, angina and PAD) and several factors including sex, age, 
socioeconomic status and concomitant disease, as well as examining the trend of 
prescribing EBTs over the study period. Prescribing of EBTs has improved over time in 
Scotland. Prescribing over the study period (1997-2005) showed a steady increase for most 
of EBTs for all conditions examined. However, although prescribing has improved, it 
remains low. To illustrate, the most commonly prescribed EBTs for MI was β-blockers 
(19.2%) and in 2005 the percentage of prescribing was (43.4%).  Factors (sex, age, 
socioeconomic status and comorbidities) have been examined to identify their association 
with prescribing EBTs.  Sex, age, socioeconomic status and comorbidities were examined 
in relation to prescribing EBTs after first diagnosis for MI, angina, PAD and PAD/CHD. 
Older age (≥ 85years old) was associated with lower rate of being prescribed EBTs 
compared to younger patients. Male sex was associated with higher prescription EBTs than 
female sex, however, differences were not always significant.  Socioeconomic status had 
little influence on prescribing of EBTs across all patient categories. However, 
comorbidities were associated with varied differences in prescribing EBTs for all 
conditions.      
 
 
  
281 
 
Patient selection bias 
This study was subject to selection bias as I have excluded those who died within 30 days 
and had a prescription of EBTs after first diagnosis of MI, angina or PAD. Although bias 
may affect the validity of the result, the number of patients excluded from the analyses was 
acceptably low (857 for MI, 99 for angina, 147 for isolated PAD and 83 for those with 
PAD and CHD). These tables (19, 29, 40 and 49) showed that the number of patients who 
died before getting a prescription is higher than those who died and had had a prescription. 
Therefore excluding those who died did not exclude people who had also had a 
prescription. Therefore, the decision made to exclude these patients is likely to have very 
little effect on the absolute rates and relative rates described in the thesis.  
6.1 Prescribing of EBTs  
The differences in prescribing EBTs after first diagnosis of MI, angina, isolated PAD and 
PAD/CH varied according to the factors that have been examined in this study. In the 
previous studies there was a wide variability in time of determining prescribing EBTs, for 
example, some studies used three months, or six months to examine prescribing inequality. 
In this study I have used 30 days after first diagnosis as time frame to examine prescribing 
EBTs inequality for sex, age, socioeconomic status and comorbidities. The rationales 
behind that were, firstly, because all guidelines recommended that patients diagnosed with 
these diseases should be discharged from hospital with a prescription for EBTs, unless 
contraindicated, to control symptoms, reduce progression, reduce the risk for further 
cardiovascular disease, and to reduce the risk of morbidity and mortality. Secondly, to get 
as many patients considering it might take them a while to fill the prescription and get on 
these therapies. Furthermore, because I have restricted the analysis to those who survived 
for 30 days to avoid losing more patients due to mortality, I have examined prescribing 
EBTs within 30 days after first diagnosis. One more reason is that these therapies can be 
prescribed for any other cardiovascular disease, so using a different time point may 
increase the chance of being prescribed for other diseases. 
Age groups were examined in this study to identify whether age differences in prescribing 
EBTs is evident. This study shows similar results to the majority of the prior literature in 
suggesting that older patients are less commonly prescribed EBTs than younger patients. 
This fact has been recognised for all cohorts included in this study, i.e. MI, angina, PAD, 
PAD/CHD. There was a dramatic difference between younger and older patients in 
prescribing β-blockers and statins, however, this not the case with ACEI/ARBs (appendix 
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7). This can be due to a specific comorbidity, for example patients with HF can establish 
treatment just when their disease becomes stable. Increase in age is associated with an 
increased risk of multiple comorbidities which consequently may decrease the opportunity 
of being prescribed EBTs due to contraindications. This is one hypothesis for fewer EBTs 
prescriptions for older patients, however, in the current study, for all cohorts, the results 
were adjusted for several “common” associated comorbidities. Increased comorbidities 
with age associated with a high chance of using different drug groups, consequently this 
increased the risk of drug–drug interaction. Older patients were more likely to be treated 
therapeutically rather than surgically, so they should benefit from the EBTs secondary 
preventive therapy. The lower use of some EBTs in older patients with CHD (e.g. statins) 
has been explained as due to prescriber perception that statins are less effective or less cost 
effective in older patients.  
Similar to most prior literature, rates of prescribing EBTs for women were less common 
compared to men for all cohorts (appendix 7). This can be interpreted as that women with 
CHD tend to be 7 to 10 years older than men, i.e. age effect. Also women are more 
sensitive than men and tend to not tolerate side effects. In this study the difference in 
prescribing EBTs between men and women was narrowed after adjustment. Men were 
significantly more likely to receive β-blockers, ACEI/ARBs and statins than women in MI, 
angina and PAD/CHD, respectively.  Although guidelines and clinical trials showed that 
both sexes benefit from the EBTs secondary preventive therapy, inequalities exist. In this 
study I did not have any information about the disease severity. Angina and PAD are 
commonly diagnosed in GPs, so may lack the most recent updated information in 
practitioners attributed to prescribing discrepancies.    
Scottish Index of Multiple Deprivation (SIMD) score was used in this study to examine 
inequalities in prescribing EBTs between the most and least deprived patients recently 
diagnosed with MI, angina or PAD. Generally no significant differences were found in 
prescribing EBTs across deprivation quintiles in Scotland. This is matched to the report of 
Simpson et al. which showed no differences in prescribing EBTs between the most and 
least deprived CHD patients. Simpson et al.
223
 used CMR data sets, which are a part of the 
datasets I used in my research, however, he analysed all patients diagnosed with CHD, 
irrespective of whether it was a first event or recurrent diagnosis. Furthermore, prescribed 
medications were assessed at any time point after diagnosis. The similarity in prescribing 
EBTs among all deprivation quintiles may be attributed to the Scottish health care system. 
This provided free prescriptions to those who were on low incomes or with chronic 
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diseases. The provision of these free prescriptions (or lower cost prescriptions through the 
use of a pre-payment scheme) may be why there was little difference in prescribing rates 
across socioeconomic groups. Influence of socioeconomic status was obvious in countries 
that do not provide free drug prescriptions for patients diagnosed with chronic disease.  
In this study numerous comorbidities were included in the model to examine their 
influence in prescribing EBTs after first diagnosis, whereas most previous studies involved 
fewer numbers of comorbidities. Most of the included comorbidities were associated to 
different tendencies in prescribing EBTs. These associations may affect positively in 
prescribing EBTs such as ACEI/ARBs in patients with a history of HF, while some other 
comorbidities may influence prescribing negatively due to certain medication 
contraindication such as β-blockers with airway obstructive disease. Previous studies 
showed similar influence of examined comorbidities in prescribing EBTs. 
Prescribing over the study time was increased for almost all medications, albeit with 
different trend patterns. Statins were the drug associated with the highest increase of 
prescribing from 1997 to 2005. This finding is similar to most of the previous studies. This 
huge increase in prescribing of statins can be related to the influence of clinical trials such 
as 4S trials.  Generally most of the prior studies reported different rates of improvement in 
prescribing of EBTs for CHD, MI, angina and PAD, however the rates remained low. The 
rate of prescribing EBTs within 30 days is lower in this study compared to others, 
however, prescribing rates at any time point (e.g. for MI) show much better trends and are 
similar to the prior studies (Appendix 8).    
CHD is one of the main causes of death in many Western countries such as Scotland. 
Studies have demonstrated that mortality rates for men due to CHD have fallen from 460 
per 100,000 population in 1979 to 136 per 100,000 population in 2010, and fallen for 
women from 208 to 64 per 100,000 population.
418
 A number of studies have suggested that 
45-75% of these falls in mortality are due to declines in the major risk factors for CHD 
such as smoking and hypertension. Furthermore, they also suggest that the use of EBTs 
decreased death rates by 25-55%.
417
 In Scotland, Hotchkiss et al. reported that the death 
rate due to CHD declined in adults aged 25 years and more by 43% between 2000 and 
2010. Improvement in medical treatment use was attributed as causing a 40% reduction in 
CHD mortality in Scotland. Lipid lowering drugs, particularly statins, are attributed to 13% 
of the fall in total CHD mortality, followed by the use of secondary prevention therapies 
after MI (9%).
417
 Hotchkiss et al.
417
 and O’Flaherty et al.418 demonstrated that the 
mortality rate due to CHD is higher among the most deprived compared to the least 
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deprived. One study examined the variation of death from CHD by day in Scotland.
419
 This 
study showed a significant day of the week variation in death due to CHD (p < 0.001), with 
higher rate on Monday (3.1% above the daily average).            
The prescribing of primary and secondary preventative medications has improved over 
time. This has occurred as the result of key randomised controlled clinical trials being 
published that have led to a change in practice. A number of key trials were published 
during the period leading up to and during the study period. These are listed in Table 58. 
While many of these medications were used in the treatment of CVD prior to the 
publication of these trials, as can be seen, the role of each of these medications was 
confirmed by trials prior to the period of the study. Therefore, there is likely to be little 
influence on the results as a consequence of new evidence. 
 
Table 58 Major primary and secondary prevention trials for MI, angina and PAD 
 Antiplatelet β-blockers ACEI Statins 
MI 
CAPRIE (1996) 
CURE     (2000) 
SIS2        (1987) 
NMS   (1985)  
BHAT (1982) 
ISIS1   (1986) 
SAVE      (1992) 
AIRE       (1993) 
4S              (1994) 
CARE        (1991) 
LIPD          (1998) 
Angina SAPAT   (1992) ASIST (1994) 
HOPE      (2000) 
EUROPA (2003) 
HPS            (2002) 
LIPD           (1998) 
PAD CAPRIE ---- HOPE      (2000) 
4S                (1994) 
HPS             (2002) 
WOSCOPS (1995) 
AFCAPS/ 
TexCAPS (1998) 
 
Other external influences could have made an impact on the changes in prescribing 
practice reported here. The Quality Outcomes Framework was introduced to incentivize 
general practices to adhere to certain standards, including prescribing standards. The 
impact of the QOF is likely to be minimal in the data used in this thesis as the first QOF 
exercise was conducted in April 2004, at the end of the study period. I did not observe any 
large step changes in prescribing practice in the period preceding this or around that time 
that would suggest that the introduction of QOF influenced the trends in prescribing 
observed.  
Finally, changes in the methods of diagnosis may have influenced the results reported here. 
The diagnosis of angina and PAD has not changed dramatically over the time period 
studied. However, towards the end of the study period new biomarkers were introduced to 
detect MI. The troponin assay is a much more sensitive and specific marker of MI than the 
previous biomarker of creatinine kinase (CK) and cardiac mitochondrial creatinine kinase 
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(CK-MB). The use of troponin has made it possible to detect smaller MIs but they were 
only widely used at the end of the study period from 2001 onwards in Scotland. While the 
inclusion of more cases with less severe infarction may lead to the inclusion of individuals 
less likely to receive treatment would decrease rates. I found the opposite trend rates 
increased over this period and there was no major change in the prescribing of drugs at this 
time during the study period.  
Prescribing of EBTs was modestly higher after first diagnosis with MI, however, it was 
lower in patients with angina and PAD. Patients with angina and PAD are more likely to 
be diagnosed for the first time in the GP and this may explain why this group of patients 
are associated with a lower rate of secondary preventions EBTs. Also, this theory may be 
supported by looking at the prescribing at any time (appendix 7) where it is shown that all 
EBTs prescriptions were increased at least twofold, this may be related to either these 
patients developing other cardiovascular diseases or being referred to a specialist. This 
study highlighted a very important public health message in prescribing of secondary 
prevention EBTs for patients with isolated PAD as these recommended medications were 
poorly prescribed compared to other cardiovascular diseases. Patients with isolated PAD 
are at risk of developing any other cardiovascular diseases so they should be prescribed 
prophylactic EBTs. As mentioned above, this group is mostly diagnosed in GP, so this 
tendency may be due to a lack of practitioners’ information for updated guidelines in the 
management of these diseases (e.g. PAD affects their decisions on prescribing EBTs).          
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Study implications 
Although clinical trials have shown that these EBTs reduce morbidity and mortality, they 
are still underused as demonstrated in these analyses. This has a number of implications for 
patients and the health care professionals looking after them. The most important 
implication of my findings is for patients who are not receiving appropriate secondary 
preventative therapies. This means that a large number of people are not benefiting from a 
potential reduction in risk with appropriate medication. This leads to potentially 
preventable morbidity and mortality. The reasons for this sub optimal prescribing rate will 
be due to a number of patient and health care professional related factors. While a number 
of patients will have a contra-indication to certain medications, the large proportion of 
patients not on particular EBTs, and the variation by diagnosis, suggests that other factors 
are involved in the low rate of prescription. These factors cannot be determined from this 
study but may be due to patient choice as patients may be unwilling to take another 
medication on top of those that they already take. They may also experience side effects 
that mean that they are unable to tolerate the drug. Such factors are hard to change except 
for educating patients as to the potential benefits of particular EBTs. Whatever the patient 
factors are for the low rate of prescribing they are undoubtedly not the only factor – health 
care provider related factors are certainly a cause as well. The results of this study have 
greater implications for health care providers and prescribers as they are responsible for 
suggesting the correct EBTs for a patient. 
Although prescribing rates rose during the period studied suggesting that improvements 
have occurred, the rates are still low. This gap in prescribing suggests that there is still 
much to be done in improving prescribing practice. Improving prescribing can be achieved 
through a number of mechanisms. Use of electronic records that prompt physicians to 
prescribe certain drugs for a certain diagnosis can be effective.
421
 Training and education is 
also potentially useful, especially in the setting of smaller practices.
422
. Using pharmacists 
in the community to help increase prescribing and optimise dosing may also be used.
423
 
However, whether these interventions translate into improvements in outcomes are 
uncertain.
423
 
Increased prescribing of EBTs may have beneficial effects on morbidity and mortality, 
however, there may be unintended consequences of more prescribing. Prescribing of more 
drugs may increase the rate of side effects experienced by patients. There may also be a 
rise in the number of significant drug interactions that occur as a result of more 
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medications being prescribed. The rate of adverse events with EBTs may also increase, for 
example bleeding in patients receiving an anticoagulant. However, these are not reasons to 
avoid prescribing but rather employ good prescribing practice such as checking for known 
drug interactions and monitoring for adverse effects. Similarly, the risk of adverse effects 
such as bleeding with anticoagulants can be reduced by the use of scores to identify high 
risk patients.
424
 
7.0 Strengths and Limitations  
This cohort study included a large sample of patients with a first diagnosis of a CVD (MI, 
angina and PAD). I used this linked dataset of primary and secondary care, which allowed 
me to follow patients in primary care after hospital discharge. The linked dataset also 
provided a longitudinal study design so the first (incident) diagnosis could be identified 
and patients could then be followed forwards and backwards for analysis. Furthermore, 
linkage to the GROS allowed those patients who died shortly after a first diagnosis to be 
removed from further analysis. The majority of prior studies that have examined 
prescribing inequalities were restricted to either primary or secondary care datasets, 
limiting their size. They were therefore also unable to find the first diagnosis irrespective 
of whether this happened in primary or secondary care in contrast to my analyses where 
this time point could be identified.  
A further strength of the dataset that I analysed was that data on prescriptions was taken 
directly from the electronic system. This removed the potential for recall-bias. Prior studies 
in the literature have relied on patient self-reported prescribing data. These studies are 
therefore prone to recall-bias and the accuracy of the results can be questioned.  
In my research I examined the influence of several factors on prescribing of EBTs, which 
has not been done before. Several variables were included in the model for statistical 
analysis (age sex, socioeconomic status, time, comorbidities and previous prescribing) to 
minimise confounding. I adjusted for the following comorbidities: a history of 
COPD/asthma, AF, hypertension, diabetes, cancer, renal failure, HF, PAD, stroke and 
angina.  In contrast, a number of prior studies either did not adjust their analyses for 
comorbidities or restricted their adjustment to one or two comorbidities such as diabetes or 
renal failure only.
267,269
 However, many diseases can confound the prescribing of EBTs 
due to contraindications such as ACEIs in patients with renal failure. Therefore, a strength 
of this study in comparison to the prior literature is that I have included a wide range of 
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comorbidities to adjust for these confounding diagnoses that may have influenced 
prescribing patterns.   
Another strength of this study is that it included all recommended secondary prevention 
therapies. Many studies have focused on only one or two therapies.
219,221,227
 This study 
describes the wide range of medications used in the secondary prevention of MI, angina 
and PAD.  A further strength in comparison to the prior literature is that I examined 
prescribing in relation to a number of cardiovascular diseases in the same cohort. This 
allowed me to make comparisons between different diagnoses. Prior studies have focussed 
on one diagnosis at a time, making comparisons difficult.
326,328
  
This study, like any work, has some points of weakness. The Secondary Care data set 
(SMR) does not provide patients’ medications at time of discharge, which can only be 
obtained from the Primary Care datasets “GPs”. Therefore, actual data users do not know 
what patients were prescribed at the point of hospital discharge. On another hand, for 
chronic serious diseases, such as MI, patients are at high risk of death, which may lead to 
miss some patients in the analysis if they died before a GP visit. Although MI is an 
emergency case and would usually be diagnosed and treated in hospital, in this study a 
number of patients were recorded as being diagnosed in the Primary Care. There is no 
marker for disease severity, and only ICD/Read codes classifications are available.  There 
is also uncertainty regarding incidence of diagnosis for the early study period because I 
have no data available before 1997. Although this study adjusted for most common 
cardiovascular disease, further confounders may be missed such as prescriber and the 
rationales behind non-prescribed EBTs. Another limitation is that multiple tests have been 
conducted in this research and because of the well recognised multiple comparisons 
problem, some of the statistically significant associations could be spurious. The majority 
of patients with angina and PAD were diagnosed in GPs and not necessarily confirmed by 
definitive investigations.  
As I have discussed in relation to the previously published literature, bias is inherent in any 
observational study. The present analyses are no exception to this. To study prescribing at 
a time point patients naturally need to survive to this point.  This leads to a survivor bias. 
As I have shown the patients who survived to 30 days were similar to those who died 
without a prescription and the numbers were small, limiting this bias. There is also the 
possibility of recording bias. Prescriptions may have been incorrectly recorded. However, 
prior audits have reported that the accuracy of prescribing data in CMR is practically 
100%.
366
 Case ascertainment bias is perhaps the largest bias in this study. While the 
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accuracy of cardiovascular diagnoses is high in SMR and CMR it is not 100%. Therefore 
bias caused by case ascertainment is present though it is low, given that the accuracy of 
cardiovascular diagnoses is high. 
One limitation of the dataset is that I could not account for the type of practices included. 
For example as discussed in section 4.1.3.2 Validity of the CMR datasets, a number of 
practices are likely to have been training practices or have Practices Accreditation (PA) or 
a Quality Practice Award (QPA). Although I used clustered standard errors in the analysis 
to try to account for this I was unable to fully adjust for these differences. 
Unfortunately, Hosmer-Lemeshow tests demonstrated that the logistic regression models 
were not always well calibrated, and sensitive to choice of number of groups used in the 
test. Calibration was best for PAD/CHD models and worst for angina models. The poor 
lack of fit for angina may be due to angina diagnosis being more heterogeneous in terms of 
severity, i.e. how severe is the angina. Furthermore, results in this study adjusted for 
limited variables. 
One assumption made during this thesis is that the baseline characteristics represent a 
lifetime risk. I have examined prescribing in a relatively short time period. Therefore there 
is little expectation that important baseline characteristics will change to a degree to affect 
the results. However, in future studies, it must be remembered that characteristics can 
change over time and these changes may influence the results. I did not have any data on 
smoking or lifestyle factors to adjust for in the models. These data are not recorded by 
CMR. 
In this study patients that did not survive 30 days after hospital discharge was excluded 
from the analysis, which certainly led to selection bias. I have discussed and justified this 
issue early in this study.  
 
 
 
 
 
 
  
290 
 
8.0 Future research  
This study can be used as a basis for further analysis. More work to identify the influence 
of the used factors in prescribing EBTs for other chronic disease such as HF, atrial 
fibrillation or stroke can be established. Further factors that may influence prescribing can 
also be included such as race, physicians’ gender or speciality, and physicians’ years of 
experience. Since this study was focused on identifying the existence of prescribing 
inequality, the reasons behind that should be investigated in future. Further prospective 
studies can be useful to follow patients from the time of hospital admission to the day of 
discharge. In such studies investigators can obtain medications at time of discharge, 
severity of disease and ensure a thorough medical history for a particular disease is 
obtained.  More analysis should be carried out to examine whether the prescribed drug 
doses match the doses used in the clinical trials. In addition, reasons for not prescribing 
any recommended EBTs should be detailed and records should be kept of any prescribed – 
if any – alternative therapy. 
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9.0 Conclusion    
This study shows that inequalities of prescribing EBTs exist in Scotland. Prescribing 
within 30 days varied by sex, age and comorbidities but not by socioeconomic status. 
Although clinical trials have demonstrated the efficacy of a number of EBTs in preventing 
events after a MI irrespective of the age, older patients, particularly those aged over 85 
years, were significantly less commonly prescribed EBTs, e.g. β-blockers and ACEIs. 
Furthermore, they were less commonly prescribed risk lowering drugs such as statins. 
Lower prescribing of EBTs for older patients (≥ 85 years) was also seen after a patient had 
a diagnosis of angina or PAD. Although older individuals are more likely to have multiple 
comorbidities, I found that these age inequalities persisted even after adjusting for a 
number of comorbidities.  
Prescribing of EBTs was higher in men compared to women after a first MI, angina and 
PAD/CHD. However, these differences were statistically significant for only a few 
medications. In patients with a MI or angina men were significantly more likely to be 
prescribed β-blockers and ACEI/ARBs, respectively. However, in contrast, the prescribing 
of EBTs was lower among men than women after diagnosis of PAD. The prescribing of 
statins after a diagnosis of PAD was significantly less common in men than women, 
however, there was no significant differences between men and women in prescribing of 
other EBTs.   
My review of the literature found numerous studies reporting that there were differences in 
prescribing of EBTs in the least and most deprived patients in several countries. I did not 
find any evidence of a significant difference in the prescribing of EBTs by socioeconomic 
status, i.e. between least and most deprived patients, after first diagnosis of MI, angina, 
PAD and PAD/CHD. This may be due to the National Health Service in Scotland and the 
availability of free health care in comparison to other countries where socioeconomic 
differences in prescribing rates have been reported.  
In this study I adjusted for a number of comorbidities. These included a history of 
COPD/asthma, AF, hypertension, diabetes, cancer, renal failure, HF, PAD, stroke and 
angina which are all known confounders of prescribing patterns as they may increase or 
decrease the rate of prescribing due to positive indications or contraindications 
respectively. I have shown that comorbidity influences the prescribing of different EBTs. 
Prescribing of drugs that also lower blood pressure, e.g. β-blockers or ACEI/ARBs after a 
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first diagnosis of MI or angina was higher in patients with hypertension. However, 
prescribing of β-blockers or ACEI/ARBs declined in patients with asthma or renal failure, 
respectively as these are contraindications to their use. I also found that some 
comorbidities may lead to the use of an alternative drug, for example patients with AF 
were more likely to be prescribed an oral anticoagulant (warfarin) instead of aspirin.  
This study examined the prescribing trend of EBTs from 1997 to 2005. The results suggest 
that prescribing EBTs within 30 days after first diagnosis, although increasing over time, 
remains low. However, further studies are required to determine whether these trends have 
continued and whether further efforts to improve prescribing are needed.  
This study highlighted an important and neglected disease. Although PAD is associated 
with significant morbidity and mortality, the rate of prescribing of EBTs was very low. 
Further studies are required to understand why this population are so under-prescribed 
EBTs and how we might change this finding.  
Finally, the results of this study would suggest that more studies examining other chronic 
diseases such as HF, atrial fibrillation and asthma should be conducted to examine 
prescribing inequalities and trends. The low rates of prescribing and inequalities in 
prescribing that I have described need to be addressed. The information from these 
analyses can be used to identify those patients who are least likely to receive appropriate 
EBTs, e.g. the elderly, women and those with comorbidities. This may help prescribers 
identify such patients so that they can be specifically targeted for review of their 
medications to ensure they are on as many EBTs as indicated or tolerated. The information 
could also be used by public health care professionals to target interventions or resources 
such as community pharmacists to these groups of patients to maximise prescribing of 
EBTs. Through identifying those at risk of low prescribing rates or EBTs, I hope that 
prescribing rates can improve generally which will hopefully translate to improved 
outcomes for these patient populations. 
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Appendices  
Appendix 1 
Searching literature key words 
Key words Main word  Synonyms  
1- Factors  Age  Older, young  
 Sex Gender, male, female, men, women 
 Socioeconomic  Poor, low income, lower income 
 Time Time trends, temporal, decade, 
trends 
 Comorbidities  
Result of search  2787266 English articles  
2- Evidence based  Evidence based Heart protection, cardiac protective, 
cardio protective, therapy, 
secondary prevention, 
pharmacotherapy, beta blocker, 
calcium channel blocker, statins, 
angiotensin converting enzyme 
inhibitors, angiotensin receptor 
blocker, ACEI, ARBs, aspirin, 
clopidogrel,  anticoagulant, 
Warfarin, cilostazol, naftidrofuryl, 
pentoxifylline, loop diuretics, 
thiazide diuretics, statins, lipid 
lowering drugs 
Result of search 1037318 English articles 
3- Prescribing  Prescribing  Missed opportunity, lower use, 
lower prescribing, use, utilisation, 
utilization, prescription, 
inequalities, underuse 
Result of search 69202 English articles 
4- Myocardial 
infarction 
MI myocardial infarction,  heart attack, 
cardiac arrest 
Result of search 129064 English articles 
5- Angina  Angina  Angina, angina pectoris, stable 
coronary artery disease 
Result of search 33106 English articles 
6- Peripheral artery 
disease (PAD) 
Peripheral artery 
disease  
peripheral arterial disease, PAD,  
peripheral vascular disease, PVD,  
intermittent claudication, peripheral 
artery disease,  lower extremity 
peripheral artery disease, lower limb 
peripheral arterial disease, lower 
extremity peripheral arterial disease, 
lower limb peripheral arterial 
disease 
Result of search 25179 English articles 
7- Coronary heart 
disease (CHD) 
CHD Coronary heart 
disease[Title/Abstract] OR Ischemic 
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heart disease, ischaemic heart 
disease,  coronary artery disease, 
acute coronary syndrome 
Result of search 100304 English articles 
8- Comorbidities   chronic obstructive pulmonary 
disease, COPD, asthma,  
hypertension, atrial fibrillation, 
diabetes, diabetes mellitus, heart 
failure, cancer, renal failure 
Result of search 1429789 English articles 
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Key words: 
1- Factors2  
((((((((((((age[Title/Abstract] OR older[Title/Abstract]) OR young[Title/Abstract]) OR 
sex[Title/Abstract]) OR gender[Title/Abstract]) OR male[Title/Abstract]) OR 
female[Title/Abstract]) OR men[Title/Abstract]) OR women[Title/Abstract]) OR 
socioeconomic[Title/Abstract]) OR poor[Title/Abstract]) OR low income[Title/Abstract]) 
OR lower income[Title/Abstract]) OR low income[Title/Abstract] OR 
temporal[Title/Abstract] OR time trends[Title/Abstract] OR decade[Title/Abstract] OR 
trends[Title/Abstract] OR comorbidities[Title/Abstract] OR mortality[Title/Abstract] 
English (2787266) 
2- Evidence based 2 
((((((((((((((((((((((((evidence based[Title/Abstract] OR heart protection[Title/Abstract]) 
OR cardioprotective[Title/Abstract]) OR cardiac protective[Title/Abstract]) OR 
therapy[Title/Abstract]) OR secondary prevention[Title/Abstract]) OR 
pharmacotherapy[Title/Abstract]) OR beta blocker[Title/Abstract]) OR calcium channel 
blocker[Title/Abstract]) OR aspirin[Title/Abstract]) OR statins[Title/Abstract]) OR 
angiotensin converting enzyme inhibitors[Title/Abstract]) OR angiotensin receptor 
blockers[Title/Abstract]) OR ARBs[Title/Abstract]) OR ACEI[Title/Abstract]) OR 
clopidogrel[Title/Abstract]) OR anticoagulant[Title/Abstract]) OR 
warfarin[Title/Abstract]) OR CILOSTAZOL[Title/Abstract]) OR 
naftidrofuryl[Title/Abstract]) OR PENTOXIFYLLINE[Title/Abstract]) OR loop 
diuretics[Title/Abstract]) OR thiazide diuretics[Title/Abstract]) OR lipid lowering 
drugs[Title/Abstract]) OR peripheral vasodilators[Title/Abstract]) OR beta 
blockers[Title/Abstract] OR calcium channel blockers[Title/Abstract] 
English (1037318) 
3- Prescribing2  
(((prescribing[Title/Abstract] OR missed opportunity[Title/Abstract]) OR lower 
use[Title/Abstract]) OR lower prescribing[Title/Abstract]) OR use[Title/Abstract] OR 
prescription[Title/Abstract] OR inequalities[Title/Abstract] OR utilisation[Title/Abstract] 
OR underuse[Title/Abstract] 
English (69202) 
4- Myocardial infarction (MI) 
((myocardial infarction[Title/Abstract] OR heart attack[Title/Abstract]) OR cardiac 
arrest[Title/Abstract]) OR MI[Title/Abstract]  
English (129064) 
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5- Angina 
(angina[Title/Abstract] OR angina pectoris[Title/Abstract]) OR stable coronary artery 
disease[Title/Abstract] 
English (33106) 
6- Coronary heart disease (CHD)  
(((Coronary heart disease[Title/Abstract] OR Ischemic heart disease[Title/Abstract]) OR 
ischaemic heart disease[Title/Abstract]) OR coronary artery disease[Title/Abstract]) OR 
acute coronary syndrome[Title/Abstract] 
English (100304) 
7- Peripheral artery disease (PAD2) 
((((((((peripheral arterial disease[Title/Abstract] OR PAD[Title/Abstract]) OR peripheral 
vascular disease[Title/Abstract]) OR PVD[Title/Abstract]) OR intermittent 
claudication[Title/Abstract]) OR peripheral artery disease[Title/Abstract]) OR lower 
extremity peripheral artery disease[Title/Abstract]) OR lower limb peripheral arterial 
disease[Title/Abstract]) OR lower extremity peripheral arterial disease[Title/Abstract]) OR 
lower limb peripheral arterial disease[Title/Abstract] 
English (25179) 
8- Comorbidities 
((((((((chronic obstructive pulmonary disease[Title/Abstract] OR COPD[Title/Abstract]) 
OR asthma[Title/Abstract]) OR hypertension[Title/Abstract]) OR atrial 
fibrillation[Title/Abstract]) OR diabetes[Title/Abstract]) OR diabetes 
mellitus[Title/Abstract]) OR heart failure[Title/Abstract]) OR cancer[Title/Abstract]) OR 
renal failure[Title/Abstract] 
English (1429789) 
9- MI+Angina+CHD 
((((((((((Coronary heart disease[Title/Abstract] OR ischaemic heart disease[Title/Abstract]) 
OR Ischemic heart disease[Title/Abstract]) OR coronary artery disease[Title/Abstract]) OR 
acute coronary syndrome[Title/Abstract]) OR angina[Title/Abstract]) OR angina 
pectoris[Title/Abstract]) OR stable coronary artery disease[Title/Abstract]) OR myocardial 
infarction[Title/Abstract]) OR cardiac arrest[Title/Abstract]) OR heart 
attack[Title/Abstract]) OR MI[Title/Abstract] 
English (223980) 
 
10- MI+Angina+CHD+PAD 
((((((((((((((((((((Coronary heart disease[Title/Abstract] OR Ischemic heart 
disease[Title/Abstract]) OR ischaemic heart disease[Title/Abstract]) OR coronary artery 
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disease[Title/Abstract]) OR disease[Title/Abstract]) OR stable coronary artery 
disease[Title/Abstract]) OR acute coronary syndrome[Title/Abstract]) OR angina 
pectoris[Title/Abstract]) OR angina[Title/Abstract]) OR cardiac arrest[Title/Abstract]) OR 
heart attack[Title/Abstract]) OR myocardial infarction[Title/Abstract]) OR 
MI[Title/Abstract]) OR peripheral arterial disease[Title/Abstract]) OR peripheral vascular 
disease[Title/Abstract]) OR PVD[Title/Abstract]) OR peripheral artery 
disease[Title/Abstract]) OR lower extremity peripheral artery disease[Title/Abstract]) OR 
lower limb peripheral arterial disease[Title/Abstract]) OR lower extremity peripheral 
arterial disease[Title/Abstract]) OR lower limb peripheral arterial disease[Title/Abstract]) 
OR intermittent claudication[Title/Abstract] 
English (1725700) 
Search strategy and combinations of key words 
1- All keys with comorbidities   
1&2&3&4&5&6&7&8= 2 (1)                1&2&3&10&8= 1045 (937) 
 
2- All keys NO comorbidities 
      1&2&3&4&5&6&7= 2 (1)                     1&2&3&10= 2311 (2051) 
3- Main keys (factors+ evidence based+ prescribing) AND (MI+ Angina+ CHD)   
1&2&3&4&5&6= 30 (24)                    1&2&3&9= 808 (709) 
4-  Main keys and MI 
1&2&3&4= 402 
5- Main keys and angina 
1&2&3&5= 82 
6- Maine keys and CHD 
1&2&3&6= 389 
7- Main keys and PAD 
1&2&3&7= 40 
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Appendix 2 
PRISMA flow diagram of the literature included in the review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies identified 
by the search 
strategy 
(n=1045) 
 
 Publications excluded after 
screening   
(n=840) 
 
Additional articles 
identified from 
references  
(n=31) 
Publications 
finally included in 
the literature 
review 
(n=128) 
 
Remaining 
studies 
(n=937) 
 
Excluded Publications  
Due to non-English publication 
or duplication across databases 
(n=108) 
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Appendix 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
300 
 
Appendix 4 
 
 
 
 
 
 
 
 
 
In the read code symbol of % means e.g. G3% means all G3 and below.  
 
 
 
 
 
Diseases  Read cods ICD9 ICD10 
Angina  ((c.readcode like 'G311.%')or (c.readcode 
like 'G33%') or(c.readcode like 'Gyu30%')) 
413 Angina pectoris or 411 
 
 I20 or I24.9 
Myocardial 
infarction 
((c.readcode like 'G30%')or (c.readcode like 
'G35%') 
or (c.readcode like 'G38%')or(c.readcode 
like 'Gyu34%')) 
410  I21 or I22 
PAD c.readcode like 'G73% 440.2, 440.8, 440.9, 443.9, 444.22, 
444.8-444.9 
I70.2, I70.8, I70.9, I73.9, I74.3-
9 
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Comorbidities read 
codes, ICD9 and ICD10 
Diseases  
Read cods ICD9 ICD10 
Asthma  (c.readcode like 'H33%') 
and ((readcode not like 'H333%') 
or( readcode not like 'H33z1%')) 
493.0, 493.1, 493.2, 493.9  
 
J45.1, J45.8, J45.9 
 
COPD H36..,  H37.., H38.., H39.., H3y1.,    
                                                             
496 
 
J44.1, J44.9 
 
Atrial fibrillation  ((c.readcode like 'G573.') 
or (c.readcode like 'G5730') 
or (c.readcode like 'G5731') 
or(c.readcode like 'G5732') 
or(c.readcode like 'G5733') 
or(c.readcode like 'G573z')) 
and  (c.readcode not like '212R') 
 
427.3 
 
 I48 
Hypertension  ((c.readcode like 'G2...%') 
or (c.readcode like 'G20%')  
or (c.readcode like 'G24..%') 
or(c.readcode like 'G2y%') 
or(c.readcode like 'G2z%')) 
 401  
 
I10-I13 
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Diabetes  c.readcode like 'C10%' 250 
  
 E10-E14) 
Cancer  B0... - B32z., B34.. - B6z0., Byu.. - 
Byu41, Byu5. - ByuE0 
140-208  
 
C00 – C99 
 
Chronic kidney disease ((c.readcode like '14D..')or (c.readcode 
like '14D1.')or (c.readcode like 
'14V2.') 
or (c.readcode like 'P7690')or 
(c.readcode like 'K05..')or (c.readcode 
like 'K050.')or (c.readcode like 
'K0D..') 
or (c.readcode like 'K138z')or 
(c.readcode like '1Z1..')or (c.readcode 
like '1Z10.')or (c.readcode like '1Z11.') 
or (c.readcode like '1Z12.')or 
(c.readcode like '1Z13.')or (c.readcode 
like '1Z14.')or (c.readcode like '8L50.') 
or (c.readcode like 'ZV451')or 
(c.readcode like 'G22..')or (c.readcode 
like 'G220.')or (c.readcode like 
'G221.') 
or (c.readcode like 'G222.')or 
(c.readcode like 'G22z.')or (c.readcode 
585, 586, 587  
 
N18,N19 
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like 'K07..')or (c.readcode like 'K070.') 
or (c.readcode like 'K071.')or 
(c.readcode like 'K072.')or (c.readcode 
like 'K07z.')or (c.readcode like 
'G701.') 
or (c.readcode like '7L1A.')or 
(c.readcode like '7L1A0')or 
(c.readcode like '7L1A1')or 
(c.readcode like '7L1A2') 
or (c.readcode like 'G703.')or 
(c.readcode like 'PD1..')or (c.readcode 
like 'PD11.')or (c.readcode like 
'PD12.') 
or (c.readcode like 'PD13.')or 
(c.readcode like 'PD1y.')or (c.readcode 
like 'PD1z.')or (c.readcode like 
'7B063') 
or (c.readcode like 'D215.')or 
(c.readcode like 'ZV560')or 
(c.readcode like 'C10E0')or 
(c.readcode like 'C10F0') 
or (c.readcode like 'K0B..')or 
(c.readcode like 'K0B1.')or 
(c.readcode like 'K0B2.')or 
(c.readcode like 'K0B3.') 
or (c.readcode like 'K0B4.')or 
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(c.readcode like 'K0B5.')or 
(c.readcode like 'K0B6.')or 
(c.readcode like 'G233.') 
or (c.readcode like '7L1B.')or 
(c.readcode like 'TA020')or 
(c.readcode like 'G232.')or (c.readcode 
like 'K09..') 
or (c.readcode like 'K090.')or 
(c.readcode like 'K091.')or (c.readcode 
like 'K09z.')or (c.readcode like 
'K0C..') 
or (c.readcode like 'K0C0.')or 
(c.readcode like 'K0C1.')or 
(c.readcode like 'K0C2.')or 
(c.readcode like 'K0C3.') 
or (c.readcode like 'K0C4.')or 
(c.readcode like 'D3101')or 
(c.readcode like 'K03..') 
or (c.readcode like 'K031.')or 
(c.readcode like 'K032.') or 
(c.readcode like 'K06%')) 
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Appendix 5 
Drugs class BNF code Description  
Angiotensin converting enzyme inhibitors 2.5.5.1  
Angiotensin II receptor antagonist  2.5.5.2  
Beta blocker 2.4  
Calcium channel blocker 2.6.2  
Nitrates 2.6.1  
Other anti-anginal drugs 2.6.3 Nicorandil and ivabradine 
Antiplatelet  2.9 Aspirin and clopidogrel 
Lipid regulating drugs 2.12 Statins  
Oral anticoagulant 2.8.2 Warfarin 
Peripheral vasodilators 2.6.4 Cilostazol, naftidrofuryl oxalate, pentoxifylline (oxpentifylline) 
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Appendix 6 
Table 1 Association between age and prescribing of evidence based therapies after a first myocardial infarction (age < 55 years reference group) 
 
ACEI/ ARBs β-blockers CCB Statins Aspirin Clopidogrel Oral anticoagulant 
Adjusted OR*, 95% 
CI 
55-64 
1.18 (0.95-1.47) 1.01 (0.85-1.21) 1.05 (0.74-1.49) 0.98 (0.83-1.15) 1.07 (0.90-1.28) 1.01 (0.81-1.26) 0.95 (0.54-1.67) 
Adjusted OR, 95% CI 
65-74 
1.04 (0.81-1.33) 0.93 (0.73-1.18) 0.98 (0.66-1.45) 0.84 (0.66-1.07) 1.07 (0.87-1.32) 0.83 (0.63-1.09) 0.95 (0.52-1.71) 
Adjusted OR, 95% CI 
75-84 
0.82 (0.62-1.08) 0.64 (0.51-0.80) 1.13 (0.76-1.67) 0.54 (0.43-0.68) 0.86 (0.70-1.05) 0.67 (0.51-0.88) 1.10 (0.56-2.17) 
Adjusted OR, 95% CI 
≥ 85 
0.46 (0.32-0.67) 0.38 (0.26-0.54) 0.89 (0.52-1.53) 0.21 (0.13-0.32) 0.66 (0.47-0.92) 0.51 (0.31-0.85) 0.33 (0.11-1.07) 
Adjusted
+
 overall 
P-value 
<0.001 <0.001 0.0.85 <0.001 0.002 0.01 0.14 
 
* Patients aged <55 years are the reference category, +Adjusted for sex, socioeconomic status, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, 
 hypertension, diabetes, cancer, renal failure,  heart failure, and stroke, peripheral arterial disease, angina, clustered practices, and whether the drug was previously prescribed. 
  
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers 
 
 
 
 
  
307 
 
 
 
Table 2  Association between sex (male vs. female) and prescribing of evidence based therapies after first myocardial infarction 
 Adjusted OR (95% CI)* 
Adjusted
+
 
p-value 
ACEI/ ARBs 1.12 (0.91-1.39) 0.27 
 β-blockers 1.18 (1.04-1.33) 0.01 
CCB 1.02 (0.81-1.28) 0.9 
Statins 1.09 (0.94-1.25) 0.20 
Aspirin 1.09 (0.96-1.24) 0.15 
Clopidogrel 1.09 (0.88-1.36) 0.41 
Oral anticoagulant 0.79 (0.55-1.15) 0.29 
 
Women are the reference category, +Adjusted for age group, socioeconomic, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes,  
cancer, renal failure, heart failure, stroke, peripheral arterial disease, angina, clustered practices, and whether the drug was previously prescribed. 
 
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers    
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Table 3 Association between socioeconomic deprivation and prescribing of evidence based therapies within 30 days after a first myocardial infarction  (quintile Q1 least deprived 
reference) 
 
* Adjusted for sex, age group, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure, heart failure, and stroke, peripheral arterial  
disease, angina, clustered practices, and whether the drug was previously prescribed. 
                 ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers 
 
 
Adjusted OR*, 
(95% CI) 
ACEI/ARBs β-blocker CCB Statins Aspirin Clopidogrel Oral anticoagulant 
Q2 1.43 (1.00-2.03) 1.00 (0.60-1.42) 1.00 (0.39-2.03) 1.00 (0.88-2.31) 0.96 (0.58-1.57) 1.32 (0.7-2.31) 0.96 (0.32-2.84) 
Q3 1.12 (0.63-1.99) 1.09 (0.61-1.95) 0.96 (0.45-2.06) 1.38 (0.65-2.94) 1.13 (0.60-2.12) 1.34 (0.81-2.23) 1.38 (0.58-3.23) 
Q4 2.00 (0.84-2.97) 1.17 (0.65-2.12) 0.83 (0.39-1.76) 1.38 (0.60-3.14) 1.00 (0.59-2.25) 1.57 (1.02-2.53) 0.50 (0.11-2.16) 
Q5 1.21 (0.62-2.37) 1.04 (0.57-1.89) 0.81 (0.38-1.69) 1.41 (0.67-2.97) 1.14 (0.56-2.32) 1.28 (0.83-2.05) 2.42 (1.01-5.82) 
Q6 1.19 (0.66-2.16) 1.08 (0.64-1.83) 1.03 (0.52-2.01) 1.25 (0.61-2.54) 1.17 (0.63-2.14) 1.27 (0.85-2.03) 1.53 (0.61-3.81) 
Q7 1.07 (0.57-2.01) 0.87 (0.48-1.56) 0.95 (0.46-1.96) 1.20 (0.59-2.45) 1.03 (0.52-2.07) 1.25 (0.77-2.22) 1.54 (0.60-3.95) 
Q8 1.22 (0.63-2.35) 0.97 (0.52-1.81) 1.28 (0.63-2.59) 1.20 (0.56-2.57) 1.107 (0.54-2.24) 1.60 (0.98-2.80) 1.36 (0.55-3.36) 
Q9 1.22 (0.63-2.37) 1.17 (0.63-2.17) 1.015 (0.51-1.98) 1.41 (0.68-2.94) 1.25 (0.59-2.66) 1.42 (0.88-2.39) 1.22 (0.37-4.02) 
Q10 1.09 (0.54-2.18) 0.86 (0.44-1.67) 1.02 (0.51-2.05) 1.18 (0.54-2.57) 1.11 (0.53-2.30) 1.35 (0.79-2.32) 1.01 (0.29-3.49) 
Adjusted
+
 overall  
P-value 
0.24 0.35 0.86 0.5 0.81 0.84 0.11 
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Table 4 Trends over time (1997-2005) in prescribing of evidence based therapies within 30 days after a first myocardial infarction (1997 reference)  
 ACEI/ARBs β-blocker CCB Statins Aspirin Clopidogrel** Oral anticoagulant 
Adjusted OR, 95% 
CI 
1998* 
1.32 (0.79-2.18) 1.43 (1.01-2.04) 0.73 (0.42-1.25) 2.36(1.55-3.59) 1.32 (1.02-1.72)  3.84 (0.80-18.37) 
Adjusted OR, 95% 
CI 
1999 
1.54 (1.01-2.3) 2.22 (1.61-3.07) 1.10 (0.61-1.99) 3.74 (2.43-5.75) 1.85 (1.34-2.56)  3.11 (0.58-16.69) 
Adjusted OR, 95% 
CI 
2000 
2.52 (1.66-3.82) 2.77(1.97-3.89) 1.41 (0.81-2.47) 4.33 (3.03-6.20) 1.89 (1.43-2.49)  3.43 (0.99-11.86) 
Adjusted OR, 95% 
CI 
2001 
3.36 (2.17-5.21) 3.11 (2.15-4.51) 1.30 (0.66-2.55) 5.17 (3.51-7.60) 1.73 (1.25-2.39) 9.1 (4.9-17.1) 5.06 (0.94-27.06) 
Adjusted OR, 95% 
CI 
2002 
4.11 (2.68-6.27) 2.93 (2.06-4.15) 1.07 (0.59-1.94) 7.23 (4.67-11.17) 2.23 (1.56-3.19) 20.1 (11.7-30.1) 2.82 (0.55-14.33) 
Adjusted OR, 95% 
CI 
2003 
3.38 (2.21-5.21) 2.59 (1.77-3.81) 1.07 (0.64-1.81) 7.21 (4.59-11.30) 2.04 (1.41-2.94) 25.8 (14.4-46.4) 3.11 (0.80-12.02) 
Adjusted OR, 95% 
CI 
2004 
3.81 (2.30-6.11) 3.41 (2.20-5.29) 0.92 (0.52-1.63) 11.74 (7.24-19.04) 2.33 (1.66-3.27) 48.6 (28.5-82.8) 5.72 (1.18-27.69) 
Adjusted OR, 95% 
CI 
2005 
5.25 (3.40-8.11) 3.60 (2.49-5.20) 0.88 (0.50-1.57) 11.11 (6.70-18.42) 2.81 (1.90-4.15) 68.4 (38.5-121) 5.91 (1.15-30.37) 
Adjusted over all p-
value 
<0.001 <0.001 0.27 <0.001 <0.001 <0.001 0.10 
 
Adjusted for sex, age group, socioeconomic status, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure,   heart failure, and stroke, 
peripheral arterial disease, angina, clustered practices, and whether the drug was previously prescribed. **2000 is the reference for clopidogrel, 
  
ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers 
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Table 5 Association between age and prescribing of evidence based therapies after a first angina (age < 55 years reference group) 
 
ACEI/ ARBs β-blockers CCB Nitrates  Statins Aspirin Clopidogrel 
Other anti-
anginal 
Adjusted OR*, 95% CI 
55-64 
1.06 (0.86-1.30) 1.07 (0.89-1.24) 1.06 (0.87-1.32) 1.07 (0.93-1.23) 0.99 (0.85-1.15) 1.20 (1.05-1.37) 0.81 (0.61-1.09) 0.66 (0.45-0.97) 
Adjusted OR, 95% CI 
65-74 
1.12 (0.90-1.38) 0.91 (0.77-1.03) 1.03 (0.86-1.25) 1.21 (1.04-1.40) 0.80 (0.70-0.92) 1.16 (1.02-1.32) 0.63 (0.46-0.87) 0.75 (0.51-1.11) 
Adjusted OR, 95% CI 
75-84 
0.97 (0.75-1.26) 0.78 (0.63-0.92) 1.00 (0.75-1.34) 1.21 (1.06-1.39) 0.52 (0.42-0.63) 0.95 (0.81-1.12) 0.58 (0.37-0.91) 0.59 (0.39-0.91) 
Adjusted OR, 95% CI 
≥ 85 
0.87 (0.56-1.35) 0.34 (0.25-0.46) 0.91 (0.58-1.42) 1.29 (1.05-1.59) 0.19 (0.12-0.33) 1.16 (0.94-1.44) 0.39 (0.19-0.77) 0.65 (0.34-1.20) 
Adjusted+ overall 
P-value 
0.5 <0.001 0.9 0.03 <0.001 0.01 0.02 
0.18 
  
* Adjusted for sex, socioeconomic status, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer,    renal failure, heart 
failure, and stroke, peripheral arterial disease, angina, and whether the drug was previously prescribed. 
  
         ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blocker. 
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Table 6 Association between sex (male versus female) and prescribing of evidence based therapies after first angina 
 Adjusted OR (95%,CI)* 
Adjusted
+
 
p-value 
ACEI/ARBs 1.26 (1.05-1.47) 0.01 
β-blockers  1.08 (0.93-1.22) 0.25 
CCB 1.01 (0.85-1.18) 0.92 
Nitrates 1.03 (0.93-1.14) 0.55 
Statins 1.09 (0.95-1.25) 1.60 
Aspirin 1.05 (0.95-1.15) 0.3 
Clopidogrel 1.27 (0.98-1.64) 0.06 
Other anti-angina 1.01 (0.75-1.36) 0.93 
 
*Women are the reference, 
+
Adjusted for age group, socioeconomic status, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, 
hypertension, diabetes, cancer,  renal failure, heart failure, and stroke, peripheral arterial disease, angina, and whether the drug was previously prescribed. 
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Table 7 Association between socioeconomic status and prescribing of evidence based therapies within 30 days after a first angina 
(Quintile Q1 least deprived reference) 
 
* Adjusted for sex, age group, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure, heart 
failure, and stroke, peripheral arterial disease, angina, and whether the drug was previously prescribed. 
  
            ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers 
 
 
Adjusted OR*, 
(95% CI) 
ACEI/ARBs β-blocker CCB Nitrates  Statins Aspirin Clopidogrel 
Other anti-
anginal 
Q2 1.35 (0.93-1.96) 0.97 (0.71-1.32) 0.93 (0.60-1.44) 0.88 (0.64-1.21) 1.09 (0.81-1.48) 1.14 (0.87-1.49) 0.94 (0.51-1.74) 1.01 (0.49-2.07) 
Q3 1.04 (0.67-1.62) 0.83 (0.62-1.13) 0.95 (0.74-1.22) 0.91 (0.75-1.11) 0.91 (0.65-1.27) 0.97 (0.75-1.24) 1.05 (0.54-2.06) 0.85 (0.43-1.69) 
Q4 1.18 (0.65-2.15) 0.97 (0.72-1.37) 1.12 (0.79-1.60) 0.93 (0.76-1.13) 0.96 (0.69-1.33) 1.17 (0.84-1.63) 0.94 (0.54-1.63) 0.78 (0.41-1.48) 
Q5 1.09 (0.70-1.68) 0.93 (0.70-1.23) 0.95 (0.67-1.35) 0.97 (0.79-1.21) 1.01 (0.69-1.49) 1.22 (0.93-1.61) 0.69 (0.37-1.29) 0.79 (0.42-1.46) 
Q6 1.29 (0.81-2.05) 0.79 (0.61-1.02) 1.11 (0.83-1.46) 0.96 (0.77-1.21) 1.04 (0.71-1.51) 1.14 (0.86-1.49) 0.88 (0.51-1.51) 0.71 (0.35-1.43) 
Q7 1.34 (0.89-2.02) 0.91 (0.67-1.20) 0.71 (0.49-1.02) 0.86 (0.70-1.05) 1.01 (0.73-1.39) 1.17 (0.93-1.47) 0.75 (0.41-1.36) 0.59 (0.32-1.07) 
Q8 1.04 (0.68-1.59) 0.79 (0.58-1.03) 0.92 (0.64-1.33) 0.81 (0.66-1.01) 0.92 (0.64-1.30) 1.08 (0.83-1.39) 0.88 (0.47-1.63) 0.56 (0.28-1.12) 
Q9 0.87 (0.59-1.28) 0.76 (0.58-1.00) 0.96 (0.70-1.32) 0.92 (0.72-1.19) 0.85 (0.62-1.17) 1.07 (0.84-1.36) 0.69 (0.38-1.27) 0.93 (0.48-1.82) 
Q10 1.13 (0.71-1.80) 0.71 (0.48-1.01) 0.86 (0.55-1.35) 0.93 (0.66-1.32) 0.87 (0.59-1.27) 1.20 (0.90-1.60) 0.88 (0.47-1.63) 0.87 (0.44-1.72) 
Adjusted
+
 
overall  
P-value 
0.20 0.12 0.14 0.85 0.77 0.56 0.8 0.6 
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Table 8 Trends over time (1997-2005) in prescribing of evidence based therapies within 30 days after a first angina (1997 reference)  
 ACEI/ARBs β-blocker CCB Nitrates  Statins Aspirin Clopidogrel** 
Other 
antianginal 
Adjusted OR, 
95% CI 
1998* 
1.18 (0.79-1.76) 1.30 (0.98-1.72) 1.15 (0.82-1.61) 0.97 (0.81-1.17) 1.71 (1.27-2.31) 1.40 (1.12-1.75)  1.67 (0.53-5.22) 
Adjusted OR, 
95% CI 
1999 
1.42 (0.92-2.19)  2.23 (1.75-2.86) 1.44 (1.15-1.80) 1.31 (1.05-1.63) 2.95 (2.27-3.82) 2.06 (1.65-2.56)  1.46 (0.63-3.35) 
Adjusted OR, 
95% CI 
2000 
2.18 (1.25-3.81) 3.21 (2.40-4.31) 1.48 (1.07-2.03) 1.51 (1.23-1.85) 3.67 (2.79-4.83) 2.53 (1.99-3.21)  2.53 (0.96-6.67) 
Adjusted OR, 
95% CI 
2001 
2.48 (1.55-3.97) 4.00 (2.86-5.48) 1.73 (1.28-2.35) 1.75 (1.34-2.29) 3.91 (2.80-5.46) 2.85 (2.30-3.55) 7.78 (4.4-13.6) 3.40 (1.42-8.14) 
Adjusted OR, 
95% CI 
2002 
2.61 (1.68-4.05) 3.38 (2.54-4.49) 1.72 (1.25-2.38) 1.91 (1.45-2.50) 4.37 (3.35-5.70) 2.99 (2.24-4.00) 14.44 (7.9-26.2) 4.49 (1.86-10.8) 
Adjusted OR, 
95% CI 
2003 
3.12 (2.06-4.72) 4.48 (3.10-6.41) 1.28 (0.86-1.89) 2.12 (1.55-2.89) 6.51 (4.83-8.78) 3.44 (2.65-4.48) 22.74 (12.2-42.4) 6.36 (2.67-15.1) 
Adjusted OR, 
95% CI 
2004 
2.75 (1.82-4.16) 4.77 (3.41-6.49) 1.15 (0.81-1.64) 1.68 (1.36-2.08) 8.73 (6.49-11.75) 2.85 (2.30-3.55) 33.54 (19.1-58.9) 10.6 (4.54-25.2) 
Adjusted OR, 
95% CI 
2005 
3.71 (2.46-5.58) 4.75 (3.26-6.73) 1.31 (0.95-1.79) 1.77 (1.32-2.38) 8.11 (5.89-11.15) 2.99 (2.24-4.00) 22.74 (12.2-42.4) 7.69 (3.03-19.5) 
Adjusted over all 
p-value 
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
*   Adjusted for sex, age group, socioeconomic status, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure, heart 
failure, and stroke, peripheral arterial disease, angina, and whether the drug was previously prescribed. **2000 is the reference for clopidogrel, 
  
  ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers  
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   Table 9 Association between age and prescribing of evidence based therapies after a first PAD (age < 55 years reference group)     
Adjusted OR*, 95% CI ACEI/ ARBs β-blockers CCB PVD  Statins Aspirin Clopidogrel 
Oral 
anticoagulant 
Adjusted OR, 95% CI 
55-64 
0.81 (0.52-
1.24) 
0.47 (0.22-
0.99) 
1.45 (0.66-
3.20) 
1.49 (0.74-
2.99) 
0.71 (0.47-
1.06) 
1.16 (0.84-
1.61) 
1.98 (0.55-
7.03) 
0.63 (0.26-
1.52) 
Adjusted OR, 95% CI 
65-74 
0.73 (0.45-
1.21) 
1.06 (0.61-
1.84) 
1.57 (0.70-
3.52) 
1.99 (1.01-
3.93) 
0.89 (0.59-
1.32) 
1.41 (1.01-
1.97) 
3.13 (1.03-
9.48) 
0.53 (0.21-
1.39) 
Adjusted OR, 95% CI 
75-84 
0.53 (0.28-
1.01) 
0.80 (0.45-
1.41) 
1.71 (0.78-
3.73) 
2.32 (1.32-
4.06) 
0.55 (0.34-
0.88) 
1.16 (0.81-
1.67) 
1.14 (0.25-
5.11) 
0.47 (0.15-
1.43) 
Adjusted OR, 95% CI 
≥ 85 
0.36 (0.17-
0.78) 
0.60 (0.20-
1.82) 
0.95 (0.36-
2.53) 
1.25 (0.50-
3.14) 
0.06 (0.01-
0.28) 
0.84 (0.53-
1.31) 
3.98 (0.99-
16.0) 
0.29 (0.08-
1.07) 
Adjusted+ overall 
P-value 
0.07 0.01 0.16 0.06 <0.001 0.05 0.12 0.41 
 
* Adjusted for sex, socioeconomic status, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer,   
 renal failure, heart failure, and stroke, whether the drug was previously prescribed. 
   
 ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD=peripheral vasodilator  
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Table 10 Association between sex (male versus female) and prescribing of evidence based therapies after first PAD 
 
Adjusted OR (95%,CI)* 
Adjusted
+
 
p-value 
ACEI/ARBs 0.84 (0.60-1.17) 0.3 
β-blockers 1.07 (0.76-1.51) 0.6 
CCB 1.00 (0.74-1.33) 0.9 
PVD 1.02 (0.77-1.36) 0.8 
Statins 0.73 (0.59-0.91) 0.004 
Aspirin 0.88 (0.71-1.08) 0.2 
Clopidogrel 0.85 (0.46-1.55) 0.6 
Oral anticoagulant 0.79 (0.38-1.62) 0.5 
*Women are the reference, 
+
Adjusted for age group, socioeconomic status, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, 
hypertension, diabetes, cancer, renal failure, heart failure, stroke, Whether the drug was previously prescribed. 
  
CCB= Calcium channel blocker, PVD= Peripheral vasodilator 
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Table 11 Association between socioeconomic status and prescribing of evidence based therapies within 30 days after a first PAD  
 (Quintile Q1 least deprived reference)  
 
* Adjusted for sex, age group, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure,   heart failure, and stroke, 
whether the drug was previously prescribed. 
  
 ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD=peripheral vasodilator 
 
 
 
Adjusted OR*, 
(95% CI) 
ACEI/ARBs β-blocker CCB PVD Statins Aspirin Clopidogrel 
Oral 
anticoagulant 
Q2 
1.12 (0.47-
2.63) 
0.29 (0.08-
1.04) 
0.91 (0.45-
1.83) 
2.22 (0.41-
11.8) 
1.01 (0.52-
1.93) 
0.56 (0.35-
0.90) 
3.23 (0.46-
22.4) 
0.61 (0.11-
3.39) 
Q3 
1.07 (0.58-
1.97) 
1.62 (0.68-
3.83) 
1.68 (0.89-
3.17) 
4.26 (1.32-
13.7) 
0.97 (0.55-
1.68) 
0.81 (0.57-
1.16) 
3.41 (0.38-
28.2) 
1.81 (0.84-
3.91) 
Q4 
1.12 (0.61-
2.05) 
0.39 (0.15-
0.97) 
0.85 (0.39-
1.84) 
3.66 (0.86-
15.4) 
0.76 (0.42-
1.38) 
0.84 (0.55-
1.27) 
3.53 (0.35-
35.3) 
2.51 (1.18-
5.34) 
Q5 
0.79 (0.34-
1.83) 
0.98 (0.49-
1.95) 
1.54 (0.66-
3.58) 
4.41 (1.15-
16.8) 
0.87 (0.41-
1.83) 
0.85 (0.58-
1.25) 
1.56 (0.14-
16.7) 
0.83 (0.25-
2.70) 
Q6 
1.06 (0.58-
1.94) 
1.45 (0.80-
2.64) 
1.21 (0.58-
2.51) 
4.47 (1.36-
14.6) 
1.06 (0.61-
1.85) 
0.87 (0.64-
1.20) 
2.69 (0.29-
24.6) 
0.85 (0.28-
2.56) 
Q7 
0.56 (0.29-
1.11) 
0.74 (0.39-
1.42) 
0.63 (0.31-
1.29) 
2.81 (0.72-
10.8) 
0.98 (0.54-
1.76) 
0.61 (0.41-
0.91) 
2.06 (0.21-
20.3) 
2.20 (0.78-
6.20) 
Q8 
0.88 (0.42-
1.84) 
0.83 (0.34-
2.03) 
0.94 (0.45-
1.96) 
2.41 (0.59-
9.81) 
0.93 (0.52-
1.68) 
0.91 (0.63-
1.31) 
1.53 (0.10-
23.6) 
1.53 (0.49-
4.72) 
Q9 
0.87 (0.38-
1.99) 
0.97 (0.43-
2.16) 
1.04 (0.52-
2.07) 
2.68 (0.69-
10.4) 
0.62 (0.38-
1.02) 
0.69 (0.47-
1.01) 
1.34 (0.24-
7.54) 
1.41 (0.64-
3.05) 
Q10 
0.72 (0.35-
1.49) 
0.69 (0.24-
1.97) 
1.44 (0.76-
2.73) 
4.17 (1.03-
16.8) 
0.71 (0.39-
1.27) 
0.55 (0.37-
0.83) 
3.02 (0.24-
37.9) 
1.06 (0.30-
3.70) 
Adjusted
+
 
overall  
P-value 
0.6 0.002 0.04 0.14 0.6 0.09 0.5 0.48 
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Table 12 Trends over time (1997-2005) in prescribing of evidence based therapies within 30 days after a first PAD (1997 reference)   
 ACEI/ARBs β-blocker CCB PVD  Statins Aspirin Clopidogrel** 
Oral 
anticoagulant 
Adjusted OR, 95% 
CI 
1998* 
1.18 (0.53-2.63) 0.58 (0.23-1.44) 0.81 (0.35-1.87) 1.37 (0.41-4.55) 1.63 (0.49-5.39) 1.34 (0.85-2.11)  0.46 (0.11-1.89) 
Adjusted OR, 95% 
CI 
1999 
1.16 (0.50-2.69) 1.53 (0.68-3.45) 1.38 (0.69-2.78) 1.56 (0.72-3.38) 4.09 (1.49-11.2) 1.98 (1.33-2.95)  0.72 (0.24-2.13) 
Adjusted OR, 95% 
CI 
2000 
1.46 (0.69-3.11) 1.04 (0.46-2.37) 1.30 (0.69-2.45) 3.15 (1.43-6.92) 4.97 (1.89-13.1) 2.39 (1.70-3.37)  1.28 (0.55-2.96) 
Adjusted OR, 95% 
CI 
2001 
2.23 (0.90-5.53) 1.14 (0.61-2.10) 1.61 (0.81-3.20) 4.93 (2.35-10.35) 5.96 (2.51-14.2) 2.29 (1.61-3.24) 2.46 (0.64-9.39) 0.35 (0.11-1.13) 
Adjusted OR, 95% 
CI 
2002 
1.59 (0.68-3.67) 1.26 (0.57-2.77) 1.11 (0.52-2.36) 4.06 (1.64-10.06) 9.34 (3.98-21.9) 3.40 (2.28-5.07) 0.75 (0.10-5.26) 0.92 (0.32-2.68) 
Adjusted OR, 95% 
CI 
2003 
2.34 (1.05-5.18) 1.68 (0.91-3.13) 1.32 (0.59-2.95) 2.38 (0.97-5.81) 12.92 (5.3-31.7) 2.41 (1.58-3.68) 5.23 (1.38-19.7) 0.40 (0.15-1.02) 
Adjusted OR, 95% 
CI 
2004 
1.11 (0.53-2.33) 1.03 (0.49-2.15) 0.80 (0.37-1.73) 3.49 (1.34-9.05) 10.61 (3.9-28.2) 3.21 (2.18-4.74) 2.58 (0.53-12.4) 0.78 (0.24-2.49) 
Adjusted OR, 95% 
CI 
2005 
1.16 (0.56-2.39) 1.39 (0.56-3.44) 1.43 (0.72-2.80) 4.71 (1.98-11.21) 20.22 (8.7-46.9) 4.06 (2.62-6.29) 3.44 (0.78-15.0) 0.37 (0.10-1.42) 
Adjusted over all  
p-value 
0.08 0.34 0.23 <0.001 <0.001 <0.001 0.02 0.25 
 
*   Adjusted for sex, age group, socioeconomic status, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure,   heart failure, and stroke, 
whether the drug was previously prescribed. **2000 is the reference for clopidogrel, 
  
  ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD= Peripheral vasodilator 
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PAD/CHD 
 
Table 13 Association between age and prescribing of evidence based therapies after a first PAD/CHD (age < 55 years reference group)   
Adjusted OR*, 95% CI ACEI/ ARBs β-blockers CCB PVD  Statins Aspirin Clopidogrel 
Oral 
anticoagulant 
Adjusted OR, 95% CI 
55-64 
0.89 (0.47-
1.65) 
0.99 (0.56-
1.73) 
0.51 (0.27-
0.91) 
8.11 (0.64-
102) 
0.86 (0.46-
1.59) 
1.20 (0.77-
1.86) 
1.94 (0.36-
10.47) 
0.84 (0.25-
2.82) 
Adjusted OR, 95% CI 
65-74 
1.11 (0.54-
2.22) 
0.77 (0.45-
1.31) 
0.56 (0.37-
0.86) 
8.07 (0.61-
106) 
0.76 (0.42-
1.37) 
1.46 (0.93-
2.28) 
0.96 (0.13-
6.82) 
0.21 (0.03-
1.21) 
Adjusted OR, 95% CI 
75-84 
0.89 (0.52-
1.52) 
0.59 (0.36-
0.97) 
0.61 (0.33-
1.11) 
14.1 (1.21-
164) 
0.51 (0.28-
0.91) 
1.41 (0.89-
2.24) 
1.62 (0.28-
9.26) 
0.66 (0.14-
3.01) 
Adjusted OR, 95% CI 
≥ 85 
0.93 (0.41-
2.13) 
0.55 (0.19-
1.58) 
0.41 (0.12-
1.35) 
3.50 (0.22-
53.8) 
0.50 (0.20-
1.22) 
0.71 (0.30-
1.66) 
5.26 (0.75-
36.7) 
0.07 (0.01-
0.75) 
Adjusted+ overall 
P-value 
0.84 0.2 0.2 0.03 0.08 0.13 0.12 0.03 
* Adjusted for sex, socioeconomic status, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer,   
 renal failure, heart failure, and stroke, whether the drug was previously prescribed. 
  
  ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD=Peripheral vasodilator     
  
319 
 
Table 14 Association between sex (male versus female) and prescribing of evidence based therapies  after PAD/CHD 
 Adjusted OR (95%,CI)* Adjusted
+
 
p-value 
ACEI/ARBs 1.08 (0.75-1.55) 0.6 
β-blockers 1.31 (0.97-1.75) 0.07 
CCB 0.94 (0.66-1.35) 0.7 
PVD 0.57 (0.28-1.16) 0.1 
Statins 1.39 (1.01-1.93) 0.04 
Aspirin 1.18 (0.96-1.45) 0.1 
Clopidogrel 1.55 (0.71-3.38) 0.2 
Oral anticoagulant 1.63 (0.53-4.99) 0.4 
*Women are the reference, +Adjusted for age group, socioeconomic status, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, 
cancer, renal failure, heart failure, stroke. Whether the drug was previously prescribed. 
 
 ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVD=Peripheral vasodilator 
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Table 15 Association between socioeconomic status and prescribing of evidence based therapies within 30 days after first PAD/CHD    
 (Quintile Q1 least deprived reference) 
 
* Adjusted for sex, age group, year of diagnosis, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure,   heart failure, and stroke, 
whether the drug was previously prescribed. 
  
 ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers, PVA=Peripheral vasodilator 
 
 
Adjusted 
OR*, 
(95% CI) 
ACEI/ARBs β-blocker CCB PVD Statins Aspirin Clopidogrel 
Oral 
anticoagulant 
Q2 
0.92 (0.36-
2.33) 
0.66 (0.29-
1.47) 
0.53 (0.21-
1.32) 
1.41 (0.22-
8.89) 
1.13 (0.38-
3.37) 
0.83 (0.43-
1.59) 
0.59 (0.02-
15.6) 
0.53 (0.02-
10.0) 
Q3 
0.91 (0.33-
2.46) 
0.81 (0.40-
1.64) 
0.56 (0.27-
1.19) 
0.55 (0.05-
5.94) 
1.19 (0.51-
2.79) 
1.06 (0.59-
1.89) 
3.49 (0.34-
35.4) 
2.05 (0.07-
52.9) 
Q4 
0.71 (0.28-
1.75) 
0.88 (0.47-
1.64) 
0.42 (0.18-
0.97) 
0.63 (0.11-
3.32) 
0.71 (0.28-
1.77) 
1.24 (0.81-
1.89) 
0.78 (0.06-
8.84) 
0.66 (0.02-
25.1) 
Q5 
1.09 (0.48-
2.45) 
1.08 (0.52-
2.24) 
0.48 (0.24-
0.96) 
0.83 (0.13-
5.29) 
1.01 (0.39-
2.55) 
1.06(0.51- 
2.20) 
1.93 (0.16-
22.6) 
1.11 (0.05-
23.8) 
Q6 
0.70 (0.29-
1.65) 
0.42 (0.22-
0.82) 
0.47 (0.30-
0.74) 
1.46 (0.31-
6.95) 
1.01 (0.42-
2.36) 
0.62 (0.41-
0.96) 
4.47 (0.60-
32.9) 
2.67 (0.13-
51.6) 
Q7 
0.72 (0.31-
1.72) 
0.86 (0.48-
1.53) 
0.77 (0.42-
1.42) 
0.44 (0.05-
3.45) 
1.06 (0.40-
2.80) 
1.23 (0.76-
1.99) 
1.84 (0.18-
18.9) 
2.39 (0.08-
63.9) 
Q8 
1.17 (0.51-
2.71) 
0.61 (0.33-
1.14) 
0.89 (0.43-
1.81) 
0.46 (0.07-
2.87) 
1.12 (0.46-
2.71) 
1.24 (0.71-
2.17) 
2.09 (0.23-
18.7) 
0.86 (0.03-
22.1) 
Q9 
1.14 (0.46-
2.81) 
0.77 (0.40-
1.47) 
0.64 (0.35-
1.16) 
0.92 (0.16-
5.38) 
1.26 (0.49-
3.22) 
1.36 (0.85-
2.18) 
3.15 (0.3-
25.46) 
0.88 (0.04-
17.2) 
Q10 
2.36 (0.96-
5.77) 
0.88 (0.48-
1.59) 
0.54 (0.25-
1.18) 
0.69 (0.13-
3.57) 
1.19 (0.51-
2.76) 
1.09 (0.65-
1.83) 
2.44 (0.2-
22.05) 
2.49 (0.09-
65.1) 
Adjusted
+
 
overall  
P-value 
0.03 0.2 0.4 0.6 0.9 0.1 0.4 0.4 
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Table 16 Trends over time (1997-2005) in prescribing of evidence based therapies within 30 days after a first PAD/CHD (1997 reference)   
 ACEI/ARBs β-blocker CCB PVD  Statins Aspirin Clopidogrel** 
Oral 
anticoagulant 
Adjusted OR, 95% 
CI 
1998* 
2.08 (0.68-6.33) 0.57 (0.20-1.61) 1.26 (0.56-2.84)  2.18 (0.81-5.86) 1.17 (0.48-2.82)  0.64 (0.25-1.62) 
Adjusted OR, 95% 
CI 
1999 
1.91 (0.62-5.85) 1.73 (0.76-3.93) 2.65 (1.31-5.35)  2.38 (0.97-5.82) 2.13 (1.01-4.51)  0.68 (0.15-3.10) 
Adjusted OR, 95% 
CI 
2000 
2.09 (0.78-5.61) 1.06 (0.37-3.02) 2.12 (0.97-4.62)  2.02 (0.72-5.64) 2.63 (1.22-5.66)  0.39 (0.07-2.14) 
Adjusted OR, 95% 
CI 
2001 
2.67 (0.83-8.57) 1.86 (0.68-5.12) 2.04 (0.88-4.71) 1.12 (0.38-3.26) 2.87 (1.02-8.04) 3.16 (1.53-6.52) 9.25 (0.8-97.98) 0.88 (0.21-3.64) 
Adjusted OR, 95% 
CI 
2002 
3.54 (1.10-11.3) 1.25 (0.48-3.25) 1.52 (0.64-3.57) 2.24 (0.63-7.95) 4.24 (1.47-12.2) 2.24 (1.07-4.68) 14.8 (1.9-115.6) 0.31 (0.06-1.54) 
Adjusted OR, 95% 
CI 
2003 
2.14 (0.69-6.64) 1.48 (0.63-3.49) 1.60 (0.67-3.82) 4.66 (0.09-2.31) 2.97 (1.06-8.34) 2.53 (1.16-5.52) 18.9 (2.4-144.2) 0.42 (0.08-2.12) 
Adjusted OR, 95% 
CI 
2004 
2.75 (0.98-7.71) 1.87 (0.74-4.70) 1.70 (0.69-4.17) 1.55 (0.57-4.17) 4.94 (1.70-14.3) 2.60 (1.19-5.67) 43.02 (5.21-135) 0.16 (0.02-1.31) 
Adjusted OR, 95% 
CI 
2005 
3.17 (1.11-9.12) 1.28 (0.53-3.05) 1.58 (0.70-3.55) 2.88 (0.84-9.83) 2.15 (0.74-6.22) 2.51 (1.19-5.28) 13.6 (1.65-112) 0.44 (0.07-2.47) 
Adjusted over all  
p-value 
0.2 0.04 0.25 0.004 0.003 0.004 <0.001 0.5 
*   Adjusted for sex, age group, socioeconomic, chronic obstructive pulmonary disease, asthma, atrial fibrillation, hypertension, diabetes, cancer, renal failure,   heart failure, and stroke, 
peripheral arterial disease, angina, whether drug was previously prescribed. **2000 is the reference for clopidogrel, 
  
  ACEI= Angiotensin converting enzyme inhibitors, ARBs= Angiotensin receptor blockers, CCB= Calcium channel blockers. 
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Appendix 7 
Prescribing EBTs before first diagnosis for MI, angina, PAD or PAD/CHD  
 ACEI/ARBs β-blockers CCB Statins Aspirin Clopidogrel Oral-anticoagulant 
MI 19.0% 24.1% 22.1% 15.6% 30.3% 2.6% 3.9% 
Angina 22.3% 33.2% 23.2% 22.1% 39.7% 3.5%  
PAD 16.5% 18.7% 16.4% 10.8% 23.0% 1.1% 3.8% 
PAD/CHD 38.6% 47.5% 44.3% 42.1% 64.0% 6.1% 9.0% 
 
 
Prescribing EBTs within 30 days after first diagnosis of MI, angina, PAD or PAD/CHD 
 ACEI/ARBs β-blockers CCB Statins Aspirin Clopidogrel Oral-anticoagulant 
MI 30.2% 35.5% 9.0% 36.1% 42.8% 11.6% 3.3% 
Angina 15.3% 30.5% 16.1% 23.7% 34.1% 4.9%  
PAD 8.9% 5.8% 9.5% 10.9% 19.2% 1.2% 2.2% 
PAD/CHD 20.1% 20.5% 20.5% 27.1% 30.4% 3.7% 4.2% 
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Prescribing EBTs at any time point after first diagnosis of MI, angina, PAD or PAD/CHD  
 ACEI/ARBs β-blockers CCB Statins Aspirin Clopidogrel Oral-anticoagulant 
MI 72.4% 72.4% 36.4% 83.5% 83.1% 29.3% 91.4% 
Angina 58.7% 72.4% 54.1% 83.8% 85.2% 22.8%  
PAD 43.0% 29.0% 36.7% 59.8% 63.7% 11.9% 8.8% 
PAD/CHD 69.0% 61.8% 57.6% 84.6% 82.7% 21.4% 31.1% 
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Sex differences in prescribing EBTs within 30 days after first diagnosis of MI, angina, PAD or PAD/CHD 
 ACEI/ARBs β-blocker CCB Statins Aspirin Clopidogrel Oral 
anticoagulant 
MI        
Male  31.3% 38.2% 8.6% 38.4% 44.2% 12.4% 2.9% 
Female 28.4% 31.4% 9.6% 32.6% 40.5% 10.3% 4.0% 
Angina        
Male 16.6% 32.1% 15.6% 26.0% 34.8% 5.8%  
Female  13.8% 28.4% 16.6% 20.9% 33.3% 3.8%  
PAD        
Male  8.4% 5.3% 8.9% 9.5% 18.2% 1.2% 2.4% 
Female 9.4% 6.4% 10.3% 12.5% 20.5% 1.3% 2.0% 
PAD/CHD        
Male 19.3% 21.9% 20.1% 29.1% 31.3% 3.8% 5.0% 
Female  16.1% 18.2% 21.2% 23.5% 28.8% 3.6% 2.8% 
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Age (older vs. younger patients) differences in prescribing EBTs within 30 days after first diagnosis of MI, angina, PAD or PAD/CHD 
Age (years)/ disease  ACEI/ARBs  β-blocker  CCB Statins Aspirin Clopidogrel Oral anticoagulant 
MI        
< 55 28.6% 40.6% 6.7% 41.0% 44.2% 12.7% 2.0% 
85+  19.9% 19.2% 7.4% 14.1% 33.3% 7.7% 2.0% 
Angina         
< 55 13.4% 33.5% 13.9% 28.5% 32.1% 6.2%  
85+ 14.9% 14.0% 14.3% 5.8% 35.6% 2.4%  
PAD        
< 55  5.4% 5.8% 4.2% 11.8% 14.0% 0.7% 2.2% 
85+ 5.7% 3.3% 7.1% 0.9% 18.0% 1.9% 2.4% 
PAD/CHD        
< 55 14.3% 24.4% 26.1% 33.6% 25.2% 2.5% 4.2% 
85+ 16.9% 11.3% 9.9% 12.7% 18.3% 9.9% 1.4% 
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Appendix 8 
 
Studies examined prescribing trends in the UK for CHD 
 ACEI/ARBs β-blockers CCB Statins Aspirin Clopidogrel  Antiplatelet  
DeWilde et al
257
 
UK,  
1994 vs. 2005 
13.5 vs. 57.0  
 
29.0 vs.55.0 
 
 4.00 vs. 80.0   31.0 vs. 75.0 
 
 12.0 vs. 51.0 
    
25.0 vs. 48.0 
 
 3.00 vs. 70.0   37.0 vs. 74.0 
 
Ryan et al
258
 
England-Wales,  
1994 vs. 1998 
   4.2   vs. 29.0 46.3 vs. 61.5    
EUROASPIRE I 
& II
259
 
9 countries  
1995-2000 
29.5 vs. 42.7 
 
53.7 vs. 66.4 
 
 18.5 vs. 57.7   81.2 vs. 83.9 
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Studies examined prescribing trends in the UK and Denmark for MI 
 ACEI/ARBs β-blockers CCB Statins Aspirin Clopidogrel 
Carey et al
294
  
UK, 
2005-2006 
6 months, GP 
   46.7 vs.94.4   
Hardoon et al
322
 
UK, 
1991 vs. 2002 
(GP 90 days) 
11.0 vs. 71.0  
 
26.0 vs. 68.0 
 
    
Gasse et al
316
 
Denmark 
1997 vs. 2003 
6 months, post 
di 
35.0 vs. 52.7 
 
74.0 vs. 76.2 
 
 17.0 vs. 70.5 38.0 vs. 83.0 
 
 
Gislason et al
287
 
Denmark,  
1995 vs. 2002 
30 days 
24.5 vs. 35.5  
 
38.1 vs. 67.9     
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This Study 
Scotland 
1997-2005 
30 days  
12.3 vs. 46.5 19.2 vs. 43.4 6.6 vs. 8.7 9.7 vs. 54.7 28.9 vs. 53.3 0.0 vs. 35.1 
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Studies examined prescribing trends in Denmark for PAD 
 ACEI/ARBs β-blockers CCB Statins Aspirin Clopidogrel  
Gasse et al 
Denmark 
1997-2003 
6 months  
23.0 vs. 41.0 
 
9.00 vs. 15.0 
 
 3.00 vs. 22.0   
Subherwal et al 
Denmark  
2000-2007 
3 months 
11.0 vs. 17.0 
 
  9.00 vs. 56.0   
This Study 
Scotland 
1997-2005 
30 days 
3.5 vs. 14.6 3.5 vs. 8.5  1.1 vs. 31.2   
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